<SEC-DOCUMENT>0001047469-19-000849.txt : 20190301
<SEC-HEADER>0001047469-19-000849.hdr.sgml : 20190301
<ACCEPTANCE-DATETIME>20190301170129
ACCESSION NUMBER:		0001047469-19-000849
CONFORMED SUBMISSION TYPE:	PRE 14A
PUBLIC DOCUMENT COUNT:		8
CONFORMED PERIOD OF REPORT:	20190301
FILED AS OF DATE:		20190301
DATE AS OF CHANGE:		20190301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adaptimmune Therapeutics PLC
		CENTRAL INDEX KEY:			0001621227
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PRE 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37368
		FILM NUMBER:		19650431

	BUSINESS ADDRESS:	
		STREET 1:		60 JUBILEE AVENUE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RX
		BUSINESS PHONE:		44 1235 430000

	MAIL ADDRESS:	
		STREET 1:		60 JUBILEE AVENUE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RX

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Adaptimmune Ltd
		DATE OF NAME CHANGE:	20141001
</SEC-HEADER>
<DOCUMENT>
<TYPE>PRE 14A
<SEQUENCE>1
<FILENAME>a2237876zpre14a.htm
<DESCRIPTION>PRE 14A
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg44001_table_of_contents">  TABLE OF CONTENTS</A><BR></font>
</P>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> SCHEDULE 14A</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Proxy
Statement Pursuant to Section 14(a) of<BR>
the Securities Exchange Act of 1934 (Amendment No.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2> Filed by the Registrant <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Filed by a Party other than the Registrant <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><BR>
Check the appropriate box:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Preliminary Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Additional Materials</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Soliciting Material under &sect;240.14a-12<BR></FONT>
</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> ADAPTIMMUNE THERAPEUTICS&nbsp;PLC</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Registrant as Specified In Its Charter)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2><B> N/A</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Person(s) Filing Proxy Statement, if other than the Registrant)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 style="font-family:times;"><FONT SIZE=2><BR>
Payment of Filing Fee (Check the appropriate box):</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>No fee required.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and&nbsp;0-11.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Title of each class of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Aggregate number of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Proposed maximum aggregate value of transaction:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Total fee paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee paid previously with preliminary materials.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Check box if any part of the fee is offset as provided by Exchange Act Rule&nbsp;0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><BR><FONT SIZE=2>Amount Previously Paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Form, Schedule or Registration Statement No.:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Filing Party:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Date Filed:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=682961,FOLIO='blank',FILE='DISK112:[19ZAF1.19ZAF44001]BA44001A.;4',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g1039423.jpg" ALT="LOGO" WIDTH="285" HEIGHT="52">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>Adaptimmune Therapeutics&nbsp;PLC<BR>  </B></FONT><FONT SIZE=2><B>60 Jubilee Avenue, Milton Park<BR>
Abingdon, Oxfordshire OX14&nbsp;4RX, U.K.<BR>
Registered Company No.&nbsp;09338148  </B></FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>March&nbsp;[&nbsp;&nbsp;&nbsp;&nbsp;], 2019 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Dear
Shareholder: </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2019 Annual General Meeting of Adaptimmune Therapeutics&nbsp;plc (the "AGM")  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This letter, the notice of the AGM set out in this document (</FONT><FONT SIZE=2><B>"the Notice"</B></FONT><FONT SIZE=2>) and associated
materials for the AGM are being sent to you because, as of March&nbsp;13, 2019 (being the latest practicable date before the circulation of this document), you are registered as a holder of ordinary
shares in the register of members of the Company. However, this letter, the Notice and associated materials will also be available to holders of American Depositary Shares
(</FONT><FONT SIZE=2><B>"ADS"</B></FONT><FONT SIZE=2>) and contain information relevant to holders of ADSs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I
am pleased to confirm that our AGM will take place at </FONT><FONT SIZE=2><B>11:00&nbsp;a.m. London time (6:00&nbsp;a.m. Eastern Standard Time) on Thursday, May&nbsp;2, 2019 at
60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14&nbsp;4RX.</B></FONT><FONT SIZE=2> The Notice is set out in this document and it contains the resolutions to be proposed at the AGM (the </FONT> <FONT SIZE=2><B>"Resolutions"</B></FONT><FONT
SIZE=2>). </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Action to be taken by holders of ordinary shares in the Company  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you are a holder of American Depositary Shares (</FONT><FONT SIZE=2><B>"ADSs"</B></FONT><FONT SIZE=2>), please ignore this section and refer
instead to the section below&#151;"</FONT><FONT SIZE=2><I>Holders of American Depositary Shares</I></FONT><FONT SIZE=2>". </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you are a holder of ordinary shares in the Company and are planning to attend the AGM in person (or by way of corporate representative) it would be helpful if you could inform
Margaret Henry, Company Secretary, by email: margaret.henry@adaptimmune.com, tel: +44 (0)1235 430036 or mobile:&nbsp;+44&nbsp;(0)7710 304249. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you are unable to attend the AGM, you can still vote on the Resolutions by appointing a proxy. A form of proxy for use at the AGM is enclosed. You are advised to complete and return
the form of proxy in accordance with the instructions printed on it and so as to arrive at the Company's registrar, Computershare Investor Services&nbsp;PLC, The Pavilions, Bridgwater Road, Bristol,
BS99&nbsp;6ZY, England as
soon as possible but in any event by no later than </FONT><FONT SIZE=2><B>11:00&nbsp;a.m. London time (6:00&nbsp;a.m. Eastern Standard Time) on Tuesday, April&nbsp;30,
2019</B></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
may also submit your proxy vote online at www.investorcentre.co.uk/eproxy (see instructions on form of proxy) to arrive by no later than </FONT><FONT SIZE=2><B>11:00&nbsp;a.m.
London time (6:00&nbsp;a.m. Eastern Standard Time) on Tuesday, April&nbsp;30, 2019.</B></FONT><FONT SIZE=2> The return of a form of proxy or the electronic appointment of a proxy does not preclude
you from attending and voting at the AGM if you so wish. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order to attend and vote at the AGM as an ordinary shareholder, you must continue to be registered as a holder of ordinary shares in the Company's register of members as of
6:30&nbsp;p.m. London time (1:30&nbsp;p.m. Eastern Standard Time) on Tuesday, April&nbsp;30, 2019. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Therefore,
if you sell or transfer your ordinary shares in the Company on or prior to April&nbsp;30, 2019, your form of proxy can no longer be used and if submitted (whether before or
after you sell or transfer your ordinary shares) will be treated as invalid. Please pass this document to the person who arranged the sale or transfer for delivery to the purchaser or transferee. The
purchaser or transferee should contact Margaret Henry, Company Secretary, to request a new form of proxy for its use. </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=645383,FOLIO='blank',FILE='DISK112:[19ZAF1.19ZAF44001]BC44001A.;7',USER='CHE109569',CD=';1-MAR-2019;12:00' -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Should
you elect to convert your holding of ordinary shares in the capital of the Company into an interest in the capital of the Company represented by ADSs before the AGM, you will
cease to be a holder of ordinary shares in your own name and will not be entitled to attend and vote at the AGM as an ordinary shareholder. You will also not be able to use the enclosed form of proxy.
However, you may be able to exercise your vote as a holder of an interest in the capital of the Company represented by American Depositary Shares&#151;please refer to the next
section&#151;"</FONT><FONT SIZE=2><I>Holders of American Depositary Shares</I></FONT><FONT SIZE=2>". </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Holders of American Depositary Shares  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to exercise your vote as a holder of an interest in the capital of the Company represented by ADSs, you or your bank, broker or nominee
must be registered as a holder of ADSs in the ADS register </FONT><FONT SIZE=2><B>by 5:00&nbsp;p.m. Eastern Standard Time on Friday, March&nbsp;15, 2019 (the record date for ADS
holders).</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you hold ADSs through a bank, broker or nominee on March&nbsp;15, 2019, the AGM documentation, including the ADS proxy card, will be sent to your broker who should forward the
materials to you. Please reach out to your broker to provide your voting instructions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
note that ADS proxy cards submitted by ADS holders must be received by Citibank, N.A. </FONT><FONT SIZE=2><B>no later than 10:00&nbsp;a.m. Eastern Standard Time on Thursday,
April&nbsp;25, 2019</B></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Contacts for ADS holders  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you have queries about how you can deliver voting instructions, please contact Citibank, N.A.&#151;ADR Shareholder Services at tel:
+1-877-248-4237 (toll free within the United States) or +1-781-575-4555 (for international callers) or by email: citibank@shareholders-online.com or at Citibank Shareholder Services,
P.O.&nbsp;Box&nbsp;43077, Providence, RI 02940-3077. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
at any point you require guidance, please contact Margaret Henry, Company Secretary, on email: margaret.henry@adaptimmune.com, tel: +44(0)1235 430036 or cell: +44 (0)7710 304249. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recommendation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You will find an explanatory note in relation to each of the Resolutions in the attached proxy statement. Your Directors consider that each
Resolution is in the best interests of the Company and its shareholders as a whole and is likely to promote the success of the Company. Accordingly, your Directors unanimously recommend that you vote
in favour of the Resolutions as each of the Directors with personal holdings of shares in the Company intends to do in respect of their own beneficial holdings of shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Thank
you for your ongoing support of Adaptimmune. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Yours
sincerely, </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;text-align:left;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=2>/s/&nbsp;DAVID M. MOTT<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2><B>David M. Mott</B></FONT><BR>
<FONT SIZE=2><B><I>Chairman, </I></B></FONT><FONT SIZE=2><B>Adaptimmune Therapeutics&nbsp;plc</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=3,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=525048,FOLIO='blank',FILE='DISK112:[19ZAF1.19ZAF44001]BC44001A.;7',USER='CHE109569',CD=';1-MAR-2019;12:00' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g1039423.jpg" ALT="LOGO" WIDTH="285" HEIGHT="52">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>Adaptimmune Therapeutics&nbsp;PLC</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>60 Jubilee Avenue, Milton Park<BR>
Abingdon, Oxfordshire OX14&nbsp;4RX, U.K.<BR>
Registered Company No.&nbsp;09338148  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTICE OF&nbsp;2019 ANNUAL GENERAL MEETING OF SHAREHOLDERS<BR>
TO BE HELD ON THURSDAY, MAY 2, 2019  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>NOTICE</B></FONT><FONT SIZE=2> is hereby given that the Annual General Meeting of Adaptimmune Therapeutics&nbsp;plc, a public limited
company incorporated under the laws of England and Wales (referred to herein as the "Company," "we," "us" and "our"), will be held on Thursday, May&nbsp;2, 2019, at 11:00&nbsp;a.m. London time
(6:00&nbsp;a.m. Eastern Standard time), at 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire&nbsp;OX14&nbsp;4RX, for transaction of the following business: </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Ordinary resolutions  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
re-elect as a director, John Furey, who retires in accordance with the Articles of Association. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
re-elect as a director, Ali Behbahani, who retires by rotation in accordance with the Articles of Association. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
re-elect as a director, James Noble, who retires by rotation in accordance with the Articles of Association. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
re-appoint KPMG&nbsp;LLP as auditors of the Company, to hold office until the conclusion of the next annual general meeting of shareholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
authorize the Audit Committee to determine our auditors' remuneration for the fiscal year ending December&nbsp;31, 2019. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
receive the U.K. statutory annual accounts and reports for the fiscal year ended December&nbsp;31, 2018 and to note that the Directors do not recommend the payment
of any dividend for the year ended December&nbsp;31, 2018. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers for the year ended December&nbsp;31, 2018. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
indicate, on a non-binding, advisory basis, the preferred frequency of future shareholder advisory votes on the compensation of the Company's named executive officers. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
receive and approve our U.K. statutory directors' remuneration report for the year ended December&nbsp;31, 2018, which is set forth as </FONT> <FONT SIZE=2><I>Annex&nbsp;A</I></FONT><FONT SIZE=2> to the attached proxy statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;&nbsp;&nbsp;To
authorize the directors, generally and unconditionally for the purpose of s551 of the U.K. Companies Act 2006 to allot shares in the Company or to grant rights to
subscribe for or to convert any security into shares in the Company (</FONT><FONT SIZE=2><B>"Rights"</B></FONT><FONT SIZE=2>) up to a maximum aggregate nominal amount of &pound;207,288.00. This
authority shall expire (unless previously renewed, varied or revoked) on May&nbsp;1, 2024 but so that the Company may make offers and enter into agreements before that expiry which would, or might,
require shares to be allotted or Rights to be granted after that expiry and the directors may allot shares or grant Rights pursuant to any of those offers or agreements as if the authority had not
expired. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
authority referred to in this resolution is in substitution for the authority conferred on the directors under s551 of the U.K. Companies Act 2006 at the annual general meeting held
on June&nbsp;21, 2017 but the directors may allot shares or grant Rights pursuant to an offer made or agreement entered into by the Company before the expiry of the authority pursuant to which that
offer was made or agreement entered into. </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=34963,FOLIO='blank',FILE='DISK112:[19ZAF1.19ZAF44001]BE44001A.;21',USER='CHE109569',CD=';1-MAR-2019;12:00' -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Special resolution  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;&nbsp;&nbsp;Subject
to the passing of Resolution 10, to empower the directors generally pursuant to s570(1) of the U.K. Companies Act 2006 to allot equity securities (as defined in
s560 of the U.K. Companies Act 2006) for cash pursuant to the general authority conferred on them by Resolution 10 as if s561(1) of the U.K. Companies Act 2006 did not apply to that allotment. This
power: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;shall
be limited to the allotment of equity securities up to an aggregate nominal amount of &pound;157,500.00; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;expires
(unless previously renewed, varied or revoked) at the end of the annual general meeting of the Company to be held in 2021 but so that the Company may make offers
and enter into agreements before that expiry which would, or might, require equity securities to be allotted after that expiry and the directors may allot equity securities pursuant to any of those
offers or agreements as if this power had not expired; and </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;applies
in relation to a sale of shares which is an allotment of equity securities by virtue of s560(3) of the U.K. Companies Act 2006 as if in the first paragraph of
this resolution the words "pursuant to the general authority conferred on them by Resolution 10" were omitted. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the purposes of this resolution, references to the allotment of equity securities shall be interpreted in accordance with s560 of the U.K. Companies Act 2006. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proposals
1 through 10 will be proposed as ordinary resolutions and under English law, assuming that a quorum is present, an ordinary resolution is passed on a show of hands if it is
approved by a simple majority (more than 50%) of the votes cast by shareholders present (in person or by proxy) at the meeting and entitled to vote. If a poll is demanded, an ordinary resolution is
passed if it is approved by holders representing a simple majority of the total voting rights of shareholders present (in person or by proxy) who (being entitled to vote) vote on the resolution.
Proposal 11 will be proposed as a special resolution. Special resolutions require the affirmative vote of not less than 75% of the votes cast by shareholders present (in person or by proxy) at the
meeting and entitled to vote. On a poll, a special resolution is passed if it is approved by holders representing not less than 75% of the total voting rights of shareholders present (in person or by
proxy) who (being entitled to vote) vote on the resolution. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
result of the shareholder votes on the ordinary resolutions in proposals 6, 7, 8 and 9 regarding receipt of our U.K. statutory annual accounts and reports for the year ended
December&nbsp;31, 2018, approval of the compensation of our named executive officers for the year ended December&nbsp;31, 2018, advisory votes on the preferred frequency of future votes on
executive compensation and approval of our U.K. statutory directors' annual report on remuneration for the year ended December&nbsp;31, 2018 will not require our Board of Directors or any committee
thereof to take any action. Our Board of Directors values the opinions of our shareholders as expressed through such votes and will carefully consider the outcome of the votes on proposals 6, 7, 8 and
9. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
results of any polls taken on the resolutions at the Annual General Meeting and any other information required by the U.K. Companies Act 2006 will be made available on our website
(https://www.adaptimmune.com) as soon as reasonably practicable following the Annual General Meeting and for the required period thereafter. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><B>BY ORDER OF THE BOARD</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B> Registered Office</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>60 Jubilee Avenue, Milton Park,</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Abingdon,</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>/s/&nbsp;MARGARET HENRY<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Margaret Henry<BR></FONT> <FONT SIZE=2><I>Company Secretary</I></FONT><FONT SIZE=2><BR>
March&nbsp;[&nbsp;&nbsp;&nbsp;&nbsp;], 2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Oxfordshire OX14&nbsp;4RX, United Kingdom<BR>
Registered in England and Wales<BR>
No 09338148</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=5,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=647350,FOLIO='blank',FILE='DISK112:[19ZAF1.19ZAF44001]BE44001A.;21',USER='CHE109569',CD=';1-MAR-2019;12:00' -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notes  </B></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Only
those members registered in the register of members of the Company at 6:30&nbsp;p.m. London time (1:30&nbsp;p.m. Eastern Standard Time) on April&nbsp;30,
2019 will be entitled to attend and vote at the Annual General Meeting ("AGM") in respect of the number of ordinary shares registered in their name at the time. Changes to entries on the relevant
register after that deadline will be disregarded in determining the rights of any person to attend and vote at the AGM. Should the AGM be adjourned to a time not more than 48&nbsp;hours after the
deadline, the same deadline will also apply for the purpose of determining the entitlement of members to attend and vote (and for the purpose of determining the number of votes they may cast) at the
adjourned AGM. Should the AGM be adjourned for a longer period, then to be so entitled, members must be entered on the Register at the time which is 48&nbsp;hours before the time fixed for the
adjourned AGM or, if the Company gives notice of the adjourned AGM, at the time specified in the notice.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Any
member may appoint a proxy to attend, speak and vote on his/her behalf. A member may appoint more than one proxy in relation to the AGM provided that each proxy
is appointed to exercise the rights attached to a different share or shares of the member. A proxy need not be a member, but must attend the meeting in person. Proxy forms should be lodged with the
Company's Registrar (Computershare) not later than 11:00&nbsp;a.m. London time (6:00&nbsp;a.m. Eastern Standard Time) on April&nbsp;30, 2019. Completion and return of the appropriate proxy form
does not prevent a member from attending and voting in person if he/she is entitled to do so and so wishes. The attached proxy statement explains proxy voting and the matters to be voted on in more
detail. Please read the proxy statement carefully. For specific information regarding the voting of your ordinary shares, please refer to the proxy statement under the section entitled
"</FONT><FONT SIZE=2><I>Questions and Answers About Voting</I></FONT><FONT SIZE=2>."
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Any
corporation which is a member can appoint one or more corporate representatives who may exercise on its behalf all of its powers as a member provided that they
do not do so in relation to the same shares.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(d)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>In
the case of joint holders, the vote of the senior who tenders the vote whether in person or by proxy will be accepted to the exclusion of the votes of any other
joint holders. For these purposes, seniority shall be determined by the order in which the names stand in the Company's relevant register or members for the certificated or uncertificated shares of
the Company (as the case may be) in respect of the joint holding.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(e)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>CREST
members who wish to appoint a proxy or proxies through the CREST electronic proxy appointment service may do so for the AGM and any adjournments of it by using
the procedures described in the CREST Manual. CREST personal members or other CREST sponsored members, and those CREST members who have appointed voting service providers, should refer to their
sponsors or voting service providers, who will be able to take the appropriate action on their behalf. <BR></FONT>
<BR>

<P style="font-family:times;"><FONT SIZE=2>For
a proxy appointment or instruction made using the CREST service to be valid, the appropriate CREST message (a </FONT><FONT SIZE=2><B>"CREST Proxy Instruction"</B></FONT><FONT SIZE=2>) must be
properly authenticated in accordance with Euroclear's specifications and must contain the information required for those instructions as described in the CREST Manual (available via
www.euroclear.com). The message, regardless of whether it relates to the appointment of a proxy or to an amendment to the instruction given to the previously appointed proxy, must, to be valid, be
transmitted so as to be received by the Company's agent 3RA50 by 11:00&nbsp;a.m. London time (6:00&nbsp;a.m. Eastern Standard Time) on April&nbsp;30, 2019. For this purpose, the time of receipt
will be taken to be the time (as determined by the timestamp applied to the message by the CREST Applications Host) from which the Company's agent is able to retrieve the message by enquiry
to CREST in the manner prescribed by CREST. After this time, any change of instructions to proxies appointed through CREST should be communicated to the appointee through other means. <BR></FONT></P>

</DD></DL>
<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=6,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=1008987,FOLIO='blank',FILE='DISK112:[19ZAF1.19ZAF44001]BE44001A.;21',USER='CHE109569',CD=';1-MAR-2019;12:00' -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>CREST
members and, where applicable, their CREST sponsors or voting service providers should note that Euroclear UK does not make available special procedures in CREST for any particular messages.
Normal system timings and limitations will, therefore, apply in relation to the input of CREST Proxy Instructions. It is the responsibility of the CREST member concerned to take (or, if the CREST
member is a CREST personal member or sponsored member or has appointed voting service providers, to procure that its CREST sponsors or voting service providers take) such action as shall be necessary
to ensure that a message is transmitted by means of the CREST system by any particular time. In this connection, CREST members and, where applicable, their CREST sponsors or voting service providers
are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings. <BR>
The Company may treat as invalid a CREST Proxy Instruction in the circumstances set out in Regulation&nbsp;35(5)(a) of the Uncertificated Securities Regulations&nbsp;2001.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(f)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>As
of March&nbsp;13, 2019 (being the last practicable date before circulation of this Notice), the Company's issued ordinary share capital consisted of
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] ordinary shares, carrying one vote each. Therefore, the total voting rights in the Company as of that date are
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;].
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(g)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Under
s527 Companies Act 2006, members meeting the threshold requirement set out in that section have the right to require the Company to publish on a website a
statement setting out any matter relating to: (i)&nbsp;the audit of the Company's accounts (including the auditor's report and the conduct of the audit) that are to be laid before the AGM; or
(ii)&nbsp;any circumstance connected with an auditor of the Company ceasing to hold office since the previous meeting at which annual accounts and reports were laid in accordance with s437 Companies
Act 2006. The Company may not require the shareholders requesting any such website publication to pay its expenses in complying with ss527 or 528 Companies Act 2006. Where the Company is required to
place a statement on a website under s527 Companies Act 2006, it must forward the statement to the Company's auditor not later than the time when it makes the statement available on the website. The
business which may be dealt with at the AGM includes any statement that the Company has been required, under s527 Companies Act 2006, to publish on a website.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(h)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Except
as set out in the notes to this Notice, any communication with the Company in relation to the AGM, including in relation to proxies, should be sent to the
Company's Registrar, Computershare Investor Services&nbsp;PLC, The Pavilions, Bridgwater Road, Bristol, BS99&nbsp;6ZY, England. No other means of communication will be accepted. In particular, you
may not use any electronic address provided either in this notice or in any related documents to communicate with the Company for any purpose other than those expressly stated.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(i)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Copies
of the service agreement for our executive director and of the letters of appointment for our non-executive directors will be available for inspection at the
registered office of the Company during normal business hours on any week day (public holidays excepted) from the date of this Notice of AGM until the date of the AGM, and at the place of the AGM for
one hour before the meeting and at the meeting itself. </FONT></DD></DL>
<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=7,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=52587,FOLIO='blank',FILE='DISK112:[19ZAF1.19ZAF44001]BE44001A.;21',USER='CHE109569',CD=';1-MAR-2019;12:00' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="BG44001A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="bg44001_table_of_contents"> </A>
<BR></FONT><FONT SIZE=2><B>  TABLE OF CONTENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG44001_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Page </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ca44001_information_concerning_proxy_solicitation_and_voting"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INFORMATION CONCERNING PROXY SOLICITATION AND VOTING</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ca44001_information_concerning_proxy_solicitation_and_voting"><FONT SIZE=2>1</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ca44001_questions_and_answers_about_voting"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>QUESTIONS AND ANSWERS ABOUT VOTING</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ca44001_questions_and_answers_about_voting"><FONT SIZE=2>1</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cc44001_election_of_directors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ELECTION OF DIRECTORS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cc44001_election_of_directors"><FONT SIZE=2>8</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cc44001_proposal_1_#151;re-election_of__pro02335"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSAL 1&#151;RE-ELECTION OF JOHN FUREY TO THE BOARD OF
DIRECTORS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cc44001_proposal_1_#151;re-election_of__pro02335"><FONT SIZE=2>9</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cc44001_proposal_2_#151;re-election_of__pro02379"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSAL 2&#151;RE-ELECTION OF ALI BEHBAHANI TO THE BOARD OF
DIRECTORS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cc44001_proposal_2_#151;re-election_of__pro02379"><FONT SIZE=2>10</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cc44001_proposal_3_#151;re-election_of__pro02342"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSAL 3&#151;RE-ELECTION OF JAMES NOBLE TO THE BOARD OF
DIRECTORS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cc44001_proposal_3_#151;re-election_of__pro02342"><FONT SIZE=2>11</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cc44001_proposal_4_#151;re-appointment__pro05509"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSAL 4&#151;RE-APPOINTMENT OF KPMG AS OUR AUDITORS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cc44001_proposal_4_#151;re-appointment__pro05509"><FONT SIZE=2>12</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cc44001_proposal_5_#151;authorization___pro04875"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSAL 5&#151;AUTHORIZATION OF THE AUDIT COMMITTEE TO DETERMINE OUR AUDITOR'S
REMUNERATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cc44001_proposal_5_#151;authorization___pro04875"><FONT SIZE=2>14</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cc44001_proposal_6_#151;resolution_to___pro03505"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSAL 6&#151;RESOLUTION TO RECEIVE THE COMPANY'S U.K. STATUTORY ANNUAL
ACCOUNTS AND REPORTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cc44001_proposal_6_#151;resolution_to___pro03505"><FONT SIZE=2>15</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#PRO7"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSAL 7&#151;APPROVAL OF EXECUTIVE COMPENSATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#PRO7"><FONT SIZE=2>16</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#PRO8"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSAL 8&#151;APPROVAL OF FREQUENCY OF FUTURE VOTES ON EXECUTIVE COMPENSATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#PRO8"><FONT SIZE=2>17</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cc44001_proposal_9_#151;approval_of_ou__pro03238"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSAL 9&#151;APPROVAL OF OUR U.K. STATUTORY DIRECTORS' ANNUAL REPORT ON
REMUNERATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cc44001_proposal_9_#151;approval_of_ou__pro03238"><FONT SIZE=2>18</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ce44001_proposal_10_#151;autho__ce401844"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSAL 10&#151;AUTHORIZATION OF ALLOTMENT OF SHARES</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ce44001_proposal_10_#151;autho__ce401844"><FONT SIZE=2>20</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ce44001_proposal_11_#151;disap__ce401775"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSAL 11&#151;AUTHORIZATION OF DISAPPLICATION OF PRE-EMPTION RIGHTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ce44001_proposal_11_#151;disap__ce401775"><FONT SIZE=2>21</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cg44001_board_of_directors_and_corporate_governance"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>BOARD OF DIRECTORS AND CORPORATE GOVERNANCE</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cg44001_board_of_directors_and_corporate_governance"><FONT SIZE=2>22</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ci44001_security_ownership_of_certain___sec02525"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ci44001_security_ownership_of_certain___sec02525"><FONT SIZE=2>30</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ci44001_section_16(a)_benefici__ci402020"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SECTION&nbsp;16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ci44001_section_16(a)_benefici__ci402020"><FONT SIZE=2>33</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ci44001_transactions_with_related_persons"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>TRANSACTIONS WITH RELATED PERSONS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ci44001_transactions_with_related_persons"><FONT SIZE=2>34</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ci44001_director_remuneration"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DIRECTOR REMUNERATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ci44001_director_remuneration"><FONT SIZE=2>35</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ck44001_executive_officers_of_the_company"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXECUTIVE OFFICERS OF THE COMPANY</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ck44001_executive_officers_of_the_company"><FONT SIZE=2>38</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ck44001_executive_compensation_discussion_and_analysis"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXECUTIVE COMPENSATION DISCUSSION AND ANALYSIS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ck44001_executive_compensation_discussion_and_analysis"><FONT SIZE=2>40</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#co44001_remuneration_committee_report"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>REMUNERATION COMMITTEE REPORT</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#co44001_remuneration_committee_report"><FONT SIZE=2>59</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cq44001_audit_committee_report"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>AUDIT COMMITTEE REPORT</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cq44001_audit_committee_report"><FONT SIZE=2>75</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cq44001_delivery_of_proxy_materials"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DELIVERY OF PROXY MATERIALS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cq44001_delivery_of_proxy_materials"><FONT SIZE=2>77</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cq44001_additional_information"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ADDITIONAL INFORMATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cq44001_additional_information"><FONT SIZE=2>78</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#la44001_annex_a_to_proxy_statement"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ANNEX A</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#la44001_annex_a_to_proxy_statement"><FONT SIZE=2>A-1</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#Form"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>FORM OF PROXY FOR ORDINARY SHAREHOLDERS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#Form"><FONT SIZE=2>A-25</FONT></A></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=8,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=248663,FOLIO='blank',FILE='DISK112:[19ZAF1.19ZAF44001]BG44001A.;10',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ca44001_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>Adaptimmune Therapeutics&nbsp;PLC<BR>  </B></FONT><FONT SIZE=2><B>60 Jubilee Avenue, Milton Park<BR>
Abingdon, Oxfordshire OX14&nbsp;4RX, U.K.<BR>
Registered Company No.&nbsp;09338148  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>PROXY STATEMENT FOR THE 2019 ANNUAL GENERAL MEETING OF<BR>
SHAREHOLDERS TO BE HELD ON MAY 2, 2019  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B> <A NAME="ca44001_information_concerning_proxy_solicitation_and_voting"> </A>
<A NAME="toc_ca44001_1"> </A>
<BR>    </B></FONT><FONT SIZE=2><B>  INFORMATION CONCERNING PROXY SOLICITATION AND VOTING    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have sent you this proxy statement and the enclosed form of proxy because the Board of Directors of Adaptimmune Therapeutics&nbsp;plc
(referred to herein as the "Company", "we", "us" or "our") is soliciting your proxy to vote at our annual general meeting of shareholders (referred
to herein as the "Meeting" or the "AGM") to be held on Thursday, May&nbsp;2, 2019, at 11:00&nbsp;a.m. London time (6:00&nbsp;a.m. Eastern Standard time), at 60 Jubilee Avenue, Milton Park,
Abingdon, Oxfordshire&nbsp;OX14&nbsp;4RX. </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> This proxy statement summarizes information about the proposals to be considered at the Meeting and other information you may find useful in
determining how to vote. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The form of proxy is the means by which you actually authorize another person to vote your shares in accordance with your instructions. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to solicitations by mail, our directors, officers and regular employees, without additional remuneration, may solicit proxies by telephone, e-mail and personal interviews.
All costs of solicitation of proxies will be covered by us. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are mailing the Notice of 2019 AGM, this proxy statement and the form of proxy to our ordinary shareholders of record as of March&nbsp;13, 2019 (being the latest practicable date
before the circulation of this document) for the first time on or about March&nbsp;[&nbsp;&nbsp;&nbsp;&nbsp;], 2019. In this mailing, we are also including our U.K. statutory annual
accounts and reports for the year ended December&nbsp;31, 2018 ("2018 U.K. Annual Report") and our annual report on Form&nbsp;10-K for the year ended December&nbsp;31, 2018 (the "Annual Report
on Form&nbsp;10-K"). In addition, we have provided brokers, dealers, bankers, and their nominees, at our expense, with additional copies of our proxy materials, the 2018 U.K. Annual Report and the
Annual Report on Form&nbsp;10-K so that our record holders can supply these materials to the beneficial owners of our ordinary shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whilst
this document is being sent to our ordinary shareholders of record, this document will also be sent to holders of American Depositary Shares ("ADSs") and contains information
relevant to holders of ADSs. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to be Held on May&nbsp;2, 2019</B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Notice of 2019 AGM, this proxy statement, the Annual Report on Form&nbsp;10-K, our 2018 U.K. Annual Report and our form of proxy are available in the Investors section of our
website at&nbsp;https://www.adaptimmune.com. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ca44001_questions_and_answers_about_voting"> </A>
<A NAME="toc_ca44001_2"> </A>
<BR></FONT><FONT SIZE=2><B>  QUESTIONS AND ANSWERS ABOUT VOTING    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Why am I receiving these materials?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have sent you this proxy statement and the enclosed form of proxy because you are an ordinary shareholder of record and our Board of
Directors (the "Board") is soliciting your proxy to vote at the Meeting, including at any adjournments or postponements of the Meeting. You are invited to attend the Meeting to vote on the proposals
described in this proxy statement. However, you do not </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=9,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=275518,FOLIO='1',FILE='DISK112:[19ZAF1.19ZAF44001]CA44001A.;10',USER='CHE109569',CD=';1-MAR-2019;12:55' -->
<A NAME="page_ca44001_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>need
to attend the Meeting to vote your shares. Instead, you may simply complete, sign and return the enclosed form of proxy. Alternatively, please submit your proxy online
at&nbsp;www.investorcentre.co.uk/eproxy (see instructions on form of proxy). All proxies, however submitted, must be lodged with our registrar, Computershare, by no later than </FONT> <FONT SIZE=2><B>11:00&nbsp;a.m. London time (6:00&nbsp;a.m.
Eastern Standard Time) on Tuesday, April&nbsp;30, 2019.</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
intend to mail this proxy statement and the accompanying form of proxy on or about March&nbsp;[&nbsp;&nbsp;&nbsp;&nbsp;], 2019 to all ordinary shareholders of record
entitled to vote at the Meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Materials
for ADS holders of record, including this proxy statement, the Annual Report on Form&nbsp;10-K and an ADS proxy card, will be mailed on or about
March&nbsp;[&nbsp;&nbsp;&nbsp;&nbsp;], 2019 to all ADS holders, including banks, brokers and nominees, who are registered as holders of ADSs in the ADS register by 5:00&nbsp;p.m.
Eastern Standard Time on March&nbsp;15, 2019 (the record date for ADS holders). </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Who can vote at the Meeting?  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Ordinary shareholders  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Only ordinary shareholders of record registered in the register of members at 6:30&nbsp;p.m. London time (1:30&nbsp;p.m. Eastern Standard
Time) on Tuesday, April&nbsp;30, 2019 will be entitled to vote at the Meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of March&nbsp;13, 2019 (being the last practicable date before the circulation of this proxy statement) there were [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] ordinary shares issued
and outstanding and entitled to vote. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whether
or not you plan to attend the Meeting, we urge you to fill out and return the enclosed form of proxy to ensure your vote is counted. Alternatively, please submit your proxy
online at&nbsp;www.investorcentre.co.uk/eproxy (see instructions on form of proxy). All proxies, however submitted, must be lodged with our registrar, Computershare, by no later than </FONT> <FONT SIZE=2><B>11:00&nbsp;a.m. London time (6:00&nbsp;a.m.
Eastern Standard Time) on Tuesday, April&nbsp;30, 2019.</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you sell or transfer your ordinary shares in the Company on or prior to April&nbsp;30, 2019, your form of proxy can no longer be used and if submitted (whether before or after you
sell or transfer your ordinary shares) will be treated as invalid. Please pass this document to the person who arranged the sale or transfer for delivery to the purchaser or transferee. The purchaser
or transferee should contact Margaret Henry, Company Secretary, to request a new form of proxy for its use. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Beneficial owners of ordinary shares which are registered in the name of a broker, bank or other agent  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If, on March&nbsp;13, 2019, your ordinary shares were held in an account at a brokerage firm, bank or other similar organization and you are
the beneficial owner of shares, these proxy materials should be forwarded to you by that organization. The organization holding your account is considered the shareholder of record for purposes of
voting at the Meeting. You are encouraged to provide voting instructions to your broker or other agent so that they may submit a proxy. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Holders of American Depositary Shares  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You are entitled to exercise your vote as a holder of an interest in the capital of the Company represented by ADSs if you or your brokerage
firm, bank or nominee is registered as a holder of ADSs in the ADS register </FONT><FONT SIZE=2><B>by 5:00&nbsp;p.m. Eastern Standard Time on Friday, March&nbsp;15, 2019 (the record date for ADS
holders).</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you hold ADSs through a brokerage firm, bank or nominee on March&nbsp;15, 2019, the materials for ADS holders, including the ADS proxy card, will be sent to that organization. The
organization holding your account is considered the ADS holder of record. Please reach out to that organization to provide your voting instructions. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=10,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=533407,FOLIO='2',FILE='DISK112:[19ZAF1.19ZAF44001]CA44001A.;10',USER='CHE109569',CD=';1-MAR-2019;12:55' -->
<A NAME="page_ca44001_1_3"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
note that ADS proxy cards submitted by ADS holders must be received by Citibank, N.A. </FONT><FONT SIZE=2><B>no later than 10:00&nbsp;a.m. Eastern Standard Time on Thursday,
April&nbsp;25, 2019</B></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Citibank,
N.A. will collate all votes properly submitted by ADS holders and submit a vote on behalf of all ADS holders. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Contacts for ADS holders  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you have queries about how you can deliver voting instructions, please contact Citibank, N.A.&#151;ADR Shareholder Services at tel:
+1-877-248-4237 (toll free within the United States) or +1-781-575-4555 (for international callers) or by email: citibank@shareholders-online.com or at&nbsp;Citibank Shareholder Services,
P.O.&nbsp;Box&nbsp;43077, Providence, RI 02940-3077. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
at any point you require guidance, please contact Margaret Henry, Company Secretary, on email: margaret.henry@adaptimmune.com, tel: +44(0)1235 430036 or cell: +44 (0)7710 304249. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What are the requirements to elect the directors and approve each of the proposals?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You may cast your vote for or against proposals 1 through 11 or abstain from voting your shares on one or more of these proposals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proposals
1 through 10 will be proposed as ordinary resolutions. Proposal 11 will be proposed as a special resolution. Under English law, assuming that a quorum is present, an ordinary
resolution is passed on a show of hands if it is approved by a simple majority (more than 50%) of the votes cast by shareholders present (in person or by proxy) at the Meeting and entitled to vote. If
a poll is demanded, an ordinary resolution is passed if it is approved by holders representing a simple majority of the total voting rights of shareholders present (in person or by proxy) who (being
entitled to vote) vote on the resolution. Special resolutions require the affirmative vote of not less than 75% of the votes cast by shareholders present (in person or by proxy) at the Meeting and
entitled to vote. On a poll, a special resolution is passed if it is approved by holders representing not less than 75% of the total voting rights of shareholders present (in person or by proxy) who
(being entitled to vote) vote on the resolution. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
result of the shareholder votes on the ordinary resolutions in proposals 6, 7, 8 and 9 regarding receipt of our U.K. statutory annual accounts and reports for the year ended
December&nbsp;31, 2018, approval of the compensation of our named executive officers for the year ended December&nbsp;31, 2018, advisory votes on the preferred frequency of future votes on
executive compensation and approval of our U.K. statutory directors' annual report on remuneration for the year ended December&nbsp;31, 2018 will not require our Board of Directors or any committee
thereof to take any action. Nonetheless, our Board of Directors values the opinions of our shareholders as expressed through such votes and will carefully consider the outcome of the votes on
proposals 6, 7, 8 and 9. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=11,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=381617,FOLIO='3',FILE='DISK112:[19ZAF1.19ZAF44001]CA44001A.;10',USER='CHE109569',CD=';1-MAR-2019;12:55' -->
<A NAME="page_ca44001_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What are the voting recommendations of our Board regarding the election of directors and other
proposals?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the items that will be brought for a vote of our shareholders at the Meeting, along with the Board's voting
recommendations. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="81pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Proposal

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description of Proposal </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Board's<BR>
Recommendation </B></FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Re-election of John Furey as a director</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Re-election of Ali Behbahani as a director</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR</B></FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Re-election of James Noble as a director</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Re-appointment of KPMG&nbsp;LLP as the Company's auditors, to hold office until the conclusion of the next annual general meeting of shareholders</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR</B></FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Authorization for the Audit Committee to determine our auditors' remuneration for the fiscal year ending December&nbsp;31, 2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>To receive the U.K. statutory annual accounts and reports for the fiscal year ended December&nbsp;31, 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR</B></FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Approval of the compensation of our named executive officers for the year ended December&nbsp;31, 2018, which is set forth in this proxy statement</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Advisory vote on the preferred frequency of future votes on executive compensation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> ANNUALLY</B></FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Approval of our U.K. statutory directors' annual report on remuneration for the year ended December&nbsp;31, 2018, which is set forth in Annex&nbsp;A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Authorization for the Board of Directors to allot shares or to grant rights to subscribe for or convert any security into shares up to a maximum aggregate nominal amount of &pound;207,288.00.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR</B></FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Empowering the Board of Directors to allot equity securities for cash up to a maximum aggregate nominal amount of &pound;157,500.00 pursuant to the authorization in Resolution 10 as if U.K. statutory pre-emption rights
did not apply.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What constitutes a quorum?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For the purposes of the Meeting, a quorum will be present if members holding at least one-third in number of the issued ordinary shares of the
Company and entitled to vote are present in person or represented by proxy at the Meeting. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you are an ordinary shareholder of record, your shares will be counted towards the quorum only if you are present in person or represented by proxy at the Meeting. If you are a
beneficial owner of ordinary shares held in an account at a brokerage firm, bank or other similar organization your shares will be counted towards the quorum if your broker or nominee submits a proxy
for those shares and the proxy represents the holder at the Meeting. A member represented by a proxy at the Meeting will be counted towards the quorum requirement even where the proxy abstains from
voting. If a form of proxy does not instruct the proxy how to vote, the proxy may vote as he or she sees fit or abstain in relation to any business of the Meeting, but the member represented by that
proxy at the Meeting will be counted towards the quorum requirement. If there is no quorum, the Meeting will stand adjourned to such time, date and place as may be fixed by the chairperson of the
Meeting (being not less than 10&nbsp;days later), and, if a quorum is not present at the adjourned meeting, the Meeting will be dissolved. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=12,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=1019478,FOLIO='4',FILE='DISK112:[19ZAF1.19ZAF44001]CA44001A.;10',USER='CHE109569',CD=';1-MAR-2019;12:55' -->
<A NAME="page_ca44001_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How do I vote my shares?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>If you are an ordinary "shareholder of record</I></FONT><FONT SIZE=2>," you may attend the Meeting in person or you may
appoint a proxy to vote on your behalf:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> By completing and signing the form of proxy and returning it in the envelope provided; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> By submitting your proxy online at www.investorcentre.co.uk/eproxy (see instructions on form of proxy). All proxies (however submitted) must be
lodged with our registrar (Computershare) by no later than </FONT><FONT SIZE=2><B>11:00&nbsp;a.m. London time (6:00&nbsp;a.m. Eastern Standard Time) on Tuesday, April&nbsp;30,
2019.</B></FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you properly give instructions as to your proxy appointment by executing and returning a form of proxy, or by submitting your proxy online, and your proxy appointment is not
subsequently revoked, your shares will be voted in accordance with your instructions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>If your ordinary shares are held in an account at a brokerage firm, bank or similar organization,</I></FONT><FONT SIZE=2> you should follow directions provided by
your broker, bank or other nominee. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How will my shares be voted if I do not specify how they should be voted?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you sign and send your form of proxy but do not indicate how you want your shares to be voted, your shares may be voted by the person that
you appoint as your proxy as he or she sees fit or such person may abstain in relation to any business of the Meeting. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Can I change my vote or revoke a proxy?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A registered shareholder can revoke his or her proxy before the time of voting at the Meeting in several ways by: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>mailing
a revised form of proxy dated later than the prior form of proxy;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>voting
in person at the Meeting; or
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>notifying
our Company Secretary in writing that you are revoking your proxy. Your revocation must be received at our registered office before the Meeting to be
effective. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
your ordinary shares are held in an account at a brokerage firm, bank or similar organization, you may change or revoke your voting instructions by contacting the broker, bank or
other nominee holding the shares or by your broker, bank or other nominee validly appointing you as proxy to attend at the Meeting. See also "What if I plan to attend the Meeting?" </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Who counts the votes?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Computershare Investor Services&nbsp;PLC ("Computershare") has been engaged as our independent agent to tabulate shareholder votes. If you are
an ordinary shareholder of record, you can return your executed form of proxy to Computershare for tabulation or directly submit your proxy online to Computershare at www.investorcentre.co.uk/eproxy
(see instructions on form of proxy). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you hold your ordinary shares through a broker, your broker will return the form of proxy to Computershare or directly submit your proxy to Computershare online. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you are a holder of record of ADSs, you can return your executed ADS proxy card to Citibank, N.A. for tabulation. If you hold your ADSs through a broker, bank or other organization,
that organization can return the ADS proxy card to Citibank, N.A. following your instruction. Citibank, N.A. will submit your votes to Computershare for tabulation. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=13,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=378949,FOLIO='5',FILE='DISK112:[19ZAF1.19ZAF44001]CA44001A.;10',USER='CHE109569',CD=';1-MAR-2019;12:55' -->
<A NAME="page_ca44001_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How are votes counted?  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Votes will be counted by Computershare, who will separately count "for" and "against" votes, and "votes withheld" or abstentions. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How many votes do I have?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On a show of hands, each ordinary shareholder of record present in person, and each duly authorised representative present in person of a
shareholder that is a corporation, has one vote. On a show of hands, each proxy present in person who has been duly appointed by one or more shareholders has one vote, but a proxy has one vote for and
one vote against a resolution if, in certain circumstances, the proxy is instructed by more than one shareholder to vote in different ways on a resolution. On a poll, each shareholder present in
person or by proxy or (being a corporation) by a duly authorised representative has one vote for each share held by the shareholder. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What if I plan to attend the Meeting?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Attendance at the Meeting will be limited to ordinary shareholders of record as of 6:30&nbsp;p.m. London time (1:30&nbsp;p.m. Eastern
Standard Time) on Tuesday, April&nbsp;30, 2019. In order to obtain admittance to the Meeting each shareholder may be asked to present valid picture identification, such as a driver's license or
passport. If your ordinary shares are held through brokerage accounts or by a bank or other nominee you may be able to attend at the discretion of the Chairman. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How do you solicit proxies?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will solicit proxies and will bear the entire cost of this solicitation. The initial solicitation of proxies may be supplemented by
additional mail communications and by telephone, fax, e-mail, internet and personal solicitation by our directors, officers or other employees. No additional
compensation for soliciting proxies will be paid to our directors, officers or other employees for their proxy solicitation efforts. We also reimburse Citibank, N.A. for their expenses in sending
materials, including ADS proxy cards, to ADS holders of record. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What do I do if I receive more than one notice or form of proxy?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you hold your ordinary shares in more than one account, you will receive a form of proxy for each account. To ensure that all of your shares
are voted, please sign, date and return all forms of proxy. Please be sure to vote all of your shares. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Will there be any other business conducted at the Meeting?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No. In accordance with our Articles of Association, no matters other than proposals 1 through 11 may be presented at this Meeting. We have not
been notified of, and our Board is not aware of, any other matters to be presented for action at the Meeting. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What is Computershare's role?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Computershare is our registrar. All communications concerning ordinary shareholder of record accounts, including address changes, name changes,
ordinary share transfer requirements and similar issues can be handled by contacting Computershare at tel: +44 (0)&nbsp;370&nbsp;702 0000 or by writing to Computershare Investor
Services&nbsp;PLC, The Pavilions, Bridgwater Road, Bristol, BS99&nbsp;6ZY, England. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Communications
concerning ADS holder of record accounts can be handled by contacting Citibank, N.A.&#151;ADR Shareholder Services at tel: +1-877-248-4237 (toll free within the
United States) or +1-781-575-4555 (for international callers) or by email: citibank@shareholders-online.com or at Citibank Shareholder Services, P.O.&nbsp;Box&nbsp;43077, Providence, RI
02940-3077. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=14,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=278247,FOLIO='6',FILE='DISK112:[19ZAF1.19ZAF44001]CA44001A.;10',USER='CHE109569',CD=';1-MAR-2019;12:55' -->
<A NAME="page_ca44001_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How can I find out the results of the voting at the Meeting?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Voting results will be announced by the filing of a current report on Form&nbsp;8-K within four business days after the Meeting. If final
voting results are unavailable at that time, we will file an amended current report on Form&nbsp;8-K within four business days of the day the final results are available. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Directions to Meeting  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Directions to our Meeting, which is to be held at 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14&nbsp;4RX, are available at:
https://www.adaptimmune.com </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=15,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=125487,FOLIO='7',FILE='DISK112:[19ZAF1.19ZAF44001]CA44001A.;10',USER='CHE109569',CD=';1-MAR-2019;12:55' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_cc44001_1_8"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="cc44001_election_of_directors"> </A>
<A NAME="toc_cc44001_1"> </A>
<BR></FONT><FONT SIZE=2><B>  ELECTION OF DIRECTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors currently consists of nine directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Articles of Association require that those directors who were appointed since our 2018 Annual General Meeting must retire from office and offer themselves for re-election.
Accordingly, Mr.&nbsp;John Furey will retire from office and offer himself for re-election by our shareholders at the 2019 AGM. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
our Articles of Association require one-third (or such number nearest to but not exceeding one-third) of our directors who are subject to retirement by rotation to retire
from office at each annual general meeting effective from the 2016 Annual General Meeting, commencing with the longest-serving directors. In the case of equal tenure, retirement is by agreement. Of
the eight directors
subject to retirement by rotation, Dr.&nbsp;Ali Behbahani and Mr.&nbsp;James Noble will, on this occasion, retire from office and stand for re-election by our shareholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Having
carried out an evaluation of the individual performance of each of Mr.&nbsp;Furey, Dr.&nbsp;Behbahani and Mr.&nbsp;Noble with the support of the Corporate Governance and
Nominating Committee, the Board is satisfied that their performance continues to be effective and that they continue to demonstrate commitment to their roles. The Board considers that it is entirely
appropriate for each of Mr.&nbsp;Furey, Dr.&nbsp;Behbahani and Mr.&nbsp;Noble to seek re-election at the AGM. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
of the above directors has been nominated for re-election and no other nominees for directors have been presented. Therefore, it is anticipated that following the AGM, if all of the
above directors are re-elected, the Board of Directors will be comprised of nine members. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with proposals 1 through 3, we set forth the biographical information for the nominees to our Board of Directors. For biographical information for the other directors see </FONT> <FONT SIZE=2><I>Board of Directors and Corporate
Governance</I></FONT><FONT SIZE=2>. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=16,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=684529,FOLIO='8',FILE='DISK112:[19ZAF1.19ZAF44001]CC44001A.;13',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_cc44001_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="cc44001_proposal_1_#151;re-election_of__pro02335"> </A>
<A NAME="toc_cc44001_2"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL 1&#151;RE-ELECTION OF JOHN FUREY TO THE BOARD OF DIRECTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;John Furey is currently a member of our Board of Directors and has been nominated for re-election as a director. If elected, he will
hold office from the date of his election until the next annual general meeting of shareholders where he must retire by rotation and offer himself for re-election, or until his earlier death,
resignation or removal. Mr.&nbsp;Furey has agreed to serve if elected, and we have no reason to believe that he will be unable to serve. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Furey,
54, has served as a Non-Executive Director since July 2018 and also serves as a member of our Remuneration Committee. He has 25&nbsp;years of experience of developing
and implementing operational strategies and leading commercial and technical teams. Mr.&nbsp;Furey served as Chief Operating Officer at Spark Therapeutics, Inc from December&nbsp;1, 2016 through
December&nbsp;31, 2018, where he was responsible for global commercial operations, medical affairs, technology development and technical
operations, and is continuing to provide consulting services to Spark Therapeutics through June&nbsp;28, 2019 to assist with the transition of his responsibilities. Prior to joining Spark
Therapeutics, Mr.&nbsp;Furey was senior vice president and head of global operations for Baxalta, where he directed manufacturing, quality, engineering, and process development. He actively managed
a $2.5&nbsp;billion production budget across Baxalta's global network and led a first-in-class supply chain organization for rare diseases. Mr.&nbsp;Furey led the team that coordinated and
delivered the successful establishment of Baxalta through a spin out from Baxter and led the Baxter Vaccine inline business to realize significant top line and bottom line growth. He also spent two
years in China as general manager of Pfizer's vaccine business unit following a role with responsibility for global pricing and reimbursement at Pfizer Vaccines. In these roles, Mr.&nbsp;Furey
gained extensive experience in pipeline development and global product launches. Earlier in his career, he held both commercial and operations positions of increasing scope and responsibility with
Pfizer and Wyeth Pharmaceuticals. Mr.&nbsp;Furey has an executive M.B.A. from St.&nbsp;Joseph's University, Philadelphia, a B.S. from Trinity College, Dublin, and a diploma in Environmental Health
from the Dublin Institute of Technology. Our Board of Directors believes Mr.&nbsp;Furey's qualifications to serve as a member of our board include his extensive experience in the biopharmaceutical
industry and his years of experience in his leadership roles as an executive officer. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on his extensive experience as a senior executive in the pharmaceutical and healthcare sectors, the Corporate Governance and Nominating Committee concluded that Mr.&nbsp;Furey is
qualified to serve on our Board of Directors. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><I>THE BOARD OF DIRECTORS RECOMMENDS A VOTE<BR>
<U>FOR</U> THE RE-ELECTION OF JOHN FUREY TO THE BOARD OF DIRECTORS</I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=17,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=969720,FOLIO='9',FILE='DISK112:[19ZAF1.19ZAF44001]CC44001A.;13',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_cc44001_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="cc44001_proposal_2_#151;re-election_of__pro02379"> </A>
<A NAME="toc_cc44001_3"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL 2&#151;RE-ELECTION OF ALI BEHBAHANI TO THE BOARD OF DIRECTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Ali Behbahani is currently a member of our Board of Directors and has been nominated for re-election as a director. If elected, he
will hold office from the date of his election until the next annual general meeting of shareholders where he must retire by rotation and offer himself for re-election, or until his earlier death,
resignation or removal. Dr.&nbsp;Behbahani has agreed to serve if elected, and we have no reason to believe that he will be unable to serve. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Behbahani,
42, has served as a Non-Executive Director since February 2015 and also serves as a member of our Corporate Governance and Nominating Committee. He formerly served
as a Non-Executive Director of Adaptimmune Limited since September 2014, initially in a capacity as a nominee of NEA, one of our shareholders. Dr.&nbsp;Behbahani has been a General Partner on the
healthcare team at NEA since 2018, having worked for the fund since 2007, specializing in investments in the biopharmaceutical, medical device, specialty pharmaceutical and healthcare services
sectors. He is currently a board member of public companies Nevro Corp (NYSE: NVRO), Genocea (NASDAQ: GNCA) and CRISPR Therapeutics AG (NASDAQ: CRSP) and also serves as a director for several private
companies, including Oyster Point Pharma,&nbsp;Inc., Minerva Surgical,&nbsp;Inc. and Nkarta,&nbsp;Inc. He has previously worked as a consultant in business development at The Medicines Company
and held positions as a Venture Associate at Morgan Stanley Venture Partners from 2000 to 2002 and as a Healthcare Investment Banking Analyst at Lehman Brothers from 1998 to 2000. Dr.&nbsp;Behbahani
conducted basic science research in the fields of viral fusion inhibition and structural proteomics at the National Institutes of Health and at Duke University. He holds an M.D. degree from The
University of Pennsylvania School of Medicine and an M.B.A. from The University of Pennsylvania Wharton School. Our Board of Directors believes Dr.&nbsp;Behbahani's qualifications to serve as a
member of our board include his financial expertise, his experience as a venture capital investor, his extensive experience in the healthcare industry and his years of experience in his leadership
roles as a director and executive officer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on his extensive experience as a senior executive and board member in the pharmaceutical and healthcare sectors, the Corporate Governance and Nominating Committee concluded that
Dr.&nbsp;Behbahani is qualified to serve on our Board of Directors. Dr.&nbsp;Behbahani recused himself from the Corporate Governance and Nominating Committee's deliberations concerning his
nomination. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><I>THE BOARD OF DIRECTORS RECOMMENDS A VOTE<BR>
<U>FOR</U> THE RE-ELECTION OF ALI BEHBAHANI TO THE BOARD OF DIRECTORS</I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=18,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=18275,FOLIO='10',FILE='DISK112:[19ZAF1.19ZAF44001]CC44001A.;13',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_cc44001_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="cc44001_proposal_3_#151;re-election_of__pro02342"> </A>
<A NAME="toc_cc44001_4"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL 3&#151;RE-ELECTION OF JAMES NOBLE TO THE BOARD OF DIRECTORS    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;James Noble is currently a member of our Board of Directors and has been nominated for re-election as a director. If elected, he will
hold office from the date of his election until the next annual general meeting of shareholders where he must retire by rotation and offer himself for re-election, or until his earlier death,
resignation or removal. Mr.Noble has agreed to serve if elected, and we have no reason to believe that he will be unable to serve. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Noble,
59, as served as our full-time Chief Executive Officer since March 2014, and part-time CEO from July 2008 to March 2014, and is one of our co-founders. From July 2008
until March 2014, Mr.&nbsp;Noble was also CEO of Immunocore. Mr.&nbsp;Noble has 28&nbsp;years of experience in the biotech industry. He has held numerous non-executive director positions,
including at CuraGen Corporation, PowderJect Pharmaceuticals&nbsp;plc, Oxford GlycoSciences&nbsp;plc, MediGene AG, and Advanced Medical Solutions&nbsp;plc. Mr.&nbsp;Noble is also Deputy
Chairman of GW Pharmaceuticals&nbsp;plc (NASDAQ: GWPH). Mr.&nbsp;Noble qualified as a chartered accountant with Price Waterhouse and spent seven years at the investment bank Kleinwort Benson
Limited, where he became a director in 1990. He then joined British Biotech&nbsp;plc as Chief Financial Officer from 1990 to 1997. Mr.&nbsp;Noble was previously Chief Executive Officer of Avidex
Limited, a privately held biotechnology company that was our predecessor, from 2000 to 2006. Mr.&nbsp;Noble holds an M.A. from the University of Oxford. Our Board of Directors believes
Mr.&nbsp;Noble's qualifications to serve as a member of our board include his financial expertise, his extensive experience in the biopharmaceutical industry and his years of experience in his
leadership roles as a director and executive officer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on his extensive experience as a senior executive and board member in the biotechnology, pharmaceutical and healthcare sectors, the Corporate Governance and Nominating Committee
concluded that Mr.&nbsp;Noble is qualified to serve on our Board of Directors. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><I>THE BOARD OF DIRECTORS RECOMMENDS A VOTE<BR>
<U>FOR</U> THE RE-ELECTION OF JAMES NOBLE TO THE BOARD OF DIRECTORS  </I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=19,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=483781,FOLIO='11',FILE='DISK112:[19ZAF1.19ZAF44001]CC44001A.;13',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_cc44001_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><I> <A NAME="cc44001_proposal_4_#151;re-appointment__pro05509"> </A>
<A NAME="toc_cc44001_5"> </A>
<BR>    </I></B></FONT><FONT SIZE=2><B>  PROPOSAL 4&#151;RE-APPOINTMENT OF KPMG&nbsp;LLP AS OUR AUDITORS, TO HOLD OFFICE UNTIL THE CONCLUSION OF THE NEXT ANNUAL GENERAL MEETING OF SHAREHOLDERS    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proposal 4 seeks your approval of the re-appointment of KPMG&nbsp;LLP to serve as our auditor, to hold office until the conclusion of the next
annual general meeting of shareholders. In the event this proposal does not receive the affirmative vote of the holders of a majority of the shares entitled to vote and who are present in person or
represented by proxy at the Meeting, the Board of Directors may appoint an auditor to fill the vacancy. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Background to Proposal 4  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Audit Committee has selected KPMG&nbsp;LLP ("KPMG") as our independent registered public accounting firm for the fiscal year ending
December&nbsp;31, 2019, and has further directed that we submit the selection of KPMG for approval by our shareholders at the Meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee approves KPMG's and its affiliates audit and non-audit services in advance as required under Sarbanes-Oxley and SEC rules. Before the commencement of each fiscal
year, the Audit Committee appoints the independent auditor to perform audit services that we expect to be performed for the fiscal year and appoints the auditor to perform audit-related, tax and other
permitted non-audit services. In addition, our Audit Committee approves the terms of the engagement letter to be entered into by us with the independent auditor. The Audit Committee has also delegated
to its chairman the authority, from time to time, to pre-approve audit-related and non-audit services not prohibited by law to be performed by our independent auditors and associated fees, provided
that the chairman shall report any decisions to pre-approve such audit-related and non-audit services and fees to our full Audit Committee at its next regular meeting. Additional information
concerning the Audit Committee and its activities can be found in the following sections of this proxy statement: "</FONT><FONT SIZE=2><I>Board Committees</I></FONT><FONT SIZE=2>" and
"</FONT><FONT SIZE=2><I>Report of the Audit Committee</I></FONT><FONT SIZE=2>." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;KPMG
commenced auditing our annual financial statements with the fiscal year 2010. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Fees for Independent Registered Public Accounting Firm&#151;KPMG  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The table below sets forth a summary of the fees billed to the Company by KPMG for professional services rendered for the fiscal years ended
December&nbsp;31, 2018 and December&nbsp;31, 2017. All such audit and audit-related services were pre-approved by the Audit Committee, which concluded that the provision of such services by KPMG
was compatible with the maintenance of that firm's independence in the conduct of its auditing functions. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Fees

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, 2018<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, 2017<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit Fees(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>589,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>193,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit-related Fees(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>172,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>110,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tax Fees(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All Other Fees(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B> 771,000</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>309,000</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Audit
Fees consist of fees billed for the audit of our annual consolidated financial statements
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Audit-related
Fees consist of fees billed for the review of our interim consolidated financial statements and related services that are normally provided in
connection with registration statements. Included in the 2018 fees are fees billed in connection with our S-3 filing. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=20,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=943718,FOLIO='12',FILE='DISK112:[19ZAF1.19ZAF44001]CC44001A.;13',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_cc44001_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Tax
Fees consist of fees for professional services, including tax consulting and compliance. There were no such fees incurred in 2018 or 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>All
Other Fees incurred were $10,000 in 2018 and $6,000 in 2017.  </FONT></DD></DL>
 </DIV>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><I>THE BOARD OF DIRECTORS RECOMMENDS A VOTE<BR>
<U>FOR</U> THE RE-APPOINTMENT OF KPMG&nbsp;LLP AS OUR AUDITORS, TO HOLD OFFICE UNTIL THE<BR>
CONCLUSION OF THE NEXT ANNUAL GENERAL MEETING OF SHAREHOLDERS</I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=21,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=532724,FOLIO='13',FILE='DISK112:[19ZAF1.19ZAF44001]CC44001A.;13',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_cc44001_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="cc44001_proposal_5_#151;authorization___pro04875"> </A>
<A NAME="toc_cc44001_6"> </A>
<BR>  PROPOSAL 5&#151;AUTHORIZATION FOR THE AUDIT COMMITTEE TO DETERMINE THE AUDITORS' REMUNERATION FOR THE FISCAL YEAR ENDING DECEMBER 31, 2019    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proposal 5 authorizes the Audit Committee to determine our auditors' remuneration for the fiscal year ending December&nbsp;31, 2019. Fees for
KPMG, our independent registered public accounting firm and U.K. statutory auditors, in respect of the years ended December&nbsp;31, 2018 and December&nbsp;31, 2017, are set forth in Proposal 4
above. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><I>THE BOARD OF DIRECTORS RECOMMENDS A VOTE<BR>
<U>FOR</U> THE AUTHORIZATION OF OUR AUDIT COMMITTEE TO DETERMINE OUR AUDITORS'<BR>
REMUNERATION FOR THE FISCAL YEAR ENDING DECEMBER 31, 2019</I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=22,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=119334,FOLIO='14',FILE='DISK112:[19ZAF1.19ZAF44001]CC44001A.;13',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_cc44001_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="cc44001_proposal_6_#151;resolution_to___pro03505"> </A>
<A NAME="toc_cc44001_7"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL 6&#151;RESOLUTION TO RECEIVE THE COMPANY'S U.K. STATUTORY ANNUAL<BR>  ACCOUNTS AND REPORTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At the Meeting, our Board of Directors will present our U.K. statutory annual accounts and reports for the period January&nbsp;1, 2018 through
December&nbsp;31, 2018, which includes the audited portion of the directors' annual report on remuneration. We will provide our shareholders with an opportunity to receive the U.K. statutory annual
accounts and reports and to raise questions in relation to them. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><I>THE BOARD OF DIRECTORS RECOMMENDS A VOTE<BR>
<U>FOR</U> THE RESOLUTION TO RECEIVE THE COMPANY'S U.K. STATUTORY ANNUAL ACCOUNTS AND<BR>
REPORTS  </I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=23,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=946850,FOLIO='15',FILE='DISK112:[19ZAF1.19ZAF44001]CC44001A.;13',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_cc44001_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="PRO7"></A>PROPOSAL 7&#151;ADVISORY (NON-BINDING) VOTE TO APPROVE THE COMPANY'S EXECUTIVE COMPENSATION  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Dodd-Frank Wall Street Reform and Consumer Protection Act, as amended, and Section&nbsp;14A of the Securities Exchange Act of 1934, as
amended (the "Exchange Act") enable our shareholders to approve, on an advisory, non-binding basis, the compensation of our named executive officers as disclosed under the "Compensation Discussion and
Analysis" section, the 2018 Summary Compensation Table and the related compensation tables, notes, and narrative in this proxy statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
proposal, known as a "Say-on-Pay" proposal, gives our shareholders the opportunity to express their views on our named executive officers' compensation as a whole. This vote is not
intended to address any specific item of compensation or any specific named executive officer, but rather the overall compensation of all of our named executive officers and the philosophy, policies
and practices described in this proxy statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
compensation programs are designed to support our business goals and promote our long-term profitable growth. Our equity plans are intended to align compensation with the long-term
interests of our shareholders. We urge shareholders to read the "Compensation Discussion and Analysis", which describes in more detail how our executive compensation policies and procedures operate
and are designed to achieve our compensation objectives. We also encourage you to review the 2018 Summary Compensation Table and other related compensation tables and narratives, which provide
detailed information on the compensation of our named executive officers. The Board and the Remuneration Committee believe that the policies and procedures described and explained in the "Compensation
Discussion&nbsp;&amp; Analysis" are effective in achieving our goals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
vote under this Proposal No.&nbsp;7 is advisory, and therefore not binding on the Company, the Board or our Remuneration Committee. However, our Board of Directors and Remuneration
Committee values the opinions of our shareholders and will review and consider the voting results when making future decisions regarding our executive compensation program. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shareholders
will be asked at the Meeting to approve the following resolution pursuant to this Proposal No.&nbsp;7: </FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>"</FONT><FONT
SIZE=2><B>RESOLVED</B></FONT><FONT SIZE=2>, that the shareholders of the Company approve, on a non-binding, advisory basis, the compensation of the Company's "named executive officers,"
as disclosed in this proxy statement under the "Compensation Discussion and Analysis" section, the compensation tables and the narrative disclosures that accompany the compensation tables." </FONT></P>

</UL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><I>THE BOARD RECOMMENDS YOU VOTE<BR>
<U>FOR</U> APPROVAL OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS<BR>
SET FORTH IN THIS PROXY STATEMENT</I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=24,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=296208,FOLIO='16',FILE='DISK112:[19ZAF1.19ZAF44001]CC44001A.;13',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_cc44001_1_17"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="PRO8"></A>PROPOSAL 8&#151;ADVISORY VOTE ON THE FREQUENCY OF FUTURE VOTES ON EXECUTIVE COMPENSATION  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Dodd-Frank Wall Street Reform and Consumer Protection Act, as amended, enables our shareholders to indicate, at least once every six years,
how frequently we should seek a non-binding vote on the compensation of our named executive officers, as disclosed pursuant to the SEC's compensation disclosure rules. By voting on this Proposal
No.&nbsp;8, shareholders may indicate whether they would prefer a non-binding vote on named executive officer compensation once every one, two, or three years. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board believes that it is appropriate to give our shareholders the opportunity to provide regular input on our executive compensation program though an advisory vote. Accordingly,
our Board recommends that you vote to hold an advisory vote on executive compensation every year. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
understand that our shareholders may have different views as to what is the best approach for the Company, and we look forward to hearing from our shareholders on this Proposal. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
may cast your vote on your preferred voting frequency by choosing the option of one year, two years, three years, or abstain from voting when you vote in response to the resolution
set forth below: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><B>RESOLVED</B></FONT><FONT SIZE=2>, that the option of once every one year, two years, or three years that receives the highest number of votes cast for this
resolution will be determined to be the preferred frequency with which the Company is to hold a shareholder vote to approve the compensation of the named executive officers, as disclosed pursuant to
the compensation disclosure rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis, the compensation tables, and the other related disclosure." </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
option of one year, two years, or three years that receives the highest number of votes cast by shareholders will be the frequency for the advisory vote on executive compensation
that has been selected by shareholders. However, because this vote is advisory and not binding on the Company, our Remuneration Committee, or our Board in any way, we may decide that it is in the best
interests of our shareholders and the Company to hold an advisory vote on executive compensation more or less frequently than the vote frequency approved by our shareholders. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><I>THE BOARD OF DIRECTORS RECOMMENDS YOU VOTE<BR>
<U>FOR</U> THE PROPOSAL THAT THE ADVISORY VOTE ON COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS OCCUR ANNUALLY  </I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>

<!-- ZEQ.=10,SEQ=25,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=459492,FOLIO='17',FILE='DISK112:[19ZAF1.19ZAF44001]CC44001A.;13',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_cc44001_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><I> <A NAME="cc44001_proposal_9_#151;approval_of_ou__pro03238"> </A>
<A NAME="toc_cc44001_8"> </A>
<BR>    </I></B></FONT><FONT SIZE=2><B>  PROPOSAL 9&#151;APPROVAL OF OUR U.K. STATUTORY DIRECTORS' ANNUAL REPORT ON REMUNERATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our U.K. statutory directors' remuneration report is set forth as </FONT><FONT SIZE=2><I>Annex&nbsp;A</I></FONT><FONT SIZE=2> to this proxy
statement. The directors' remuneration report includes the annual report on remuneration. This document describes in detail our remuneration policies and procedures and explains how these policies and
procedures help to achieve our compensation objectives with regard to our directors and the retention of high-quality directors. Our Board of Directors and the Remuneration Committee believe that the
policies and procedures as articulated in the directors' remuneration report are effective and
that as a result of these policies and procedures we have and will continue to have high-quality directors. Our Board of Directors has approved and signed the report in accordance with English law. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the Meeting, the shareholders will vote on the annual report on remuneration. This vote is advisory and non-binding. Although non-binding, our Board of Directors and Remuneration
Committee will review and consider the voting results when making future decisions regarding our director remuneration program. Following the Meeting, and as required under English law, the directors'
annual report on remuneration will be delivered to the U.K. Registrar of Companies. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><I>THE BOARD RECOMMENDS YOU VOTE<BR>
<U>FOR</U> APPROVAL OF OUR U.K. STATUTORY DIRECTORS' ANNUAL REPORT ON REMUNERATION<BR>
SET FORTH IN ANNEX A  </I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=26,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=646273,FOLIO='18',FILE='DISK112:[19ZAF1.19ZAF44001]CC44001A.;13',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ce44001_1_19"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ce44001_background_to_proposals_10_and_11"> </A>
<A NAME="toc_ce44001_1"> </A>
<BR></FONT><FONT SIZE=2><B>  BACKGROUND TO PROPOSALS 10 AND 11    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the U.K. Companies Act 2006, our Board of Directors may only allot shares or grant rights over shares if authorized to do so by our
shareholders. If so authorized, the U.K. Companies Act 2006 requires us, where the allotment is for cash, to offer them in the first instance to our existing shareholders in proportion to their
holdings, unless the shareholders have sanctioned the disapplication of their statutory rights of pre-emption in respect of such allotment or grant of rights. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board of Directors anticipates that there may be occasions when they need flexibility to finance business opportunities and growth, or otherwise act in the best interests of the
Company, by the issuance of shares or grant of rights over shares without a pre-emptive offer to existing shareholders. To ensure our continued ability to respond to market conditions and address
business needs, our Board of Directors considers it appropriate that they be authorized to allot shares up to an aggregate nominal amount of &pound;207,288.00 and within this amount be empowered
to allot shares or grant rights over shares up to an aggregate nominal amount of &pound;157,500.00 on a
non-pre-emptive basis. This authority to allot shares and power to allot shares on a non-pre-emptive basis will replace all of the existing authorities and powers granted by our shareholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
proposals are fully compliant with U.K. company law, consistent with U.S. capital markets practice and governance standards, and if approved, will keep us on an equal footing with
our peer companies who are incorporated in the U.S.A. We are asking you to approve these proposals to allow us to continue to execute on our business and growth strategy in a timely and competitive
manner. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
full details of the proposals are set forth below. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=27,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=94277,FOLIO='19',FILE='DISK112:[19ZAF1.19ZAF44001]CE44001A.;7',USER='CHE109569',CD=';1-MAR-2019;12:02' -->
<A NAME="page_ce44001_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ce44001_proposal_10_#151;autho__ce401844"> </A>
<A NAME="toc_ce44001_2"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL 10&#151;AUTHORIZATION OF ALLOTMENT OF SHARES    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the U.K. Companies Act 2006, our Board of Directors cannot allot shares in the Company (other than pursuant to an employee share scheme)
unless they are authorized to do so by the Company in general meeting. The Directors currently have an existing authority to allot shares in the Company and to grant rights to subscribe for or convert
securities into shares in the Company. This authority was granted to the Directors on June&nbsp;21, 2017 and was in respect of a maximum aggregate nominal amount of &pound;140,000.00, which
represented approximately 25% of the then issued ordinary share capital of the Company, and it remains unexercised in respect of approximately 11% of the Company's issued ordinary share capital.
Resolution 10 is an ordinary resolution to seek a new authority, which will replace the existing authority. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Resolution
10 proposes that the Directors are granted authority to allot new shares or to grant rights to subscribe for or to convert any security into shares in the Company up to a
maximum aggregate nominal amount of &pound;207,288.00. This amount represents approximately [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]% of the issued share capital of the Company as of
March&nbsp;13, 2019. If approved by shareholders, this authority will run for five years and will expire on May&nbsp;1, 2024. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Directors have no present intention of exercising this authority, except in relation to the Company's share incentive schemes, but believe it is in the interests of shareholders for
the Directors
to have this flexibility to allot shares otherwise than just in relation to the Company's share incentive schemes should circumstances and their intentions change. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE</B></FONT><BR><FONT SIZE=2><B><I><U>FOR</U></I></B></FONT><FONT SIZE=2><B> THE APPROVAL OF PROPOSAL 10</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=28,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=234164,FOLIO='20',FILE='DISK112:[19ZAF1.19ZAF44001]CE44001A.;7',USER='CHE109569',CD=';1-MAR-2019;12:02' -->
<A NAME="page_ce44001_1_21"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ce44001_proposal_11_#151;disap__ce401775"> </A>
<A NAME="toc_ce44001_3"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL 11&#151;DISAPPLICATION OF PRE-EMPTION RIGHTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Resolution seeks a disapplication of pre-emption rights for cash issues of up to a certain proportion of the Company's issued ordinary
share capital. Our Board of Directors currently has a power to allot shares as if the rights of pre-emption applicable under the U.K. Companies Act did not apply for cash issues. This power was
granted to the Directors pursuant to shareholder resolutions passed on June&nbsp;21, 2017 and was in respect of a maximum aggregate nominal amount of &pound;140,000.00, which represented
approximately 25% of the then issued ordinary share capital of the Company, and it remains unexercised in respect of approximately 11% of the Company's issued ordinary share capital. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Directors have decided to seek a new disapplication of pre-emption rights for cash issues to replace the existing power. This Resolution will, if passed, give the Directors power,
pursuant to the authority to allot granted by Resolution 10, to allot shares for cash or to grant rights to subscribe for or to convert any security into shares without first offering them to existing
shareholders in proportion to their existing holdings up to an aggregate maximum nominal amount of &pound;157,500.00, which represents approximately [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]% of
the Company's issued share capital as of March&nbsp;13, 2019. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Resolution will be required to be passed as a special resolution and, if passed, this power will expire at the end of the AGM of the Company to be held in 2021. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Directors have no present intention of exercising this power, except in relation to the Company's share incentive schemes, but believe it is in the interests of shareholders for the
Directors to have this flexibility to allot shares for cash otherwise than just in relation to the Company's share incentive schemes should circumstances and their intentions change. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE</B></FONT><BR><FONT SIZE=2><B><I><U>FOR</U></I></B></FONT><FONT SIZE=2><B> THE APPROVAL OF PROPOSAL 11  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=29,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=821290,FOLIO='21',FILE='DISK112:[19ZAF1.19ZAF44001]CE44001A.;7',USER='CHE109569',CD=';1-MAR-2019;12:02' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_cg44001_1_22"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="cg44001_board_of_directors_and_corporate_governance"> </A>
<A NAME="toc_cg44001_1"> </A>
<BR></FONT><FONT SIZE=2><B>  BOARD OF DIRECTORS AND CORPORATE GOVERNANCE    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


BOARD OF DIRECTORS  </B></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Below is a list of our Directors and their ages as of the date of this proxy statement. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="210pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Position </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>David M. Mott</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>53</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chairman of the Board of Directors</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Lawrence M. Alleva</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>69</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Non-Executive Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Ali Behbahani, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>42</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Non-Executive Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Barbara Duncan</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>54</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Non-Executive Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>John Furey</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>54</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Non-Executive Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Giles Kerr.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>59</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Non-Executive Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Elliott Sigal, Ph.D, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>67</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Non-Executive Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Tal Zaks, Ph.D, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>53</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Non-Executive Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>James Noble</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>59</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Executive Officer and Director</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the year ended December&nbsp;31, 2018, there were six full meetings of our Board of Directors. All of our then Directors attended a minimum of 75% of the aggregate of the
meetings of the Board of Directors and meetings of the committees of which he or she was a member during 2018, with the exception of Dr.&nbsp;Tal Zaks who attended 64% of the meetings.
Dr.&nbsp;Zaks had to give apologies for Board and Remuneration Committee meetings in December 2018, due to a clash with the launch of the IPO of Moderna Inc, of which he is Chief Medical Officer,
but he reviewed the Board and Committee papers in advance and provided feedback to the meetings through the chairman. Mr.&nbsp;Furey was appointed to the Board of Directors and the Remuneration
Committee effective from July&nbsp;5, 2018 and attended 100% of the meetings of the Board of Directors and of the Remuneration Committee from his appointment date through to the end of 2018.
Effective July&nbsp;5, 2018, Peter Thompson, M.D., Ph.D stepped down as a member of the Board of Directors. During his service as a director in 2018, Dr.&nbsp;Thompson attended over 75% of the
meetings of the Board of Directors and of the Remuneration Committee prior to July&nbsp;5, 2018. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
biographical information for John Furey, Ali Behbahani and James Noble, the nominees to our Board of Directors, is provided in "Proposal 1&#151;Re-Election of John Furey to
the Board of Directors", "Proposal 2&#151;Re-Election of Ali Behbahani to the Board of Directors" and "Proposal 3&#151;Re-Election of James Noble to the Board of Directors" respectively. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Below
is biographical information for those directors who are not standing for re-election at this Meeting and who will remain seated following the Meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>David M. Mott</I></FONT><FONT SIZE=2> has served as our Chairman since January 2017 and as a Non-Executive Director since February 2015. He also serves as
Chairman of our Remuneration Committee and of our Corporate Governance and Nominating Committee. He formerly served as a Non-Executive Director of Adaptimmune Limited since September 2014, initially
in a capacity as a nominee of New Enterprise Associates ("NEA"), one of our shareholders. Mr.&nbsp;Mott has served as a General Partner of NEA, an investment firm focused on venture capital and
growth equity investments, since 2008, and leads its healthcare investing practice. Prior to joining NEA, he was President and Chief Executive Officer of MedImmune Limited, a subsidiary of
AstraZeneca&nbsp;Plc, and Executive Vice President of AstraZeneca. From 1992 to 2008, Mr.&nbsp;Mott worked at MedImmune and served in roles including Chief Operating Officer, Chief Financial
Officer, President and Chief Executive Officer. Prior to joining MedImmune, Mr.&nbsp;Mott was Vice President in the Health Care Investment Banking Group at Smith Barney, Harris
Upham&nbsp;&amp;&nbsp;Co.,&nbsp;Inc. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=30,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=896724,FOLIO='22',FILE='DISK112:[19ZAF1.19ZAF44001]CG44001A.;7',USER='CHE107322',CD=';1-MAR-2019;12:53' -->
<A NAME="page_cg44001_1_23"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Mott
is currently Chairman of Ardelyx,&nbsp;Inc. (NASDAQ: ARDX), Epizyme,&nbsp;Inc. (NASDAQ: EPZM) and Mersana Therapeutics, Inc, (NASDAQ: MRSN), and is a director of
Nightstar Therapeutics&nbsp;plc (NASDAQ: NITE). He previously served as Chairman of TESARO, Inc (NASDAQ: TSRO). He is also a director of several private companies and has previously served on
numerous public and private company boards. Mr.&nbsp;Mott received a Bachelor of Arts degree from Dartmouth College. Our Board of Directors believes Mr.&nbsp;Mott's qualifications to serve as a
member of our board include his financial expertise, his experience as a venture capital investor, his extensive experience in the pharmaceutical industry and his years of experience in his leadership
roles as a director and executive officer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Lawrence Alleva</I></FONT><FONT SIZE=2> has served as a Non-Executive Director since March 2015 and also serves as Chairman of our Audit Committee. He is a former
partner with PricewaterhouseCoopers&nbsp;LLP (PwC), where he worked for 39&nbsp;years from 1971 until his retirement in June 2010, including 28&nbsp;years' service as a partner.
Mr.&nbsp;Alleva worked with numerous pharmaceutical and biotechnology companies as clients and, additionally, served PwC in a variety of office, regional and national practice leadership roles, most
recently as the U.S. Ethics and Compliance Leader for the firm's Assurance Practice from 2006 until 2010. Mr.&nbsp;Alleva currently serves as a director for public companies Bright Horizons Family
Solutions,&nbsp;Inc. (NYSE: BFAM) and Mersana Therapeutics,&nbsp;Inc. (NASDAQ: MRSN) and chairs the audit committee for those companies. He previously served as a director of TESARO,&nbsp;Inc.
(NASDAQ: TSRO) and Mirna Therapeutics,&nbsp;Inc. (NYSE: MIRN), and of GlobalLogic,&nbsp;Inc. through the sale of the company in 2013 and chaired the audit committee for those companies.
Mr.&nbsp;Alleva is a Certified Public Accountant (inactive). He received a B.S. degree in Accounting from Ithaca College and attended Columbia University's Executive M.B.A. non-degree program. Our
Board of Directors believes Mr.&nbsp;Alleva's qualifications to serve as a member of our board include his financial expertise, his extensive experience working with public companies on corporate
finance and accounting matters as a Certified Public Accountant (inactive), his experience serving as a director on other corporate boards and his experience in a senior leadership role at PwC. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Barbara Duncan</I></FONT><FONT SIZE=2> has served as a Non-Executive Director since June 2016 and also serves as a member of our Audit Committee. She has over
16&nbsp;years of experience in the life sciences industry and served as Chief Financial Officer and Treasurer at Intercept Pharmaceuticals,&nbsp;Inc. (Nasdaq: ICPT) from May 2009 through June
2016, and as Chief Financial Officer and then Chief Executive Officer at DOV Pharmaceuticals,&nbsp;Inc. from 2001 to 2009. Prior to joining DOV, Ms.&nbsp;Duncan served as Vice President of
Corporate Finance&#151;Global Healthcare at Lehman Brothers&nbsp;Inc. from 1998 to 2001, and as Director of Corporate Finance at SBC Warburg Dillon Read&nbsp;Inc. from 1994 to 1998. She
also worked for PepsiCo,&nbsp;Inc. from 1989 to 1992 in its international audit division, and was a certified public accountant in the audit division of Deloitte&nbsp;&amp; Touche&nbsp;LLP from 1986
to 1989. Ms.&nbsp;Duncan currently serves as a director for Aevi Genomic Medicine (NASDAQ: GNMX), Jounce Therapeutics,&nbsp;Inc. (NASDAQ: JNCE), ObsEva&nbsp;SA (NASDAQ: OBSV) and Ovid
Therapeutics,&nbsp;Inc. (NASDAQ: OVID). She holds an M.B.A. from the Wharton School of the University of Pennsylvania and a Bachelor of Business Administration from Louisiana State University. Our
Board of Directors believes Ms.&nbsp;Duncan's qualifications to serve as a member of our board include her financial expertise, her extensive experience in the healthcare industry and her years of
experience in her leadership roles as a director and executive officer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Giles Kerr</I></FONT><FONT SIZE=2> has served as a Non-Executive Director since November 2016 and also serves as a member of our Audit Committee and of our
Corporate Governance and Nominating Committee. He has substantial commercial and financial experience gained from service on numerous public and private
company boards and as an audit partner. Mr.&nbsp;Kerr served as Director of Finance of the University of Oxford from January 2005 through December 2018. He currently serves as a Board member and
Audit Committee member of public companies Abcam&nbsp;plc (LSE: ABC), Arix Bioscience&nbsp;plc (LSE: ARIX) Paypoint&nbsp;plc (LSE: PAY) and Senior&nbsp;plc (LSE: SNR) and on the boards </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=31,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=271590,FOLIO='23',FILE='DISK112:[19ZAF1.19ZAF44001]CG44001A.;7',USER='CHE107322',CD=';1-MAR-2019;12:53' -->
<A NAME="page_cg44001_1_24"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>of
several private companies including Oxford Sciences Innovation&nbsp;plc and Oxford Capital Fund. Mr.&nbsp;Kerr previously served in roles of increasing seniority at Amersham&nbsp;plc since
1990, including as Chief Financial Officer and a Board member from 1997 to 2004, when the company was acquired by GE Healthcare, and as a director of BTG&nbsp;plc (LSE: BTG), Victrex&nbsp;plc and
of Elan Corporation&nbsp;Inc. Prior to his role at Amersham, Mr.&nbsp;Kerr was a National Partner with Arthur Andersen. He is a Fellow of the Institute of Chartered Accountants of England and
Wales and holds a B.A. degree in Economics from the University of York, U.K. Our Board of Directors believes Mr.&nbsp;Kerr's qualifications to serve as a member of our board include his financial
expertise, his extensive experience in the healthcare industry and his years of experience in his leadership roles as a director and executive officer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Elliott Sigal</I></FONT><FONT SIZE=2> has served as a Non-Executive Director since February 2015 and also serves as a member of our Corporate Governance and
Nominating Committee. He formerly served as a Non-Executive Director of Adaptimmune Limited since September 2014. Dr.&nbsp;Sigal is a former Executive Vice President and member of the Board of
Directors of Bristol-Myers Squibb ("BMS"). He joined BMS in 1997 as head of Applied Genomics, went on to head Discovery Research followed by clinical development and ultimately served as Chief
Scientific Officer and President of R&amp;D from 2004 until 2013. Dr.&nbsp;Sigal serves as a board member for Spark Therapeutics, Inc (NASDAQ: ONCE), Surface Oncology, Inc (NASDAQ: SURF) and the
Melanoma Research Alliance, and previously served as a director of the Mead Johnson Nutrition Company. He also serves as a senior advisor to the healthcare team of NEA and consults for several
biotechnology companies. Dr.&nbsp;Sigal holds an M.D. from the University of Chicago and trained in Internal Medicine and Pulmonary Medicine at the University of California, San Francisco, where he
was on faculty from 1988 to 1992. He also holds a B.S., M.S., and Ph.D. in engineering from Purdue University. Our Board of Directors believes Dr.&nbsp;Sigal's qualifications to serve as a member of
our board include his extensive experience in the pharmaceutical industry and his years of experience in his leadership roles as a director and executive officer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Tal Zaks</I></FONT><FONT SIZE=2> has served as a Non-Executive Director since November 2016 and also serves as a member of our Remuneration Committee. He has
substantial research, development and commercialization experience gained from service in industry and academia. Dr.&nbsp;Zaks has served as the Chief Medical Officer of Moderna ,&nbsp;Inc.
(NASDAQ: MRNA) since March 2015. He previously served as Senior Vice President and Head of Global Oncology at Sanofi Inc, where he was responsible for all aspects of oncology drug discovery,
development and commercialization. Dr.&nbsp;Zaks began his industry career at GlaxoSmithKline in the genetics research group, where he built the oncology translational medicine team and led
translational research on lapatinib as well as the in-licensing and clinical development of foretinib. In addition to his industry work, Dr.&nbsp;Zaks is an Adjunct Associate Professor of Medicine
at the University of Pennsylvania and has served as a volunteer physician at the Philadelphia Veterans Administration Medical Center, treating patients with genitourinary cancers. Dr.&nbsp;Zaks
received his M.D.
and Ph.D. degrees from the Ben Gurion University in Israel and conducted post-doctoral research at the U.S. National Institutes of Health. He completed his clinical training in internal medicine at
Temple University Hospital followed by a fellowship in medical oncology at the University of Pennsylvania. Our Board of Directors believes Dr.&nbsp;Zaks' qualifications to serve as a member of our
board include his extensive experience in the biopharmaceutical industry and his years of experience in his leadership roles as an executive officer. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CORPORATE GOVERNANCE  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Structure of our Board of Directors  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The leadership structure of our Board of Directors separates the positions of Chief Executive Officer and Chairman of the Board in order to
ensure independent leadership of the Board. Our Board believes that this separation is appropriate for the Company at this time because it allows for a division of responsibilities, with our CEO
focused on leading the Company while the Chairman can </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=32,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=560381,FOLIO='24',FILE='DISK112:[19ZAF1.19ZAF44001]CG44001A.;7',USER='CHE107322',CD=';1-MAR-2019;12:53' -->
<A NAME="page_cg44001_1_25"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>focus
on leading the Board in overseeing management, and for a sharing of ideas between individuals having different perspectives. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Independence of our Board of Directors  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors has determined that all of our directors, other than James Noble, our CEO, qualify as "independent" directors in
accordance with the independence requirements
under the applicable listing standards of The Nasdaq Global Market as well as applicable rules promulgated by the SEC. Mr.&nbsp;Noble is not considered independent because he is an employee of the
Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board of Directors has made a subjective determination as to each independent director that no relationships exist that would interfere with the exercise of independent judgment in
carrying out the responsibilities of a director. In making these determinations, our Board of Directors reviewed and discussed information provided by the directors and us with regard to each
director's business and personal activities and relationships as they may relate to us and our management. There are no family relationships among any of our directors or executive officers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
independent directors meet in regularly scheduled executive sessions at which only independent directors are present. All of the committees of our Board of Directors are comprised
entirely of directors determined by the Board of Directors to be independent. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board Oversight of Risk Management  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our management is primarily responsible for assessing and managing risk, while our Board of Directors is responsible for overseeing management's
execution of its responsibilities. Our Board of Directors is supported by its committees in fulfillment of this responsibility. For example, our Audit Committee focuses on our overall financial risk
by evaluating our internal controls and disclosure policies as well as ensuring the integrity of our financial statements and periodic reports. The Audit Committee also monitors compliance with legal
and regulatory requirements. Our Remuneration Committee strives to create incentives that encourage an appropriate level of risk-taking consistent with our business strategy. Finally, our Corporate
Governance and Nominating Committee ensures that our governance policies and procedures are appropriate in light of the risks we face. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


COMMITTEES OF OUR BOARD OF DIRECTORS  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors has three standing committees: the Audit Committee, the Remuneration Committee, and the Corporate Governance and
Nominating Committee. The charters for each of these committees can be found on our website at https://www.adaptimmune.com. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="35pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="75pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Audit </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Remuneration </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Corporate<BR>
Governance<BR>
and Nominating </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>David M. Mott</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chair</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chair</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Lawrence M. Alleva</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chair</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Ali Behbahani, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Barbara Duncan</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>John Furey</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Giles Kerr.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Elliott Sigal, Ph.D, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Tal Zaks, Ph.D, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=33,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=70848,FOLIO='25',FILE='DISK112:[19ZAF1.19ZAF44001]CG44001A.;7',USER='CHE107322',CD=';1-MAR-2019;12:53' -->
<A NAME="page_cg44001_1_26"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Audit Committee  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Audit Committee is currently composed of Mr.&nbsp;Alleva, Ms.&nbsp;Duncan and Mr.&nbsp;Kerr, with Mr.&nbsp;Alleva serving as
chairman of the committee. Our Board of Directors has determined that each member of the Audit Committee meets the independence requirements of Rule&nbsp;10A-3 under the Exchange Act and the
applicable listing standards of The Nasdaq Global Market. Our Board of Directors has determined that each of Mr.&nbsp;Alleva, Ms.&nbsp;Duncan and Mr.&nbsp;Kerr is an "audit committee financial
expert" within the meaning of SEC regulations and the applicable listing standards of The Nasdaq Global Market. The Audit Committee held eight meetings during 2018. The Audit Committee's
responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing and reviewing our internal controls, accounting policies and financial reporting and provide a forum through which our independent
registered public accounting firm reports; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> meeting at least once a year with our independent registered public accounting firm without executive Board members present; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing the activities of our independent registered public accounting firm, including their appointment, reappointment or removal, as well
as monitoring of their objectivity and independence; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> considering the fees paid to the independent registered public accounting firm and determine whether the fee levels for non-audit services,
individually and in aggregate, relative to the audit fee are appropriate to enable an effective and high quality audit to be conducted; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> maintaining oversight over related person transactions to ensure that they are appropriately disclosed and to make recommendations to the Board
of Directors regarding authorization, and for considering noteworthy questions of possible conflicts of interest involving directors. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Remuneration Committee  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Remuneration Committee is currently composed of Mr.&nbsp;Mott, Mr.&nbsp;Furey and Dr.&nbsp;Zaks, with Mr.&nbsp;Mott serving as
chairman of the committee. Our Board of Directors has determined that each member of the Remuneration Committee is "independent" as defined under the applicable listing standards of The Nasdaq Global
Market. The Remuneration Committee held five meetings during 2018. The Remuneration Committee's responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing corporate goals and objectives relevant to the compensation of our senior executive officers and making recommendations concerning
such objectives to the Board of Directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> appointing, compensating and overseeing the work of any compensation consultant or other advisor retained by the Remuneration Committee; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing the performance of our senior executive officers and our Chief Executive Officer who is our sole executive director; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> setting the policy for the remuneration of the senior executive officers and executive directors and the basis of their service and employment
agreements with due regard to the interests of the shareholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and approving the compensation of our senior executive officers other than our Chief Executive Officer; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> making recommendations to the Board of Directors with respect to the compensation of the Chief Executive Officer and the Non-Executive
Directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> determining the allocation of awards under our share option schemes to our senior executive officers, making recommendations to the Board of
Directors with respect to the allocation of </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=34,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=548488,FOLIO='26',FILE='DISK112:[19ZAF1.19ZAF44001]CG44001A.;7',USER='CHE107322',CD=';1-MAR-2019;12:53' -->
<A NAME="page_cg44001_1_27"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>option
awards to our Chief Executive Officer and setting the overall allocation of option awards to our employees and consultants; </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> producing a directors' remuneration policy and an annual directors' remuneration report to be included in our U.K. statutory annual report and
financial statements; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> producing a remuneration committee report on executive compensation when required by the rules of the SEC to be included in our annual proxy
statement. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Remuneration Committee Interlocks and Insider Participation  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None of the members of our Remuneration Committee has at any time during the prior three years been one of our officers or employees. None of
our executive officers currently serves, or in the past fiscal year has served, as a member of our Remuneration Committee or the remuneration committee of any entity that has one or more executive
officers serving on our Board of Directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
noted above, our Board of Directors has delegated to the Remuneration Committee the authority to determine the compensation for our executive officers with the exception of our Chief
Executive Officer who is also our sole executive director. Executive and non-executive director compensation is recommended by our Remuneration Committee to the Board of Directors for approval. Our
Chief Executive Officer may participate in general discussions with our Remuneration Committee and Board of Directors about these compensation matters but he does not participate in discussions during
which his individual compensation is being considered and approved. Our policy is that no individual will participate in discussions or decisions concerning his or her own compensation. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
2017, the Committee retained Willis Towers Watson, an independent compensation consultant, to assist the Committee with respect to compensation actions in 2018 with the goal of
ensuring that our compensation arrangements for our CEO, our other senior executive officers and our non-executive directors were competitive. Willis Towers Watson provided data from comparable
publicly traded biopharmaceutical companies and otherwise assisted the Committee in its design of competitive compensation for our senior executives and non-executive directors. The Committee expects
to continue to use compensation consultants to assist the Committee in determining competitive levels of executive and non-executive compensation and specific design elements of our executive
compensation program and non-executive directors' compensation program. The Committee continued to retain Willis Towers Watson through 2018 and 2019 in order to ensure that our compensation
arrangements are competitive for 2019. After review and consultation with Willis Towers Watson, the Committee determined that Willis Towers Watson is independent and that there is no conflict of
interest resulting from retaining Willis Towers Watson in 2018 or in 2019. In reaching these conclusions, our Remuneration Committee considered the factors set forth in the SEC rules and the
applicable listing standards of The Nasdaq Global Market. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Corporate Governance and Nominating Committee  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Corporate Governance and Nominating Committee is composed of Mr.&nbsp;Mott, Dr.&nbsp;Behbahani, Mr.&nbsp;Kerr and Dr.&nbsp;Sigal,
with Mr.&nbsp;Mott serving as chairman of the committee. Our Board of Directors has determined that each member of the Corporate Governance and Nominating Committee is "independent" as defined under
the applicable listing standards of The Nasdaq Global Market. The Corporate Governance and Nominating Committee held three meetings during 2018. The Nominating and Corporate Governance Committee's
responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing the structure, size and composition of the Board of Directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> recommending to our Board of Directors individuals to be nominated for election as directors and to each of the committees of our Board; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=35,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=270956,FOLIO='27',FILE='DISK112:[19ZAF1.19ZAF44001]CG44001A.;7',USER='CHE107322',CD=';1-MAR-2019;12:53' -->
<A NAME="page_cg44001_1_28"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> supervising the selection and appointment process of directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> making recommendations to the Board of Directors with regard to any changes and using an external search consultant if considered appropriate; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> appointing, compensating and overseeing the work of any search firm or other advisor retained by the Committee; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> making final recommendations to the Board of Directors with respect to new appointments, which includes meeting the candidate prior to
approving the appointment; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing the induction of new directors and providing appropriate training to the Board of Directors during the course of the year in order
to ensure that they have the knowledge and skills necessary to operate effectively; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> evaluating the performance of the Board of Directors, both on an individual basis and for the Board of Directors as a whole, taking into
account such factors as attendance record, contribution during board meetings and the amount of time that has been dedicated to board matters during the course of the year. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Nomination Process  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Corporate Governance and Nominating Committee of the Board of Directors reviews possible candidates for the Board and recommends the
nominees for Directors to the Board for approval. The criteria that the Corporate Governance and Nominating and Committee and the Board of Directors look for in determining candidates for election to
the Board, include, among others:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the highest personal and professional ethics, integrity and values; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> commitment to representing the long-term interests of the Company's shareholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> independence under the standards promulgated by The Nasdaq Global Market; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> ability to dedicate the time and resources sufficient to ensure the diligent performance of his or her duties on our behalf, including
attending all Board of Directors and applicable committee meetings. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
we do not have a standalone diversity policy, diversity is among the critical factors that the Board of Directors considers when evaluating its composition. It is the Corporate
Governance and Nominating Committee's policy that the composition of the Board of Directors reflect a range of talents, ages, skills, character, diversity and expertise, particularly in the areas of
accounting and finance, management, domestic and international markets, leadership, corporate governance, and biotechnology and related industries, sufficient to provide sound and prudent guidance
with respect to the operations and interests of the Company. The independent directors of our Board of Directors believe that the current members of the Board of Directors reflect an appropriate
diversity of gender, age, race, geographical background and experience but are committed to continuing to consider diversity issues in evaluating the composition of the Board of Directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Nominating and Corporate Governance Committee's policy does not contemplate any disparate treatment of management nominees versus those put forth by our shareholders. To date, the
Committee has worked with Egon Zehnder and Perspective, each of whom is an independent global board and executive search firm, to assist in identifying and evaluating potential nominees against role
specifications. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=36,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=1025392,FOLIO='28',FILE='DISK112:[19ZAF1.19ZAF44001]CG44001A.;7',USER='CHE107322',CD=';1-MAR-2019;12:53' -->
<A NAME="page_cg44001_1_29"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Shareholder Recommendations and Nominees  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It is the policy of our Board of Directors that the Nominating and Corporate Governance Committee consider both recommendations and nominations
for candidates to the Board from shareholders so long as such recommendations and nominations comply with our Articles of Association and applicable laws, including the rules and regulations of the
SEC. Shareholders may recommend director nominees for consideration by the Corporate Governance and Nominating Committee by writing to our Company Secretary at the address below, or the Company's
registered office address from time to time, and providing evidence of the shareholder's ownership of our ordinary shares and/or ADSs, the nominee's name, home and business address and other contact
information, as well as the nominee's detailed biographical data and qualifications for board membership, and information regarding any relationships between the recommended candidate and the Company
within the last three fiscal years. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Following
verification of the shareholder status of the person submitting the recommendation, all properly submitted recommendations will be promptly brought to the attention of the
Corporate Governance and Nominating Committee. Shareholders who desire to nominate persons directly for election to the Board at an annual general meeting of shareholders must meet the deadlines and
other requirements set forth under "Additional Information&#151;Shareholder Proposals for 2020 Annual General Meeting." Any vacancies on the Board of Directors occurring between our annual
general meetings of shareholders may be filled by persons selected by a majority of the directors then in office, in which case any director so elected will serve until the next annual general meeting
of shareholders when such director will offer himself/herself for re-election, or by persons elected by an ordinary resolution of the shareholders of the Company. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
may write to the Corporate Governance and Nominating Committee at: </FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>c/o
Margaret Henry<BR>
Company Secretary<BR>
Adaptimmune Therapeutics&nbsp;plc<BR>
60 Jubilee Avenue<BR>
Abingdon<BR>
Oxfordshire OX14&nbsp;4RX<BR>
United Kingdom </FONT></P>

</UL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Code of Business Conduct and Ethics  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have adopted a Code of Business Conduct and Ethics applicable to all of our directors, officers and employees. The Code of Business Conduct
and Ethics is available on our website at&nbsp;http://www.adaptimmune.com. We expect that any amendments to this code or any waivers of its requirements will be disclosed on our website. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Shareholder Communication with the Board of Directors  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It is the policy of our Board of Directors to allow shareholders to communicate with its members. Communications may be addressed to the entire
board or to any individual director. All such communications will initially be received and processed by our Company Secretary. Spam, junk mail, advertisements and threatening, hostile, illegal and
similar unsuitable communications will not be delivered to the Board. Shareholders can contact members of the Board Directors by writing care of our Company Secretary at the Company's registered
office address. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=37,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=908751,FOLIO='29',FILE='DISK112:[19ZAF1.19ZAF44001]CG44001A.;7',USER='CHE107322',CD=';1-MAR-2019;12:53' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ci44001_1_30"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ci44001_security_ownership_of_certain___sec02525"> </A>
<A NAME="toc_ci44001_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table and related footnotes set forth information with respect to the beneficial ownership of our ordinary shares, as of
March&nbsp;1, 2019, by:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each beneficial owner of more than 5% of our ordinary shares </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each of our named executive officers and directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> all of our executive officers and directors as a group. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial
ownership is determined in accordance with the rules and regulations of the SEC. Under these rules, beneficial ownership includes any shares as to which a person has sole or
shared voting power or investment power. In computing the number of ordinary shares beneficially owned by a person and the percentage ownership of that person, ordinary shares subject to options, or
other rights held by such person that are currently exercisable or will become exercisable within 60&nbsp;days of March&nbsp;1, 2019 are considered outstanding. These ordinary shares, however, are
not included in the computation of the percentage ownership of any other person. Applicable percentage ownership is based on 628,148,866 ordinary shares outstanding as of March&nbsp;1, 2019. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
otherwise indicated, the address for each of the shareholders listed in the table below is&nbsp;c/o&nbsp;Adaptimmune Therapeutics&nbsp;plc, 60 Jubilee Avenue, Milton Park,
Oxfordshire OX14&nbsp;4RX, United Kingdom. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="37pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Ordinary Shares<BR>
Beneficially Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name of Beneficial Owner

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percent </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Greater than 5% Shareholders</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Matrix Capital Management Master Fund L.P(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>162,894,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25.93</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>New Enterprise Associates(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>94,995,666</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15.12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Capital World Investors(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>40,756,200</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6.49</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Named Executive Officers and Directors</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>James Noble(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>19,844,263</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Helen Tayton-Martin, Ph.D.(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,533,157</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.20</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rafael Amado, M.D.(6)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,942,505</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.95</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adrian Rawcliffe(7)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,183,157</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.83</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William Bertrand(8)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,012,517</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.32</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David M. Mott(9)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>95,652,866</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15.23</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ali Behbahani, M.D.(10)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>95,556,698</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15.21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Elliott Sigal, M.D., Ph.D.(11)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,316,465</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lawrence M. Alleva(12)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,108,492</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.18</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Barbara Duncan(13)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>540,737</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.09</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Giles Kerr(14)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>369,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.06</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tal Zaks, Ph.D.(15)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>369,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.06</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>John Furey(16)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>All Executive Officers and Directors as a Group (13 persons</I></FONT><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>140,433,191</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>22.36</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>As
of December&nbsp;31, 2018 based on information provided in a Form&nbsp;13F Report filed with the Securities and Exchange Commission ("SEC") on
February&nbsp;14, 2019 and a Schedule&nbsp;13G/A filed with the SEC on January&nbsp;10, 2019. Matrix Capital Management Company&nbsp;L.P., as investment manager of Matrix Capital Management
Master Fund&nbsp;L.P., holds these shares in the form of ADSs. The registered office of Matrix Capital Management Master Fund&nbsp;L.P. is c/o Matrix Capital Management&nbsp;L.P., 1000 Winter
Street, Suite&nbsp;4500, Waltham, MA 02451. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=38,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=601850,FOLIO='30',FILE='DISK112:[19ZAF1.19ZAF44001]CI44001A.;8',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_ci44001_1_31"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>As
of December&nbsp;31, 2018 based on information provided in a Form&nbsp;13F Report filed with the SEC on January&nbsp;18, 2019 and a Schedule&nbsp;13D
filed with the SEC on September&nbsp;17, 2018. Beneficial ownership consists of (i)&nbsp;82,978,668 ordinary shares represented by 13,829,778 ADSs directly held by New Enterprise Associates
14,&nbsp;L.P., or NEA 14; (ii)&nbsp;12,000,000 ordinary shares represented by 2,000,000 ADSs directly held by New Enterprise Associates 16,&nbsp;L.P., or NEA 16; and (iii)&nbsp;16,998 ordinary
shares represented by 2,833 ADSs directly held by NEA Ventures 14,&nbsp;L.P., or NEA Ven 14. The shares directly held by NEA 14 are indirectly held by NEA Partners 14,&nbsp;L.P., or NEA Partners
14, the sole general partner of NEA 14, NEA 14&nbsp;GP,&nbsp;LTD, or NEA 14&nbsp;LTD, the sole general partner of NEA Partners 14 and each of the individual Directors of NEA 14&nbsp;LTD. The
individual Directors, or collectively, the Directors of NEA 14&nbsp;LTD, are Peter J. Barris, Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, David M. Mott (a member of our Board),
Scott D. Sandell, Peter W. Sonsini and Ravi Viswanathan. The managers of NEA 16 are Peter J. Barris, Forest Baskett, David M. Mott, Scott D. Sandell, Peter W. Sonsini, Ravi Viswanathan, Ali Behbahani
(a member of our Board), Carmen Chang, Mohamad H. Makhzoumi and Joshua Makower. All indirect holders of the above referenced shares disclaim beneficial ownership of all applicable shares except to the
extent of their actual pecuniary interest therein. The principal business address of New Enterprise Associates,&nbsp;Inc. is 1954 Greenspring Drive, Suite&nbsp;600, Timonium, MD 21093.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>As
of December&nbsp;31, 2018 based on information provided in a Schedule&nbsp;13G/A filed with the SEC on February&nbsp;14, 2019. Capital World Investors, a
division of Capital Research and Management Company (CRMC), a U.S.-based investment management company, holds these shares in the form of ADSs. The Capital Group Companies,&nbsp;Inc. is the parent
company of CRMC. The business address for CRMC is 333 South Hope Street, Los&nbsp;Angeles, CA 90071.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Beneficial
ownership for Mr.&nbsp;Noble consists of (i)&nbsp;9,972,600 ordinary shares; (ii)&nbsp;1,200,000 ordinary shares represented by 200,000 ADSs and
(ii)&nbsp;options to purchase 8,671,663 ordinary shares that are or will be exercisable within 60&nbsp;days of March&nbsp;1, 2019.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Beneficial
ownership for Dr.&nbsp;Tayton-Martin consists of (i)&nbsp;1,815,000 ordinary shares and (ii)&nbsp;options to purchase 5,718,157 ordinary shares that
are or will be exercisable within 60&nbsp;days of March&nbsp;1, 2019.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Beneficial
ownership for Dr.&nbsp;Amado consists of (i)&nbsp;144,012 ordinary shares represented by 24,002 ADSs and (ii)&nbsp;options to purchase 5,798,493
ordinary shares that are or will be exercisable within 60&nbsp;days of March&nbsp;1, 2019.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Beneficial
ownership for Mr.&nbsp;Rawcliffe consists of (i)&nbsp;38,412 ordinary shares represented by 6,402 ADSs and (ii)&nbsp;options to purchase 5,144,745
ordinary shares that are or will be exercisable within 60&nbsp;days of March&nbsp;1, 2019.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Beneficial
ownership for Mr.&nbsp;Bertrand consists of (i)&nbsp;36,012 ordinary shares represented by 6,002 ADSs and (ii)&nbsp;options to purchase 1,976,505
ordinary shares that are or will be exercisable within 60&nbsp;days of March&nbsp;1, 2019.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(9)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
the shares set forth in footnote (1)&nbsp;above and options held by Mr.&nbsp;Mott to purchase 657,200 ordinary shares that are exercisable immediately.
Mr.&nbsp;Mott is a member of the Board at NEA 14&nbsp;GP,&nbsp;Ltd, which has ultimate voting and investment power over shares held of record by New Enterprise Associates 14, Limited
Partnership. He disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(10)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
the shares set forth in footnote (1)&nbsp;above and options held by Dr.&nbsp;Behbahani to purchase 561,032 ordinary shares that are exercisable
immediately. Dr.&nbsp;Behbahani is a </FONT></DD></DL>
 </DIV>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=39,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=545719,FOLIO='31',FILE='DISK112:[19ZAF1.19ZAF44001]CI44001A.;8',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_ci44001_1_32"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <UL>

<P style="font-family:times;"><FONT SIZE=2>partner
of New Enterprise Associates,&nbsp;Inc., which has ultimate voting and investment power over shares held of record by New Enterprise Associates 14, Limited Partnership.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(11)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
254,100 ordinary shares, and 60,000 ordinary shares represented by 10,000 ADSs held by Sigal Family Investments,&nbsp;LLC, and options held by
Dr.&nbsp;Sigal to purchase 949,427 ordinary shares that are or will be exercisable within 60&nbsp;days of March&nbsp;1, 2019. Dr.&nbsp;Sigal is a manager of Sigal Family
Investments,&nbsp;LLC. Dr.&nbsp;Sigal may be deemed to have voting and investment power over the shares held by Sigal Family Investments,&nbsp;LLC. Dr.&nbsp;Sigal disclaims beneficial
ownership of such shares except to the extent of any pecuniary interest therein. Also included in the ordinary shares beneficially owned are 52,938 ordinary shares represented by 8,823 ADSs that
Dr.&nbsp;Sigal purchased during the IPO.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(12)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of (i)&nbsp;options held by Mr.&nbsp;Alleva to purchase 990,628 ordinary shares that are or will be exercisable within 60&nbsp;days of
March&nbsp;1, 2019; (ii)&nbsp;70,584 ordinary shares represented by 11,764 ADSs purchased by Mr.&nbsp;Alleva during the IPO; and (iii)&nbsp;47,280 ordinary shares represented by 7,880 ADS
purchased by the Lawrence M. Alleva Revocable Trust in December 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(13)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of options held by Ms.&nbsp;Duncan to purchase 540,737 ordinary shares that are or will be exercisable within 60&nbsp;days of March&nbsp;1, 2019.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(14)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of options held by Mr.&nbsp;Kerr to purchase 369,000 ordinary shares that are or will be exercisable within 60&nbsp;days of March&nbsp;1, 2019.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(15)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of options held by Dr.&nbsp;Zaks to purchase 369,000 ordinary shares that are or will be exercisable within 60&nbsp;days of March&nbsp;1, 2019.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(16)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Mr.&nbsp;Furey
was appointed as a Board member effective July&nbsp;5, 2018. He holds options to purchase 284,233 ordinary shares of which 71,058 will be
exercisable on July&nbsp;5, 2019.  </FONT></DD></DL>
 </DIV>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=40,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=608159,FOLIO='32',FILE='DISK112:[19ZAF1.19ZAF44001]CI44001A.;8',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_ci44001_1_33"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ci44001_section_16(a)_benefici__ci402020"> </A>
<A NAME="toc_ci44001_2"> </A>
<BR></FONT><FONT SIZE=2><B>  SECTION&nbsp;16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All of our directors, executive officers and any greater than 10&nbsp;percent shareholders are required by Section&nbsp;16(a) of the
Exchange Act to file with the SEC initial reports of ownership and reports of changes in ownership of shares and to furnish us with copies of such reports. Based on a review of those reports and
written representations that no other reports were required, we believe that our Section&nbsp;16 directors and officers complied with all of their applicable Section&nbsp;16(a) filing
requirements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=41,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=639726,FOLIO='33',FILE='DISK112:[19ZAF1.19ZAF44001]CI44001A.;8',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_ci44001_1_34"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ci44001_transactions_with_related_persons"> </A>
<A NAME="toc_ci44001_3"> </A>
<BR></FONT><FONT SIZE=2><B>  TRANSACTIONS WITH RELATED PERSONS    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Certain Relationships and Related Party Transactions  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Related Person Transactions  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other than the compensation arrangements described below under the sections "Director Remuneration" and "Executive Compensation Discussion and
Analysis", in the period from January&nbsp;1, 2018 through the date of this proxy statement, we were not a party to any transactions between us and certain "related persons", which are generally
considered to be our executive officers, directors, director nominees or 5% shareholders, or their immediate family members. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Related Person Transactions Policy  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have adopted a policy with respect to the review, approval and ratification of related party transactions. Under the policy, our Audit
Committee will be responsible for reviewing and approving related person transactions. In the course of its review and approval of related person transactions, our Audit Committee will consider the
relevant facts and circumstances to decide whether to approve such transactions. In particular, our policy will require our Audit Committee to consider, among other factors it deems
appropriate:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the related person's relationship to us and interest in the transaction; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the interests, direct or indirect, of any related person in the transaction in sufficient detail so as to enable the Audit Committee to assess
such interests; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the material facts of the proposed related-person transaction, including the proposed aggregate value of such transaction, or, in the case of
indebtedness, that amount of principal that would be involved; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the benefits to us of the proposed transaction; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an assessment of whether the proposed transaction is on terms that are comparable to the terms available to an unrelated third party or to
employees generally; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> management's recommendation with respect to the proposed related-person transaction. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee may only approve those transactions that are in, or are not inconsistent with, our best interests and those of our shareholders, as the Audit Committee determines in
good faith. If Audit Committee review and approval would be inappropriate, the relevant related party transaction will be referred to another independent body of our Board for review, consideration,
approval or ratification. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of the policy we refer to transactions in which (a)&nbsp;we were a participant, (b)&nbsp;the amount involved exceeded $120,000 and (c)&nbsp;one or more of our
executive officers, directors, director nominees
or 5% shareholders, or their immediate family members (each of whom we refer to as a "related person") had a direct or indirect material interest as "related person transactions." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Investors Rights Agreement  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are party to an investors rights agreement entered into on February&nbsp;23, 2015, with certain of our shareholders, including New
Enterprise Associates 14,&nbsp;L.P., NEA Ventures 2014,&nbsp;L.P., OrbiMed Private Investments V,&nbsp;L.P. and Sigal Family Investments,&nbsp;LLC pursuant to which certain of our
shareholders, including certain holders with beneficial ownership of five percent or more of our ordinary shares and entities affiliated with certain of our directors, have the right to demand that we
file&nbsp;a registration statement for their ordinary shares or request that their ordinary shares be covered by a registration statement that we are otherwise filing. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=42,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=683182,FOLIO='34',FILE='DISK112:[19ZAF1.19ZAF44001]CI44001A.;8',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_ci44001_1_35"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ci44001_director_remuneration"> </A>
<A NAME="toc_ci44001_4"> </A>
<BR></FONT><FONT SIZE=2><B>  DIRECTOR REMUNERATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under our Directors' Remuneration Policy, the Board has the discretion to pay our Non-Executive Directors for their Board and committee service
in the form of cash fees or stock options or a mixture of cash fees and stock options. Our remuneration arrangements for Non-Executive Directors during 2018 comprised an award of a fixed number of
stock options, plus an additional number of stock options or cash payment at the director's election. The option awards and cash payments were made at competitive levels of peer group data from
comparable companies provided in a competitive benchmarking analysis undertaken by Willis Towers Watson in 2018 and are compliant with the Directors' Remuneration policy approved by our shareholders
at our Annual General Meeting on June&nbsp;20, 2018. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
our Directors' Remuneration Policy in effect in 2018, our Non-Executive Directors earned the following annual cash compensation or made an election to receive such compensation in
the form of an additional number of stock options. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 Cash<BR>
Compensation </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Board of Directors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>40,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chairman (additional retainer)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit Committee Chair (additional retainer)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>20,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Remuneration Committee Chair (additional retainer)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate Governance and Nominating Committee Chair (additional retainer)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit Committee member/non-Chair (additional retainer)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Remuneration Committee member/non-Chair (additional retainer)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate Governance and Nominating Committee member/non-Chair (additional retainer)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
cash payments are payable monthly in arrears at the end of each month during which such individual served as a director (with prorated payments for service during a portion of such
month). The cash compensation is targeted at the 50<SUP>th</SUP>&nbsp;percentile of peer group data. Our Non-Executive Directors are also entitled to receive reimbursement of expenses incurred in
the course of performing services to the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Non-Executive Directors do not receive any pension from the Company nor do they participate in any performance-related incentive plans. Our Non-Executive Directors participate in the
Group's long-term incentive plans on terms similar to those used for our executive directors and officers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
joining the Board, our Non-Executive Directors are eligible to receive an initial award of stock options covering up to 288,000 of our ordinary shares and, at their election, either
cash compensation, as set forth above, or additional options of equivalent value. All such options vest over three years with the first 25% vesting on the first anniversary of the date of grant.
Subsequently, all Non-Executive Directors are eligible to receive an annual award of stock options covering up to 144,000 of our ordinary shares and, at their election, either cash compensation, as
set forth above, or additional options of equivalent value. All options awarded annually are exercisable on the first anniversary of the date of grant. These long-term equity incentive awards are
targeted at the 50<SUP>th</SUP>&nbsp;percentile of peer group data. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
2018, all Non-Executive Directors were granted an annual award of stock options, with the exception of John Furey, who was awarded stock options on joining the Board of Directors
and the Remuneration Committee effective July&nbsp;5, 2018, and Dr.&nbsp;Peter Thompson who stood down from the Board of Directors effective July&nbsp;5, 2018. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=43,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=823843,FOLIO='35',FILE='DISK112:[19ZAF1.19ZAF44001]CI44001A.;8',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_ci44001_1_36"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
determining option awards, our Board of Directors works within benchmarking guidelines provided by compensation consultants and seeks recommendations from our Remuneration Committee.
All options are granted with an exercise price that is no lower than the fair market value of an ordinary share on the date prior to the date of grant. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2018 Director Compensation Table  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The table below shows the compensation paid to our Non-Executive Directors during the year ended December&nbsp;31, 2018. The compensation paid
to James Noble, our Chief Executive Officer and an executive director, is set forth in "</FONT><FONT SIZE=2><I>Executive Compensation Discussion and Analysis</I></FONT><FONT SIZE=2>" below. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fees Earned<BR>
or paid<BR>
in cash$(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
awards($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total ($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David M. Mott(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>225,486</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>225,486</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lawrence Alleva(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>149,257</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>179,257</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ali Behbahani(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>186,341</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>186,341</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Barbara Duncan(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>190,463</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>190,463</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>John Furey (7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>309,788</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>309,788</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Giles Kerr(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,523</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>149,257</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>199,780</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Elliott Sigal(9)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>186,341</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>186,341</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Peter Thompson(10)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tal Zaks(11)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>43,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>149,257</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>193,007</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
fees paid to Mr.&nbsp;Kerr were denominated in pounds sterling. For purposes of this table, the 2018 amount paid to Mr.&nbsp;Kerr has been converted based on
the pound sterling/U.S. dollar exchange rate in effect as of December&nbsp;31, 2018 (&pound;1/$1.27602).
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Amounts
reflect the aggregate grant date fair value of share options granted during 2018 and computed in accordance with ASC Topic 718. The assumptions used in the
valuation of these awards are set forth in Note&nbsp;2 (r), Note&nbsp;2 (x)&nbsp;and Note&nbsp;11 to our consolidated financial statements, which are included in our Annual Report on
Form&nbsp;10-K for the year ended December&nbsp;31, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Mr.&nbsp;Mott
received an option award covering 187,330 ordinary shares on June&nbsp;22, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Mr.&nbsp;Alleva
received an option award covering 124,000 ordinary shares on June&nbsp;22, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Dr.&nbsp;Behbahani
received an option award covering 154,809 ordinary shares on June&nbsp;22, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Ms.&nbsp;Duncan
received an option award covering 158,233 ordinary shares on June&nbsp;22, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Mr.&nbsp;Furey
received an option award covering 284,233 ordinary shares on July&nbsp;5, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Mr.&nbsp;Kerr
received an option award covering 124,000 ordinary shares on June&nbsp;22, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(9)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Dr.&nbsp;Sigal
received an option award covering 154,809 ordinary shares on June&nbsp;22, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(10)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Dr.&nbsp;Thompson
stood down from the Board on July&nbsp;5, 2018 and did not receive an annual award of options in 2018. In recognition of Dr.&nbsp;Thompson's
service as a Board member and as a member of the Remuneration Committee up to July&nbsp;5, 2018, he was permitted a 12&nbsp;month period in which to exercise those options which had vested as at
July&nbsp;5, 2018. Any options that are not exercised by July&nbsp;5, 2019 will lapse and cease to be exercisable.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(11)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Dr.&nbsp;Zaks
received an option award covering 124,000 ordinary shares on June&nbsp;22, 2018.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=44,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=215531,FOLIO='36',FILE='DISK112:[19ZAF1.19ZAF44001]CI44001A.;8',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_ci44001_1_37"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Deeds of Indemnification  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not have any third party indemnification provisions in place for the benefit of one or more of our directors. However, we agree to use all
reasonable endeavors to provide and maintain appropriate directors' and officers' liability insurance (including ensuring that premiums are properly paid) for their benefit for so long as any claims
may lawfully be brought against them. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Non-Executive Director Appointment Letters  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered into letters of appointment with each of our Non-Executive Directors. These letters set forth the main terms on which each of
our Non-Executive Directors serve on our Board of Directors. Continued appointment under the letter is contingent on continued satisfactory performance as a member of the Board of Directors and as a
member of a committee, if applicable, as well as being re-elected at the annual general meetings in accordance with our Articles of Association. The appointment may be terminated by the Company or the
Non-Executive Director with three months' prior written notice. Upon termination, the Non-Executive Director is entitled to a pro-rata amount of the annual fee (if applicable) that is outstanding and
payable up to the date of termination, and reimbursement in the normal way of any expenses properly incurred before that date. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=45,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=374710,FOLIO='37',FILE='DISK112:[19ZAF1.19ZAF44001]CI44001A.;8',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ck44001_1_38"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ck44001_executive_officers_of_the_company"> </A>
<A NAME="toc_ck44001_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXECUTIVE OFFICERS OF THE COMPANY    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Below is a list of our executive officers and their ages as of the date of this proxy statement. There are no family relationships between any
of our executive officers, and there is no arrangement or understanding between any executive officer and any other person pursuant to which the executive officer was selected. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="210pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Position </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>James Noble</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>59</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Executive Officer and Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Adrian Rawcliffe</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>47</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Financial Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Rafael Amado, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>55</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>President, Research&nbsp;&amp; Development</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Helen Tayton-Martin, Ph.D</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>52</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Business Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>William Bertrand</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>54</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Operating Officer</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;James Noble.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;For biographical information regarding Mr.&nbsp;Noble, please refer to "Proposal 3&#151;Re-Election of James Noble to the
Board
of Directors". </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adrian Rawcliffe.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Rawcliffe has served as our Chief Financial Officer since March 2015 and leads our financial strategy and
operations, as
well as investor relations, corporate communications, manufacturing and supply chain, product development and global IT and facilities. He has 21&nbsp;years of experience within the
biopharmaceutical industry and most recently served as Senior Vice President, Finance of GSK's North American Pharmaceuticals business. Mr.&nbsp;Rawcliffe currently serves as a non-executive
director of WAVE Life Sciences (NASDAQ: WVE). Mr.&nbsp;Rawcliffe joined GSK in 1998 and his other senior roles at the company included Senior Vice President Worldwide Business Development and R&amp;D
Finance, where he was responsible for all business development and finance activities for GSK's Pharmaceuticals R&amp;D business and Managing Partner and President of SR One&nbsp;Ltd, GSK's
venture-capital business. Mr.&nbsp;Rawcliffe qualified as a chartered accountant with PwC and holds a B.Sc. degree in Natural Sciences from the University of Durham, U.K. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rafael Amado, M.D.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Amado has served as our President, Research&nbsp;&amp; Development since August 2018. In this role, he
brings together
our clinical and research teams under a single leadership, allowing better alignment and integration of all parts of R&amp;D, from target identification and selection, to regulatory filings. Before
assuming the President role, Dr.&nbsp;Amado served as our Chief Medical Officer
since March 2015. He has over 15&nbsp;years of experience within the biotech and pharmaceutical industries. Dr.&nbsp;Amado formerly served as Senior Vice President and Head of Oncology R&amp;D at GSK,
where he was responsible for integrating oncology R&amp;D activities, from drug target identification to clinical development and registration globally. He oversaw the development and registration
globally of over 15 novel indications across six products and led the development of a pipeline of products with companion diagnostics in novel areas of cancer biology. Prior to joining GSK,
Dr.&nbsp;Amado was Executive Director of Therapeutic Oncology at Amgen where he was responsible for development activities of several assets, including the development of products in molecularly
characterized tumors. Dr.&nbsp;Amado trained as a Hematologist/Oncologist at the University of California, Los Angeles, where he remained as faculty until joining Amgen. He holds an M.D. from the
University of Seville School of Medicine, and performed his residency in Internal Medicine at Michael Reese Hospital, a University of Chicago Affiliated Hospital, and his fellowship in
Hematology/Oncology at the University of California, Los Angeles. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Helen Tayton-Martin, Ph.D.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Tayton-Martin has served as our Chief Business Officer since March 2017, having formerly served as
our Chief
Operating Officer since 2008, a role in which she oversaw the transition of all operations in the company from five to 300 staff, through transatlantic growth, multiple clinical, academic and
commercial collaborations and private and public financing through to its NNASDAQ IPO. As our CBO, Dr.&nbsp;Tayton-Martin is responsible for optimizing the strategic and commercial opportunity for
Adaptimmune's assets, leading on business development and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=46,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=95109,FOLIO='38',FILE='DISK112:[19ZAF1.19ZAF44001]CK44001A.;8',USER='CHE109569',CD=';1-MAR-2019;12:03' -->
<A NAME="page_ck44001_1_39"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>commercial
activities. Her role encompasses all aspects of pipeline and technology assessment, strategic portfolio analysis, integrated program management and commercial planning and partnerships,
including the company's strategic partnership with GlaxoSmithKline (LSE/NYSE: GSK) ("GSK"). Dr.&nbsp;Tayton-Martin has over 26&nbsp;years of experience working within the pharma, biotech and
consulting environment in disciplines across preclinical and clinical development, outsourcing, strategic planning, due diligence and business development. She co-founded Adaptimmune from the former
company, Avidex Limited, where she had been responsible for commercial development of the soluble TCR program in cancer and HIV from 2005 to 2008. Dr.&nbsp;Tayton-Martin also serves as a
non-executive director of Trillium Therapeutics&nbsp;Inc. (NASDAQ and TSX: TRIL). She holds a Ph.D. in molecular immunology from the University of Bristol, U.K. and an M.B.A. from London Business
School. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;William Bertrand.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Bertrand has served as our Chief Operating Officer since March 2017 and is responsible for a range of
operational
functions including compliance, risk management, human resources, quality and legal/IP. Mr.&nbsp;Bertrand's prior experience includes a 12&nbsp;year tenure at MedImmune, where he served as its
first General Counsel and Chief Compliance Officer, along with holding a variety of operational and corporate strategy roles. He has also formerly served as Executive Vice President, General Counsel
for Infinity Pharmaceuticals,&nbsp;Inc., and as Senior Vice President, Acting
Chief Operating Officer and General Counsel for Salix Pharmaceuticals, where he remained as General Manager to help finalize the integration of the company's $14&nbsp;billion acquisition by Valeant
Pharmaceuticals in April 2015. He is currently a member of the board of directors of Ardelyx,&nbsp;Inc. (NASDAQ: ARDX) and has served as a member of the board of directors of several private
companies including Trustwave and Inotek Pharmaceuticals. Mr.&nbsp;Bertrand received a J.D. from the University of Wisconsin and a B.S. in biology from Wayne State University. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>39</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=47,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=1045489,FOLIO='39',FILE='DISK112:[19ZAF1.19ZAF44001]CK44001A.;8',USER='CHE109569',CD=';1-MAR-2019;12:03' -->
<A NAME="page_ck44001_1_40"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ck44001_executive_compensation_discussion_and_analysis"> </A>
<A NAME="toc_ck44001_2"> </A>
<BR></FONT><FONT SIZE=2><B>  EXECUTIVE COMPENSATION DISCUSSION AND ANALYSIS    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Compensation Discussion and Analysis ("CD&amp;A") discusses the compensation philosophy, policies and principles underlying our executive
compensation decisions for 2018. This section discusses the material components of the executive compensation program offered to our named executive officers, or NEOs, who for the year ended
December&nbsp;31, 2018, were:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> James Noble, Chief Executive Officer; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Adrian Rawcliffe, Chief Financial Officer; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Rafael Amado, President, Research&nbsp;&amp; Development; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Helen Tayton-Martin, Chief Business Officer; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> William Bertrand, Chief Operating Officer. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Summary  </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2018 Business Highlights  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018 was a year of strong operational performance for Adaptimmune. Key business highlights during 2018 included: </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Advancement of our clinical trials for ADP-A2M10, ADP-A2M4 and ADP-A2AFP  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have three SPEAR T-cells in clinical trials, ADP-A2M10 (MAGE-A10), ADP-A2M4 (MAGE-A4) and ADP-A2AFP (AFP). </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Two Phase&nbsp;1 clinical trials are ongoing with ADP-A2M10. The first clinical trial is in patients with non-small cell lung cancer
("NSCLC"). The second clinical trial is in patients with three cancer tumor types, urothelial, melanoma and head and neck cancers.  </FONT> <FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> In 2018, both trials have progressed to the expansion phase, with patients being treated with up to 10&nbsp;billion transduced
SPEAR T-cells. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD></DL>
</DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> A Phase&nbsp;1 clinical trial is ongoing with ADP-A2M4 in bladder, melanoma, head and neck, ovarian, NSCLC, synovial sarcoma, myxoid round
cell liposarcoma ("MRCLS"), esophageal and gastric cancers.  </FONT> <FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> In 2018, this trial progressed to the expansion phase with patients being treated with up to 10&nbsp;billion transduced SPEAR
T-cells. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD></DL>
</DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> A Phase&nbsp;1 clinical trial is ongoing with ADP-A2AFP in patients with hepatocellular cancer.  </FONT> <FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> In 2018, this trial moved into the dose escalation phase within the second dose cohort, with patients in Cohort 2 receiving target
doses of 1&nbsp;billion SPEAR T-cells. </FONT></DD></DL>
</DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Successful transition of NY-ESO program  </I></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> During 2018, a fourth SPEAR T-cell, the NY-ESO SPEAR T-cell was transitioned to GlaxoSmithKline ("GSK") following GSK's exercise of its option
to obtain an exclusive global license to the NY-ESO SPEAR T-cell program in September 2017. GSK has assumed full responsibility for all development, manufacturing and commercialization activities for
the NY-ESO SPEAR T-cell including progression of this SPEAR T-cell into further clinical trials. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>40</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=48,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=927530,FOLIO='40',FILE='DISK112:[19ZAF1.19ZAF44001]CK44001A.;8',USER='CHE109569',CD=';1-MAR-2019;12:03' -->
<A NAME="page_ck44001_1_41"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Optimization and expansion of our manufacturing capabilities  </I></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Impressive progress was achieved in manufacturing: </FONT> <FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we initiated manufacture of cell product in January 2018 at the Adaptimmune SPEAR T-cell manufacturing plant in Philadelphia </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we scaled to the routine manufacture of SPEAR T-cells at target doses to treat patients across a broad range of solid tumors </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we established a dedicated vector manufacturing capability in the U.K. and our first vector production run to support pilot
clinical trials is anticipated for late 2019  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we secured existing vector production with our third party vendor </FONT><FONT SIZE=2>
<BR><BR></FONT></DD></DL>
</DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> These achievements enable us to continue to develop manufacturing enhancements and improvements with the aim of reducing the time taken to
manufacture and supply patient products. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Progression of our pre-clinical pipeline  </I></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We continued to maintain development of our pipeline, including: </FONT> <FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> making good progress with an off-the-shelf product and presenting progress to date at ASGCT 2018  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> continuing to develop multiple next generation approaches, with the goal of having the first next generation construct ready for
IND submission in 2H 2019  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> investigating new targets and additional HLAs to be brought to the clinic beyond 2019 </FONT></DD></DL>
</DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other corporate achievements  </I></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The Company completed a Registered Direct Offering raising net proceeds of approximately $100&nbsp;million in September 2018 </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2018 Executive Compensation Highlights  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following key compensation actions were taken with respect to our NEOs for 2018:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Base Salaries&#151;the 2018 base salaries for our NEOs were determined, and were effective from January&nbsp;1, 2018. A summary of the
2018 base salaries for our NEOs, together with the percent increase compared to their 2017 base salaries, is set forth in the table below. </FONT></DD></DL>
</UL>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="53pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 Annual<BR>
Base Salary<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 Annual<BR>
Base Salary<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>% Increase </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>James Noble(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>520,399</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>536,011</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adrian Rawcliffe</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>443,700</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>457,011</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rafael Amado(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>442,900</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>458,402</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Helen Tayton-Martin(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>364,279</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>382,566</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William Bertrand</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>400,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>416,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Compensation
paid to Mr.&nbsp;Noble and Dr.&nbsp;Tayton-Martin is denominated in pounds sterling. For purposes of this table, 2017 and 2018 amounts for
Mr.&nbsp;Noble and Dr.&nbsp;Tayton-Martin in the table above have been converted based on the pound sterling/U.S. dollar exchange rate in effect as of December&nbsp;31, 2018
(&pound;1/$1.27602). </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>41</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=49,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=431720,FOLIO='41',FILE='DISK112:[19ZAF1.19ZAF44001]CK44001A.;8',USER='CHE109569',CD=';1-MAR-2019;12:03' -->
<A NAME="page_ck44001_1_42"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
2018 annual base salary for Dr.&nbsp;Amado was increased to $481,322 effective August&nbsp;1, 2018 on his promotion to the new role of President,
Research&nbsp;&amp; Development.  </FONT></DD></DL>
 </DIV>
 <UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Annual Cash Bonuses&#151;Our NEOs received annual cash bonuses at 85% of their target annual cash bonus opportunities. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Long-Term Incentive Compensation&#151;Our NEOs were granted long-term incentive compensation opportunities in January 2018 in the form
of stock options to purchase ordinary shares, in amounts ranging from 789,024 options to 1,052,028 options, with grant date fair values ranging from $685,114 to $913,480, including options covering
2,104,056 ordinary shares granted to our CEO, with a grant date fair value of $1,826,960. In August 2018, Dr.&nbsp;Amado was promoted to the new role of President, Research and Development, bringing
together our clinical and research teams under a single leadership, and was granted an option covering 678,720 ordinary shares with a grant date fair value of $977,579. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation Philosophy and Program Design  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our philosophy in setting compensation policies for executive officers has two objectives: (1)&nbsp;to attract and retain a highly skilled
team of executives and (2)&nbsp;to align our executives' interests with those of our shareholders by rewarding short-term and long-term performance. Our Remuneration Committee believes that
executive compensation should be directly linked both to continuous improvements in corporate performance ("pay for performance") and accomplishments that are expected to increase shareholder value. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
furtherance of this goal, our Remuneration Committee has adhered to the following guidelines as a foundation for decisions that affect the levels of
compensation:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> provide a competitive total compensation package that enables the Company to attract and retain highly qualified executives with the skills and
experience required for the achievement of business goals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> align compensation elements with the Company's annual goals and long-term business strategies and objectives; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> promote the achievement of key strategic and financial performance measures by linking short-term and long-term cash and equity incentives to
the achievement of corporate and individual performance goals; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> align executives' incentives with the creation of shareholder value. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on this philosophy, our performance-driven executive compensation program has three primary components: base salary, annual cash bonuses, and long-term equity-based compensation.
Our Remuneration Committee believes that cash compensation in the form of base salary and annual bonuses provides our executives with short-term rewards for success in operations, and that long-term
compensation through the grant of equity awards aligns the objectives of management with those of our shareholders with respect to long-term performance and success. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
it does not have any formal policies for allocating compensation among the three components, our Remuneration Committee reviews relevant competitive market data and uses its
judgment to determine the appropriate level and mix of compensation on an annual basis to ensure that compensation levels and opportunities are competitive and that we are able to attract and retain
capable executive officers to work for our long-term prosperity and shareholder value, without taking unnecessary or excessive risks. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>42</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=50,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=544862,FOLIO='42',FILE='DISK112:[19ZAF1.19ZAF44001]CK44001A.;8',USER='CHE109569',CD=';1-MAR-2019;12:03' -->
<A NAME="page_ck44001_1_43"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pay-for-Performance  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We view our compensation practices as an avenue to communicate our goals and standards of conduct and a means to reward our NEOs for their
achievements. We believe our executive compensation program is reasonable, competitive, and appropriately balances the goals of attracting, motivating, rewarding, and retaining our executive officers
and that it therefore promotes stability in our leadership. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
ensure our NEOs' interests are aligned with those of our shareholders and to motivate and reward them for achievement of our yearly corporate performance objectives, a significant
portion of their target annual total direct compensation opportunity is "at-risk" and will vary above or below target levels commensurate with our performance. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
emphasize performance-based compensation that appropriately rewards our executive officers for delivering financial, operational, and strategic results that meet or exceed
pre-established goals through our annual cash bonus plan, as well as share options that make up a significant portion of our long-term incentive compensation arrangements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
target total direct compensation opportunity for our CEO and our other Named Executive Officers during 2018 reflects this philosophy. The substantial majority of our 2018
compensation to our NEOs was in the form of equity incentive awards, which our Remuneration Committee believes aligns our NEOs' interests with those of our shareholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following charts illustrate the portion of compensation attributable to base salary, annual performance-based cash incentive awards (annual bonus) and long-term equity incentive
awards for our Chief Executive Officer, and the average for our other NEOs, as a group, for the year ended December&nbsp;31, 2018. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CEO 2018 Compensation Mix  </I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g751951.jpg" ALT="GRAPHIC" WIDTH="435" HEIGHT="247">
  </B></FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>43</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=51,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=483413,FOLIO='43',FILE='DISK112:[19ZAF1.19ZAF44001]CK44001A.;8',USER='CHE109569',CD=';1-MAR-2019;12:03' -->
<A NAME="page_ck44001_1_44"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Named Executive Officers 2018 Average Compensation Mix  </I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g151688.jpg" ALT="GRAPHIC" WIDTH="435" HEIGHT="247">
  </B></FONT></P>

</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2018 Executive Compensation Policies and Practices  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We endeavor to maintain sound executive compensation policies and practices, including compensation-related corporate governance standards,
consistent with our executive compensation philosophy. During 2018 our executive compensation policies and practices included the following: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Remuneration Committee of Independent Directors.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Our Remuneration Committee
is composed of all independent directors.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Annual Compensation Review.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Our Remuneration Committee undertakes a
comprehensive review of compensation of our executives, including our NEOs, on an annual basis.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Independent Compensation Consultant.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Our Remuneration Committee engages its
own compensation consultant, and reviews its independence from management. The Remuneration Committee engaged Willis Towers Watson to assist with its 2018 compensation reviews.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Risk Analysis.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;We believe the structure of our executive compensation
program minimizes the likelihood of inappropriate risk-taking by our executive officers.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Compensation At-Risk.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Our executive compensation program is designed so
that a significant portion of compensation is "at risk" based on Company performance, as well as short-term cash and long-term equity incentives to align the interests of our executive officers and
shareholders. None of our employment agreements with our NEOs provides any guarantees relating to base salary increases or the amounts of any annual incentive awards or long-term equity awards. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> No Special Retirement Benefits.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;We do not provide special pension
arrangements or post-retirement health coverage for our executives or employees. Our U.S.-based executives and other U.S.-based employees are eligible to participate in our Section&nbsp;401(k) plan,
which is a retirement savings defined contribution plan established in accordance with Section&nbsp;401(a) of the Code. Our U.K.-based exeuctives and other U.K.-based employees are eligible to
participate in our U.K. defined contribution plan.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Policy Against Hedging, Speculative Trading and Pledging our Stock.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Our
insider trading policy prohibits our employees, including our NEOs, and our directors from engaging in "hedging" or other inherently speculative transactions with respect to our securities or
borrowing against our securities.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> No Special Perquisites.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Consistent with other high growth,
development-stage biotechnology companies, we generally do not provide perquisites or other personal benefits to our executive </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>44</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=52,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=544734,FOLIO='44',FILE='DISK112:[19ZAF1.19ZAF44001]CK44001A.;8',USER='CHE109569',CD=';1-MAR-2019;12:03' -->
<A NAME="page_ck44001_1_45"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>officers
other than those we provide to our employees generally. From time to time we have provided relocation assistance benefits to our executive officers and other employees in order to attract
talent.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> No Special Health or Welfare Benefits.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Our executive officers participate
in broad-based company-sponsored health and welfare benefits programs on the same basis as our other employees. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Process for Setting Executive Compensation  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Role of the Remuneration Committee  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Remuneration Committee is responsible for reviewing and establishing our executive compensation policy and determines the framework for the
compensation of our Company's senior executive officers. Our Remuneration Committee determines the remuneration of our NEOs (except for our CEO) and makes recommendations regarding the compensation of
our CEO to the Board for its determination. Our Remuneration Committee also determines the corporate performance goals under the Company's annual bonus plan and achievement of these goals, and
determines the policy for and scope of service agreements for the executive officers and contractual severance payments. Our Remuneration Committee makes recommendations regarding these matters in
respect of our CEO to our Board for its determination. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
our Remuneration Committee draws on a number of resources, including input from our CEO and independent compensation consultants, to make decisions regarding the Company's
executive compensation program, ultimate decision-making authority rests with the Remuneration Committee, subject in relation to our CEO's compensation, to approval by the independent members of the
Board. The Remuneration Committee relies upon the judgment of its members in making compensation decisions, after reviewing the performance of the Company and evaluating an executive's performance
during the year against established goals, operational performance and responsibilities. In addition, the Remuneration Committee incorporates judgment in the assessment process to respond to and
adjust for the evolving business environment. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Role of Chief Executive Officer  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Remuneration Committee solicits and reviews our CEO's recommendations and proposals with respect to to annual cash bonus opportunities,
long-term incentive compensation opportunities, program structures and other compensation-related matters for our executive officers
(other than with respect to his own compensation). Our Remuneration Committee reviews and discusses these recommendations and proposals with our CEO and uses them as one factor in determining and
approving the compensation for our executive officers (other than our CEO). Our Remuneration Committee works directly with its compensation consultants to determine compensation actions our CEO, who
does not participate in deliberations or determination of his own compensation. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Role of Compensation Consultant  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Remuneration Committee is authorized to engage a compensation consultant or other advisors to review our executive officers' compensation,
including a benchmarking analysis against the compensation of executive officers at comparable companies, to ensure that our compensation is market competitive, with the goal of retaining and
adequately motivating our senior management. During 2017, our Remuneration Committee retained Willis Towers Watson to make recommendations for updating our compensation peer group, and to review and
make recommendations regarding our executive and director compensation for 2018. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>45</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=53,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=583560,FOLIO='45',FILE='DISK112:[19ZAF1.19ZAF44001]CK44001A.;8',USER='CHE109569',CD=';1-MAR-2019;12:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_cm44001_1_46"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Remuneration Committee regularly evaluates the performance of its compensation consultants, considers alternative compensation consultants, and has the final
authority to engage and terminate such services. The Remuneration Committee has assessed the independence of Willis Towers Watson pursuant to SEC rules and the applicable listing standards of The
Nasdaq Global Market and concluded that no conflict of interest exists that would prevent Willis Towers Watson from serving as an independent consultant to our Remuneration Committee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
2018, Willis Towers Watson regularly attended the meetings of our Remuneration Committee (both with and without management present) and provided the following
services:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> consulting with the Remuneration Committee chair and other members between committee meetings; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> conducting a review of the 2017 compensation comparator peer group and making recommendations, as appropriate, for changes for use when making
2018 compensation decisions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> providing competitive market data based on the compensation peer group for our executive officer positions and evaluating how the compensation
we pay our executive officers compares both to our performance and to how the companies in our compensation peer group compensate their executives; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and analyzing the base salary levels, annual cash bonus opportunities, and long-term incentive compensation opportunities of our
executive officers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> assessing executive compensation trends within our industry, and updating on corporate governance and regulatory issues and developments; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing market equity compensation practices, including burn rate and overhang, and advising on the mix of equity award types; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> providing competitive market data based on the compensation peer group for the non-employee members of our Board and evaluating the
compensation we pay to our non-employee directors. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Competitive Positioning  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Remuneration Committee reviews the compensation of similarly-situated executive officers at companies that we consider to be our peers,
taking into consideration the experience, position and functional role, level of responsibility and uniqueness of applicable skills of both our executive officers and those of our peers, and the
demand and competitiveness for attracting and retaining an individual with each executive officer's specific expertise and experience. While this analysis is helpful in determining market-competitive
compensation for senior management, it is only one factor in determining our executive officers' compensation, and our Remuneration Committee exercises its judgment in determining the nature and
extent of its use. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of comparing our executive compensation against the competitive market, our Remuneration Committee reviews and considers the compensation levels and practices of a group of
comparable biotechnology companies. The companies in this compensation peer group for 2018 were selected by our Remuneration Committee in October 2017, in consultation with Willis Towers Watson, on
the basis of their similarity to us in terms of size, market capitalization, stage of development, research and development spend, industry sector, business strategy, and number of employees. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>46</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=54,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=69221,FOLIO='46',FILE='DISK112:[19ZAF1.19ZAF44001]CM44001A.;10',USER='CHE109868',CD=';1-MAR-2019;12:03' -->
<A NAME="page_cm44001_1_47"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Set
forth in the following table is a list of the peer group used for 2017 as compared to the peer group used for 2018: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Acceleron Pharma&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Acceleron Pharma&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Aduro BioTech,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Aduro BioTech,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Agenus&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Alder Biopharmaceuticals,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Alder Biopharmaceuticals,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Atara Biotherapeutics, Inc</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Atara Biotherapeutics, Inc</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>bluebird bio,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Bellicum Pharmaceuticals,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Cytokinetics, Incorporated</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>bluebird bio,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Dynavax Technologies Corp.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Circassia Pharmaceuticals&nbsp;Plc</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Epizyme,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Cytokinetics, Incorporated</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Five Prime Therapeutics,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Epizyme,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>GW Pharmaceuticals&nbsp;plc</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>GW Pharmaceuticals&nbsp;plc</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>ImmunoGen, Inc</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>ImmunoGen,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Intellia Therapeutics,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Inovio Pharmaceuticals,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Inovio Pharmaceuticals,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Juno Therapeutics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>MacroGenics,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Kite Pharma,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Oxford BioMedica&nbsp;plc</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>MacroGenics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Rigel Pharmaceuticals,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Sangamo Therapeutics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Spark Therapeutics,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Spark Therapeutics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Xencor,&nbsp;Inc.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
analyze the compensation practices of the companies in our compensation peer group, Willis Towers Watson gathered data from public filings (primarily proxy statements) and from the
Radford Global Life Sciences Survey (including a custom cut). This market data was then used as a reference point for our Remuneration Committee to assess our current compensation levels in the course
of its deliberations on forms and amounts of compensation. Given our objective of attracting, retaining, motivating, and rewarding a highly-skilled team of executive officers and other employees, we
aim to deliver a total compensation package that is within a competitive range around the median as compared to peers, with an emphasis on equity incentive compensation so as to more effectively tie
our NEOs' and employees' interests to those of our shareholders. In light of this, when undertaking its competitive analysis, our Remuneration Committee reviews data pertaining to the
25<SUP>th</SUP>, 50<SUP>th</SUP>&nbsp;and 75<SUP>th</SUP>&nbsp;percentiles for base salary, total cash compensation (base salary plus annual bonus) and long-term incentive compensation.
This competitive analysis is one factor, among others, taken into account by our Remuneration Committee in assessing current compensation levels and recommending changes to compensation or additional
awards. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Remuneration Committee reviews our compensation peer group at least annually and makes adjustments to its composition, taking into account changes in both our business and the
businesses of the companies in the peer group. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Compensation Program and Compensation Decisions for the Named Executive Officers  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The components of our executive compensation program in 2018 for our NEOs consisted of base salary, an annual cash bonus opportunity, and a
long-term incentive compensation opportunity delivered in the form of options to purchase ordinary shares (including RSU-style options). </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>47</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=55,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=1045661,FOLIO='47',FILE='DISK112:[19ZAF1.19ZAF44001]CM44001A.;10',USER='CHE109868',CD=';1-MAR-2019;12:03' -->
<A NAME="page_cm44001_1_48"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Annual Base Salary  </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The base salaries of our executive officers are designed to compensate them for day-to-day services rendered during the fiscal year. Appropriate
base salaries are used to recognize the experience, skills, role and responsibilities required of each executive officer and to allow us to attract and retain individuals capable of leading us to
achieve our business goals in competitive market conditions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
initial base salaries of our executive officers are established through arm's-length negotiation at the time we hire the individual executive officer, taking into account his or her
position, qualifications, experience, prior salary level, and the base salaries of our other executive officers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Thereafter,
the base salaries of our executive officers are reviewed at least annually by our Remuneration Committee, and by our Board in the case of our CEO, and adjustments are made to
reflect Company and individual performance, as well as competitive market practices. Our Remuneration Committee also takes into account subjective performance criteria, such as an executive officer's
ability to lead, organize and motivate others, set realistic goals to be achieved in his or her respective area, and recognize and pursue new business opportunities that enhance our growth and
success. Our Remuneration Committee does not apply specific formulas to determine increases, but instead makes an evaluation of each executive officer's contribution to our long-term success. Annual
adjustments to base salaries are effective as of January&nbsp;1 of each year, with off-cycle adjustments to base salaries made under special circumstances, such as promotions or increased
responsibilities. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Changes in base salaries for fiscal year 2018  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December 2017, our Remuneration Committee reviewed the base salaries of our NEOs, taking into consideration a competitive market analysis
prepared by Willis Towers Watson, the recommendations of our CEO (except with regard to his own base salary), and the other factors described above. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Following
this review, our Remuneration Committee determined increases in the annual base salaries of our NEOs, other than our CEO, with all revised annual base salaries effective from
January&nbsp;1, 2018. A 3% increase in the base salary of Mr.&nbsp;Rawcliffe was approved, resulting in a revised base salary of $457,011. A 3.5% increase in the base salary of Dr.&nbsp;Amado
was approved, resulting in a revised base salary of $458,402. A 4% increase in the base salary of Mr.&nbsp;Bertrand was approved, resulting in a revised base salary of $416,000. A 5% increase in the
base salary of Dr.&nbsp;Tayton-Martin was approved, resulting in a revised base salary of $382,566. Effective from August&nbsp;1, 2018, Dr.&nbsp;Amado was promoted to the new role of President,
Research and Development, bringing together our clinical and research teams under a single leadership, and our Remuneration Committee approved an increase in Dr.&nbsp;Amado's base salary from
$458,402 to $481,322 effective from August&nbsp;1, 2018. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
regard to our CEO, our Remuneration Committee recommended, and the Board approved, a 3% increase to Mr.&nbsp;Noble's base salary, resulting in a revised base salary of $536,011
effective from January&nbsp;1, 2018. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>48</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=56,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=683047,FOLIO='48',FILE='DISK112:[19ZAF1.19ZAF44001]CM44001A.;10',USER='CHE109868',CD=';1-MAR-2019;12:03' -->
<A NAME="page_cm44001_1_49"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
summary of the 2018 base salaries for our NEOs, together with the percent increase compared to their 2017 base salaries, is set forth in the table below. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="84pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="84pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="53pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 Annual Base<BR>
Salary ($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 Annual Base<BR>
Salary ($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>% Increase </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>James Noble(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>520,399</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>536,011</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adrian Rawcliffe</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>443,700</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>457,011</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rafael Amado(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>442,900</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>458,402</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Helen Tayton-Martin(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>364,279</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>382,566</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William Bertrand</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>400,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>416,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Compensation
paid to Mr.&nbsp;Noble and Dr.&nbsp;Tayton-Martin is denominated in pounds sterling. For purposes of this table, 2017 and 2018 amounts for
Mr.&nbsp;Noble and Dr.&nbsp;Tayton-Martin in the table above have been converted based on the pound sterling/U.S. dollar exchange rate in effect as of December&nbsp;31, 2018
(&pound;1/$1.27602).
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
2018 annual base salary for Dr.&nbsp;Amado was increased to $481,322 effective August&nbsp;1, 2018 on his promotion to the new role of President,
Research&nbsp;&amp; Development.  </FONT></DD></DL>
 </DIV>
 <UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Annual Cash Bonus Plan  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our NEOs are eligible to earn annual performance-based cash bonuses, which are designed to provide appropriate incentives to our executive
officers to achieve annual corporate goals and to reward them for individual performance towards these goals. The annual performance-based bonus each NEO is eligible to receive is generally based on
the extent to which we achieve the corporate objectives that the Board establishes each year, following a recommendation from our Remuneration Committee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Remuneration Committee determines annual bonuses for our NEOs, and the Board determines the annual bonus for our CEO. At the end of the year, the Board and our Remuneration Committee
review our performance and approve the extent to which we achieved each of these corporate goals. Generally, the Board and Remuneration Committee will assess each NEO's individual contributions
towards reaching our annual corporate goals but does not typically establish specific individual goals for our NEOs. Our Remuneration Committee and our Board may award above-target bonuses, in amounts
up to 150% of the target annual cash bonus opportunities for extraordinary performance in any given year. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
target annual cash bonus opportunities of our NEOs for 2018 are summarized in the table below. All target annual cash bonus opportunities were set as a percentage of base salaries. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 Target<BR>
Annual<BR>
Cash Bonus<BR>
Opportunity<BR>
% </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 Target<BR>
Annual<BR>
Cash Bonus<BR>
Opportunity<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>James Noble(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>55</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>294,806</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adrian Rawcliffe</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>45</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>205,655</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rafael Amado(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>233,976</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Helen Tayton-Martin(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>45</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>172,155</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William Bertrand(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>45</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>187,200</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Compensation
paid to Mr.&nbsp;Noble and Dr.&nbsp;Tayton-Martin is denominated in pounds sterling. For purposes of this table, amounts for Mr.&nbsp;Noble and
Dr.&nbsp;Tayton-Martin in the </FONT></DD></DL>
 </DIV>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>49</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=57,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=546666,FOLIO='49',FILE='DISK112:[19ZAF1.19ZAF44001]CM44001A.;10',USER='CHE109868',CD=';1-MAR-2019;12:03' -->
<A NAME="page_cm44001_1_50"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <UL>

<P style="font-family:times;"><FONT SIZE=2>table
above have been converted based on the pound sterling/U.S. dollar exchange rate in effect as of December&nbsp;31, 2018 (&pound;1/$1.27602).  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
2018 Target Annual Cash Bonus Opportunity percent for Dr.&nbsp;Amado was increased from 45% to 50% effective August&nbsp;1, 2018 on his promotion to the new
role of President, Research&nbsp;&amp; Development. The 2018 Target Annual Cash Bonus Opportunity amount represented 50% of Dr.&nbsp;Amado's pro-rated 2018 base salary received of $467,952 (based on
the aggregate of six months of his base salary of $458,402, from January&nbsp;1, 2018 through July&nbsp;31, 2018, and six months of his base salary of $481,322, from August&nbsp;1, 2018 through
December&nbsp;31, 2018).  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
corporate goals used in our 2018 annual cash bonus plan were proposed by management, and reviewed and approved by our Board following recommendation by our Remuneration Committee. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
primary goal in 2018 was to progress the development of the Group with our key corporate goals including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> advancement of our clinical trials for ADP-A2M10, ADP-A2M4 and ADP-A2AFP; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> continuing to use our SPEAR T-cell platform to generate SPEAR T-cells for cancers where existing therapeutic approaches are limited; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> continuing to understand, further enhance and improve the effectiveness and persistence of our SPEAR T-cell therapies; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the optimisation and expansion of our process development and manufacturing capabilities to maintain our leadership position in the TCR space
and the continued expansion of our intellectual property portfolio. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2018 annual bonus payments  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December 2018, our Remuneration Committee and our Board reviewed our 2018 corporate goals and determined that we had achieved most of our
corporate goals. We believe that 2018 was a year of strong operational performance for us due, in large part, to our achievement of clinical and manufacturing milestones, as described below: </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Advancement of our clinical trials for ADP-A2M10, ADP-A2M4 and ADP-A2AFP  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have three SPEAR T-cells in clinical trials, ADP-A2M10 (MAGE-A10), ADP-A2M4 (MAGE-A4) and ADP-A2AFP (AFP). </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Two Phase&nbsp;1 clinical trials are ongoing with ADP-A2M10. The first clinical trial is in patients with non-small cell lung cancer
("NSCLC"). The second clinical trial is in patients with three cancer tumor types, urothelial, melanoma and head and neck cancers.  </FONT> <FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> In 2018, both trials have progressed to the expansion phase, with patients being treated with up to 10&nbsp;billion transduced
SPEAR T-cells. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD></DL>
</DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> A Phase&nbsp;1 clinical trial is ongoing with ADP-A2M4 in bladder, melanoma, head and neck, ovarian, NSCLC, synovial sarcoma, myxoid round
cell liposarcoma ("MRCLS"), esophageal and gastric cancers.  </FONT> <FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> In 2018, this trial progressed to the expansion phase with patients being treated with up to 10&nbsp;billion transduced SPEAR
T-cells. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD></DL>
</DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> A Phase&nbsp;1 clinical trial is ongoing with ADP-A2AFP in patients with hepatocellular cancer. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>50</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=58,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=578446,FOLIO='50',FILE='DISK112:[19ZAF1.19ZAF44001]CM44001A.;10',USER='CHE109868',CD=';1-MAR-2019;12:03' -->
<A NAME="page_cm44001_1_51"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> In 2018, this trial moved into the dose escalation phase within the second dose cohort, with patients in Cohort 2 receiving target
doses of 1&nbsp;billion SPEAR T-cells. </FONT></DD></DL>
</UL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Successful transition of NY-ESO program  </I></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> During 2018, a fourth SPEAR T-cell, the NY-ESO SPEAR T-cell was transitioned to GlaxoSmithKline ("GSK") following GSK's exercise of its option
to obtain an exclusive global license to the NY-ESO SPEAR T-cell program in September 2017. GSK has assumed full responsibility for all development, manufacturing and commercialization activities for
the NY-ESO SPEAR T-cell including progression of this SPEAR T-cell into further clinical trials. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Optimization and expansion of our manufacturing capabilities  </I></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Impressive progress was achieved in manufacturing: </FONT> <FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we initiated manufacture of cell product in January 2018 at the Adaptimmune SPEAR T-cell manufacturing plant in Philadelphia </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we scaled to the routine manufacture of SPEAR T-cells at target doses to treat patients across a broad range of solid tumors </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we established a dedicated vector manufacturing capability in the U.K. and our first vector production run to support pilot
clinical trials is anticipated for late 2019  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we secured existing vector production with our third party vendor </FONT><FONT SIZE=2>
<BR><BR></FONT></DD></DL>
</DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> These achievements enable us to continue to develop manufacturing enhancements and improvements with the aim of reducing the time taken to
manufacture and supply patient products. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Progression of our pre-clinical pipeline  </I></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We continued to maintain development of our pipeline, including: </FONT> <FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> making good progress with an off-the-shelf product and presenting progress to date at ASGCT 2018  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> continuing to develop multiple next generation approaches, with the goal of having the first next generation construct ready for
IND submission in 2H 2019  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> investigating new targets and additional HLAs to be brought to the clinic beyond 2019 </FONT></DD></DL>
</DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other corporate achievements  </I></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The Company completed a Registered Direct Offering raising net proceeds of approximately $100&nbsp;million in September 2018 </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Remuneration Committee determined an overall corporate performance level of 85% of target for purposes of the 2018 Bonus Plan for our NEOs other than our CEO, and recommended an
overall corporate performance level of 85% in respect of our CEO, which was approved by the Board. This resulted in awards at 85% of their target annual cash bonus opportunities for 2018 for our NEOs. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>51</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=59,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=27953,FOLIO='51',FILE='DISK112:[19ZAF1.19ZAF44001]CM44001A.;10',USER='CHE109868',CD=';1-MAR-2019;12:03' -->
<A NAME="page_cm44001_1_52"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
2018 bonus payments are summarized in the table below: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 Target<BR>
Annual<BR>
Cash Bonus<BR>
Opportunity<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 Actual<BR>
Annual<BR>
Cash Bonus<BR>
Payment<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>James Noble(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>294,806</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>250,585</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adrian Rawcliffe</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>205,655</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>174,807</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rafael Amado(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>233,976</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>198,879</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Helen Tayton-Martin(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>172,155</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>146,331</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William Bertrand</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>187,200</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>159,120</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Compensation
paid to Mr.&nbsp;Noble and Dr.&nbsp;Tayton-Martin is denominated in pounds sterling. For purposes of this table, 2018 amounts for Mr.&nbsp;Noble
and Dr.&nbsp;Tayton-Martin in the table above have been converted based on the pound sterling/U.S. dollar exchange rate in effect as of December&nbsp;31, 2018 (&pound;1/$1.27602).
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
2018 Actual Cash Bonus Payment amount for Dr.&nbsp;Amado was a pro-rated amount, based on his pro-rated 2018 base salary received of $467,952 (based on the
aggregate of six months of his base salary of $458,402, from January&nbsp;1, 2018 through July&nbsp;31, 2018, and six months of his base salary of $481,322, from August&nbsp;1, 2018 through
December&nbsp;31, 2018).  </FONT></DD></DL>
 </DIV>
 <UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Long-Term Incentive Compensation  </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We provide long-term incentive compensation to our executive officers through the grant of equity awards. We believe that equity awards create
incentives for our executive officers to assist with the achievement of near and long term corporate objectives to create long-term shareholder value and align their interests with those of our
shareholders by creating a return tied to the performance of our stock price. We also believe equity awards create an ownership culture. In addition, the vesting requirements of our equity awards
contribute to executive retention by providing an incentive to our executive officers to remain employed by us during the vesting period. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity Award Grant Policy.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We have an equity award grant policy that formalizes our process for granting equity-based awards to
officers and
employees. Under our equity award grant policy, all grants to our CEO must be approved by our Board, all grants to our other executive officers must be approved by our Remuneration Committee and all
grants to other employees must be granted within guidelines approved by our Remuneration Committee. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Generally,
equity awards are granted at the time an executive officer commences employment. Thereafter, equity awards may be granted at varying times and in varying amounts in the
discretion of our Remunerrtion Committee or, if awards are being granted to our Chief Executive Officer, in the discretion of the Board, but are generally made once a year unless such executive
officer is promoted, or for recognition of outstanding performance. None of our executive officers is currently party to an employment agreement that provides for an automatic grant of stock options
or other equity awards. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
trade American Depositary Shares (ADSs) on the Nasdaq Global Select Market, or NASDAQ, and one ADS represents six ordinary shares. Our stock options cover our ordinary shares. The
exercise price of our stock options, other than our RSU-style options, is equal to the fair market value of our ordinary shares, which is based on the closing market price on NASDAQ of an ADSs divided
by six. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>52</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=60,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=372397,FOLIO='52',FILE='DISK112:[19ZAF1.19ZAF44001]CM44001A.;10',USER='CHE109868',CD=';1-MAR-2019;12:03' -->
<A NAME="page_cm44001_1_53"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Historically,
we have granted equity awards to our employees, including our NEOs, in the form of options to purchase our ordinary shares. In December 2017, our Remuneration Committee
determined that an increasing number of companies in our compensation peer group grant full value awards, such as restricted stock unit awards and approved the addition of RSU-style options (which are
substantively similar to restricted stock units) to our compensation program to attract and retain highly qualified executives and employees. In this regard, while both stock options and RSU-style
options enable our executive officers to benefit, like shareholders, from any increases in the value of our stock, our stock options deliver future value only if the value of our stock increases above
the exercise price. In contrast, RSU-style options are set with an exercise price fixed at the nominal value of an ordinary share so, during periods of stock market volatility, RSU-style options may
help retain employees. In addition, full value awards, such as RSU-style options, are less dilutive to existing shareholders since fewer shares are needed to achieve an equivalent value relative to
stock options. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
stock options generally vest as to 25% upon the first anniversary of the grant date and 1/36th&nbsp;of the remaining shares each month thereafter until such award is fully vested
on the four year anniversary of the grant date, subject to the holder's continued service with us. Our RSU-style options vest in four annual installments from the grant date, subject to the holder's
continued service with us. The terms of the equity awards are governed by our option plans, as described under the heading "</FONT><FONT SIZE=2><I>Equity Compensation Plan
Information</I></FONT><FONT SIZE=2>" below. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
determining the appropriate mix of stock options and RSU-style options, our Remuneration Committee and the Board (in the case of grants to the CEO) consider the current stock and
other equity holdings of each executive officer and competitive market data of the types of equity compensation provided to executive officers by the companies in our compensation peer group, with a
goal of reaching a mix that would provide the appropriate incentives while staying competitive in our market. Regular LTI awards for each of our NEOs were more heavily weighted towards stock options
(75%) than RSU-style options (25%). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
with their other elements of compensation, our Remuneration Committee determines the amount of long-term incentive compensation for our NEOs (except for our CEO), and recommends to
the Board the amount of long-term incentive compensation for our CEO, as part of its annual compensation review. Our Remuneration Committee does so after taking into consideration a competitive market
analysis prepared by its compensation consultant, the recommendations of our CEO (except with respect to his own long-term incentive compensation), the outstanding equity holdings of each executive
officer, the proportion of our total shares outstanding used for annual employee long-term incentive compensation awards (our "burn rate") in relation to the proportions of the companies in our
compensation peer group, the potential voting power dilution to our shareholders (our "overhang") in relation to the practices of the companies in our compensation peer group, and the other factors
described above. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2018 Equity Awards  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In January 2018, after considering the factors described above, our Remuneration Committee granted stock options and RSU-style options to our
NEOs and our Remuneration Committee </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>53</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=61,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=497956,FOLIO='53',FILE='DISK112:[19ZAF1.19ZAF44001]CM44001A.;10',USER='CHE109868',CD=';1-MAR-2019;12:03' -->
<A NAME="page_cm44001_1_54"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>recommended,
and the Board granted, stock options and RSU-style options to our CEO, in the following amounts: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="74pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="74pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="75pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Named Executive Officer


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Options for<BR>
ordinary shares<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>RSU-Style<BR>
Options for<BR>
ordinary shares<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Equity Awards<BR>
(Aggregate<BR>
Grant Date Fair<BR>
Value) ($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>James Noble</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,719,936</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>384,120</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,826,960</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adrian Rawcliffe</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>687,984</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>153,648</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>730,791</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rafael Amado</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>859,968</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>192,060</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>913,980</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Helen Tayton-Martin</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>687,984</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>153,648</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>730,791</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William Bertrand</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>644,976</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>144,048</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>685,114</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
August 2018, our Remuneration Committee granted RSU-style options covering 678,720 ordinary shares to Rafael Amado, on his promotion to the new role of President, Research&nbsp;&amp;
Development, which had a grant date fair value of $977,579. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Retirement, Health, Welfare  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our NEOs are eligible to participate in our employee benefit plans and programs, including medical and dental benefits and life insurance, to
the same extent as our other full-time employees, subject to the terms and eligibility requirements of those plans. We also sponsor a 401(k) defined contribution plan in which our NEOs based in the
United States may participate, subject to limits imposed by the Internal Revenue Code, to the same extent as all of our other full-time employees. During 2018, we made discretionary employer matching
contributions equal to 50% of the first 4% of the elective contributions made by participants in the 401(k) plan. These matching contributions are subject to a vesting schedule. In addition, we made a
3% discretionary Safe Harbor match which is fully vested as of the date on which the contribution is made. We believe that providing a vehicle for tax-deferred retirement savings through our 401(k)
plan adds to the overall desirability of our executive compensation package and further incentivizes our employees, including our NEOs, in accordance with our compensation policies. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Retirement Plans  </I></B></FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


401(k) Plan  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We maintain a tax-qualified retirement plan for our U.S.-based employees that provides eligible employees with an opportunity to save for
retirement on a tax-advantaged basis. We make discretionary employer matching contributions equal to 50% of the first 4% of the elective contributions made by participants in the 401(k) plan. These
company matching contributions are subject to a vesting schedule. In addition, we make a 3% discretionary Safe Harbor matching contribution, which is fully vested as of the date of the contribution.
Pre-tax contributions are allocated to each participant's individual account and are then invested in selected investment alternatives according to the participant's directions. The 401(k) plan is
intended to qualify under Sections&nbsp;401(a) and 501(a) of the Internal Revenue Code. As a tax-qualified retirement plan, contributions to the 401(k) plan and earnings on those contributions are
not taxable to the employees until distributed from the 401(k) plan. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


U.K. Defined Contribution Plan  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the U.K., we maintain a defined contribution plan that provides all U.K. employees, including our NEOs based in the U.K., with an opportunity
to contribute a portion of their monthly salary into the plan. If an employee elects to participate in the plan, there is a minimum employee contribution of 3% of monthly salary and the maximum
contribution is subject to limits imposed by HM Revenue and Customs and pension legislation. The employee contribution to this plan is matched by an employer </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>54</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=62,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=735135,FOLIO='54',FILE='DISK112:[19ZAF1.19ZAF44001]CM44001A.;10',USER='CHE109868',CD=';1-MAR-2019;12:03' -->
<A NAME="page_cm44001_1_55"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>contribution
of up to a maximum of 5% of monthly salary. The method by which our U.K. employees participate is through a so-called "salary exchange" pursuant to which employees agree to a reduction in
monthly salary in an amount equal to the defined contribution plan election. Salary sacrifice arrangements enable employees and the Company to make tax and national insurance savings because the
employee's contribution is taken out of his or her gross pay. The amount of the reduction is contributed into the plan in addition to the employer contribution. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Perquisites and Other Personal Benefits  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consistent with other high growth, development-stage biotechnology companies, we do not currently view perquisites or other personal benefits as
a significant component of our executive compensation program. During 2018, none of our NEOs received perquisites or other personal benefits. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Generally,
we may provide perquisites or other personal benefits to our employees, including our NEOs, in limited circumstances where we believe it is appropriate to assist an individual
in the performance of his or her duties, to make our employees more efficient and effective, and for recruitment and retention purposes. We may provide, and have previously provided, our NEOs and
other employees with relocation benefits in order to attract critical talent. Any future perquisites or other personal benefits provided to our NEOs would require approval by the Remuneration
Committee and by the Board (in the case of the CEO). </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Tax and Accounting Considerations  </I></B></FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Deductability of Executive Compensation  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;162(m) of the Code limits the compensation deduction for a publicly-traded company for U.S. federal income tax purposes to not
more than $1&nbsp;million of remuneration paid to certain executive officers ("covered employees") in the company's taxable year (generally, its fiscal year). With respect to taxable years prior to
January&nbsp;1, 2018, remuneration in excess of $1&nbsp;million was exempt from this deduction limit if it qualified as "performance-based compensation" within the meaning of
Section&nbsp;162(m). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recently-enacted
tax legislation, effective for taxable years beginning after December&nbsp;31, 2017, expands the scope of Section&nbsp;162(m) such that all named executive officers
(i.e.,&nbsp;the corporation's principal executive officer, its principal financial officer, and the three highest compensated officers whose compensation is required to be reported under the U.S.
securities laws) are "covered employees." Additionally, anyone who was a covered employee in any year after 2016 will remain a covered employee for as long as he or she (or his or her beneficiaries)
receive compensation from the Company. Also, the legislation eliminates the exception to the deduction limit for commission-based compensation and performance-based compensation except with respect to
certain grandfathered arrangements in effect as of November&nbsp;2, 2017 that are not subsequently materially modified. Accordingly, compensation paid to our NEOs in excess of $1&nbsp;million
that, but for the limits under Section&nbsp;162(m), is otherwise deductible on a U.S. federal income tax return will not be deductible unless it qualifies for the transition relief applicable to
certain arrangements in place as of November&nbsp;2, 2017, as described above. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
maintain flexibility in compensating our NEOs in a manner designed to promote our corporate goals, our Remuneration Committee has not adopted a policy that all compensation payable to
our NEOs that is subject to Section&nbsp;162(m) must be deductible. Our Remuneration Committee intends to continue to consider the impact of Section&nbsp;162(m) rules in determining compensation
but will not necessarily limit compensation to amounts deductible under Section&nbsp;162(m); it intends to continue to provide future compensation in a manner consistent with the best interests of
the Company and its shareholders. It should also be noted that in the case of some of our NEOs, some or all of their </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>55</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=63,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=936256,FOLIO='55',FILE='DISK112:[19ZAF1.19ZAF44001]CM44001A.;10',USER='CHE109868',CD=';1-MAR-2019;12:03' -->
<A NAME="page_cm44001_1_56"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>compensation
is not deducted on a United States federal income tax return because they perform some or all of their services outside the United States, and accordingly, the deductibility of their
compensation is subject to, and deductible under the tax laws of other countries and is not limited by Section&nbsp;162(m). </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Accounting for share-based compensation  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We follow the Financial Accounting Standard Board's ASC Topic 718, or ASC Topic 718, for our share-based compensation awards. FASB ASC Topic 718
requires us to estimate and record a compensation expense for all share-based payment awards made to our employees and Board members over the vesting period of the award and based on the grant date
"fair value" of the award. This calculation is performed for accounting purposes and reported in the executive compensation tables required by the federal securities laws, even though the recipient of
the awards may never realize any value from their awards. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Clawback  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not have a formal compensation recovery policy, often referred to as a "clawback" policy, which would typically provide that the officers
or directors subject to the policy must reimburse the Company for any bonus or other incentive-based or equity-based compensation improperly received. Our Remuneration Committee intends to keep under
consideration the adoption of a clawback policy. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risk Assessment Concerning Compensation Practices and Policies  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Remuneration Committee reviews our compensation policies and practices to assess whether they encourage our employees to take inappropriate
risks. Our Remuneration Committee has determined that any risks arising from our compensation policies and practices for our employees are not reasonably likely to have a material adverse effect on
our Company as a whole. In
addition, our Remuneration Committee believes that the mix and design of the elements of executive compensation do not encourage management to assume excessive risks and, as described above under the
heading "Compensation Discussion and Analysis," significant compensation decisions, and decisions concerning the compensation of our executive officers, include subjective considerations by our
Remuneration Committee or our Board, which restrain the influence of formulae or objective factors on excessive risk taking. Finally, the mix of short-term compensation (in the form of base salary and
annual bonus, if any), and long-term incentive compensation (in the form of share options) also prevents undue focus on short-term results and helps align the interests of our executive officers with
the interests of our shareholders. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employment Arrangements  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have service agreements with each of our Chief Executive Officer and our Chief Business Officer and we have employment agreements with each
of our other NEOs. These agreements set forth the individual's base salary, bonus compensation, principles for equity compensation and other employee benefits as described above, as well as providing
the NEO with the opportunity to receive certain post-employment payments and benefits in the case of certain involuntary terminations of employment or resignations for good reason. The agreements also
prohibit our NEOs from engaging directly or indirectly in competition with us, recruiting or soliciting our employees, diverting our customers to a competitor, or disclosing our confidential
information or business practices. The Company's executive severance policy is applicable in relation to our NEOs and provides for post-employment compensation arrangements in certain circumstances. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>56</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=64,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=173790,FOLIO='56',FILE='DISK112:[19ZAF1.19ZAF44001]CM44001A.;10',USER='CHE109868',CD=';1-MAR-2019;12:03' -->
<A NAME="page_cm44001_1_57"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Post-Employment Compensation  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our post-employment compensation arrangements are designed to provide reasonable compensation to executive officers who leave the Company under
certain circumstances to facilitate their transition to new employment. Further, we seek to mitigate any potential employer liability and avoid future disputes or litigation by requiring a departing
executive officer to sign a separation and release agreement acceptable to us as a condition to receiving post-employment compensation payments or benefits. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Remuneration Committee and the Board do not consider specific amounts payable under these post-employment compensation arrangements when establishing annual compensation. It does
believe, however, that these arrangements are necessary to offer compensation packages that are competitive. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
more information on the service and employment agreements with our NEOs and post-employment compensation arrangements, see the discussion under the headings
"</FONT><FONT SIZE=2><I>Employment, Change of Control and Severance Arrangements with Named Executive Officers</I></FONT><FONT SIZE=2>" and "</FONT><FONT SIZE=2><I>Potential Payments upon
Termination or Change in Control</I></FONT><FONT SIZE=2>" later in this proxy statement. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Compensation Policies and Practices  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Policy on Stock Ownership  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not have a policy requiring our NEOs and our non-employee directors to hold a certain number or value of our shares. However, we encourage
our CEO and other NEOs to have a shareholding in the Company and all of our NEOs and our non-employee directors hold shares and/or stock options in the Company. Our Remuneration Committee and the
Board are keeping under consideration the adoption of a formal stock ownership policy. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table sets forth information with respect to the beneficial ownership of our ordinary shares, as of December&nbsp;31, 2018, by our NEOs, and the value of that beneficial
ownership as a multiple of the 2018 base salaries of our NEOs. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="91pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=4 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Ordinary Shares Beneficially<BR>
Owned as of December&nbsp;31, 2018 </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Named Executive Officer

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value(2) </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>James Noble</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17,439,001</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>31&nbsp;x&nbsp;base salary</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Helen Tayton-Martin, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,343,301</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16&nbsp;x&nbsp;base salary</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rafael Amado, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,464,301</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9&nbsp;x&nbsp;base salary</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adrian Rawcliffe</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,768,301</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8&nbsp;x&nbsp;base salary</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William Bertrand(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,490,958</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3&nbsp;x&nbsp;base salary</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
number of ordinary shares is comprised of ordinary shares as to which each NEO has sole voting power and ordinary shares subject to options that are exercisable
as of December&nbsp;31, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
value is computed based on the closing price of the ADSs on December&nbsp;31, 2018 of $5.75 divided by six to generate $0.96 per ordinary share, which is
multiplied by the number of ordinary shares held by each NEO. Vested stock options where the exercise price equates to an amount greater than $0.96 per ordinary share have been excluded. This value is
compared to the 2018 base salary earned for each of the NEOs in the table above.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Mr.&nbsp;Bertrand
joined the Company on March&nbsp;15, 2017.  </FONT></DD></DL>
 </DIV>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>57</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=65,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=117054,FOLIO='57',FILE='DISK112:[19ZAF1.19ZAF44001]CM44001A.;10',USER='CHE109868',CD=';1-MAR-2019;12:03' -->
<A NAME="page_cm44001_1_58"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Policy against Hedging and Pledging of our Stock  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our insider trading policy prohibits our directors, officers, employees and consultants from engaging in transactions in publicly traded
options, such as puts and calls, and other derivative securities with respect to the Company's securities. This prohibition extends to any hedging or similar transaction designed to decrease the risks
associated with holding our securities. Our insider trading policy also prohibits our directors, officers, employees, and consultants from pledging our securities as collateral for loans or holding
our securities in margin accounts. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>58</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=66,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=503468,FOLIO='58',FILE='DISK112:[19ZAF1.19ZAF44001]CM44001A.;10',USER='CHE109868',CD=';1-MAR-2019;12:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_co44001_1_59"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="co44001_remuneration_committee_report"> </A>
<A NAME="toc_co44001_1"> </A>
<BR></FONT><FONT SIZE=2><B>  REMUNERATION COMMITTEE REPORT    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>The material in this report is not (1)&nbsp;"soliciting material," (2)&nbsp;deemed "filed" with the SEC,
(3)&nbsp;subject to Regulations&nbsp;14A or 14C of the Exchange Act, or (4)&nbsp;subject to the liabilities of Section&nbsp;18 of the Exchange Act. The report shall not be deemed to be
incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Company
specifically incorporates this information by reference such filing.</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Remuneration Committee has reviewed and discussed the Compensation Discussion and Analysis contained in this proxy statement with management. Based on the review and discussions, the
Remuneration Committee recommended to our Board that the Compensation Discussion and Analysis be included in this proxy statement for the fiscal year ended December&nbsp;31, 2018. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><I> The Remuneration Committee of the Board of Directors</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>David M. Mott, Chairman<BR>
John Furey<BR>
Dr.&nbsp;Tal Zaks<BR></FONT>
</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>59</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=67,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=429912,FOLIO='59',FILE='DISK112:[19ZAF1.19ZAF44001]CO44001A.;6',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_co44001_1_60"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="co44001_2018_summary_compensation_table"> </A>
<A NAME="toc_co44001_2"> </A>
<BR></FONT><FONT SIZE=2><B>  2018 Summary Compensation Table    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information concerning the compensation of our NEOs for the fiscal years ended December&nbsp;31, 2018 and
December&nbsp;31, 2017 and with respect to Mr.&nbsp;Noble, Mr.&nbsp;Rawcliffe, Dr.&nbsp;Amado and Dr.&nbsp;Tayton-Martin for the fiscal year ended December&nbsp;31, 2016. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company has never made, and does not currently make, restricted stock awards or restricted stock unit awards. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:57%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"140%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="140%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Salary<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
awards<BR>
($)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Non-equity<BR>
incentive plan<BR>
compensation<BR>
($)(4) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All other<BR>
compensation<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 James Noble(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>536,011</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,826,960</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>250,585</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27,957</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,641,513</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Chief Executive Officer</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>520,399</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>849,927</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>234,180</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27,097</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,631,604</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>401,946</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,411,405</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>100,487</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21,179</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,935,017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adrian Rawcliffe</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>457,011</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>730,791</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>174,807</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>46,778</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,409,387</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Chief Financial Officer</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>443,700</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>849,927</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>199,665</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>42,556</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,535,848</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>435,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>674,104</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>117,450</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>34,262</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(7)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,260,816</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Rafael Amado</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>467,952</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(8)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,891,059</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>198,879</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>43,306</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(9)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,601,196</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>President, Research&nbsp;&amp; Development</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>442,900</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>849,927</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>199,305</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>43,037</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(10)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,535,169</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>430,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>674,104</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>116,100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>20,290</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(11)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,240,494</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Helen Tayton-Martin</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>382,566</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>730,791</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>146,331</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>20,619</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,280,308</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Chief Business Officer</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>364,279</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>849,927</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>163,925</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>19,481</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,397,613</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>299,865</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>674,104</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>80,963</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>16,424</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,071,356</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 William Bertrand</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>416,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>685,114</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>159,120</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>33,403</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(12)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,293,637</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Chief Operating Officer</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>316,666</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(13)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,517,348</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>128,250</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>34,192</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(14)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,996,456</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Mr.&nbsp;Noble
also serves as a director but receives no additional compensation for his service as a director.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Compensation
paid to Mr.&nbsp;Noble and Dr.&nbsp;Tayton-Martin is denominated in pounds sterling. For purposes of this table, all amounts in the columns titled
"Salary", "Non-equity incentive plan compensation" and "All other compensation" have been converted based on the pound sterling/U.S. Dollar exchange rate in effect as of December&nbsp;31, 2018
(&pound;1/$1.27602).
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Amounts
reflect the aggregate grant date fair value of share options granted during 2018, 2017 and 2016 computed in accordance with ASC Topic 718. The assumptions
used in the valuation of these awards are set forth in Note&nbsp;2 (r), Note&nbsp;2 (x)&nbsp;and Note&nbsp;11 to our consolidated financial statements, which are included in our Annual Report
on Form&nbsp;10-K for the year ended December&nbsp;31, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Amount
represents sums paid under our annual cash bonus program.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of Company payments in the amount of (i)&nbsp;$17,780.88 to subsidize city of Philadelphia taxes, (ii)&nbsp;$13,250.00 in matching contributions under
the 401(k) plan and (iii)&nbsp;$15,747.28 to medical insurance on behalf of Mr.&nbsp;Rawcliffe.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of Company payments in the amount of (i)&nbsp;$17,306.04 to subsidize city of Philadelphia taxes, (ii)&nbsp;$13,250.00 in matching contributions under
the 401(k) plan and (iii)&nbsp;$12,000.00 to medical insurance on behalf of Mr.&nbsp;Rawcliffe.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of Company payments in the amount of (i)&nbsp;$16,962.14 to subsidize city of Philadelphia taxes, (ii)&nbsp;$5,300 in matching contributions under the
401(k) plan and (iii)&nbsp;$12,000.00 to medical insurance on behalf of Mr.&nbsp;Rawcliffe. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>60</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=68,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=276313,FOLIO='60',FILE='DISK112:[19ZAF1.19ZAF44001]CO44001A.;6',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_co44001_1_61"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Dr.&nbsp;Amado's
base salary was increased to $481,322 effective August&nbsp;1, 2018. The amount of $467,952 represents the aggregate of six months of his base
salary of $458,402 (from January&nbsp;1, 2018 through July&nbsp;31, 2018) and six months of his base salary of $481,322 (from August&nbsp;1, 2018 through December&nbsp;31, 2018).
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(9)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of Company payments in the amount of (i)&nbsp;$16,164.04 to subsidize city of Philadelphia taxes, (ii)&nbsp;$13,250.00 in matching contributions under
the 401(k) plan and (iii)&nbsp;$13,891.62 to medical insurance on behalf of Dr.&nbsp;Amado.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(10)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of Company payments in the amount of (i)&nbsp;$15,386.76 to subsidize city of Philadelphia taxes, (ii)&nbsp;$13,250.00 in matching contributions under
the 401(k) plan and (iii)&nbsp;$14,400.00 to medical insurance on behalf of Dr.&nbsp;Amado.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(11)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of Company payments in the amount of (i)&nbsp;$14,989.90 to subsidize city of Philadelphia taxes and (ii)&nbsp;$5,300 in matching contributions under
the 401(k) plan.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(12)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of Company payments in the amount of (i)&nbsp;$13,250.00 in matching contributions under the 401(k) plan and (ii)&nbsp;$20,152.92 to medical insurance
on behalf of Mr.&nbsp;Bertrand.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(13)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Mr.&nbsp;Bertrand
has served as our Chief Operating Officer since March&nbsp;15, 2017. His annualized base salary for 2017 was $400,000.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(14)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of Company payments in the amount of (i)&nbsp;$13,250.00 in matching contributions under the 401(k) plan and (ii)&nbsp;$20,941.67 to medical insurance
on behalf of Mr.&nbsp;Bertrand.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Narrative Disclosure to Summary Compensation Table  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The amounts reported in the Summary Compensation Table, including base salary, annual cash bonuses and long-term, equity-based compensation
awards, are discussed more fully under "</FONT><FONT SIZE=2><I>Executive Compensation Discussion and Analysis</I></FONT><FONT SIZE=2>". Our NEOs also participate in employee benefit plans and
programs that we offer to our other full-time employees on the same basis and have from time to time received relocation or other expense reimbursements from us. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>61</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=69,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=533199,FOLIO='61',FILE='DISK112:[19ZAF1.19ZAF44001]CO44001A.;6',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_co44001_1_62"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Grants of Plan-Based Awards  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information concerning grants of plan-based incentive awards to our NEOs during the fiscal year ended
December&nbsp;31, 2018. All options are options to purchase ordinary shares. The Company has never made, and does not currently make, restricted stock awards or restricted stock unit awards. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="69pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="73pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Grant Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Estimated<BR>
Future<BR>
Payouts Under<BR>
Non-Equity<BR>
Incentive Plan<BR>
Awards<BR>
Target<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Option Awards:<BR>
Number of<BR>
Securities<BR>
underlying<BR>
Options (#)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exercise or<BR>
Base Price<BR>
of Option<BR>
Awards<BR>
($/Sh) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Grant Date<BR>
Fair Value<BR>
of Stock<BR>
and Option<BR>
Awards ($)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 James Noble</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>294,806</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/12/2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,719,936</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.22</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,313,321</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/12/2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>384,120</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.0013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>513,639</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adrian Rawcliffe</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
205,655</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/12/2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>687,984</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.22</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>525,336</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/12/2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>153,648</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.0013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>205,456</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Rafael Amado</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
233,976</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/12/2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>859,968</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.22</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>656,660</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/12/2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>192,060</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.0013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>256,820</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>08/06/2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>678,720</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.0013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>977,579</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Helen Tayton-Martin</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
172,155</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/12/2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>687,984</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.22</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>525,336</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/12/2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>153,648</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.0013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>205,456</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 William Bertrand</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
187,200</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/12/2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>644,976</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.22</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>492,495</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/12/2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>144,048</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.0013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>192,619</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Amounts
shown in the target column represent target amounts payable under our annual cash bonus plan for each NEO for 2018. The actual amounts paid are presented
above in the 2018 Summary Compensation Table under the heading "Non-Equity Inventive Plan Compensation." Awards are not subject to threshold or maximum payout amounts.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
securities underlying the options are ordinary shares.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Amounts
reflect the aggregate grant date fair value of share options granted during 2018 and computed in accordance with ASC Topic 718. The assumptions used in the
valuation of these awards are set forth in Note&nbsp;2 (r), Note&nbsp;2 (x)&nbsp;and Note&nbsp;11 to our consolidated financial statements, which are included in our Annual Report on
Form&nbsp;10-K for the year ended December&nbsp;31, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>25%
of the ordinary shares underlying the options vest on January&nbsp;12, 2019 and the remaining 75% of the ordinary shares vest monthly over 36&nbsp;months
beginning February&nbsp;12, 2019.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>For
purposes of this table, the exercise price was converted from GBP0.96 based on an exchange rate of $U.S. 1.27602&#151;GBP1.00 in effect as of
December&nbsp;31, 2018. The actual exercise price will be the pounds sterling amount. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>62</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=70,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=170430,FOLIO='62',FILE='DISK112:[19ZAF1.19ZAF44001]CO44001A.;6',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_co44001_1_63"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>25%
of the ordinary shares underlying the options vest on January&nbsp;12, 2019 and the remaining ordinary shares vest as to 25% on each the second, third and
fourth anniversaries of the grant date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>For
purposes of this table, the exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S.
1.27602&#151;GBP1.00 in effect as of December&nbsp;31, 2018. The actual exercise price will be the pounds sterling amount.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>25%
of the ordinary shares underlying the options vest on August&nbsp;6, 2019 and the remaining ordinary shares vest as to 25% on each the second, third and fourth
anniversaries of the grant date.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>63</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=71,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=537260,FOLIO='63',FILE='DISK112:[19ZAF1.19ZAF44001]CO44001A.;6',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_co44001_1_64"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="co44001_outstanding_equity_awards_at_2018_fiscal_year-end"> </A>
<A NAME="toc_co44001_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Outstanding Equity Awards at 2018 Fiscal Year-End    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information regarding equity awards held by our NEOs as of December&nbsp;31, 2018. All options are options to
purchase ordinary shares. The Company has never made, and does not currently make, restricted stock awards or restricted stock unit awards. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:57%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"140%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="140%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="73pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="78pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>First date some<BR>
or all options<BR>
are exercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options (#)<BR>
Exercisable(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options(#)<BR>
Unexercisable(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Exercise<BR>
Price ($/Sh) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Expiration<BR>
Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 James Noble</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>03/31/2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,335,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.14</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>03/30/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>03/31/2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>438,100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.14</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>03/30/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/19/2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,500,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.45</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/19/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/18/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,435,004</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>533,012</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.14</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/18/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/13/2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>993,301</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,079,675</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.75</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/13/2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/12/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(9)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,719,936</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.22</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(10)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/12/2028</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/12/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(11)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>384,120</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.0013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(12)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/12/2028</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rafael Amado</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>03/16/2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(13)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,375,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>225,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.64</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(14)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>03/16/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/18/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(15)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>685,373</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>254,575</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.14</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/18/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/13/2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>993,301</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,079,675</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.75</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/13/2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/12/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(16)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>859,968</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.22</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(10)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/12/2028</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/12/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(17)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>192,060</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.0013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(12)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/12/2028</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>08/06/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(18)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>678,720</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.0013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(12)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>08/06/2028</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 William Bertrand</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>03/15/2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(19)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,490,958</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,916,946</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.83</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(20)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>03/15/2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/12/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(21)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>644,976</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.22</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(10)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/12/2028</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/12/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(22)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>144,048</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.0013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(12)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/12/2028</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adrian Rawcliffe</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>03/16/2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(13)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,775,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>225,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.64</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(14)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>03/16/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/18/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(15)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>685,373</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>254,575</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.14</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/18/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/13/2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>993,301</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,079,675</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.75</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/13/2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/12/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(23)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>687,984</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.22</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(10)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/12/2028</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/12/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(24)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>153,648</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.0013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(12)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/12/2028</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Helen Tayton-Martin</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/25/2013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>192,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.14</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/25/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/01/2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>742,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.14</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/01/2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>04/11/2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>850,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.14</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>04/14/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/19/2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,750,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.45</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/19/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/18/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(15)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>685,373</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>254,575</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.14</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/18/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/13/2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>993,301</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,079,675</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.75</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/13/2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/12/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(23)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>687,984</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.22</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(10)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/12/2028</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/12/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(24)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>153,648</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.0013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(12)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/12/2028</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Vesting
of all options is subject to continued service through the applicable vesting date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
securities underlying the options are ordinary shares.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>For
purposes of this table, the exercise price was converted from GBP0.112 based on an exchange rate of $U.S. 1.27602&#151;GBP1.00 in effect as of
December&nbsp;31, 2018. The actual exercise price will be the pounds sterling amount.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>For
purposes of this table, the exercise price was converted from GBP0.3557 based on an exchange rate of $U.S. 1.27602&#151;GBP1.00 in effect as of
December&nbsp;31, 2018. The actual exercise price will be the pounds sterling amount. </FONT></DD></DL>
 </DIV>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>64</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=72,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=333742,FOLIO='64',FILE='DISK112:[19ZAF1.19ZAF44001]CO44001A.;6',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_co44001_1_65"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
option was partially vested and the remainder will vest in monthly installments of 41,000 ordinary shares on the eighteenth of each month from
January&nbsp;18, 2019 through December&nbsp;18, 2019, and in one installment of 41,012 ordinary shares on January&nbsp;18, 2020.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>For
purposes of this table, the exercise price was converted from GBP0.89 based on an exchange rate of $U.S. 1.27602&#151;GBP1.00 in effect as of
December&nbsp;31, 2018. The actual exercise price will be the pounds sterling amount.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
option was partially vested and the remainder will vest in monthly installments of 43,187 ordinary shares on the thirteenth of each month from
January&nbsp;13, 2019 through January&nbsp;13, 2021.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>For
purposes of this table, the exercise price was converted from GBP0.59 based on an exchange rate of $U.S. 1.27602&#151;GBP1.00 in effect as of
December&nbsp;31, 2018. The actual exercise price will be the pounds sterling amount.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(9)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
option partially vests as to 429,984 ordinary shares on January&nbsp;12, 2019 and the remainder will vest in monthly installments of 35,832 ordinary shares on
the twelfth of each month from February&nbsp;12, 2019 through January&nbsp;12, 2022.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(10)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>For
purposes of this table, the exercise price was converted from GBP0.96 based on an exchange rate of $U.S. 1.27602&#151;GBP1.00 in effect as of
December&nbsp;31, 2018. The actual exercise price will be the pounds sterling amount.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(11)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
option partially vests as to 96,030 ordinary shares on January&nbsp;12, 2019 and the remainder will vest in annual installments of 96,030 ordinary shares on
January&nbsp;12, 2020 and January&nbsp;12, 2021 and January&nbsp;12, 2022.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(12)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>For
purposes of this table, the exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S.
1.27602&#151;GBP1.00 in effect as of December&nbsp;31, 2018. The actual exercise price will be the pounds sterling amount.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(13)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
option was partially vested and the remainder will vest in monthly installments of 75,000 ordinary shares on the sixteenth of each month from
January&nbsp;16, 2019 through March&nbsp;16, 2019.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(14)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>For
purposes of this table, the exercise price was converted from GBP0.50 based on an exchange rate of $U.S. 1.27602&#151;GBP1.00 in effect as of
December&nbsp;31, 2018. The actual exercise price will be the pounds sterling amount.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(15)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
option was partially vested and the remainder will vest in monthly installments of 19,582 ordinary shares on the eighteenth of each month from
January&nbsp;18, 2019 through December&nbsp;18, 2019, and in one installment of 19,591 ordinary shares on January&nbsp;18, 2020.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(16)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
option partially vests as to 214,992 ordinary shares on January&nbsp;12, 2019 and the remainder will vest in monthly installments of 17,916 ordinary shares
on the twelfth of each month from February&nbsp;12, 2019 through January&nbsp;12, 2022.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(17)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
option partially vests as to 48,015 ordinary shares on January&nbsp;12, 2019 and the remainder will vest in annual installments of 48,015 ordinary shares on
January&nbsp;12, 2020 and January&nbsp;12, 2021 and January&nbsp;12, 2022.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(18)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
option partially vests as to 169,680 ordinary shares on August&nbsp;6, 2019 and the remainder will vest in annual installments of 169,680 ordinary shares on
August&nbsp;6, 2020 and August&nbsp;6, 2021 and August&nbsp;6, 2022.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(19)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
option was partially vested and the remainder will vest in monthly installments of 70,998 ordinary shares on the fifteenth of each month from
January&nbsp;15, 2019 through March&nbsp;15, 2021. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>65</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=73,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=503125,FOLIO='65',FILE='DISK112:[19ZAF1.19ZAF44001]CO44001A.;6',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_co44001_1_66"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(20)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>For
purposes of this table, the exercise price was converted from GBP0.65 based on an exchange rate of $U.S. 1.27602&#151;GBP1.00 in effect as of
December&nbsp;31, 2018. The actual exercise price will be the pounds sterling amount.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(21)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
option partially vests as to 161,244 ordinary shares on January&nbsp;12, 2019 and the remainder will vest in monthly installments of 13,437 ordinary shares
on the twelfth of each month from February&nbsp;12, 2019 through January&nbsp;12, 2022.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(22)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
option partially vests as to 36,012 ordinary shares on January&nbsp;12, 2019 and the remainder will vest in annual installments of 36,012 ordinary shares on
January&nbsp;12, 2020 and January&nbsp;12, 2021 and January&nbsp;12, 2022.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(23)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
option partially vests as to 171,996 ordinary shares on January&nbsp;12, 2019 and the remainder will vest in monthly installments of 14,333 ordinary shares
on the twelfth of each month from February&nbsp;12, 2019 through January&nbsp;12, 2022.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(24)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
option partially vests as to 38,412 ordinary shares on January&nbsp;12, 2019 and the remainder will vest in annual installments of 38,412 ordinary shares on
January&nbsp;12, 2020 and January&nbsp;12, 2021 and January&nbsp;12, 2022.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>66</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=74,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=814820,FOLIO='66',FILE='DISK112:[19ZAF1.19ZAF44001]CO44001A.;6',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_co44001_1_67"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="co44001_option_exercises_and_stock_vested"> </A>
<A NAME="toc_co44001_4"> </A>
<BR></FONT><FONT SIZE=2><B>  Option Exercises and Stock Vested    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth the number of shares acquired by our NEOs upon the exercise of stock options during the year ended
December&nbsp;31, 2018. All options are options to purchase ordinary shares. The Company has never made, and does not currently make, restricted stock awards or restricted stock unit awards. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="98pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="83pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=4 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of Shares<BR>
Acquired on Exercise<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value Realized on<BR>
Exercise<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>James Noble</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adrian Rawcliffe</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
100,000(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1,027,000(2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rafael Amado</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Helen Tayton-Martin</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William Bertrand</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Each
American Depositary Share ("ADS") represents six ordinary shares of the Company. Mr.&nbsp;Rawcliffe acquired 100,000 ADSs, representing 600,000 ordinary
shares, from the partial exercise of an option covering 3,600,000 ordinary shares granted on March&nbsp;16, 2015 of which 3,000,000 ordinary shares remain outstanding, unexercised and held by
Mr.&nbsp;Rawcliffe. For more details, see "</FONT><FONT SIZE=2><I>Outstanding Equity Awards at 2018 Fiscal Year End</I></FONT><FONT SIZE=2>" above.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
value realized on exercise amount was derived from the sale price of $10.27 per ADS on March&nbsp;20, 2018 multiplied by the number of ADSs sold, and is prior
to payment of applicable withholding taxes.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>67</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=75,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=904367,FOLIO='67',FILE='DISK112:[19ZAF1.19ZAF44001]CO44001A.;6',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_cq44001_1_68"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employment, Change of Control and Severance Arrangements with Named Executive Officers  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered into service agreements with our Chief Executive Officer and our Chief Business Officer, and we have entered into employment
agreements with each of our other NEOs. These agreements set forth the individual's base salary, bonus compensation, equity compensation and other employee benefits, which are described above in the
"Compensation Discussion and Analysis". In addition, these agreements provide for severance payments pursuant to our Executive Severance Policy upon a termination of employment under certain
circumstances as described below. Certain key terms of those agreements and our executive severance policy are described below. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


James Noble  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We entered into a service agreement with Mr.&nbsp;Noble dated March&nbsp;10, 2017 that sets forth the terms and conditions under which
Mr.&nbsp;Noble serves as our Chief Executive Officer and as a director. The agreement set out the initial annual base salary for Mr.&nbsp;Noble, subject to periodic review by the Company, and the
initial annual target bonus opportunity and annual bonus process. The employment shall continue until terminated by either party giving no less than nine months' written notice. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we may terminate the agreement immediately by notice if Mr.&nbsp;Noble (i)&nbsp;commits a material breach under the agreement, (ii)&nbsp;is guilty of conduct tending
to bring him or the company into disrepute, (iii)&nbsp;becomes bankrupt, (iv)&nbsp;fails to perform his duties to a satisfactory standard, (v)&nbsp;is disqualified from being a director by
reason of any order made under the Companies Directors Disqualification Act 1986 or any other enactment, or (vi)&nbsp;is convicted of an offence under any statutory enactment or regulation
(including the criminal offence of insider dealing under the Criminal Justice Act 1993 or any similar conviction in the United States, but excluding a motoring offence for which no custodial sentence
is given). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Noble
is eligible to participate in the Company's share option schemes, Group Personal Pension Scheme and in the private health care cheme and permanent health insurance
schemes which the Company or any Group Company may maintain for the benefit of its senior executives. Mr.&nbsp;Noble's service agreement contains non-solicitation and non-competition provisions for
a twelve month period as well as confidentiality provisions. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Adrian Rawcliffe and Rafael Amado  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The employment agreements for Mr.&nbsp;Rawcliffe and Dr.&nbsp;Amado were entered into on March&nbsp;10, 2017. The agreements have no
specific term and establish an at-will employment relationship. The agreements set out the initial annual base salary, for each of Mr.&nbsp;Rawcliffe and Dr.&nbsp;Amado, subject to periodic review
by the Company, and the initial annual target bonus opportunity for each of Mr.&nbsp;Rawcliffe and Dr.&nbsp;Amado and annual bonus process. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Rawcliffe
and Dr.&nbsp;Amado are eligible to participate in the equity plans sponsored and/or maintained by the Company and its affiliates from time to time, in accordance
with the terms of any such plans, at the sole and absolute discretion of the Company and the Board of Directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company may terminate either of their employment with or without cause and without notice, but Mr.&nbsp;Rawcliffe and Dr.&nbsp;Amado are required to provide at least
60&nbsp;days' advance written notice to us if he is terminating his employment. In the event of a termination of his employment by the Company without cause or by Mr.&nbsp;Rawcliffe or
Dr.&nbsp;Amado for good reason, any portion of his initial award of 3,600,000 stock options that was granted on March&nbsp;16, 2015, which is unvested as of the date of termination shall vest and
immediately become exercisable on the date of termination. The agreements contain non-solicitation and non-competition provisions for a twelve month period as well as standard confidentiality
provisions. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>68</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=76,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=105509,FOLIO='68',FILE='DISK112:[19ZAF1.19ZAF44001]CQ44001A.;10',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_cq44001_1_69"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


William Bertrand  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The employment agreement for Mr.&nbsp;Bertrand was entered into on March&nbsp;15, 2017. The agreement has no specific term and establishes
an at-will employment relationship. The agreement sets out the initial annual base salary, subject to periodic review by the Company, and initial annual target bonus opportunity and annual bonus
process. Mr.&nbsp;Bertrand is eligible to participate in the equity plans sponsored and/or maintained by the Company and its affiliates from time to time, in accordance with the terms of any such
plans, at the sole and absolute discretion of the Company and the Board of Directors. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company may terminate Mr.&nbsp;Bertrand's employment with or without cause and without notice, but he is required to provide at least 60&nbsp;days' advance written notice to us
if he is terminating his employment. The agreement contains non-solicitation and non-competition provisions for a twelve month period as well as standard confidentiality provisions. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Helen Tayton-Martin  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We entered into a service agreement with Dr.&nbsp;Tayton-Martin dated March&nbsp;15, 2017 that sets forth the terms and conditions under
which Dr.&nbsp;Tayton-Martin serves as our Chief Business Officer and as a director of Adaptimmune Limited. The agreement set out the initial annual base salary for Mr.&nbsp;Tayton-Martin, subject
to periodic review by the Company, and the initial annual target
bonus opportunity and annual bonus process. The employment shall continue until terminated by either party giving no less than nine months' written notice. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we may terminate the agreement immediately by notice if Dr.Tayton-Martin (i)&nbsp;commits a material breach under the agreement, (ii)&nbsp;is guilty of conduct tending
to bring her or the company into disrepute, (iii)&nbsp;becomes bankrupt, (iv)&nbsp;fails to perform her duties to a satisfactory standard, (v)&nbsp;is disqualified from being a director by
reason of any order made under the Companies Directors Disqualification Act 1986 or any other enactment, or (vi)&nbsp;is convicted of an offence under any statutory enactment or regulation
(including the criminal offence of insider dealing under the Criminal Justice Act 1993 or any similar conviction in the United States, but excluding a motoring offence for which no custodial sentence
is given). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Tayton-Martin
is eligible to participate in the Company's share option schemes, Group Personal Pension Scheme and in the private health care cheme and permanent health
insurance schemes which the Company or any Group Company may maintain for the benefit of its senior executives. Dr.&nbsp;Tayton-Martin's service agreement contains non-solicitation and
non-competition provisions for a twelve month period as well as confidentiality provisions. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Severance Policy  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's executive severance policy, adopted on March&nbsp;10, 2017, (the "Executive Severance Policy") is applicable in relation to our
NEOs. If the employment of any of our NEOs is terminated by the Company without cause, or if he or she resigns for good reason, then the NEO will be entitled under his or her service or employment
agreement, as applicable, and the Executive Severance Policy to receive a severance payment equal to his or her annual base salary for nine months and to payment of premiums for continuation of
healthcare benefits for a period of nine months following such termination. Our NEOs resident in the U.K. may elect to waive continuation of payment of healthcare premiums and accept a payment in lieu
of such premiums. In addition, at the sole discretion of the Board (or an authorized committee thereof), the NEO may be paid a lump sum cash amount equal to his or her annual performance bonus for the
year of termination, prorated based on the number of calendar days he or she was employed during the year. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>69</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=77,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=580384,FOLIO='69',FILE='DISK112:[19ZAF1.19ZAF44001]CQ44001A.;10',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_cq44001_1_70"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furthermore,
if the employment of any of our NEOs is terminated without cause or he or she resigns for good reason within 12&nbsp;months following a change in control, he or she will
be entitled to receive a
severance payment equal to his or her annual base salary for 12&nbsp;months, payment of premiums for continuation of healthcare benefits for a period of 12&nbsp;months. Our NEOs resident in the
U.K. may elect to waive continuation of payment of healthcare premiums and accept a payment in lieu of such premiums. In addition, the NEO will be paid a lump sum cash amount equal to the full annual
performance bonus for the year of termination, and is entitled to accelerated vesting of any unvested and outstanding equity awards. In addition, the Board has discretion under our option plan rules
to allow some or all of the options held by our NEOs to vest in the event of a change of control or otherwise. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order to receive severance benefits under his or her service or employment agreement and the Executive Severance Policy, the NEO is required to execute a release of claims in favor of
the Company and comply with certain other post-employment covenants set forth in his or her service or employment agreement, as applicable. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>70</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=78,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=418197,FOLIO='70',FILE='DISK112:[19ZAF1.19ZAF44001]CQ44001A.;10',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_cq44001_1_71"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Potential Payments upon Termination or Change in Control  </B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides information concerning the estimated payments and benefits, pursuant to the service or employment agreement and the
Executive Severance Policy, that would be provided in the circumstances described below for each of our NEOs. Payments and benefits are estimated assuming that the triggering event took place on
December&nbsp;31, 2018, and the closing price per share of an American Depositary Share (ADS) on The Nasdaq Global Select Market as of that date ($5.75). There can be no assurance that a triggering
event would produce the same or similar results as those estimated below if such event occurs on any other date or at any other price, of if any other assumption used to estimate potential payments
and benefits is not correct. Due to the number of factors that affect the nature and amount of any potential payments or benefits, any actual payments and benefits may be different. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:57%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"140%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="140%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="208pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="82pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="103pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Benefit(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Termination<BR>
without Cause or<BR>
Resignation for<BR>
Good Reason Not<BR>
in Connection<BR>
with a Change in<BR>
Control ($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Termination<BR>
without Cause or<BR>
Resignation for<BR>
Good Reason in<BR>
Connection with a<BR>
Change in Control ($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>James Noble</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Lump Sum Cash Severance Payment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>402,009</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>536,011</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Lump Sum Bonus Payment(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>250,585</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>250,585</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Vesting Acceleration(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>650,469</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Health Insurance Premiums(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>867</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,156</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B> Benefit Total</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>653,461</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>1,438,221</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adrian Rawcliffe</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Lump Sum Cash Severance Payment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>342,758</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>457,011</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Lump Sum Bonus Payment(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>174,807</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>174,807</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Vesting Acceleration(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>81,448</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>501,739</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Health Insurance Premiums(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,810</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,747</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B> Benefit Total</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>610,823</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>1,149,304</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rafael Amado</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Lump Sum Cash Severance Payment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>360,992</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>481,322</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Lump Sum Bonus Payment(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>198,879</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>198,879</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Vesting Acceleration(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>81,448</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,217,956</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Health Insurance Premiums(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,419</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13,892</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B> Benefit Total</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>651,737</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>1,912,048</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Helen Tayton-Martin</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Lump Sum Cash Severance Payment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>286,925</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>382,566</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Lump Sum Bonus Payment(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>146,331</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>146,331</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Vesting Acceleration(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>420,291</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Health Insurance Premiums(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,119</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,491</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B> Benefit Total</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>434,374</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>950,679</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William Bertrand</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Lump Sum Cash Severance Payment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>312,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>416,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Lump Sum Bonus Payment(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>159,120</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>159,120</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Vesting Acceleration(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>470,869</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Health Insurance Premiums(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,115</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20,153</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B> Benefit Total</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>486,235</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>1,066,142</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Reflects
the terms of: (a)&nbsp;the service agreements and employment agreements between us and our NEOs described above; (b)&nbsp;the Executive Severance Policy
described above; and (c)&nbsp;equity award grant agreements between us and our NEOs for equity grants included in the </FONT><FONT SIZE=2><I>Outstanding Equity Awards at 2018 Fiscal Year
End</I></FONT><FONT SIZE=2> table above. Pursuant to the Executive Severance Policy, any severance payment or benefit provided under the Executive Severance Policy is reduced by the value of any
corresponding payment or benefit provided under the NEO's applicable service or employment agreement or equity award agreement. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>71</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=79,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=73128,FOLIO='71',FILE='DISK112:[19ZAF1.19ZAF44001]CQ44001A.;10',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_cq44001_1_72"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Assumes
a lump sum bonus payment based on the bonus payment made in respect of year ended December&nbsp;31, 2018 in both scenarios. If an NEO's employment is
terminated by the Company without cause or the NEO resigns for good reason outside of a change of control scenario, any lump sum bonus payment is at the sole discretion of the Remuneration Committee
or the Board (in the case of the CEO), prorated based on the number of calendar days of employment.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Reflects
stock option awards. The Company has never made, and does not currently make, restricted stock awards or restricted stock unit awards. Our options cover
ordinary shares that are represented by ADSs. Each ADS represents six ordinary shares of the Company. Stock option awards where the exercise price equates to an amount greater than $0.96 per ordinary
share have been excluded. $0.96 is based on the closing price of an ADS on 31&nbsp;December 2018, of $5.75, divided by six. For stock options, aggregate market value is computed by multiplying the
product of (a)&nbsp;the number of unvested shares accelerating as of December&nbsp;31, 2018, by the sum of (b)&nbsp;(i)&nbsp;$0.96 less (ii)&nbsp;the option's exercise price.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>In
the event of a termination of his employment by the Company without cause or by Mr.&nbsp;Rawcliffe or Dr.&nbsp;Amado for good reason, any portion of his
initial award of 3,600,000 stock options that was granted on March&nbsp;16, 2015, which is unvested as of the date of termination shall vest and immediately become exercisable on the date of
termination. The market value amounts represent an amount for the unvested stock options from the initial award.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Assumes
a lump sum payment based on the estimated premiums for COBRA continuation coverage for our NEOs resident in the U.S. (Mr.&nbsp;Rawcliffe, Dr.&nbsp;Amado
and Mr.&nbsp;Bertrand) and a lump sum payment based on the estimated premiums for health insurance for our NEOs resident in the U.K. (Mr.&nbsp;Noble and Dr.&nbsp;Tayton-Martin). </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>72</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=80,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=744231,FOLIO='72',FILE='DISK112:[19ZAF1.19ZAF44001]CQ44001A.;10',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_cq44001_1_73"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CEO Pay Ratio  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to a mandate of the Dodd-Frank Act, the SEC adopted a rule requiring annual disclosure of the ratio of the median employee's total
annual compensation to the total compensation of the principal executive officer ("PEO"). The PEO of our Company is James Noble, our Chief Executive Officer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that our compensation philosophy must be consistent and internally equitable to motivate our employees to create shareholder value. The purpose of the new required disclosure
is to provide a measure of pay equity within the organization. We are committed to internal pay equity, and our Remuneration Committee monitors the relationship between the pay our PEO receives and
the pay our non-executive employees receive. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
illustrated in the table below, our 2018 PEO to median employee pay ratio was approximately&nbsp;19:1. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PEO 2018 Compensation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,613,556</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Median Employee 2018 Compensation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>137,800</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Ratio of PEO to Median Employee Compensation</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B> 19:1</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
identified the median employee using annualized base salary for 2018, annual bonus earned in 2018 and aggregate grant date fair values for equity awards granted in 2018 to all
indiviudals who were employed by us on December&nbsp;31, 2018, the last day of our fiscal year (whether employed on a full-time or part-time basis). Reportable wages were annualized for those
employees who were not employed for the full calendar year. Equity awards were excluded from the calculation of determining the median employee due to the high volume of staff who had joined our
Company during 2018. Equity awards were then included to the median employee to ensure comparability with the PEO. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
pay ratio reported above is a reasonable estimate calculated in a manner consistent with SEC rules, based on our internal records and the methodology described above. The SEC rules
for identifying the median compensated employee allow companies to adopt a variety of methodologies, to apply certain exclusions and to make reasonable estimates and assumptions that reflect their
employee populations and compensation practices. Accordingly, the pay ratio reported by other companies may not be comparable to the pay ratio reported above, as other companies have different
employee populations and compensation practices and may use different methodologies, exclusions, estimates and assumptions in calculating their own pay ratios. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>73</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=81,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=574171,FOLIO='73',FILE='DISK112:[19ZAF1.19ZAF44001]CQ44001A.;10',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_cq44001_1_74"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Equity Compensation Plan Information  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides information on our equity compensation plans as of December&nbsp;31, 2018. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="73pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="70pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="98pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Plan Category


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities to be<BR>
Issued Upon<BR>
Exercise of<BR>
Outstanding<BR>
Options </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
Average<BR>
Exercise Price<BR>
of Outstanding<BR>
Options $ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of Securities<BR>
Available for<BR>
Future Issuance<BR>
Under Equity<BR>
Compensation Plans </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity compensation plans</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>87,564,719</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.77</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,974,382</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>87,564,719</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.77</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,974,382</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of this table, the Weighted Average Exercise Price of Outstanding Options has been converted from &pound;0.60 based on the pound sterling/U.S. dollar exchange rate in
effect as of December&nbsp;31, 2018 (&pound;1/$1.27602). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company grants options over ordinary shares in Adaptimmune Therapeutics&nbsp;plc under the following option plans: (i)&nbsp;the Adaptimmune Therapeutics&nbsp;plc Employee Share
Option Scheme (adopted January&nbsp;14, 2016), (ii)&nbsp;the Adaptimmune Therapeutics&nbsp;plc 2015 Share Option Scheme (adopted March&nbsp;16, 2015) and (iii)&nbsp;the Adaptimmune
Therapeutics&nbsp;plc Company Share Option Plan (adopted March&nbsp;16, 2015).The Company grants RSU-style options over ordinary shares in Adaptimmune Therapeutics&nbsp;plc under the Adaptimmune
Therapeutics&nbsp;plc Employee Share Option Scheme (adopted January&nbsp;14, 2016). The maximum aggregate number of options which may be granted under these plans and any incentive plans adopted
by the Company cannot exceed a scheme limit that equates to 8% of the initial fully diluted share capital of the Company immediately following our IPO plus an automatic annual increase of an amount
equivalent to 4% of the issued share capital on each June&nbsp;30 (or such lower number as the Board, or an appropriate committee of the Board, may determine). The automatic increase is effective
from July&nbsp;1, 2016. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to December&nbsp;31, 2014, the Company granted options to purchase ordinary shares in Adaptimmune Limited under three option schemes: (i)&nbsp;the Adaptimmune Limited Share
Option Scheme (adopted May&nbsp;30, 2008), (ii)&nbsp;the Adaptimmune Limited 2014 Share Option Scheme (adopted April&nbsp;11, 2014) and (iii)&nbsp;the Adaptimmune Limited Company Share Option
Plan (adopted December&nbsp;16, 2014). As part of
the corporate reorganization in connection with our IPO, the holders of options granted under these schemes over ordinary shares of Adaptimmune Limited were granted equivalent options on substantially
the same terms over ordinary shares of Adaptimmune Therapeutics&nbsp;plc ("Replacement Options") in exchange for the release of these options. The Company does not intend to grant any further
options under these schemes. Further details of our option plans are set forth in Note&nbsp;11 titled "Share based compensation" to our consolidated financial statements, which are included in our
Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2018. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>74</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=82,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=428707,FOLIO='74',FILE='DISK112:[19ZAF1.19ZAF44001]CQ44001A.;10',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_cq44001_1_75"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="cq44001_audit_committee_report"> </A>
<A NAME="toc_cq44001_1"> </A>
<BR></FONT><FONT SIZE=2><B>  AUDIT COMMITTEE REPORT    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Audit Committee oversees the accounting and financial reporting processes of the Company and the audits of the Company's financial
statements, evaluates auditor performance, manages relations with the Company's independent registered public accounting firm and evaluates policies and procedures relating to internal control
systems. The Audit Committee operates under a written Audit Committee charter that has been adopted by the Board. All members of the Audit Committee currently meet the independence and qualification
standards for Audit Committee membership set forth in the listing standards provided by Nasdaq and the SEC, and the Board has determined that each Audit Committee member is an "audit committee
financial expert," as the SEC has defined that term in Item&nbsp;407 of Regulation&nbsp;S-K. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee members are not professional accountants or auditors. The members' functions are not intended to duplicate or to certify the activities of management and the
independent registered public accounting firm. The Audit Committee serves a board-level oversight role in which it provides advice, counsel and direction to management and the auditors on the basis of
the information it receives, discussions with management and the auditors, and the experience of the Audit Committee's members in business, financial and accounting matters. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee oversees the Company's financial reporting process on behalf of the Board. The Company's management has the primary responsibility for the financial statements and
reporting process, including the Company's system of internal controls. In fulfilling its oversight responsibilities, the Audit Committee reviewed with management the audited financial statements
included in the Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2018. This review included a discussion of the quality and the acceptability of the Company's financial
reporting, including the nature and extent of disclosures in the financial statements and the accompanying notes. The Audit
Committee also reviewed the progress and results of the testing of the design and effectiveness of its internal controls over financial reporting pursuant to Section&nbsp;404 of the Sarbanes-Oxley
Act of 2002. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee also reviewed with KPMG&nbsp;LLP ("KPMG"), our independent registered public accounting firm, which is responsible for expressing an opinion on the conformity of
the audited financial statements with accounting principles generally accepted in the United States of America, their judgments as to the quality and the acceptability of the Company's financial
reporting and such other matters as are required to be discussed with the Committee by Public Company Accounting Oversight Board ("PCAOB") AU380, </FONT><FONT SIZE=2><I>Communications with Audit
Committees</I></FONT><FONT SIZE=2>, and SEC Regulation&nbsp;S-X Rule&nbsp;207, </FONT><FONT SIZE=2><I>Communication with Audit Committees</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee has received the written disclosures and the letter from KPMG required by the applicable requirements of the PCAOB regarding communications with the audit committee
concerning independence. The Audit Committee has discussed with KPMG its independence from management and the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to the matters specified above, the Audit Committee discussed with KPMG the overall scope, plans and estimated costs of their audit. The Committee met with KPMG periodically,
with and without management present, to discuss the results of KPMG's examinations, the overall quality of the Company's financial reporting and KPMG's reviews of the quarterly financial statements,
and drafts of the quarterly and annual reports. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
reliance on the reviews and discussions referred to above, and subject to the limitations of the Audit Committee's role and responsibilities referred to above and in the Audit
Committee charter, the Audit Committee recommended to the Board of Directors that the Company's audited financial </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>75</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=83,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=613008,FOLIO='75',FILE='DISK112:[19ZAF1.19ZAF44001]CQ44001A.;10',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_cq44001_1_76"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>statements
should be included in the Company's Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2018. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><I> The Audit Committee of the Board of Directors</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lawrence M. Alleva, Chairman<BR>
Barbara Duncan<BR>
Giles Kerr<BR></FONT>
</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>The foregoing report of the Audit Committee shall not be deemed incorporated by reference by any general statement incorporating by reference this proxy statement
into any filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, except to the extent that the Company specifically incorporates this information
by reference, and shall not otherwise be deemed filed under such acts.</I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>76</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=84,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=716996,FOLIO='76',FILE='DISK112:[19ZAF1.19ZAF44001]CQ44001A.;10',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_cq44001_1_77"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="cq44001_delivery_of_proxy_materials"> </A>
<A NAME="toc_cq44001_2"> </A>
<BR></FONT><FONT SIZE=2><B>  DELIVERY OF PROXY MATERIALS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2018, including audited financial statements, accompanies
this Proxy Statement. Copies of our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2018 and the exhibits thereto are available from the Company without charge upon
written request of a shareholder. Copies of these materials are also available online through the SEC at </FONT><FONT SIZE=2><I>www.sec.gov</I></FONT><FONT SIZE=2>. The Company may satisfy SEC rules
regarding delivery of proxy materials, including this Proxy Statement and the Annual Report, by delivering a single set of proxy materials to an address shared by two or more Company shareholders or
ADS holders. This delivery method can result in meaningful cost savings for the Company. In order to take advantage of this opportunity, the Company may deliver only a single set of proxy materials to
multiple shareholders or ADS holders who share an address, unless contrary instructions are received prior to the mailing date. Similarly, if you share an address with another shareholder or ADS
holders and have received multiple copies of our proxy materials, you may write or call us at the address and phone number below to request delivery of a single copy of the proxy materials in the
future. We undertake to deliver promptly upon written or oral request a separate copy of the proxy materials, as requested, to a shareholder or ADS holders at a shared address to which a single copy
of the proxy materials was delivered. If you are an ordinary shareholder of record and prefer to receive separate copies of proxy materials either now or in the future, please contact Margaret Henry,
Company Secretary, Adaptimmune Therapeutics&nbsp;plc, 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14&nbsp;4RX, United Kingdom or by telephone at +(44) 1235 430036. If you hold ADSs and
you prefer to receive separate copies of proxy materials either now or in the future, please contact the Depositary, your brokerage firm or bank, as applicable. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>EACH SHAREHOLDER IS URGED TO COMPLETE, DATE, SIGN<BR>
AND PROMPTLY RETURN THE ENCLOSED FORM OF PROXY OR TO SUBMIT<BR>
YOUR PROXY ONLINE.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>EACH ADS HOLDER IS URGED TO COMPLETE, DATE, SIGN AND PROMPTLY RETURN<BR>
THE ADS PROXY CARD TO CITIBANK, N.A., THE DEPOSITARY FOR THE ADSs.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>77</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=85,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=237215,FOLIO='77',FILE='DISK112:[19ZAF1.19ZAF44001]CQ44001A.;10',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_cq44001_1_78"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="cq44001_additional_information"> </A>
<A NAME="toc_cq44001_3"> </A>
<BR></FONT><FONT SIZE=2><B>  ADDITIONAL INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


U.K. Statutory Annual Accounts and Reports of the Board of Directors and Auditors of Adaptimmune
Therapeutics&nbsp;plc for the year ended December&nbsp;31, 2018  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consistent with its obligations under the U.K. Companies Act 2006, our Board of Directors will present at the Meeting our U.K. statutory annual
accounts and reports for the year ended December&nbsp;31, 2018. Accordingly, our Board of Directors will lay before the Company at the Meeting the Company's U.K. statutory annual accounts and
reports for the year ended December&nbsp;31, 2018, which have been approved by and, where appropriate, signed on behalf of our Board of Directors and will be delivered to the Registrar of Companies
in the United Kingdom following the Meeting. A copy of our U.K. statutory directors' remuneration report, including the annual report on remuneration, is included as Annex&nbsp;A to this proxy
statement. A complete copy of our U.K. statutory annual accounts and reports, including the statutory Board of Directors report, strategic report, and auditor's report on our U.K. accounts will be
sent separately to you no less than 21&nbsp;days prior to the Meeting. You will be provided an opportunity to raise questions in relation to such accounts and reports at the Meeting. Full accounts
and reports will be available for inspection prior to and during the Meeting. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Shareholders' Rights to Call a General Meeting  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our shareholders have the right to call a meeting of our shareholders. The U.K. Companies Act 2006 generally requires the directors to call a
general meeting once we have received requests to do so from shareholders representing at least 5% of our paid-up shares entitled to vote at a general meeting. The U.K. Companies Act 2006 generally
prohibits shareholders of a U.K. public limited company from passing written resolutions. However, significant shareholders would, in any case, still have the power to call a general meeting and
propose resolutions. These provisions are mandatory under the U.K. Companies Act 2006 and cannot be waived by our shareholders. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Shareholder Proposals for 2020 Annual General Meeting  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to be considered for inclusion in our proxy statement for our 2020 annual general meeting of shareholders, shareholder proposals must
be received by the Company at the Office of the Company Secretary, 60&nbsp;Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14&nbsp;4RX no later than 120&nbsp;days before the anniversary of
the date on which we sent our proxy materials for the Meeting, or November&nbsp;[&nbsp;&nbsp;&nbsp;&nbsp;], 2019. However, if the date of such annual general meeting is more than 30
calendar days from the date of the anniversary of the Meeting, then the notice must be received by our Company Secretary a reasonable time before we begin to print and send our proxy materials. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shareholder
proposals submitted for consideration at our 2020 annual general meeting of shareholders, but not submitted for inclusion in our proxy statement for our 2020 annual general
meeting of shareholders, must be received by the Company at the Office of the Company Secretary, 60&nbsp;Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14&nbsp;4RX no later than
45&nbsp;days before the anniversary of the date of the Meeting, or March&nbsp;18, 2020. However, if the date of the 2020 annual general meeting is changed by more than 30 calendar days from the
date of the anniversary of the Meeting, the notice must be received by our Company Secretary at least 45&nbsp;days prior to the date we intend to distribute our proxy materials with respect to the
2020 annual general meeting. If a shareholder does not timely provide notice as described above, proxies solicited on behalf of our management for the 2020 annual general meeting will confer
discretionary authority to vote with respect to any such matter, as permitted by the proxy rules of the SEC. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
section&nbsp;338 of the U.K. Companies Act (2006), shareholders representing at least 5% of holders entitled to vote on a resolution at an annual general meeting may require the
Company to include such resolution in its notice of an annual general meeting. Provided the applicable thresholds are met, notice of the resolution must be received by the Company at the Office of the
Company </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>78</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=86,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=923694,FOLIO='78',FILE='DISK112:[19ZAF1.19ZAF44001]CQ44001A.;10',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_cq44001_1_79"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Secretary,
60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14&nbsp;4RX at least six weeks prior to the date of the annual general meeting, or, if later, at the time notice of the annual
general meeting is delivered to shareholders. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Questions?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you have any questions or need more information about the Meeting please write to us at: </FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>Margaret
Henry<BR></FONT> <FONT SIZE=2><I>Company Secretary</I></FONT><FONT SIZE=2><BR>
Adaptimmune Therapeutics&nbsp;plc<BR>
60 Jubilee Avenue<BR>
Milton Park<BR>
Abingdon<BR>
Oxfordshire OX14&nbsp;4RX<BR>
United Kingdom </FONT></P>

</UL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>79</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=87,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=349234,FOLIO='79',FILE='DISK112:[19ZAF1.19ZAF44001]CQ44001A.;10',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_la44001_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="la44001_annex_a_to_proxy_statement"> </A>
<A NAME="toc_la44001_1"> </A>
<BR></FONT><FONT SIZE=2><B>  ANNEX A TO PROXY STATEMENT    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Directors' Remuneration Report  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Remuneration Committee Chairman's Statement  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On behalf of the Board of Directors of Adaptimmune Therapeutics&nbsp;plc, I am pleased to present the Directors' Remuneration Report for the
year ended 31&nbsp;December 2018. Shareholders will be invited to approve the Report on Remuneration (which will be a non-binding advisory vote) at the Annual General Meeting of shareholders to be
held on 2&nbsp;May 2019. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Period Covered by the Directors' Remuneration Report  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Directors' Remuneration Report that follows is for the full year period from 1&nbsp;January 2018 to 31&nbsp;December 2018 except where
otherwise stated. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The Remuneration Committee  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Committee is responsible for reviewing and establishing our executive remuneration policy and philosophy, including making recommendations
regarding the remuneration of our Chief Executive Officer ("CEO") to the Board for its approval, and determining and approving the remuneration of other senior executive officers. While the Board sets
the remuneration of our CEO, who is our sole Executive Director, the Committee makes recommendations on such matters to the Board. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Philosophy  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We seek to attract and retain outstanding employees who have the potential to support the growth of the Group and to attract and retain
Non-Executive Directors who can substantially contribute to our success as an innovative, clinical-stage biopharmaceutical company. As the Group has operations in the United Kingdom and the United
States, our senior executives and our Non-Executive Directors live and work in the U.K. and the U.S., and we are listed on a U.S. stock
exchange, we assess the competitiveness of our policies against both U.K. and U.S. benchmarks and practices, with an increasing focus on U.S. benchmarks and practices. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Business Strategy during 2018  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our primary goal in 2018 was to progress the development of the Group including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> advancement of our clinical trials for ADP-A2M10, ADP-A2M4 and ADP-A2AFP; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> continuing to use our SPEAR T-cell platform to generate SPEAR T-cells for cancers where existing therapeutic approaches are limited; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> continuing to understand, further enhance and improve the effectiveness and persistence of our SPEAR T-cell therapies; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the optimisation and expansion of our process development and manufacturing capabilities to maintain our leadership position in the TCR space
and the continued expansion of our intellectual property portfolio. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2018 Business Highlights  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018 was a year of strong operational performance for Adaptimmune. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=88,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=618867,FOLIO='A-1',FILE='DISK112:[19ZAF1.19ZAF44001]LA44001A.;9',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_la44001_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Key
business highlights during 2018 included: </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Advancement of our clinical trials for ADP-A2M10, ADP-A2M4 and ADP-A2AFP  </I></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Two Phase&nbsp;1 clinical trials are ongoing with ADP-A2M10. The first clinical trial is in patients with non-small cell lung cancer
("NSCLC"). The second clinical trial is in patients with three cancer tumour types, urothelial, melanoma and head and neck cancers.  </FONT> <FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> In 2018, both trials have progressed to the expansion phase, with patients being treated with up to 10&nbsp;billion transduced
SPEAR T-cells. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD></DL>
</DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> A Phase&nbsp;1 clinical trial is ongoing with ADP-A2M4 in bladder, melanoma, head and neck, ovarian, NSCLC, synovial sarcoma, myxoid round
cell liposarcoma ("MRCLS"), oesophageal and gastric cancers.  </FONT> <FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> In 2018, this trial progressed to the expansion phase with patients being treated with up to 10&nbsp;billion transduced SPEAR
T-cells. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD></DL>
</DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> A Phase&nbsp;1 clinical trial is ongoing with ADP-A2AFP in patients with hepatocellular cancer.  </FONT> <FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> In 2018, this trial moved into the dose escalation phase within the second dose cohort, with patients in Cohort 2 receiving a
target dose of 1&nbsp;billion SPEAR T-cells. </FONT></DD></DL>
</DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Successful transition of NY-ESO program  </I></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> During 2018, a fourth SPEAR T-cell, the NY-ESO SPEAR T-cell was transitioned to GlaxoSmithKline ("GSK") following GSK's exercise of its option
to obtain an exclusive global license to the NY-ESO SPEAR T-cell programme in September 2017. GSK has assumed full responsibility for all development, manufacturing and commercialization activities
for the NY-ESO SPEAR T-cell including progression of this SPEAR T-cell into further clinical trials. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Optimization and expansion of our manufacturing capabilities  </I></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Impressive progress was achieved in manufacturing: </FONT> <FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we initiated manufacture of cell product in January 2018 at the Adaptimmune SPEAR T-cell manufacturing plant in Philadelphia </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we scaled to the routine manufacture of SPEAR T-cells at target doses to treat patients across a broad range of solid tumours </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we established a dedicated vector manufacturing capability in the U.K. and our first vector production run to support pilot
clinical trials is anticipated for late 2019  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we secured existing vector production with our third party vendor </FONT><FONT SIZE=2>
<BR><BR></FONT></DD></DL>
</DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> These achievements enable us to continue to develop manufacturing enhancements and improvements with the aim of reducing the time taken to
manufacture and supply patient products. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Progression of our pre-clinical pipeline  </I></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We continued to maintain development of our pipeline, including: </FONT> <FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> making good progress with an off-the-shelf product and presenting progress to date at ASGCT 2018  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> continuing to develop multiple next generation approaches, with the goal of having the first next generation construct ready for
IND submission in 2H 2019 </FONT></DD></DL>
</DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=89,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=390394,FOLIO='A-2',FILE='DISK112:[19ZAF1.19ZAF44001]LA44001A.;9',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_la44001_1_3"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> investigating new targets in the context of new HLA types to be brought to the clinic beyond 2019 </FONT></DD></DL>
</UL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other corporate achievements  </I></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The Company completed a Registered Direct Offering raising net proceeds of approximately $100&nbsp;million in September 2018. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Activities and major decisions  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Committee's activities during the year included a benchmarking review of executive compensation, which was undertaken to ensure that
remuneration for the senior executive team remains competitive for the purposes of retention and engagement. The Committee engaged Willis Towers Watson as independent advisors to benchmark executive
compensation against a selected peer group consisting largely of comparable U.S.-listed biopharmaceutical companies, with some U.K.-listed biopharmaceutical companies, and to provide recommendations
for base salaries, equity based awards and the structure of bonus incentive awards for 2019. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a result of this benchmarking exercise, our CEO and senior executive officers received increased base salaries at levels that remain compliant with the last approved Directors'
Remuneration Policy. For our CEO, this resulted in a base salary of &pound;457,126 effective from 1&nbsp;January 2019, to maintain competitive positioning against the peer group. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2018 the Committee also considered the extent of achievement of 2018 calendar year objectives by the executive team and determined the level of bonus incentive awards payable
in respect of the 2018 calendar year. The awards made to our CEO and senior executive officers recognised that most of our corporate objectives for 2018 were achieved, with our CEO receiving a bonus
award at 85% of the target amount. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
January 2019 the Committee approved the objectives to be achieved by the executive team during 2019. These are considered to be commercially sensitive and will not be disclosed in
detail, but are designed to support achievement of our strategic objective to be a world leader in discovering, developing and commercialising TCR-based T-cell therapies that transform the clinical
outcomes of patients with cancer and our ambition to be a fully integrated cell therapy company and to have the first TCR T-cell approved for a solid tumour indication. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
2019 objectives are linked to our business goals, which include the continuation of some 2018 goals, with the addition of a key objective for
2019:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the advancement of our clinical trials for ADP-A2M10, ADP-A2M4 and ADP-A2AFP. A key objective is to advance these wholly owned SPEAR T-cells
further during 2019 with the aim of providing initial clinical data for ADP-A2M10 and ADP-A2M4 during the first half of 2019; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> continuing to use our SPEAR T-cell platform to generate SPEAR T-cells for cancers where existing therapeutic approaches are limited; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> continuing to understand, further enhance and improve the effectiveness and persistence of our SPEAR T-cell therapies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the optimisation and expansion of our process development and manufacturing capabilities to maintain our leadership position in the TCR space;
and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the continued expansion of our intellectual property portfolio. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Generally,
the remuneration arrangements adopted in 2019 recognise the greater demands placed on our CEO and senior executive team to deliver on our strategy and create value for our
shareholders. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=90,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=152458,FOLIO='A-3',FILE='DISK112:[19ZAF1.19ZAF44001]LA44001A.;9',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<A NAME="page_la44001_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Finally,
under the last approved Directors' Remuneration Policy, the Board has discretion to pay Non-Executive Directors in the form of a mixture of cash and equity. The remuneration
arrangements for Non-Executive Directors during 2018 comprised an award of a fixed number of share options, plus an additional number of share options or cash payment at the Director's election. The
option awards and cash payments were made at competitive levels aligned with peer group data from comparable companies provided in a benchmarking analysis undertaken by Willis Towers Watson in 2018. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>/s/&nbsp;DAVID M. MOTT<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2><B>David M Mott</B></FONT><BR>
<FONT SIZE=2><I>Director and Chairman of the Remuneration Committee</I></FONT><FONT SIZE=2><BR>
26&nbsp;February 2019</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=91,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=60000,FOLIO='A-4',FILE='DISK112:[19ZAF1.19ZAF44001]LA44001A.;9',USER='CHE107322',CD=';1-MAR-2019;12:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_lc44001_1_5"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


PART I&#151;REPORT ON REMUNERATION  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The information provided in this part of the Directors' Remuneration Report is subject to audit.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Remuneration Committee presents the Report on Remuneration for the year ended 31&nbsp;December 2018, which will be put to shareholders for
a non-binding vote at the Annual General Meeting to be held on 2&nbsp;May 2019. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Single Total Figure of Remuneration for each Director  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table shows the remuneration received by the Directors for the year ended 31&nbsp;December 2018. For reference only, the table
also shows the remuneration received by the Directors for the year ended 31&nbsp;December 2017, which information was included in the Company's annual report and financial statements for the year
ended 31&nbsp;December 2017 and approved by shareholders at the Annual General Meeting held on 20&nbsp;June 2018. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="34pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="31pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="31pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="31pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="34pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="31pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="31pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="31pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=17 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the year ended 31&nbsp;December 2018: </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=17 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the year ended 31&nbsp;December 2017: </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Variable Pay(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Variable Pay(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fixed Pay(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fixed Pay(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Equity-<BR>
Based<BR>
Awards<BR>
(6) &pound; </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Equity-<BR>
Based<BR>
Awards<BR>
(6) &pound; </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name of Director

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Salary<BR>
and fees<BR>
&pound; </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Taxable<BR>
benefit<BR>
&pound; </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Annual<BR>
bonus<BR>
&pound; </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Pension<BR>
allowance<BR>
&pound; </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
&pound; </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Salary<BR>
and fees<BR>
&pound; </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Taxable<BR>
benefit<BR>
&pound; </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Annual<BR>
bonus<BR>
&pound; </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Pension<BR>
allowance<BR>
&pound; </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
&pound; </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B><I>Executive</I></B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>James Noble (CEO)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>420,065</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>906</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>196,380</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>21,003</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>638,354</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>407,830</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>844</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>183,524</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>20,392</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>612,590</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B><I>Non-executives</I></B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>David Mott (Chairman)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Lawrence Alleva</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>23,511</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>23,511</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Ali Behbahani</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Barbara Duncan</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>John Furey</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Giles Kerr</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>39,594</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>39,594</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>37,648</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>37,648</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Elliott Sigal</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Peter Thompson</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Tal Zaks</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>34,286</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>34,286</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>33,493</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>33,493</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:times;"><FONT SIZE=1>Notes
to table of Single Total Figure of Remuneration for each Director  </FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
majority of the remuneration was set and paid in pounds sterling (&pound;). For the purpose of this table, the fees paid in U.S. dollars to
Mr&nbsp;Lawrence Alleva and Dr&nbsp;Tal Zaks for the year ended 31&nbsp;December 2018 have been translated into pounds sterling based on the U.S. dollar/pound sterling exchange rate at
31&nbsp;December 2018 ($1.27602 to &pound;1). The fees paid in U.S. dollars to Dr&nbsp;Tal Zaks for the year ended 31&nbsp;December 2017, have been translated into pounds sterling based on
the U.S. dollar/pound sterling exchange rate at 31&nbsp;December 2017 ($1.35005 to &pound;1).
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
base salary levels of our CEO and all other employees of the Group are reviewed and, to the extent deemed necessary, adjusted to be effective from
1&nbsp;January in each year.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Taxable
benefits comprise medical insurance. Generally, Mr&nbsp;Noble participates in the same benefits as we offer to all our employees in the United Kingdom
where Mr&nbsp;Noble resides.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
annual bonus amount for each of the year ended 31&nbsp;December 2018 and the year ended 31&nbsp;December 2017 represents the total bonus payment that related
to performance in each of 2018 and 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
pension allowance for each of the year ended 31&nbsp;December 2018 and the year ended 31&nbsp;December 2017 represents an amount equating to 5% of the base
salary for each of 2018 and 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>There
were no performance obligations linked to the equity-based awards. In each of the year ended 31&nbsp;December 2018 and the year ended 31&nbsp;December
2017, the value of equity-based awards included in the table is based on the market value of underlying shares at the date of grant, less the applicable exercise price, which is nil because the
exercise price was based on the market value of the underlying shares at the date of grant. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Annual Bonus  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The annual bonus for the year ended 31&nbsp;December 2018 shown in the table above for Mr&nbsp;Noble, our CEO, was based on the achievement
of objectives primarily linked to our business strategies and which included: the continued advancement of our clinical trials for ADP-A2M10, ADP-A2M4 and ADP-A2AFP; continuing to use our SPEAR T-cell
platform to generate SPEAR T-cells for cancers where existing therapeutic approaches are limited; continuing to understand, further enhance and improve the effectiveness and persistence of our SPEAR
T-cell therapies; optimization and expansion </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=92,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=858296,FOLIO='A-5',FILE='DISK112:[19ZAF1.19ZAF44001]LC44001A.;12',USER='CHE107322',CD=';1-MAR-2019;12:53' -->
<A NAME="page_lc44001_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>of
our process development and manufacturing capabilities to maintain our leadership position in the TCR space and the continued expansion of our intellectual property portfolio. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board has considered whether it would be in the best interests of the Company and its shareholders to disclose the precise targets agreed for the performance measures in 2018. An
additional consideration is that most of our competitors are based in the U.S. where market practice is not to disclose precise annual bonus targets for biotechnology companies at the
pre-commercialization stage. As the specific objectives for a single year are based on the Group's long-term strategies, the Board has concluded that disclosing such targets would necessarily involve
divulging competitively sensitive information that we believe would be detrimental to our commercial performance going forward and, therefore, we are providing the categories of objectives, rather
than the precise targets. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Statement of Directors' Shareholdings and Share Interests  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The table below shows, for each Director, the total number of shares owned, the total number of share options held and the number of share
options vested as at 31&nbsp;December 2018. No Director exercised any share options during the year ended 31&nbsp;December 2018. The table only reflects shares held individually by each Director,
or a family investment vehicle or trust, and does not include shares held by any investment fund with which the Director is affiliated. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="16pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="86pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name of Director

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total share<BR>
options </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Vested share<BR>
options(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Options exercised<BR>
during year ended<BR>
31&nbsp;December 2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Executive Director</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>James Noble (CEO)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,172,600</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,418,148</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,701,405</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Non-Executive Directors</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David Mott (Chairman)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>844,530</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>657,200</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lawrence Alleva</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>117,864</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,114,628</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>958,143</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ali Behbahani</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>715,841</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>561,032</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Barbara Duncan</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>719,774</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>499,141</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>John Furey</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>284,233</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Giles Kerr</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>556,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>333,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Elliott Sigal</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>367,038</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,104,236</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>916,942</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Peter Thompson</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>565,603</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>565,603</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tal Zaks</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>556,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>333,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>All
share options that were outstanding as at 31&nbsp;December 2018 use time-based vesting and are not subject to performance targets other than continued service
until the date of vesting.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
1,200,000 Ordinary shares represented by 200,000 ADSs that Mr&nbsp;Noble purchased in October 2015.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 70,584 Ordinary shares represented by 11,764 ADSs that Mr&nbsp;Alleva purchased during the IPO and 47,280 Ordinary shares represented by 7,880 ADSs
purchased by the Lawrence M. Alleva Revocable Trust in December 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
254,100 Ordinary shares held by Sigal Family Investments&nbsp;LLC, as well as 52,938 Ordinary shares represented by 8,823 ADSs that Dr&nbsp;Sigal
purchased during the IPO and 60,000 Ordinary shares represented by 10,000 ADSs purchased by Sigal Family Investments&nbsp;LLC in May 2016.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Policy on Shareholding Requirements  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not currently have a policy requiring our Directors to hold a certain number or value of our shares. However, we encourage our Executive
Director and senior executive officers to have a </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=93,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=236367,FOLIO='A-6',FILE='DISK112:[19ZAF1.19ZAF44001]LC44001A.;12',USER='CHE107322',CD=';1-MAR-2019;12:53' -->
<A NAME="page_lc44001_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>shareholding
in the Company. The scale of our CEO's share ownership is well in excess of the most stretching shareholding guidelines demanded by investors and proxy advisors. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Directors' Equity-based Awards Held at 31&nbsp;December 2018  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The table below presents the interests of the Directors in options to acquire our Ordinary shares with a nominal value of &pound;0.001 per
share as at 31&nbsp;December 2018. 3,415,470 options were granted to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=94,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=128996,FOLIO='A-7',FILE='DISK112:[19ZAF1.19ZAF44001]LC44001A.;12',USER='CHE107322',CD=';1-MAR-2019;12:53' -->
<A NAME="page_lc44001_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>Directors
during the year ended 31&nbsp;December 2018. None of our Directors exercised any options during the year ended 31&nbsp;December 2018. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:57%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"140%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="140%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="110pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name of Director


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Options<BR>
Held </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Grant<BR>
date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Start date<BR>
for vesting </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exercise<BR>
price </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>First date of exercise of<BR>
some or all options(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Date of<BR>
expiry </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B><I>Executive Director</I></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>James Noble (CEO)(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1,335,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>20/03/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>31/03/14</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.1120</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>31/03/14</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>30/03/24</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>438,100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>20/03/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>31/03/14</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.1120</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>31/03/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>30/03/24</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>3,500,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>20/03/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>19/12/14</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.3557</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>19/12/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>19/12/24</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1,968,016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>18/01/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>18/01/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.89</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>18/01/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>18/01/26</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2,072,976</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>13/01/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>13/01/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.59</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>13/01/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>13/01/27</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1,719,936</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>12/01/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>12/01/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.96</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>12/01/19</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>12/01/28</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>384,120</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>12/01/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>12/01/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.001</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>12/01/19</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>12/01/28 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><I>Total</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><I> 11,418,148</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B><I>Non-Executive Directors</I></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>David Mott (Chairman)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>163,229</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.82</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/05/25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>191,410</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/08/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/08/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.97</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/08/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/08/26</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>302,561</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>03/07/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>03/07/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>03/07/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>03/07/27</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>187,330</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22/06/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22/06/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.65</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22/06/19</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22/06/28 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><I>Total</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><I> 844,530</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Lawrence Alleva(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>519,481</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>16/03/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>16/03/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>

<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>16/03/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>16/03/25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>30,745</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.82</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/05/25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>196,678</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/08/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/08/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.97</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/08/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/08/26</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>243,724</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>03/07/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>03/07/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>03/07/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>03/07/27</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>124,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22/06/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22/06/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.65</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22/06/19</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22/06/28 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><I>Total</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><I> 1,114,628</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Ali Behbahani</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>155,682</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>

<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.82</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/05/25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>184,562</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/08/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/08/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.97</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/08/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/08/26</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>220,788</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>03/07/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>03/07/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>03/07/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>03/07/27</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>154,809</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22/06/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22/06/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.65</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22/06/19</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22/06/28 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><I>Total</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><I> 715,841</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Barbara Duncan(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>332,776</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>23/06/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>23/06/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>

<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.01</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>23/06/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>23/06/26</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>228,765</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>03/07/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>03/07/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>03/07/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>03/07/27</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>158,233</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22/06/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22/06/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.65</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22/06/19</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22/06/28 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><I>Total</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><I> 719,774</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>John Furey(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>284,233</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>05/07/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>05/07/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>

<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.49</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>05/07/19</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>05/07/28</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Giles Kerr(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
288,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
29/11/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
29/11/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>

<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
0.65</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
29/11/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
29/11/26</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>144,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>03/07/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>03/07/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>03/07/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>03/07/27</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>124,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22/06/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22/06/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.65</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22/06/19</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22/06/28 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><I>Total</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><I> 556,000</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Elliott Sigal(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>519,481</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>16/03/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>16/03/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>

<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>16/03/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>16/03/25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>24,596</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.82</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/05/25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>184,562</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/08/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/08/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.97</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/08/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/08/26</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>220,788</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>03/07/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>03/07/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>03/07/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>03/07/27</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>154,809</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22/06/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22/06/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.65</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22/06/19</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22/06/28 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><I>Total</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><I> 1,104,236</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Peter Thompson(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>155,682</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>

<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.82</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/05/25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>186,142</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/08/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/08/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.97</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/08/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/08/26</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>223,779</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>03/07/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>03/07/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>03/07/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>03/07/27 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><I>Total</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><I> 565,603</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Tal Zaks(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>288,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>29/11/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>29/11/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>

<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.65</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>29/11/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>29/11/26</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>144,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>03/07/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>03/07/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>03/07/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>03/07/27</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>124,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22/06/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22/06/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.65</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22/06/19</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22/06/28 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><I>Total</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><I> 556,000</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <UL>

<P style="font-family:times;"><FONT SIZE=1>Notes
to table of Directors' Equity-based Awards Held at 31&nbsp;December 2018  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>All
share options awarded to Directors that were outstanding as at 31&nbsp;December 2018 use time-based vesting and are not subject to performance targets other
than continued service until the date of vesting. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=95,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=963127,FOLIO='A-8',FILE='DISK112:[19ZAF1.19ZAF44001]LC44001A.;12',USER='CHE107322',CD=';1-MAR-2019;12:53' -->
<A NAME="page_lc44001_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>All
options granted to James Noble on 20&nbsp;March 2015 were granted as replacement options in exchange for options formerly held over Ordinary shares of
Adaptimmune Limited. Generally, these replacement options vest and become exercisable as follows: 25% on the first anniversary of the grant date of the original options and 75% in monthly instalments
over the following three years.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>519,481
options granted to Lawrence Alleva and 519,481 options granted to Dr&nbsp;Elliott Sigal vest and become exercisable as follows: 25% on the first
anniversary of the grant date and 75% in monthly instalments over the following three years. All options granted to Non-Executive Directors on 11&nbsp;May 2015 vested and became exercisable on
11&nbsp;May 2015. All options granted to Non-Executive Directors on 11&nbsp;August 2016 vested and became exercisable on 11&nbsp;August 2017. All options granted to Non-Executive Directors on
3&nbsp;July 2017 vested and became exercisable on 3&nbsp;July 2018. All options granted to Non-Executive Directors on 22&nbsp;June 2018 vest and become exercisable on 22&nbsp;June 2019.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>332,776
options granted to Barbara Duncan, 288,000 options granted to Giles Kerr 288,000 options granted to Tal Zaks and 284,233 options granted to John Furey were
awarded on appointment as new Directors, and vest and become exercisable as follows: 25% on the first anniversary of the grant date and 75% in monthly instalments over the following two years.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Peter
Thompson stood down from the Board on 5&nbsp;July 2018 and did not receive an annual award of options in 2018. In recognition of Dr&nbsp;Thompson's service
as a Board member and as a member of the Remuneration Committee up to 5&nbsp;July 2018, he was permitted a 12&nbsp;month period in which to exercise those options which had vested as at
5&nbsp;July 2018. Any options that are not exercised by 5&nbsp;July 2019 will lapse and cease to be exercisable. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
closing market price of our ADSs on 31&nbsp;December 2018 was $5.75. One ADS represents six Ordinary shares. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Payments Made to Past Directors  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the year ended 31&nbsp;December 2018, we made no payments to former Directors of the Company. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Payments for Loss of Office  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the year ended 31&nbsp;December 2018, we made no payments with respect to a Director's loss of office. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Illustration of Total Shareholder Return  </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The information provided in this part of the Directors' Remuneration Report is not subject to audit.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following graph compares the cumulative total shareholder return on our ADSs, each representing six Ordinary shares, with that of the Nasdaq
Biotech Index and the Nasdaq Composite Index for the period that our shares were publicly traded, which commenced on 6&nbsp;May 2015.
We selected the Nasdaq Biotech Index because our ADSs trade on The Nasdaq Global Select Market and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=96,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=697422,FOLIO='A-9',FILE='DISK112:[19ZAF1.19ZAF44001]LC44001A.;12',USER='CHE107322',CD=';1-MAR-2019;12:53' -->
<A NAME="page_lc44001_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>we
believe this indicates our relative performance against a group consisting of more similarly situated companies. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g436184.jpg" ALT="GRAPHIC" WIDTH="634" HEIGHT="370">
  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Chief Executive Officer Total Remuneration History  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The table below sets out total remuneration details for the Chief Executive Officer. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="96pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="98pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="116pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Period


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Single total figure of<BR>
remuneration &pound;(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Annual bonus payout<BR>
against maximum<BR>
opportunity(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Long term incentive<BR>
vesting rates against<BR>
maximum opportunity(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Year ended 31&nbsp;December 2018:</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>638,354</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>47</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Year ended 31&nbsp;December 2017:</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>612,590</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>45</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
Single total figure of remuneration for the year ended 31&nbsp;December 2018 includes the annual bonus payment for performance in the year ended
31&nbsp;December 2018. The Single total figure of remuneration for the year ended 31&nbsp;December 2017 includes the annual bonus payment for performance in the year ended 31&nbsp;December 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
bonus payout percentage amount for the year ended 31&nbsp;December 2018 relates to the total annual bonus payment for performance in the year ended
31&nbsp;December 2018. The bonus payout percentage amount for the year ended 31&nbsp;December 2017 relates to the total annual bonus payment for performance in the year ended 31&nbsp;December
2017. In both years, the maximum opportunity was an annual bonus payment of up to 100% of salary, which was in line with the last approved Directors' Remuneration Policy.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amount shown represents the percentage of the options that actually vested during the period expressed as a percentage of the maximum number of options that
could have vested during the period. There were no performance obligations linked to these equity-based awards, other than service obligations, and therefore, all options that could have vested during
the period have actually vested.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=97,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=281091,FOLIO='A-10',FILE='DISK112:[19ZAF1.19ZAF44001]LC44001A.;12',USER='CHE107322',CD=';1-MAR-2019;12:53' -->
<A NAME="page_lc44001_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Chief Executive Officer's Remuneration Compared to Other Employees  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Chief Executive Officer's average fixed salary of &pound;420,065 for the year ended 31&nbsp;December 2018 was 5.8 times the value of
the average fixed salary of the Group's comparator employees for such period. His average fixed salary of &pound;407,830 for the year ended 31&nbsp;December 2017 was 6.1 times the value of the
average fixed salary of the Group's comparator employees for that period. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table shows the percentage change in remuneration of the Chief Executive Officer in comparison to the percentage change in remuneration of an employee in the comparator
group&nbsp;(1) between the year ended 31&nbsp;December 2018 and the year ended 31&nbsp;December 2017. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="lc44001_percentage_change_in_remunerat__per04443"> </A>
<A NAME="toc_lc44001_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Percentage change in remuneration in the year ended 31&nbsp;December 2018<BR>  compared with remuneration in the year ended 31&nbsp;December 2017    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="26pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="75pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>CEO </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Average change<BR>
per employee(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Base salary</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Annual bonus</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10.8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Taxable benefits</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (1.1)%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
employee comparator group comprises all UK and US employees who were employed for the full 24&nbsp;month period ended 31&nbsp;December 2018. The percentage
change calculations were performed in local currency and then combined using a weighted average based on the number of employees. This group is considered to be an appropriate comparator group because
it is representative of the Group's employees in terms of seniority and demographics; additionally, using a consistent employee group, with the same individuals appearing in the 2017 and 2018 groups,
enables a meaningful comparison to be made.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Taxable
benefits for the CEO and for employees comprise small amounts and, therefore, any change generates a significant percentage decrease or increase. For the
year ended 31&nbsp;December 2018, the CEO's taxable benefits totalled &pound;906 (2017: &pound;844)&#151;for more details, please refer to the table for
'</FONT><FONT SIZE=2><I>Single Total Figure of Remuneration for each Director'</I></FONT><FONT SIZE=2> earlier in this report.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Relative Importance of Spend on Pay  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth the total amounts spent by the Company and its direct and indirect subsidiaries on remuneration for the year
ended 31&nbsp;December 2018 and the year ended 31&nbsp;December 2017. Given that the Group remains in the early phases of its business life cycle, the comparator chosen to reflect the relative
importance of the Group's spend on pay is the Group's research and development expenses as shown in its consolidated income statement on page&nbsp;57 of its Annual Report and Financial Statements
for the year ended 31&nbsp;December 2018. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="86pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="86pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Period:

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year ended<BR>
31&nbsp;December 2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year ended<BR>
31&nbsp;December 2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total spend on remuneration(1):</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>64,276,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>47,358,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development expenses:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>115,242,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>96,381,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
total spend on remuneration includes the value of equity-based awards as recognised in the financial statements in accordance with International Financial
Reporting Standard&nbsp;2 "Share-Based Payments".  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=98,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=811302,FOLIO='A-11',FILE='DISK112:[19ZAF1.19ZAF44001]LC44001A.;12',USER='CHE107322',CD=';1-MAR-2019;12:53' -->
<A NAME="page_lc44001_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Director Remuneration for the year ending 31&nbsp;December 2019  </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Salary  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 2018, the Committee engaged Willis Towers Watson as independent advisors to benchmark executive compensation, to ensure that it remains
competitive for the purposes of retention and engagement. Willis Towers Watson benchmarked executive compensation against a selected peer group consisting largely of comparable U.S.-listed
biopharmaceutical companies, with some U.K.-listed biopharmaceutical companies, and to provide recommendations for base salaries, equity based awards and the structure of bonus incentive awards for
2019. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a result of this benchmarking exercise, our CEO and senior executive officers received increased base salaries at levels that remain compliant with the last approved Directors'
Remuneration Policy. For our CEO, this resulted in a base salary of &pound;457,126 effective from 1&nbsp;January 2019. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Annual bonus  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For the year ending 31&nbsp;December 2019, the CEO is eligible for a target bonus award of 60% of his base salary of &pound;457,126
(that is, &pound;274,276), subject to the achievement of objectives. These are linked to our business strategies, which include: the advancement of our clinical trials for ADP-A2M10, ADP-A2M4
and ADP-A2AFP. A key objective is to advance these wholly owned SPEAR T-cells further during 2019 with the aim of providing initial clinical data for ADP-A2M10 and ADP-A2M4 during the first half of
2019; continuing to use our SPEAR T-cell platform to generate SPEAR T-cells for cancers where existing therapeutic approaches are limited; continuing to understand, further enhance and improve the
effectiveness and persistence of our SPEAR T-cell therapies; the optimisation and expansion of our process development and manufacturing capabilities to maintain our leadership position in the TCR
space; and the continued expansion of our intellectual property portfolio. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It
is anticipated that the Board will meet in the first quarter of 2020 to assess the performance of the CEO for the year ending 31&nbsp;December 2019 against the objectives. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board has considered whether it would be in the best interests of the Company and its shareholders to disclose the precise targets agreed for the performance measures in 2019. An
additional consideration is that most of our competitors are based in the U.S. where market practice is not to disclose precise annual bonus targets for biotechnology companies at the
pre-commercialization stage. As the specific objectives for a single year are based on the Group's long-term strategies, the Board has concluded that disclosing such targets would necessarily involve
divulging competitively sensitive
information that we believe would be detrimental to our commercial performance going forward and, therefore, we are providing the categories of objectives, rather than the precise targets. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Long-term incentives  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During January 2019, awards of share options were made to our CEO and other Senior Executive Officers. These awards were within market
competitive levels provided by Willis Towers Watson, following their benchmarking assessment of equity awards made to executive teams in a peer group of comparable U.S. and U.K. listed
biopharmaceutical companies, with a priority focus on U.S. companies, and were also within the principles of the last approved Directors' Remuneration Policy. These awards were disclosed on
Form&nbsp;4s submitted to the Securities and Exchange Commission on 8&nbsp;January 2019. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The Remuneration Committee  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Remuneration Committee is comprised of Mr&nbsp;Mott (Chairman), Mr&nbsp;Furey and Dr&nbsp;Zaks. All members have continued to serve
until the date of this Report on Remuneration. The charter of the Committee is set forth on our website at http://www.adaptimmune.com </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=99,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=29301,FOLIO='A-12',FILE='DISK112:[19ZAF1.19ZAF44001]LC44001A.;12',USER='CHE107322',CD=';1-MAR-2019;12:53' -->
<A NAME="page_lc44001_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Advice Provided to the Remuneration Committee  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Committee retained Willis Towers Watson to provide independent advice and consultation with respect to remuneration arrangements for the CEO
(being our sole Executive Director) and senior management. Willis Towers Watson is a global remuneration consultant with a well-established reputation for the design and implementation of remuneration
programmes, including the design and implementation of equity-based incentive programmes. The Committee also sourced
certain market research data reports from Radford remuneration consultants. In the year ended 31&nbsp;December 2018, the amounts paid to Willis Towers Watson totalled $130,783 and the amounts paid
to Radford totalled $7,050. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to Willis Towers Watson and Radford, the Committee solicited and received input from the CEO concerning the remuneration of senior executives other than himself. The CEO
provided recommendations with respect to annual cash bonuses to be paid to these persons for service in the year ended 31&nbsp;December 2018 and base salaries effective from 1&nbsp;January 2019
and with respect to equity-based awards made to these persons in January 2019. Finally, the CEO also provided input to the Committee regarding the implementation of equity-based remuneration as an
element of all other employees' remuneration. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Statement of Voting Results  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Voting at our shareholder meetings has generally been conducted by show of hands by shareholders who are in attendance at the meeting. At the
Annual General Meeting held on 20&nbsp;June 2018, all of the resolutions set out in the Notice of the Annual General Meeting sent to shareholders were duly proposed and passed by unanimous approval,
including the resolution proposing the approval of the Directors' Remuneration Report for the year ended 31&nbsp;December 2017 and the resolution proposing the approval of the Directors'
Remuneration Policy to apply effective from the end of that Annual General Meeting. No votes were withheld. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Details
of the proxy votes received in relation to the resolution proposing the approval of the Directors' Remuneration Report for the year ended 31&nbsp;December 2017, and in relation
to the resolution proposing the approval of the Directors' Remuneration Policy were as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Resolution

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Votes For </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>% of Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Votes<BR>
Against </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>% of Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Votes<BR>
Withheld </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>% of Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>To approve the Directors' Remuneration Report</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>444,072,376</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>99.88</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>523,800</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>144,768</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.033</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>To approve the Directors' Remuneration Policy</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>444,092,212</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>99.88</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>514,152</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>134,580</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.0003</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Statement of Implementation of Remuneration Policy in the Year ended 31&nbsp;December 2018  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There have been no changes to the Directors' Remuneration Policy, as approved at the Annual General Meeting of shareholders held on
20&nbsp;June 2018. In 2019, the Company intends to adhere to the policy as approved. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=100,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=231831,FOLIO='A-13',FILE='DISK112:[19ZAF1.19ZAF44001]LC44001A.;12',USER='CHE107322',CD=';1-MAR-2019;12:53' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_le44001_1_14"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


PART II&#151;DIRECTORS' REMUNERATION POLICY  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The information provided in this part of the Directors' Remuneration Report is not subject to audit.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have set forth below a summary of the remuneration policy for the Executive Directors and for our Non-Executive Directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Directors' Remuneration Policy was approved at the Annual General Meeting held on 20&nbsp;June 2018 and remains effective for a maximum of three years, until 19&nbsp;June 2021,
or until a revised policy is approved by shareholders. The last approved remuneration policy can also be found in the Annual Report and Financial Statements of the Company for the year ended
31&nbsp;December 2017, which is available in the Investors section of our website: http://www.adaptimmune.com </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Summary of remuneration policy&#151;Executive Directors  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As Adaptimmune Therapeutics&nbsp;plc is a U.K. incorporated company listed on NASDAQ, the Group has operations in the U.K. and the U.S., our
senior executives and our Non-Executive Directors live and work in the U.K. and the U.S., the Committee considers it appropriate to examine and be informed by compensation practices in both the U.K.
and U.S., particularly in the matter of equity-based incentives, with an increasing focus on U.S. benchmarks and practices. The Committee considers that the last approved Directors' Remuneration
Policy continues to be appropriate and fit for purpose, but the Committee is committed to reviewing the remuneration policy on an ongoing basis in order to ensure that it remains effective and
competitive. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Directors' Remuneration Policy is used to determine the remuneration for our CEO, our sole Executive Director, as well as for our other senior executives, and would also apply to
other Executive Directors and senior executives that we appointed. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
described in the last approved Directors' Remuneration Policy, the elements of remuneration for the Executive Director(s) and Senior Executives comprise: base salary, pension or
pension allowance payment, benefits (currently, access to death-in-service life insurance, family private medical cover and ill-health income protection), annual bonus and long term equity incentives
(currently, share option awards). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
remuneration of our CEO is determined by the Board after having considered recommendations from the Committee. The remuneration of other senior executives in the Company, excluding
our CEO, (the "Senior Executives") is determined by the Committee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
2018, the Committee retained an independent remuneration consultant, Willis Towers Watson, to assist the Committee in ensuring that our remuneration arrangements for the Executive
Director and senior executives are competitive for the calendar year commencing 1&nbsp;January 2019. Willis Towers Watson provided data from comparable publicly traded biopharmaceutical companies
and otherwise assisted the Committee in its design of competitive remuneration for the Executive Director and senior executives. We expect to continue to use remuneration consultants to assist the
Committee in
determining competitive levels of executive remuneration and specific design elements of our remuneration programme. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=101,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=345224,FOLIO='A-14',FILE='DISK112:[19ZAF1.19ZAF44001]LE44001A.;18',USER='CHE107322',CD=';1-MAR-2019;12:53' -->
<A NAME="page_le44001_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following tables present the elements of remuneration for our CEO (our sole Executive Director) and our other senior executives. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="17%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="25%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="17%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="17%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Element of<BR>
Remuneration

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Purpose and link to strategy </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Operation </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Maximum </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Performance targets </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Base salary</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Rewards skills and experience and provides the basis for a competitive remuneration package.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Salaries will be reviewed annually by reference to: (i)&nbsp;market practice and market data on which the Committee receives independent advice; (ii)&nbsp;the individuals' experience and scope of the role; (iii)
&nbsp;broader employee increases and (iv)&nbsp;rates of inflation.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Salaries will not generally exceed the 75<SUP>th</SUP>&nbsp;percentile of peer group comparator data for the relevant role unless there is a clear business rationale to do so.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Not applicable.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><BR><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 Salaries will be benchmarked against comparable roles in a selected peer group of US- and European-listed biopharmaceutical companies with similar market capitalisations and/or scale of operational complexity.<BR></FONT> <FONT
 SIZE=2>&nbsp;&nbsp;<BR></FONT> <FONT SIZE=2></font> <p align=left style="font-family:times;margin-top:0pt;margin-left:0pt;"> <font size=2> We typically expect to align salaries with the 50<SUP>th</SUP>&nbsp;percentile of peer group comparator data but may vary from
 this general rule where we consider that special circumstances apply or where recruitment or retention of a particular role is required.<BR></FONT> <FONT SIZE=2>&nbsp;&nbsp;<BR></FONT> <FONT SIZE=2></font> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:0pt;"> <font size=2> The Committee may also decide to approve future increases following changes to job responsibilities or to reflect experience within the role.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><BR><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 The Committee will reference alternative data for roles not widely represented in the core peer group.<BR></FONT> <FONT SIZE=2>&nbsp;&nbsp;<BR></FONT> <FONT SIZE=2></font> <p align=left style="font-family:times;margin-top:0pt;margin-left:0pt;"> <font size=2> The
 Committee retains discretion to adjust the Executive Directors' base salaries to ensure that we can attract and retain the necessary talent to effectively compete in the global marketplace.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> Pension</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Enables Executive Directors to build long-term retirement savings.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Company contribution to a personal pension scheme or a pension allowance payment, at the election of the Executive Director. Levels will be reviewed annually and the Committee may decide to increase future
contribution levels should the review indicate such a change is appropriate.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>5% of basic salary.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Not applicable.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=102,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=874413,FOLIO='A-15',FILE='DISK112:[19ZAF1.19ZAF44001]LE44001A.;18',USER='CHE107322',CD=';1-MAR-2019;12:53' -->
<A NAME="page_le44001_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="17%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="25%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="17%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="17%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Element of<BR>
Remuneration

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Purpose and link to strategy </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Operation </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Maximum </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Performance targets </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Benefits</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Protects against risks and provides other benefits in line with market practice.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 Benefits currently include death-in-service life insurance, family private medical cover and ill-health income protection. The Committee will review benefits offered from time to time and retains the discretion to add or substitute benefits to
 ensure they remain market competitive.<BR></FONT> <FONT SIZE=2>&nbsp;&nbsp;<BR></FONT> <FONT SIZE=2></font> <p align=left style="font-family:times;margin-top:0pt;margin-left:0pt;"> <font size=2> In the event that the Group requires an Executive Director to relocate,
 we would offer appropriate relocation assistance.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Not applicable.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Not applicable.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Annual Bonus</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rewards achievement of the near-term business objectives set at the start of each calendar year and reflects individual and team performance
of the Executive Director and other Senior Executives in achieving those objectives, and progress towards achieving our strategic goals.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 Objectives are set at the start of each calendar year.<BR></FONT> <FONT SIZE=2>&nbsp;&nbsp;<BR></FONT> <FONT SIZE=2></font> <p align=left style="font-family:times;margin-top:0pt;margin-left:0pt;"> <font size=2> The choice of annual performance objectives will reflect
 the Committee's assessment of the key milestones/metrics required to be achieved within the calendar year in order to make progress towards achieving our strategic goals.<BR></FONT> <FONT SIZE=2>&nbsp;&nbsp;<BR></FONT> <FONT SIZE=2></font> <p
 align=left style="font-family:times;margin-top:0pt;margin-left:0pt;"> <font size=2> The target annual cash bonus for our Executive Directors will be established as a percentage of base salary.<BR></FONT> <FONT SIZE=2>&nbsp;&nbsp;<BR></FONT> <FONT SIZE=2></font> <p
 align=left style="font-family:times;margin-top:0pt;margin-left:0pt;"> <font size=2> The annual bonus is payable in cash after award.<BR>
</FONT><FONT SIZE=2>&nbsp;&nbsp;<BR></FONT> <FONT SIZE=2></font> <p align=left style="font-family:times;margin-top:0pt;margin-left:0pt;"> <font size=2> When business opportunities or challenges change substantially during the course of the year, the Committee may
adjust objectives to meet the changed circumstances and correspondingly realign potential rewards.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 Awards will normally be limited to a maximum of 100% of basic salary.<BR></FONT> <FONT SIZE=2>&nbsp;&nbsp;<BR></FONT> <FONT SIZE=2></font> <p align=left style="font-family:times;margin-top:0pt;margin-left:0pt;"> <font size=2> In exceptional periods, considered to be
 those years in which achievements lead to a transformational effect on the future prospects or the valuation of the business, the annual maximum may increase to up to 150% of basic salary.<BR></FONT> <FONT SIZE=2>&nbsp;&nbsp;<BR>
</FONT><FONT SIZE=2></font> <p align=left style="font-family:times;margin-top:0pt;margin-left:0pt;"> <font size=2> Judgement as to whether achievements in a calendar year are considered to be exceptional is at the discretion of the Committee.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


<BR>
The Committee retains the ability to set performance objectives annually.<BR></FONT> <FONT SIZE=2>&nbsp;&nbsp;<BR></FONT> <FONT SIZE=2></font> <p align=left style="font-family:times;margin-top:0pt;margin-left:0pt;"> <font size=2> These objectives can be group-based
and /or individual, financial and/ or non-financial, and are likely to include milestones linked to:<BR></FONT> <FONT SIZE=2>&nbsp;&nbsp;<BR></FONT> <FONT SIZE=2></font> <p align=left style="font-family:times;margin-top:0pt;margin-left:0pt;"> <font size=2>
</FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:9pt;"><font size=2></FONT><FONT SIZE=2>successful execution of key
elements of pipeline development programmes;<BR>
</FONT><FONT SIZE=2>&nbsp;&nbsp;<BR></FONT> <FONT SIZE=2></font> <p align=left style="font-family:times;margin-top:0pt;margin-left:0pt;"> <font size=2> </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><font size=2>
&#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:9pt;"><font size=2></FONT><FONT SIZE=2>progress with clinical trials programmes;<BR></FONT> <FONT SIZE=2>&nbsp;&nbsp;<BR></FONT> <FONT SIZE=2></font> <p align=left
style="font-family:times;margin-top:0pt;margin-left:0pt;"> <font size=2> </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:9pt;"><font
size=2></FONT><FONT SIZE=2>key regulatory steps (IND grants, regulatory approvals);<BR></FONT> <FONT SIZE=2>&nbsp;&nbsp;<BR></FONT> <FONT SIZE=2></font> <p align=left style="font-family:times;margin-top:0pt;margin-left:0pt;"> <font size=2> </FONT><FONT SIZE=2> </font>
<p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:9pt;"><font size=2></FONT><FONT SIZE=2>progress with business development activities;<BR>
</FONT><FONT SIZE=2>&nbsp;&nbsp;<BR></FONT> <FONT SIZE=2></font> <p align=left style="font-family:times;margin-top:0pt;margin-left:0pt;"> <font size=2> </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><font size=2>
&#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:9pt;"><font size=2></FONT><FONT SIZE=2>the Group's financial position and equity liquidity and valuation.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=103,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=590348,FOLIO='A-16',FILE='DISK112:[19ZAF1.19ZAF44001]LE44001A.;18',USER='CHE107322',CD=';1-MAR-2019;12:53' -->
<A NAME="page_le44001_1_17"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="17%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="25%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="17%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="17%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Element of<BR>
Remuneration

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Purpose and link to strategy </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Operation </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Maximum </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Performance targets </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>A number of these objectives are considered to be commercially sensitive and are therefore not disclosed here in detail.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> Long term equity incentives</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><BR><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 Motivates and rewards multi-year performance, encouraging achievement of strategy over the medium to long term.<BR></FONT> <FONT SIZE=2>&nbsp;&nbsp;<BR></FONT> <FONT SIZE=2></font> <p align=left style="font-family:times;margin-top:0pt;margin-left:0pt;"> <font size=2>
 Aligns the interests of our Executive Directors and Senior Executives with those of our shareholders.<BR></FONT> <FONT SIZE=2>&nbsp;&nbsp;<BR></FONT> <FONT SIZE=2></font> <p align=left style="font-family:times;margin-top:0pt;margin-left:0pt;"> <font size=2> Encourages
 retention as entitlement to full benefits arising from equity-based awards only accrues over a period of years.<BR>
</FONT><FONT SIZE=2>&nbsp;&nbsp;<BR></FONT> <FONT SIZE=2></font> <p align=left style="font-family:times;margin-top:0pt;margin-left:0pt;"> <font size=2> Enables us to compete with equity-based remuneration offered by a set of comparable companies with whom we may
compete for executive talent.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><BR><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 Under our share option schemes, the Committee is able to grant awards of CSOP options in the UK, and unapproved share options (non-qualifying options) in the UK and US, which includes the ability to grant RSU-style awards. All awards may be subject
 to performance targets.<BR></FONT> <FONT SIZE=2>&nbsp;&nbsp;<BR></FONT> <FONT SIZE=2></font> <p align=left style="font-family:times;margin-top:0pt;margin-left:0pt;"> <font size=2> The Committee generally grants equity-based remuneration to Executive Directors and
 Senior Executives at the time they commence employment and from time to time thereafter based on performance.<BR>
</FONT><FONT SIZE=2>&nbsp;&nbsp;<BR></FONT> <FONT SIZE=2></font> <p align=left style="font-family:times;margin-top:0pt;margin-left:0pt;"> <font size=2> The Committee is able to grant share options which permit phased vesting over the period. Currently, awards vest
over a period of four years, with the first 25% vesting after 12&nbsp;months.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><BR><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 There is no fixed annual maximum limit to the size or value of equity-based compensation awards made in a year to Executive Directors and Senior Executives, or in the aggregate over a period of years.<BR></FONT> <FONT SIZE=2>&nbsp;&nbsp;<BR></FONT>
 <FONT SIZE=2></font> <p align=left style="font-family:times;margin-top:0pt;margin-left:0pt;"> <font size=2> However, the Committee will always work within benchmarking guidelines provided by our compensation consultants. Additionally, our option scheme rules set a
 maximum limit on the grant of options to all participants of 8% of our initial issued share capital on the date of our IPO increased by 4% on each 30&nbsp;June to be effective from 1&nbsp;July 2016.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><BR><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 Generally, we grant equity-based remuneration awards that vest over time without specific performance targets other than continued service.<BR></FONT> <FONT SIZE=2>&nbsp;&nbsp;<BR></FONT> <FONT SIZE=2></font> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:0pt;"> <font size=2> When making awards, the Committee considers: the size and value of past awards; the performance of the Executive Director or Senior Executive; and competitive data on awards made to executives at
 comparable companies.<BR></FONT> <FONT SIZE=2>&nbsp;&nbsp;<BR></FONT> <FONT SIZE=2></font> <p align=left style="font-family:times;margin-top:0pt;margin-left:0pt;"> <font size=2> Our Severance Policy entitles the Executive Director and Senior Executives to accelerated
 vesting of options on termination without cause on a change of control.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=104,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=541926,FOLIO='A-17',FILE='DISK112:[19ZAF1.19ZAF44001]LE44001A.;18',USER='CHE107322',CD=';1-MAR-2019;12:53' -->
<A NAME="page_le44001_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="17%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="25%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="17%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="17%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Element of<BR>
Remuneration

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Purpose and link to strategy </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Operation </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Maximum </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Performance targets </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 Expected values are calculated in accordance with generally accepted methodologies based on Black-Scholes models.<BR></FONT> <FONT SIZE=2>&nbsp;<BR></FONT> <FONT SIZE=2></font> <p align=left style="font-family:times;margin-top:0pt;margin-left:0pt;"> <font size=2> We
 seek to establish equity-based remuneration to be reasonably competitive to that offered by a set of comparable companies with whom we may compete for executive talent.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 Additionally, the Board has discretion to accelerate vesting of options including in connection with a change of control event or when an Executive Director's service is terminated on account of disability or death.<BR></FONT> <FONT
 SIZE=2>&nbsp;&nbsp;<BR></FONT> <FONT SIZE=2></font> <p align=left style="font-family:times;margin-top:0pt;margin-left:0pt;"> <font size=2> </FONT><FONT SIZE=2><I>See Policy on Payments for Loss of Office.</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notes to policy tables  </I></B></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
use of time-based vesting for share option awards is consistent with U.S. practice, to which we look for guidance on our policies. We examine, with assistance
from Willis Towers Watson, our independent remuneration consultant, comparative data on both a (i)&nbsp;fair market value basis and (ii)&nbsp;percentage of salary basis. The Committee uses a blend
of the two methods to establish appropriate levels of equity-based remuneration for the Executive Director and Senior Executives. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=105,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=444188,FOLIO='A-18',FILE='DISK112:[19ZAF1.19ZAF44001]LE44001A.;18',USER='CHE107322',CD=';1-MAR-2019;12:53' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_lg44001_1_19"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Application of the Remuneration Policy to Executive Director Remuneration for the year ending
31&nbsp;December 2019  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides an illustration of the potential remuneration for the year ending 31&nbsp;December 2019 for the CEO, as the sole
Executive Director, computed in accordance with the Remuneration Policy outlined above and by applying the following assumptions: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="24%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="73%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Minimum</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>The base salary for the Executive Director is assumed to be the base salary of &pound;457,126 per annum effective from 1&nbsp;January 2019.<BR></FONT> <BR><FONT SIZE=2>The value of benefits receivable for the year ending
31&nbsp;December 2019 is assumed to be 5% of base salary for a pension allowance payment and the same rate of contribution for private health insurance as for 2018.<BR></FONT> <FONT SIZE=2><BR></FONT> <FONT SIZE=2>No bonus is assumed for the
Executive Director.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> In line with expectations</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>The same components for base salary and benefits as reflected for the minimum above.<BR></FONT> <BR> <FONT SIZE=2>The expected level of bonus is taken to be 60% of base salary, being the target level of bonus payment
for the year ending 31&nbsp;December 2019.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> Maximum</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>The same components for base salary and benefits as reflected for the minimum above.<BR></FONT> <FONT SIZE=2><BR></FONT> <FONT SIZE=2>The maximum level of bonus is taken to be 100% of current base salary.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
bar chart below does not include any value for equity-based award remuneration in either the minimum illustration or the illustration of remuneration in line with expectations. We do
not believe it is possible to reasonably quantify the value that might result from outstanding options and other equity-based awards. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g550440.jpg" ALT="GRAPHIC" WIDTH="541" HEIGHT="361">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=106,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=992313,FOLIO='A-19',FILE='DISK112:[19ZAF1.19ZAF44001]LG44001A.;12',USER='CHE107322',CD=';1-MAR-2019;12:53' -->
<A NAME="page_lg44001_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Service Contracts  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It is Group policy that Executive Directors should have contracts with an indefinite term providing for a maximum of up to 12&nbsp;months'
notice. We currently employ our CEO, our sole Executive Director, on a service agreement providing for termination, other than for cause, upon nine months' advance notice by either the Company or the
CEO. The CEO is required to resign his position as a Director if the Board requires a resignation in conjunction with the end of the employment relationship. We expect service contracts with future
Executive Directors will have comparable provisions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
termination of the service contract without cause, we have the right to require the Executive Director to take garden leave for all or part of the notice period (the remaining term of
the contract) and we have the right to pay salary and benefits in lieu of notice. During the period of any garden leave, the Executive Director must continue to be available to the Company and will
continue to receive his full salary and other contractual entitlements. The Company may terminate the Executive Director's employment with immediate effect in certain circumstances including
bankruptcy, criminal convictions, gross misconduct or serious or repeated breaches of obligations of his service. In the event of termination of the Executive Director for cause, we are not obligated
to make any payment in lieu of notice. The service agreement contains non-solicitation and non-competition provisions for a 12&nbsp;month period as well as confidentiality provisions. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Policy on Payments for Loss of Office  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our approach to payments in the event of termination of an Executive Director is to take account of the individual circumstances including the
reason for termination, individual performance, contractual obligations and the terms of the long-term incentive plans in which the Executive Director participates. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
previously reported in our approved Directors' Remuneration Report for the year ended 31&nbsp;December 2016, and subsequent reports, during March 2017, the Company entered into an
amended service agreement with our Executive Director and adopted an executive severance policy that is applicable to our Executive Director and senior executive officers on termination other than for
cause. The amended service agreement and executive severance policy are compliant with our last approved Directors' Remuneration Policy. In particular, all employment arrangements for any Executive
Director(s) will continue to include a notice provision and continuing payment obligations for not more than a maximum period of one year following our termination of an Executive Director other than
for cause. Payment obligations would include base salary, bonus and benefits. In the event of termination without cause following a change of control, the Executive Director is entitled to accelerated
vesting of any unvested and outstanding equity awards. In addition, the Board has discretion under our option scheme rules to allow some or all of the options held by our Executive Director and senior
executives to vest in the event of a change of control or otherwise. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order to receive severance benefits under the employment agreement and executive severance policy, the Executive Director is required to execute a release of claims in favour of the
Company and comply with certain other post-employment covenants set forth in his employment agreement. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will comply with applicable disclosure and reporting requirements of the Securities and Exchange Commission with respect to remuneration arrangements with a departing Executive
Director. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Policy on Recruitment Arrangements  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our policy is to pay a fair remuneration package for the role being undertaken and the experience of the individual to be appointed. We expect
remuneration packages will include base salary, targeted level of annual cash incentive, initial and ongoing equity-based awards, standard benefits and special provisions tailored to the recruiting
situation, such as: sign-on bonus, reasonable relocation support and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=107,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=772061,FOLIO='A-20',FILE='DISK112:[19ZAF1.19ZAF44001]LG44001A.;12',USER='CHE107322',CD=';1-MAR-2019;12:53' -->
<A NAME="page_lg44001_1_21"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>make-whole
awards for remuneration forfeited from a prior employer (whether on account of cash bonuses, share awards, pension benefits or other forfeited items). </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board retains the discretion to provide additional benefits where necessary or useful to recruit new Executive Directors or to secure the ongoing service of existing Executive
Directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we appoint an existing employee as an Executive Director of the Company, we would expect to retain legacy obligations to the employee with respect to remuneration, such as outstanding
share awards. Should these differ materially from current arrangements, these will be disclosed in the next Directors' Remuneration Report following such appointment. We will also disclose
remuneration details for a new Executive Director in accordance with applicable reporting requirements of the Securities and Exchange Commission. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Summary of remuneration policy&#151;Non-Executive Directors  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the last approved Directors' Remuneration policy, the Board has the discretion to pay fees to any or all Non-Executive Directors and/or to
pay Non-Executive Directors in the form of a mixture of cash and share options. Our remuneration arrangements for Non-Executive Directors continue to comprise an award of a fixed number of share
options, plus an additional number of share options or cash payment at the Director's election. The option awards and cash payments made in 2018 were established at competitive levels taking into
account peer data from comparable
companies provided in a benchmarking analysis undertaken by Willis Towers Watson in 2018 and are compliant with the last approved Directors' Remuneration policy. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Committee has retained Willis Towers Watson to assist the Committee in ensuring that our remuneration arrangements for the Non-Executive Directors are competitive and appropriate by
benchmarking them against comparable publicly traded biopharmaceutical companies, with an increasing focus on U.S. benchmarks and practices. We expect to continue to use remuneration consultants to
assist the Committee in determining competitive levels of Non-Executive Director remuneration and specific design elements of our Non-Executive Director remuneration programme. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Non-Executive Directors participate in the Group's long-term incentive plans on terms similar to those used for Executive Directors. In accordance with their Letters of Appointment,
each Non-Executive Director is entitled to receive an annual award of share options, and incoming Non-Executive Directors receive an initial award of share options, and which may include RSU-style
awards, with such number to be determined by the Board. In determining option awards, the Board works within benchmarking guidelines provided by remuneration consultants. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
share options that are awarded will not be subject to performance conditions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Non-Executive Directors do not receive any pension from the Company nor do they participate in any performance-related incentive plans. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=108,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=1009060,FOLIO='A-21',FILE='DISK112:[19ZAF1.19ZAF44001]LG44001A.;12',USER='CHE107322',CD=';1-MAR-2019;12:53' -->
<A NAME="page_lg44001_1_22"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table presents the elements of remuneration for Non-Executive Directors. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="77pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="40%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Element of<BR>
Remuneration

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Purpose and link to<BR>
strategy </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Operation </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Maximum </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Non-Executive fees</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Reflects time commitments and responsibilities of each role.<BR></FONT> <FONT SIZE=2><BR></FONT> <FONT SIZE=2>Reflects fees paid by similarly sized companies.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>The remuneration of the Non-Executive Directors will be determined by the Board as a whole by reference to market practice and market data, on which the Committee receives independent advice, and reflects individual
experience, scope of the role, time commitment and changes to responsibilities.<BR></FONT> <FONT SIZE=2><BR></FONT> <FONT SIZE=2>We typically expect to align fees with the 50<SUP>th</SUP>&nbsp;percentile of peer group comparator data but may vary
from this general rule where we consider that special circumstances apply or where recruitment or retention of a particular role is required.<BR>
</FONT><FONT SIZE=2><BR></FONT> <FONT SIZE=2>Fees will typically consist of a basic fee for Non-Executive Director responsibilities plus incremental fees for additional roles/responsibilities such as chairmanship of Board committees and a senior
independent Non-Executive Director role.<BR></FONT> <FONT SIZE=2><BR></FONT> <FONT SIZE=2>The Non-Executive Directors may elect to receive the fees in cash or in the form of an award of additional share options.<BR></FONT> <FONT SIZE=2><BR></FONT>
<FONT SIZE=2>The Non-Executive Directors do not receive any pension from the Company, nor do they participate in any performance-related incentive plans.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>The value of each individual's aggregate fees will not exceed the 75<SUP>th</SUP>&nbsp;percentile of peer group comparator data for the relevant role.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=109,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=730505,FOLIO='A-22',FILE='DISK112:[19ZAF1.19ZAF44001]LG44001A.;12',USER='CHE107322',CD=';1-MAR-2019;12:53' -->
<A NAME="page_lg44001_1_23"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="77pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="40%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Element of<BR>
Remuneration

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Purpose and link to<BR>
strategy </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Operation </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Maximum </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Long term equity incentives</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>For public companies listed in the United States, equity-based remuneration is a standard component of Director remuneration.<BR></FONT> <FONT SIZE=2><BR></FONT> <FONT SIZE=2>We extend equity-based awards to our
Non-Executive Directors in order to be competitive with comparable companies seeking qualified Directors and to align the interests of our Non- Executive Directors with those of our shareholders.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Non-Executive Directors participate in the Group's long-term incentive plans on terms similar to those used for Executive Directors.<BR></FONT> <FONT SIZE=2><BR></FONT> <FONT SIZE=2>Under their appointment letters, each
Non-Executive Director is entitled to receive an annual award of options, provided that he or she continues to serve as a Director. When a new Non-Executive Director is appointed, he or she may receive an initial award of options. In either scenario,
these may include RSU-style awards.<BR>
</FONT><FONT SIZE=2><BR></FONT> <FONT SIZE=2>The Board is able to grant share options which permit phased vesting over the period. Currently, options awarded to new Directors become fully exercisable over three years while options awarded annually
are exercisable on the first anniversary of the date of grant. Any share options awarded will not be subject to performance conditions. Expected values are calculated in accordance with generally accepted methodologies based on Black-Scholes
models.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Not applicable.<BR></FONT> <FONT SIZE=2><BR></FONT> <FONT SIZE=2>The option awards will be determined by the Board as a whole working within benchmarking guidelines provided by our compensation consultants. Additionally,
our option scheme rules set a maximum limit on the grant of options to all participants of 8% of our initial issued share capital on the date of our IPO increased by 4% on each 30&nbsp;June effective from 1&nbsp;July 2016.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Letters of Appointment  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Chairman and all other Non-Executive Directors have letters of appointment which set out the terms under which they provide their services
to the Company and which are subject to a three month notice period either by the Company or the Non-Executive Director. Their remuneration is reviewed by the Board annually. In accordance with the
Company's Articles of Association, Non-Executive Directors are included in the requirement that one-third of Directors are subject to retirement by rotation at each Annual General Meeting of
shareholders. There is no remuneration payable on loss of office when, for example, a Director is not re-elected at an Annual General Meeting. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Statement of Consideration of Employment Conditions and Differences to the Executive Director Policy  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All our employees are paid a base salary and receive standard employee benefits, which vary according to whether they are employed in the UK or
in the US but all are entitled to a contribution from the Group towards a pension scheme or retirement plan, as well as access to health insurance and income protection. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
employees are eligible to be considered for an annual increase in their base salaries, provided they have worked for a sufficient portion of the prior fiscal year. In addition, all
employees are eligible to be considered for target annual cash bonus awards, subject to the achievement of objectives and to the overall performance of the Company, and for consideration for regular
option awards. Eligibility is dependent on the employee's position and performance, with more senior employees eligible for higher bonus and option award levels. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=110,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=335340,FOLIO='A-23',FILE='DISK112:[19ZAF1.19ZAF44001]LG44001A.;12',USER='CHE107322',CD=';1-MAR-2019;12:53' -->
<A NAME="page_lg44001_1_24"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
specific consultation with employees has been undertaken in respect of the design of the Company's senior executive remuneration policy to date although the Committee will keep this
under review. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Statement of Consideration of Shareholder Views  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This policy for remuneration of both Executive Directors and Non-Executive Directors was devised by a Remuneration Committee of which all
members are Non-Executive Directors. The policy was also approved by the full Board. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Approval  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This report was approved by the Board of Directors on 26&nbsp;February 2019 and signed on its behalf by: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="50%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="50%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=2>/s/&nbsp;DAVID M. MOTT<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2><B>David M Mott</B></FONT><BR>
<FONT SIZE=2><I>Director</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>26&nbsp;February
2019 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=111,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=433129,FOLIO='A-24',FILE='DISK112:[19ZAF1.19ZAF44001]LG44001A.;12',USER='CHE107322',CD=';1-MAR-2019;12:53' -->
<A NAME="page_lg44001_1_25"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg44001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<A NAME="Form"></A>Form of Proxy For Ordinary Shareholders  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=112,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=111688,FOLIO='A-25',FILE='DISK112:[19ZAF1.19ZAF44001]LG44001A.;12',USER='CHE107322',CD=';1-MAR-2019;12:53' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">Adaptimmune   Therapeutics plc All Correspondence to: Computershare Investor Services PLC   The Pavilions, Bridgwater Road, Bristol, BS99 6ZY MR $&nbsp;SAMPLE DESIGNATION   ADD1 ADD2 ADD3 ADD4 SG350 C1234567890 Cast your Proxy online...It&#146;s fast,   easy and secure! www.investorcentre.co.uk/eproxy You will be asked to enter   the Control Number, Shareholder Reference Number (SRN) and PIN shown opposite   and agree to certain terms and conditions. Control Number: 915628 SRN:   C1234567890 PIN: 1234 @ View the Annual Report online:   http://ir.adaptimmune.com/ Register at www.investorcentre.co.uk - elect for   electronic communications &amp; manage your shareholding online! To be   effective, all proxy appointments must be lodged with the Company&#146;s   registrars at: Computershare Investor Services PLC, The Pavilions, Bridgwater   Road, Bristol BS99 6ZY by 30 April 2019 at 11.00 am (London Time).   Explanatory Notes: 1. Every holder has the right to appoint some other   person(s) of their choice, who need not be a shareholder, as his proxy to   exercise all or any of his rights, to attend, speak and vote on their behalf   at the meeting. If you wish to appoint a person other than the Chairman,   please insert the name of your chosen proxy holder in the space provided (see   reverse). If the proxy is being appointed in relation to less than your full   voting entitlement, please enter in the box next to the proxy holder&#146;s name   (see reverse) the number of shares in relation to which they are authorised   to act as your proxy. If returned without an indication as to how the proxy   shall vote on any particular matter, the proxy will exercise his discretion   as to whether, and if so how, he votes (or if this proxy form has been issued   in respect of a designated account for a shareholder, the proxy will exercise   his discretion as to whether, and if so how, he votes). To appoint more than   one proxy, an additional proxy form(s) may be obtained by contacting the   Registrar&#146;s helpline on 0370 702 0000 or you may photocopy this form. Please   indicate in the box next to the proxy holder&#146;s name (see reverse) the number   of shares in relation to which they are authorised to act as your proxy.   Please also indicate by marking the box provided if the proxy instruction is   one of multiple instructions being given. All forms must be signed and should   be returned together in the same envelope. The &#145;Vote Withheld&#146; option   overleaf is provided to enable you to abstain on any particular resolution.   However, it should be noted that a &#145;Vote Withheld&#146; is not a vote in law and   will not be counted in the calculation of the proportion of the votes &#145;For&#146;   and &#145;Against&#146; a resolution. 4. Pursuant to Regulation 41 of the   Uncertificated Securities Regulations 2001, entitlement to attend and vote at   the meeting and the number of votes which may be cast thereat will be   determined by reference to the Register of Members of the Company at 6.30pm   (London Time) on 30 April 2019. Changes to entries on the Register of Members   after that time shall be disregarded in determining the rights of any person   to attend and vote at the meeting. To appoint one or more proxies or to give   an instruction to a proxy (whether previously appointed or otherwise) via the   CREST system, CREST messages must be received by the issuer&#146;s agent (ID   number 3RA50) by 11.00am (London Time) on 30 April 2019. For this purpose,   the time of receipt will be taken to be the time (as determined by the   timestamp generated by the CREST system) from which the issuer&#146;s agent is   able to retrieve the message. The Company may treat as invalid a proxy   appointment sent by CREST in the circumstances set out in Regulation 35(5)(a)   of the Uncertificated Securities Regulations 2001. The above is how your   address appears on the Register of Members. If this information is incorrect   please ring the Registrar&#146;s helpline on 0370 702 0000 to request a change of   address form or go to www.investorcentre.co.uk to use the online Investor   Centre service. Any alterations made to this form should be initialled. The   completion and return of this form will not preclude a member from attending   the meeting and voting in person. 5. 2. 6. 3. 7. 8. All Named Holders Kindly   Note: This form is issued only to the addressee(s) and is specific to the   unique designated account printed hereon. This personalised form is not   transferable between different: (i) account holders; or (ii) uniquely   designated accounts. The Company and Computershare Investor Services PLC   accept no liability for any instruction that does not comply with these   conditions. MR A SAMPLE &lt;Designation&gt; ADDITIONAL HOLDER 1 ADDITIONAL   HOLDER 2 ADDITIONAL HOLDER 3 ADDITIONAL HOLDER 4 *000001010101000*   00000XXX/000000/000000 12JDYE D01 SG151 000001 Form of Proxy - Annual General   Meeting to be held on 2 May 2019 at 11.00 am (London Time) </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="816" height="1153" src="g26402bgi001.gif"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=113,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=227785,FOLIO='',FILE="DISK112:[19ZAF2.19ZAF44002]2640-2-BG_ZAF44002.CHC",USER="JTAYLORA",CD='Mar  1 14:28 2019' -->

<div style="page-break-before:always;"></div>
<div>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">Form of Proxy   Please complete this box only if you wish to appoint a third party proxy   other than the Chairman. Please leave this box blank if you want to select   the Chairman. Do not insert your own name(s). C1234567890 I/We hereby appoint   the Chairman of the Meeting OR the person indicated in the box above as   my/our proxy to attend, speak and vote in respect of my/our full voting   entitlement* on my/our behalf at the Annual General Meeting of Adaptimmune   Therapeutics plc (the &#147;Company&#148;) to be held at 60 Jubilee Avenue, Milton Park,   Abingdon, Oxfordshire OX14 4RX on 2 May 2019 at 11:00 a.m. (London time), and   at any adjourned meeting. * For the appointment of more than one proxy,   please refer to Explanatory Note 2 (see front). Please use a black pen. Mark   with an X inside the box as shown in this example. Please mark here to   indicate that this proxy appointment is one of multiple appointments being   made. Vote Against Withheld Ordinary Resolutions For 1. To re-elect as a   director, John Furey, who retires in accordance with the Articles of   Association. 2. To re-elect as a director, Ali Behbahani, who retires by   rotation in accordance with the Articles of Association. 3. To re-elect as a   director, James Noble, who retires by rotation in accordance with the   Articles of Association. 4. To re-appoint KPMG LLP as auditors of the   Company, to hold office until the conclusion of the next annual general   meeting of shareholders. 5. To authorize the Audit Committee to determine our   auditors&#146; remuneration for the fiscal year ending December 31, 2019. 6. To   receive the U.K. statutory annual accounts and reports for the fiscal year   ended December 31, 2018 and to note that the Directors do not recommend the   payment of any dividend for the year ended December 31, 2018. 7. To approve,   on a non-binding, advisory basis, the compensation of the Company&#146;s named   excecutive officers for the year ended December 31, 2018. 12 Year Years 3Vote   Years Withheld 8. To indicate, on a non-binding, advisory basis, the   preferred frequency of future shareholder advisory votes on the compensation   of the Company&#146;s named executive officers. Vote Against Withheld For 9. To   receive and approve our U.K. statutory directors&#146; remuneration report for the   year ended December 31, 2018. 10. To authorize the Directors under Section   551 of the U.K. Companies Act 2006 (the &#147;2006 Act&#148;) to allot shares or to   grant rights to subscribe for or to convert any security into shares. Special   Resolution 11. To empower the Directors to allot equity securities for cash   pursuant to Section 570(1) of the 2006 Act as if Section 561(1) of the 2006   Act did not apply to that allotment. I/We instruct my/our proxy as indicated   on this form. Unless otherwise instructed the proxy may vote as he or she   sees fit or abstain in relation to any business of the meeting. Signature   Date In the case of a corporation, this proxy must be given under its common   seal or be signed on its behalf by an attorney or officer duly authorised,   stating their capacity (e.g. director, secretary). / / WK F 1 8 4 3 0 5   00000XXX/000000/000000 AD T 12JDYE D01 X * </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="816" height="1155" src="g26402bgi002.gif"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=114,EFW="2237876",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=241614,FOLIO='',FILE="DISK112:[19ZAF2.19ZAF44002]2640-2-BG_ZAF44002.CHC",USER="JTAYLORA",CD='Mar  1 14:28 2019' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g1039423.jpg
<DESCRIPTION>G1039423.JPG
<TEXT>
begin 644 g1039423.jpg
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MSXH[7I$TBL*6$NN12<\02%R%\HQKOOPY1A/Z[\#/#R^7.%4F\>.,>'AG&?\
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MP]H/IG2'X<)06OD2<8L5Q+EQI,:+F#$?Q(D1WV&?.ZTXA.RV"SUNIPF25HL
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M*Y'I7G=(X.;5Y5AM'[-X[VP'4N07&J\R+K0'+&]B (,MS9 (F]$46^.*MCC
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MXT&;( DU)Q!,,0Y3HY^2W'>4B1D=;MR--M2OB=*XD,A*SMOP^(KU[%^%,BP
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*%<$)!(@*@@?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g751951.jpg
<DESCRIPTION>G751951.JPG
<TEXT>
begin 644 g751951.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ X1$E32S$Q,CI;,3E:048Q+C$Y6D%&
M-#0P,#$N3U544%5473(V-#!?,5]#14]?2U]0244N15!3_]L 0P ! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ ]P&S
M P$B  (1 0,1 ?_$ !X  0 " P # 0$            '" $)"@(#!@4$_\0
M4!    8"  (## @#!08!#0    $" P0%!@<($1(A,0D3%!<8.%97EI?5UA5!
M<79WL;3%%B)1(S(W89$D,T)2@:'P"ADF)S1#1D=38G*"T?_$ !D! 0 # 0$
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MT9[\5#Q"4_K&WG[Z,]^*B=0 $%>(2G]8V\_?1GOQ4/$)3^L;>?OHSWXJ)U
M05XA*?UC;S]]&>_%0\0E/ZQMY^^C/?BHG4 !!7B$I_6-O/WT9[\5&#T+4$1_
M^L;>?8?_ ,Z,]^*B=AA78?V'^0 T:;KVSMW7&U<XPC&-L[':H,?NW8E8U995
M.N)K4=UEB6;;UE9>$SI)(=D.):5(?=6VR3;)*Z#:2(/@N*?S@]I_>/\ ;X(
M#:;P$^9YP]_AS5_JIPMX*A\!/F></?X<U?ZJ<+>
M                     #Q4M".726E//LZ2B+G]G,R!2NB7/^II275SZU*)
M)&9<RYD1F7/K+J^L<C6DLN[IIW;7=O&WM71'=#LP[GQPG<,/$=E_"]P^X;JG
M46'9GD6R,EUU'8>R;8>U++(+FGN76K!N?C5DW1>'RZQJ/>.4M=5U;U'8661
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M(JB":G&J]O):&UH;RPK83KM96W<VU@51MUL>)'8 V]
M                       PKL/[#_(9&%=A_8?Y #GWXI_.#VG]X_V^" <4
M_G![3^\?[?!  ;3> GS/.'O\.:O]5.%O!4/@)\SSA[_#FK_53A;P
M                                 &%%TBY?YD9<^LN:3)23,N9<^1D1
M\N9<_P"HY1L;X/.[%]RMW_QBU7<T-.\-G%=PF<7>X,CXDL1Q_<6SEZPRGATV
MUF[?>,HJY$&5DF.Q\JP]+B:]EB+5R+!ZZHL<H>E-Q:V:M8]QU=  .4?BQ[F%
MW4[:7<X^#'!<RVSA7&AQPZD[H1K+C:VP]L[,XF&ZJA5>)TV;/-Z=PFXDTD9Z
M1@>.2I]!0-).GARK5VSR6\A5\&O7"JHU]^'*5W5//]LUN"<6?<^N!/3_  Z9
MU0Y]C&U\[TYO.7E>Q(6/WF&WS,6LJZ%.,516S%_>JJJ:W2Y*;1&K9DFS)*G8
M32%;P0 ')7PX\+_=T^Y9:/V-P"<'^GN&GBGT1'R[8T[A0XH,_P!ZMZPRC1>+
M;.LIEPB)M+4UO =DYC-Q#([6QREJ'BLN1$79R;$V)]W72H-+!W,]R#[GI_YL
MK@?UYPTV^9,;%V0NZRK9NY\\@MRFJG*-L[#L&[+)Y%(B>RQ8NT=-%BU&+T]A
M9QXMG<0*)JZL(%;+LGJV)L[
M      85V']A_D,C"NP_L/\ ( <^_%/YP>T_O'^WP0#BG\X/:?WC_;X( #:;
MP$^9YP]_AS5_JIPMX*A\!/F></?X<U?ZJ<+>
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M%"T.)2M"DK0HB4E23)25$?8:5),TJ(_J,C,C_P"H\A81
M                     #"NP_L/\AD85V']A_D .??BG\X/:?WC_;X(!Q3^
M<'M/[Q_M\$ !M-X"?,\X>_PYJ_U4X6\%0^ GS/.'O\.:O]5.%O
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M]7+0I3;C-GFRV9D><\PKHJ<BXQ!O"YDIB1,@NDKHZ5=S=T/XJ-T*F1)NPI&
MXS*6X18KK)+V*1$QW$F@XTR_8D/9;:(4@^B\4B\;BO*YK*"T1DVFD!$1$1$1
M$1$1)21$24D741)(N1$1%U$1$1$741 ,]6I55O"Y*WKNS=1H:=&W%5_:J_HL
M+ROU9['G79$AV9)==DS'U&M^9)<<D3'UJ/FI;\M]3DEY:CZS6ZZM1GVF/ S,
M^TS/[>L8 5EIE/:7VE^8WP<-7^ 6I?N=%_76 T/I[2^TOS&^#AJ_P"U+]SHO
MZZP%&OBGN_8KU-O/[$W@9$9<E$2B_HHB47^A\R_[  S%9]/CV:97BCJ7<>OK
M&M(C(U1VWS>@N<CZB>KY)/PG"ZS[6.D7,S)1'UBQ^'<33J.]Q,WJ2<01$GZ9
MHV^2^?82Y=0ZYR/K_F<<@R.?_)#^H5) 6Z>MJ:;\-3C^KO2^D/W4/DR-5%-7
MS+S5GZFUZBR*CR: W9T-G$M(3G43T5TE][5_])]H^B]&?+_B8D-M.I^M _:&
MJ7',GO<3LD6V/V+]=,3R2X;1])B4T1\^\3HJ^;$Q@^76V^A1I_O-*:<)*RO+
MJ_=U1G'>:BX2Q2Y09=%$7IF4"V,BYFNJ>=4:B?[5.5CRE2$$1JCNRVDK6CT=
M'XJG4:IJ7!6\7\-3Y)O=\GY-LS5Z3IEJ]/U7?IU]B=0 !J*@
M                 #"NP_L/\AD85V']A_D .??BG\X/:?WC_;X(!Q3^<'M/
M[Q_M\$ !M-X"?,\X>_PYJ_U4X6\%0^ GS/.'O\.:O]5.%O
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M4^C\+\0ZO\5;\27AJ>:DMGS:6'NIFZOGU=/A\5.-UR?3H^6W:RG   ;B@
M                       ,*[#^P_R&1A78?V'^0 Y]^*?S@]I_>/\ ;X(!
MQ3^<'M/[Q_M\$ !M-X"?,\X>_P .:O\ 53A;P5#X"?,\X>_PYJ_U4X6\
M                        [ $!\3V[('#UHW8.U99,O3<>IEM8Y7OK2E-K
MEELZBKQBMZ)GTEMR+B5&7*)!&I$%F4[R)+9F1N$V\*[.I-M)9;27=V-('=9^
M*-[-\^C\.F)6)GB.N94>QSYR*X?>KS8"V2>AT[ZT+-+T/"X$A"W&3Y(_B.QD
M$\WX11QU(TY#^VRLK"XLK"XMYCUC;6T^;:6MC(6IR186=E*=FV$Y]:C-2WID
MQ]^0XI1F9K</K,?Q#!54ZJG4]_IM'[WW/4HH5%*I6V>KW?[M8  #A,
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M_MY2^1=$S.W0]K1U%JZ=->[45+E4L_E=&C#73PU.GECML  !:1
M             PKL/[#_ "&1A78?V'^0 Y]^*?S@]I_>/]O@@'%/YP>T_O'^
MWP0 &TW@)\SSA[_#FK_53A;P5#X"?,\X>_PYJ_U4X6\
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M=]==K>_K,^M7?27_ ,0]#X-\/'1,S%2^B?K;T,^NOE?=/W7W)]  &XS@
M                  85V']A_D,C"NP_L/\ ( <^_%/YP>T_O'^WP0#BG\X/
M:?WC_;X( #:;P$^9YP]_AS5_JIPMX*A\!/F></?X<U?ZJ<+>
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MNN\NKFDQ*U/NVAE$ENZKYM2Z9D1O1N5E#_S5_*34QM/+KY&P\9%_Q&9'SK"
M@Z*7M';]@XZ*7-HGE^P7RJKZDO6R<I[6#8D9$9HC/I4^CG]3D970DMF7U]-H
MB+^H_6_J7UEU&7]#_H8U\H6MI:76EK:=09&AUI:FW4&78:'$&E:>7_VJ(??T
MVT,RIN@V5F=G&01)\&MT>&D2>?\ =1)-2)K?5U$92%$7_*?8(.A[.?H0=#V<
M_0N.*M\2G$=;\/<S2S<;4F19[3;:W7J_3=EF,/),9H<9U]-V;F$'$ZN7=QYT
MJ3E=U923EOS::LQ_')=7(*!);OLBQU*XRY'V=/N^ID&EN\JI5:H^1')@K*PB
ME_52F5DS,;3V_P!TI!ER+MZQ^?M;7.O^)&BP2CEY=+B-8%N74V[ZP\?>KTV4
MK(=0Y.G*:*IL(EJPMY%/:34%&MSCL-STQN?@;[+O\XXE#7$GP[_[7[[$*J:D
MG"OY<_0J'DW=&;>@S3)6*WANRO,-51MH\06@<"S/&,VKIV?;!WMPZ819YCE>
M+1]2M8V_/I\2OWJ&_H,6RLK^WM)4ZH>EO8MWF1$B/37P^\7B=W/8E766&56$
M6=PC,7KB3,S"Q;QZ7%A7\K'M6S-8O9QAFNLMV G<BZ7,;W&JN7AV,7]=B>#9
M!D4JIEUTFADV?KQ3@;P#$=\>.>+G^SIU'7[@V3Q"8II&=-QM&LL*WAMS'2Q?
M/MATDB+0,9J_(M*UVS?K\=MLBF8_1W-Q97,&(<QQ/+^+9G AKW;>6TF>9EFV
M9OY?&SF^S'*[R+5X2_+S&):9;K[**;'8\G(J#(K'7"\,AZGUSAN+YKK6QQW.
M8>&45G2KNU(RJZ6N?^.(B+?-=N;Y4P]L1?%KJ'C[WQ;%MX5VY\GS@O&-QG<S
M(3K>!;.L5-)2U+S:LB-O<N2W%0,;BN.MF?1+I(9.>@T%TE$2G7#Y)49]+3LX
MM3KKCJ^CTWG7'5]!))3TW5J<7T4%U)3TE'T4EU)+DDNHAO@[GWCC]'P[5M@^
MV2%99E649&U_*1*7%*6S01%F?::7&J+OC9G_ .[6GEU<A+X93J]J6W]%[M$=
M9Q0^K2^L_8NZ  /1,@                      &%=A_8?Y#(PKL/[#_( <
M^_%/YP>T_O'^WP0#BG\X/:?WC_;X( #:;P$^9YP]_AS5_JIPMX*A\!/F></?
MX<U?ZJ<+>                           !ES(R/ZRY?ZCE2[J?KAS!>+C
M)[MJ&<:JV?CF-YU"<21&R_8-PBQ?(B0HNKOR;&A:ER4'_.E5BVX9=%Y!JZK1
MJ0[KYIE_-M%X[M:HA'(M=/9 X_<+:0WWU.#9:B/5W3RU=3KK-7=QL<L74$2B
M8BIG23Z*$.&=6M3-#>]-_P _2_D7_#U<.HN57A?GCZI+S.:8 ,N1F1]I=1@,
MAZ(&MG8W%%MNOXEMH:7QK)=?XC2X5XHH]"Y<\.6^MTVE[,V-BS=U.5;7^JLB
M@T&)L0+!:(D(LBCP"DQ7U2T//1ZZ<^6R85OR;AAQ#(=A9;LZNV)OW7N49TUB
MK66EJK<E[K^FO3PJH^@L;>L*FIA.-27Z^L-V.AUYU9F4B3T203RTGU-*94VM
MC,KFGM)&M5-+A<>)3=J5>5*A\GY'PTKC8P"-EB,=1K_;\RAE9OL?7%-M%C&:
M%G6F2YCJ/&<DR/8590VTK*VKM]%,>+6M1$DR:&/%N;-ITZJ1*@0;";&^9SGC
M6Q<L'@V^&L9!06]QJKAPWC7V&0XC59'!CX)OW;E'KJLJ9=/%S*G6[D[?ADMJ
MQ4S9'6TB7F;:%)R!V(=1)_MR7@FPYS:VM]@X98WU;1U.VLZV+L+ ;W.\MGX)
M-C[%P#*L7S%W!,(2E^DQ_),KN;V)99!.[]"0N*W-*NDP3=.#)_8I.!'0M'36
M%$VK9MI L,9UWAA%D>R[K(GZS$]4[ A;*P''*)^UCOG2TF.Y%71&8E;!2W$^
MAFUP%-=_?D3G>^"5\VTXYW5^EYQ+PD0C5<ING+OTX5$-)/+>TJ,NQ\?@?'%"
M=5>EN'7V0:ZA-;FXG-:X_DS9T,W%DQN'>JM,JEU>0R(^6V]E&S&3C%-9L+5&
MAIH;G(:^1'HEE!-#ZKF8!E[.P,%PS/(M-=8]$S7%J++(5'DC,2-D%7!R&NCV
ML")=1H,N?$C6284J.Y*C,3)*(ZW>\J=4XA9)I_N[@EQS9&'3-=8Q,:@8GGO$
MI%WYLY.87F07<BA<GRK&QSUG3\"'';8HK'8B[";2W4&YGJI6:RXL9K3CDB/%
M@.7L0VTTA#3#3<=AI"6F([222U'8:23;$=I)$1):8:2AEI)$1);0E)$1%R''
MP[3O,[8C=YO/;;!*GCEJJ(24/FX4[+':\]#R  '"8       !DC-*B6DS2M)
MD:5I,TK29=AI61DI)E]1I,C(8  ?=4^R<RI20VS;NS8R#ZHMJ@K!HDEV)2X\
M92FT_5_9R4D1<N1=0E>FWC =)+=]3OPU\B(Y56X4Q@S/E_,J+(4U(1]?,D//
M<B[!6X!%TTO;TL1=-+V]+%Z*/*:#)5-,T-K#GS7U(:CP.^>#SER'5DTPR<.2
M34@UN/*0V1(0LC4HB)77S'4]J;"VM=:SP7"&BY'C&+TU3(42B43DZ/#;.R?Y
MD1%_;V"Y3W_[]I]I\LG<Y=+%N?BGP9NP@E,QC6_?-G9+WQI+L=18X^P6,P7B
M69(45AEDBI6;1]+OT6!.(VW$(<Y=;A%R+E_K]7,_K/J_J?68T_#Z:IXJN?A7
M:S?JX]#%\3"JII3F%+Z3C[^ID  :3,                      !A78?V'^
M0R,*[#^P_P @!S[\4_G![3^\?[?! .*?S@]I_>/]O@@ -IO 3YGG#W^'-7^J
MG"W@J'P$^9YP]_AS5_JIPMX                           #Y_*\8I<TQ
MC(,0R2"U98_D]+9T%U7O)2IN95VT-Z#.CJ)1*(C<CON$A7(S0OHK+DI)&/H
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M2(B(B(B(>0W4I4I)82_7YGEUU.NIU/+<_A>2L  !TB
M    !A78?V'^0R,*[#^P_P @!S[\4_G![3^\?[?! .*?S@]I_>/]O@@ -IO
M3YGG#W^'-7^JG"W@J'P$^9YP]_AS5_JIPMX
M      9<_P#Q_H?_ $/K'.%W2_@57K*UM>(34E,HM<7LYR9L3&JUA:FL#O;!
M_IO9+!8;2KO&'WTUY;EF@NA&QFX?)39-4UBVBLZ/1_+.@P[.'+KK&)&GU\^,
M_"G09C#4J',ARFEL28DN*^AQB3&D,..,OQWVW&7FEK;<0I"E).%="K4/.SW3
M_'-;]X9/3U*M.KBI\ULUR?V>QP@]G:/XK*N^F*Z?3^%V,#Z6A2ZOP^GGKJ[>
M%](QW(7AE5:-)4[6V<7O_?Z^P;2IR#+;9E(2I31$>YKCM[FG<ZXE7&VN'FAE
M76M30Y8Y)KRL1)GWN!]$E+EV&-Q/[:9=8:DB[^]7,*D6^-)-PVF9E$WWRITY
M$9&1*29&1\E)4D^9'U]2DJ2?(^LNHR/J,NWF0R54U4.'9[/9]4_WU/2HKIU*
M552^ZW3Y/]A[6-+K&2Y/7XW5[%@\1>^*#AXV]Q=8AP]LYGF.X;"^N\3TIB,S
M,*;,-HL9[D$=4?7UGM#9N.)Q^#D3,>*C&<'CQVWI)R[J7)9^EU=D7$O9X1JW
M=\?>4[,L7KLMS37V#T%Y/R)^TVZQC^?[3QO#YUS14<$L;V959[C2<9RK+-B6
M[\6]PW$M7W=YB$.P?O)+Q[9%XYCKM,O''<>Q]W'7&ULN8Z[15#F/N,N/JE.,
MN42X2JA;+DI2I2VE0C;7)4J2I)OJ-P_Z45-2U]$]ZJZQKZ )94/>JZ$T5$3D
M)=:M-(EIA":A*JUURN--<48CKW'(/+P5:VC[Q8M[76.66HE[P16F[>)V2LI5
MY3>_RRK+:>A7#A2W?C>Y]>FFBEY99S,(8Q6KN;[,+7%;VWRA>48Q$R^IRF39
M8;>Y#30I]_7V*IUGA<J9$R/7LA2,3OZBO>@Q4NV?'Y];45-*P[%IJFJIHLB9
M+L7XM/60*F,_8SW._3[!^/71XS+UA/>_MITYU"Y<QW^TDO.K(E#] 0=VW$+D
M64II)-RTLQ    Z         %D^&;A8VAQ2YI_#&!P"ATE:XPO,,ZM&'CQK$
M83I\R.4XA32K2ZD((RK,;@/?2,U1D_(5 K&Y-DP2;<*[9QM4INII)9;/P^'3
MAXS_ (F=DUVN<"C(;<4VFRR7(YC3BZ;#\<;?;9E7EJILN;BC6LHU35MJ3*N;
M%2(C!MLMS9</KYTCIG"=!:UQO5^ P/ Z+'HII<DO$VJSN[:29/6V074E"4^%
MV]Q,-<J8[R2TT1M0XC;$&+%CM?+<.'#9K;AAU_'P37L!PUONHGY/E%D3#F19
M?==[[TJTNY;+32#2RV9QZRMC(:KJB%RC0F$FJ0_(L"-FGI\"E_,\].B/.UM9
MZCA6I3LN?5[3RY2^;   L*0                          PKL/[#_ "&1
MA78?V'^0 Y]^*?S@]I_>/]O@@'%/YP>T_O'^WP0 &TW@)\SSA[_#FK_53A;P
M5#X"?,\X>_PYJ_U4X6\                                  &#(C+D?
M_C_,C[2/_,AJKXMNY>ZXW6];YWJ-ZOU9M":MV;.B)CK+7V7SW%FX^]=54)I<
MC'K:6H^D]?8\RIM]WIR+6CM)#JI*-JH"-5*J4-3[KLR5-=5#FEM/Z/HUAKN<
M2>X-$;<T+?GCFV,&NL1F./.M5T^4R4G'KU+2N1O8_DD,WJ:X:47)9-Q99S6D
MF12X<5TE-)B,=TF68?BF=T,_%\TQRDRO'+1HVK"DR"LAVU7+09&1&]"G-/,*
M<09FIIXD$\RODXTXA:246JW=/<@=(9B4RTU!D-]J*Z<Z;K-0ZI[,<'6X9&HF
MBK+24UD%6VM9D1'79"J-'1_NZY9$2#SU:-2^6ZY.S_#^G8V4?%4M)5ITOFKI
M]8RNT/N<UH#8MLKN6O%Q@!29-1BV/;0JXY+7X7K[(8[MBII/62CQW)&Z"U6Z
MI)?^SUY6;G3_ )$FO^4U4MRW4.V,"6MO-]7[$Q$T&9+7D6$Y+51RY=I^%R:U
M$-22[>FB0I!ER42C+K%3IJ64UW3CUQN:*:Z*OEJ3\[^F2.P'J4^P@^2WV&S(
MS(R<>:09&1\C29+61DHCZC2?61\R,NH>/A44^HI<0S^HBDL&9_Y$1.<S/_(A
MPD>\!^M44%]D#J6*"AO;YY7/DU14MK=.'RZ77T*N'+5R_E5U\N7\J_\ D5RM
M'K_@/XM]E&VNATAEM5"<22RM,X3"P&O[V?(^^)+*9-=9/HY'S+P2LD*/ZDF.
MI-X3?93[$752LU4KNTO=E1A_77U\^VL(534P9MI:V<AN)6U=9$D6%E8RGEDV
MU%@5\-IZ9-D.N*2AMB,RZZI2B(DF9C>%J#N,EO*3#LMZ;58K$*[TY(Q36,),
MV423(E+8?S+(XR8K;B?[BS@8N^GI&9M2S))+/;QI'A:T3P\P$QM6Z^IZ2R6S
MWF=E,M"[G,K0E$DG"GY3:')MULNFDEG!CR(U:VHN3$)I)$DK*=&MY\*ZW?IZ
M[KZE-?Q-%/RS6^EDN[?V3\C2/PM]R8SW.':S+^(N3*UUB*N]2V]?US[2M@WC
M)DEQMFZF-]_@X5#>29$^RVJQR;H$['6Q02B3(1T$X#KW"=78M583K[&:G$L5
MI6>\UU+2Q4Q8C!*ZW7G.M;TN9)7S>F6$QZ1/FOJ6_+DO/+4L_L@&BBBFA6SN
MWE_A=#'7J5ZC\3MLE9+R^[E@  3*P                             #"
MNP_L/\AD85V']A_D .??BG\X/:?WC_;X(!Q3^<'M/[Q_M\$ !M-X"?,\X>_P
MYJ_U4X6\%0^ GS/.'O\ #FK_ %4X6\
M            ,B/M(C^WK'BI"5$:5%S29&1I/K29']1I/FDR_P C(R^KER'D
M  ^3GX%A%J22L\/Q:Q)#BWD%/QVFF$EUPC)QU)28+O1<<(S):RY*41GTC,?G
MMZLUHTXAUK7N#-NM+2XVXWB..H6VXA1*0M"TUI*0M"B)25),E)41&1D9$8^\
M <A<E^_Z7H=E\W^_Z7H?R1($*"T3$&)&AL%SZ+,1AJ*TGFHUGR;CH;27-2E*
M/JZU*4?:9\_ZN1=O+K_K]?\ KVC(#IP
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M-*^FB?9[+OEX/*8TKZ:)]GLN^7@  /*8TKZ:)]GLN^7@\IC2OIHGV>R[Y>
M \IC2OIHGV>R[Y>#RF-*^FB?9[+OEX  #RF-*^FB?9[+OEX/*8TKZ:)]GLN^
M7@  /*8TKZ:)]GLN^7@\IC2OIHGV>R[Y>   \IC2OIHGV>R[Y>#RF-*^FB?9
M[+OEX  #RF-*^FB?9[+OEX/*8TKZ:)]GLN^7@  /*8TKZ:)]GLN^7AA7$QI7
MD?\ Z:)[#_\ A[+OZ?=X  &EOB$NJS+-T[%R&@D^'U%ED#KD*7WF1%[\AF-'
<BN'X/-:C2F^B^PZCDZPV9]'I))2%)4H  #__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g151688.jpg
<DESCRIPTION>G151688.JPG
<TEXT>
begin 644 g151688.jpg
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M A$#(3%!$E%A<8&1H;$$,L'1\")"4N$3(X)RDJ+"\?_:  P# 0 "$0,1 #\
MM_\ %*CR&U^.FH-B73:.[)"U6VF,9B=?-MM7*-1=R"[AV118C!A(H,FI1(FF
M4$FJ"*( 4!!/O"8QI">@2'^<;>?WT7W]5S7' GX'G'O^7,7^:?9+S -%>@2'
M^<;>?WT7W]5QZ!(?YQMY_?1??U7-ZXP#17H$A_G&WG]]%]_5<>@2'^<;>?WT
M7W]5S>N, T5Z!(?YQMY_?1??U7'H$A_G&WG]]%]_5<WKC -%>@2'^<;>?WT7
MW]5QZ!(?YQMY_?1??U7-ZXP#17H$A_G&WG]]%]_5<>@2'^<;>?WT7W]5S>N,
M T5Z!(?YQMY_?1??U7'H$A_G&WG]]%]_5<WKC -%>@2'^<;>?WT7W]5QZ!(?
MYQMY_?1??U7-ZXP#17H$A_G&WG]]%]_5<>@2'^<;>?WT7W]5S>N, T5Z!(?Y
MQMY_?1??U7'H$A_G&WG]]%]_5<WKC -%>@2'^<;>?WT7W]5QZ!(?YQMY_?1?
M?U7-ZXP#17H$A_G&WG]]%]_5<>@2'^<;>?WT7W]5S>N, T5Z!(?YQMY_?1??
MU7'H$A_G&WG]]%]_5<WKC -%>@2'^<;>?WT7W]5QZ!(?YQMY_?1??U7-ZXP#
M17H$A_G&WG]]%]_5<>@2'^<;>?WT7W]5S>N, T5Z!(?YQMY_?1??U7'H$A_G
M&WG]]%]_5<WKC -%>@2'^<;>?WT7W]5QZ!(?YQMY_?1??U7-ZXP#17H$A_G&
MWG]]%]_5<>@2'^<;>?WT7W]5S>N, T5Z!(?YQMY_?1??U7'H$A_G&WG]]%]_
M5<WKC -%>@2'^<;>?WT7W]5QZ!(?YQMY_?1??U7-ZXP#17H$A_G&WG]]%]_5
M<>@2'^<;>?WT7W]5S>N, T5Z!(?YQMY_?1??U7'H$A_G&WG]]%]_5<WKC -%
M>@2'^<;>?WT7W]5QZ!(?YQMY_?1??U7-ZXP#17H$A_G&WG]]%]_5<>@2'^<;
M>?WT7W]5S>N, T5Z!(?YQMY_?1??U7'H$A_G&WG]]%]_5<WKC -%>@2'^<;>
M?WT7W]5QZ!(?YQMY_?1??U7-ZXP#17H$A_G&WG]]%]_5<P.A8@ '_P!XV\_
M?_SHOOZKF]LP;P'Z!_# .&FZ]L[=UQM6\4BL;9V.E 5^;5:1B4E:GTP]2;JH
MH.Q36DI+SE\Y BKA0J1G"ZITT031 W<3* ,^"Y3_  @]I_6/^WL<8!U-X$_
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M!/P/./?\N8O\T^R7F ,8Q@#&,8 S!@ZAT\/6 A_#UE$#!U_T$0Z#\8=0S.,
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MY$$;*&+!/"-YJR*VYV4K9%\Z*_0*)BMTD;@N, IWVCLL.TCUEJ#L$I[36FM
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M_A![3^L?]O8XP#J;P)^!YQ[_ )<Q?YI]DO,B'P)^!YQ[_ES%_FGV2\P!C&,
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M^#T\*9&4(RU6?/?S.KL!9(.T1Z<I 23638J#W?+-S]3)*>H11<(G JS9P4!
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M&,8P!GF10Z1R*)'.DHF<BB:B9S)J)J)F R:B:A!*=-0A@ Q#D,4Y# !BF P
M.>&, F[I7=)K$9O4K:X3+.%3*E$2RABIA-@F4 \T=]1 H3 % 3D.3NDD2%,(
M$([(8KB3><B2'.D<BB9SIJ)G(HFHF82*)J)F Z:B9RB!B*)G*4Z9RB!B'*4Y
M1 P (= ]);0"\0YHF77 ;3#)$!V8W=*,LQ 031E4RE H>6[PE1D2$+W4W(D7
M "I.DRE]+X7XCB_US?ZE\K?[DMF]VMN:US6>;%P^']4=-URO==.FSTRTWGC&
M,W% QC& ,8Q@#&,8 QC& ,8Q@#&,8 QC& ,P;P'Z!_#,Y@W@/T#^& 5]^4_P
M@]I_6/\ M['&.4_P@]I_6/\ M['& =3>!/P/./?\N8O\T^R7F1#X$_ \X]_R
MYB_S3[)>8 QC& ,8Q@#&,8 QC& ,8Q@#&,8 QC& ,"/0!$? /6.,T!RAW4RX
M^:*V)M-P9$TA 0:J-:9K"02R5OESEBJM'^3.(>536F7351T0O42L4'2@]"IF
M$.-TFWHDWY'4FVDM6TEW>1Q([6;E,XNEZ1XXU"2#VHZ^<M9/8*K4X]V;OQDO
M+L8)PH4PD684UBX1<K(![P]CD#@N7SB"1[G&W/[I23DIJ2D9F9?.)28EW[R4
MEI-VH99U)2DBY5>2#]RJ<1.HN\>+K.%3&$1[Z@@'J  #^',4I.4G)[^AZF'!
M0@HK99OF]WXOTR&,8R),8QC &,8P#)?$/I#\<[P<:O\ (+4OU.:_GI#.#Y?$
M/I#\<[P<:O\ (+4OU.:_GI#*,?2/=^Q7B;>/T-WYS1[1S;G*K6J''^%XQ(W!
M9*\72]DVT.CM9:GW[RH;TVJ4DLO$/-%<>MO6RL0FT(]O8G2)]KN(5&:L=1K
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M_P"!GG/#Z*:\*B_.X^1GQU\K[I^Z^ILC&,9Z)G&,8P!C&, 8QC &,8P!C&,
M8QC &8-X#] _AF<P;P'Z!_# *^_*?X0>T_K'_;V.,<I_A![3^L?]O8XP#J;P
M)^!YQ[_ES%_FGV2\R(? GX'G'O\ ES%_FGV2\P!C&, 8QC &,8P!C&, 8QC
M&,8P!C&, _-90B29U5#=TB914.8?X$3 3G$?] *41'*+MPF5;';[;8ECF46L
M%KLTZJH<RACG/,SLA)"8QE3&5$1\Z#UJ&,I_SF$W4<O#6S_[+V/_ /89G_\
MS7644T?_ (*/_P"BE_\ UES/C_L_Y?\ J:_A-9]H_7^C],8SXO8>PJCJJFS>
MP+Y+>P52KI8\\Q*^8OY+S0LK+Q\$P'S*+;/'Z_EY658->C=LH*?E_+*]Q!-5
M0F?70VZ:GVF,RH I"H"G0GD1,"IC&*4B8E/Y,1.<P@0H=\0*!A, "82E 1$P
M /B8>Z82&]Z<.YU(80*</*& B?4AA _^T.($3][[\X@0G>,(!@&<9@P@40 P
M@41$H !Q @B)Q.!.A3"!A[XIJ=SH ]_R:G=Z]P_=C[M;E%IS2E@C*SL25N$7
M*S)HA&)]B-5;1M\9)OIX[TD1#L)RHU&:A7E@?FCW?D*XW?J3H@CWQCP(<AC$
MF]$WVS.-I*VTES;I>I(/&>H@IMA8X2*L,8+P(V9B8^;9^R<;(0<BG'2C9-VS
M4DH:9;,9>&<'14+Y9C+LF3UJJ!T'*"2R:A"^T Y##T Y!'W@= 43$>JA@(F'
M0#B/50Y@(F'3JH<0(3O'$"B.GZ%\0^D/QSO!QJ_R"U+]3FOYZ0S@^4?6 _P[
MQ@Z@("7J0PD. &#J B0X"0Y>O4AP$AP*8! .V?&N_4DND=9Q2EK@4I&,K:4=
M(,EI%!!PS?H/'AUFC@JXI@FNF59,3$[P^].0P"(&RC'3J.6Y7B;>/T).8S^)
MK)1KT.K*1CW@#X"T>M7(#_$>GD%E/#/[^X</$I@#XQ*(!_7IT'_IF8K/'&,8
M QC& ,8Q@#)V\9GPN*&_9F[PC'6-^F01'J7R;QLR? 4OQ=%%E1$!$>@C_KTR
M"632XMG,,#:TQ,(D).LSE+_ IE(I(#B'^I@3)U]?K[H?]=7P;K&76,EZ7]"O
M&7^M]&GZU]24V,8SUC&,8Q@#&,8 QC& ,8Q@#&,8 QC& ,P;P'Z!_#,Y@W@/
MT#^& 5]^4_P@]I_6/^WL<8Y3_"#VG]8_[>QQ@'4W@3\#SCW_ "YB_P T^R7F
M1#X$_ \X]_RYB_S3[)>8 QC& ,8Q@#&,8 QC& ,8Q@#&,8 QC& >KG&9Y"&E
MF"9NX=[&2#0A^X*G<,Y9KHE-W"B!C]TQP'N (";_ (0$!'*)RB!VISM50,"C
M111JH!B&3,"C4YFZ@&3-[XA@.F8#$-[X@]2F]\ Y?$-X>/3H("(_Z ("/_\
M 925W_3QU_O3<E)[G<)6=GWB,;%Z=/\ <0L+]W&&#WI>I3QCIFH00  $ABB
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M!_# *^_*?X0>T_K'_;V.,<I_A![3^L?]O8XP#J;P)^!YQ[_ES%_FGV2\R(?
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M/OD/.A I@3,&6) ]7_U\?CFCX6+_ %S>[I>[?75>I5CM7&*V6GMZ<AC&,UE
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MAZ\I<9+6+7=?B\C0L2$M)Q?2U?EJ:4QG[.VSE@?R3]LY8*@( *3]LX8J@(E
MX *;M-$X"8ABG* EZB00.'4H@(_@F8JI@(D<JIS=>Z1(P*G-T 1'ND3[QS=
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MNATZ '0/B*(E_ 0S., ]<]B(J2[H2$:P?@0PG(#UDV=]PXE @G+YPDIT,)0
MHF#U]T +UZ!TS^9"MUYJJ5=K!P[9<G>[BR$6P15)WBB0W=43;E.7O$,8IN@A
MU*(E'U"(9[K& >($*4 *4.Z4H="E*(E*  '0  I>A0  \  .@?P ,R  '@ !
M] 9G& ,8Q@#&,8 QC& ,8Q@#&,8 QC& ,8Q@#&,8 QC& ,8Q@#&,8 S!O ?H
M'\,SF#> _0/X8!7WY3_"#VG]8_[>QQCE/\(/:?UC_M['& 3PX6;VU94^*VBZ
M]/6@&$O%T&.:OV@PMD<B@NFZ?=Y/R[&&=-5>G4/?(KJ$'KZC#TZY*'W3&E?E
MH7[/6[]O8Q@#W3&E?EH7[/6[]O8]TQI7Y:%^SUN_;V,8 ]TQI7Y:%^SUN_;V
M/=,:5^6A?L];OV]C& /=,:5^6A?L];OV]CW3&E?EH7[/6[]O8Q@#W3&E?EH7
M[/6[]O8]TQI7Y:%^SUN_;V,8 ]TQI7Y:%^SUN_;V/=,:5^6A?L];OV]C& /=
M,:5^6A?L];OV]CW3&E?EH7[/6[]O8Q@#W3&E?EH7[/6[]O8]TQI7Y:%^SUN_
M;V,8 ]TQI7Y:%^SUN_;V/=,:5^6A?L];OV]C& /=,:5^6A?L];OV]CW3&E?E
MH7[/6[]O8Q@#W3&E?EH7[/6[]O8]TQI7Y:%^SUN_;V,8 ]TQI7Y:%^SUN_;V
M/=,:5^6A?L];OV]C& /=,:5^6A?L];OV]CW3&E?EH7[/6[]O8Q@#W3&E?EH7
M[/6[]O8]TQI7Y:%^SUN_;V,8 ]TQI7Y:%^SUN_;V/=,:5^6A?L];OV]C& /=
M,:5^6A?L];OV]CW3&E?EH7[/6[]O8Q@#W3&E?EH7[/6[]O8]TQI7Y:%^SUN_
M;V,8 ]TQI7Y:%^SUN_;V/=,:5^6A?L];OV]C& /=,:5^6A?L];OV]CW3&E?E
MH7[/6[]O8Q@#W3&E?EH7[/6[]O8]TQI7Y:%^SUN_;V,8 ]TQI7Y:%^SUN_;V
M/=,:5^6A?L];OV]C& /=,:5^6A?L];OV]CW3&E?EH7[/6[]O8Q@#W3&E?EH7
M[/6[]O8]TQI7Y:%^SUN_;V,8 ]TQI7Y:%^SUN_;V/=,:5^6A?L];OV]C& /=
M,:5^6A?L];OV]CW3&E?EH7[/6[]O8Q@#W3&E?EH7[/6[]O8]TQI7Y:%^SUN_
M;V,8 ]TQI7Y:%^SUN_;V8-R8TKT'_P!M"^ __AZW?%]7L8P#BWR$FHRV;IV+
M88!SY_$25@549._(N&OEB(MF[50?-WJ39TGW5T%2=%4$Q'N]XH&(8IC,8P#_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g436184.jpg
<DESCRIPTION>G436184.JPG
<TEXT>
begin 644 g436184.jpg
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M=[3P-$=B9F>&ML'1\4-9=7:%DK7&X8(92%-E<H2'IK/_Q  < 0$  @,! 0$
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MC3RMZ[?IUCVO6+Q_T*W_ )4\K>NVJ99XY6W:#A;8LQY0N)LMDS%M\FK)6JG
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M---*4UX:WTU7^D/_ &AU[FO#6^FJ_P!(?^T.E*K;L7X>T\VV\ $ ]AZE<./
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M#DKX%_MICN\1YZ_KR-2_340\8WCS6KW;%[ZH:>,;SYJUWMD]]3]-X<E? O\
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MVHE(U?'\2P>RDA6*BT81S1P]>.G$'#I(-VK5(ZZZRRIVI2)III$,<YSB!2@
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M'P\4QAHYDU91L>R08-6#5$B#-NU;I%13;H-R "::!2% I4RE HEZP'B/'T0
M _\ R(CU=72/$=9UZ#LOLE(L4NXW2Z;0W'::[W2+!AR)UQ8A1T,1X+T]]N/
MC0V6T18RW+@XM;.^Z"M"5[W #Z)1NDDJ*E$ $G T!)P  ,#)/.J.8(V:5[&>
M0[)DBQJ)RTNTMMH5QO'MW2B\/7:K*.3KQ[A9FY;%,G82%=/"#WE8[1D"HJH=
M\=*"NG>,0 0$! ! 0X" ](" ]8"'N@.FFMKLYLQ9-E+>JV6.$W"BKD/2G@G5
MQ^0^1OO/.'VG%A"4-(SHAEMMI "$) E*4I&$@ 9S@<Z   '  X '0 !U 'DT
MTTUOZM37,S?MCNSY'OF ZI3R%+,VY/(%<,Y=>$)1A&J2%>ES)R;Q!LZ%JV,1
MHNJ)N]&,8R10*4W2&NF>L< $0$0 1#J'ATAQZ!X>3B&N5VTV5C;:;/2]G9<A
MR+&FOVYQ]YE&^[T,*Y1)SS365HW%R6HSD5+V5=#TW2]&Z$=$NCB XDI)(!*2
M<<<!041[\8]]<<F6X[*. <4V;%=B:5BQ3^/+U"X@9MF)72 LZD\H$N\1D6:Z
M)$5Y)\9\P C)TZ;% QN^)K-C]TGW-J.3[G5W&WIO!R119N:3:[1 JMW13-W#
M9N+A*< SI%8"*-S I*NN[*J &("?S7  X!H.]XKL<1R@-"L,M&'-2K_;6MC@
MG**I7#5W)5&C&.[,\;I=T+1Y&RR1%4Q=D(*K=P"K=0Y3*][_ (R71/:X;HV^
M7'LVNZH>48[+\HYCT5#(NV,T>D2TI)1*C4!28NFBCGP!>(654!55P8R"I"';
MIKJ?G2Q2]JMF+\Y?[FJ?-V?V-OTWT;.1;BZ6G+;8[G+MTB#M$](=;4](BJ;5
M8DI;#2DNLH:>:?:96C<QT[Z%;Q)*4++6#U).Z0O.-1C<T'?FKAX@W&-,MY@R
M[0X0D,\JM":U]6O6.+=J.E)TSH5VTVJHJ4YV2K1O()E28JM. '2XF.=03E$M
MHM<&<4W%YM*GL)Y"L4?(-X'(&&YM6T5V)0;C+2@-;/-#"2+L'8IH$[IL[@Y%
MJHFN186" -U2=T?O8]V(R1:R\:PE61C'9R3)I(-3G(*9S-GK=)T@8Q!Z2&,B
MJ03%'I*(B4>D->N>B;;25M5:9\>]O@;2P)BIL^"4%M<6VWT"[V8-I*4GU=J'
M+3!;W_\ WI,-0>&2A;GV:<*P=[18.2.05[2>60 <9P#IKS/[M--->LU]::\-
M;Z:K_2'_ +0Z]S7AK?35?Z0_]H=*56[8P'#9YMM#_H>I/_TE'XQ_3JUH_P#Y
M]&JH[%^'M/-MG#J]AZD]8</K2C\0?H#5K1ZA^X.JI_"G^T=G5RJR_P :O[E?
M4UP)Q?B+9-AKE 8*CH\HANGONY.(OLG)GP!928XGZ*:PVVO/[8E5;/.T?:W#
M$C2L:Y.-Y=K&/,GQ,XV8C"C+NUS.R%?=]B\.Y#@(B' . CUB'#K'JZ1^X&OF
MR(_LE:Y:>P,8FP9H@65PS;!*R^!*]GK=0PC;G'&V\UOO^YZ5Q6RJ(;4GV'6R
M<.WI<]&/)TMA<3M52?.;"I;D652U])I?H2\>(?,AT"/$>KW1]T?*/ET3C&F.
M/4,=0T[_  Y8TJ">'8.S_ SX\_>:$;KZS?)'<'L4N=(PODC)#3&N;+=,WVVT
MV=H4=#T*AVW$5[QN[7GXNY9-I3R:27M%OJDZZ;5ROVJ31@*S,NVR/C!K'1$Q
MJ?-&']XN3=X&V;.-.:8^B<,XQO!X]W4+_*6QI?*5$N*QE^KY'O\ X@IUG>X^
MN"M\2>45K3#.IH9N"@SM$7\/$J2EH&-ZH< \FFA2#GCKC.#R\^30''4#WC/G
MA]:UE98G)"L%(IQETJC%WX(Y$J[R@2$BB"8-U>^$%LE?HXPG.7H(IX4!4S?-
M&35#YD8;A!A<S88Q$*%E@4D!Q?C_ +TDI4GBRB:?-&'[DJBP6Q(%3@7@!CE2
M3 QN)@(0! H;OEOY,D/ZB\_V576N\%?42P]_JLQ[[G#^:$/[GN?<U&Z,@95P
M/_97-/7G-3G3JXCJ';V=GUJ2^+KQYTU[L<]]<-/%UY\Z:]V.>^N&I?IJ=T<U
M?&O]U1GN\!]JB'BZ\>=->['/?6_3Q=>/.FO=CGOK?J7Z:;HYJ^-?[J9[O >>
MKZ\S40\77CSIKW8Y[ZWZ>+KQYTU[L<]]<-2_33='-7QK_=3/=X#SU?7F:B'B
MZ\>=->['/?7#3Q=>/.FO=CGOK?J7Z:;HYJ^)7WIGN\!YZOKS-1#Q=>/.FO=C
MGOK?IXNO'G37NQSWUOU+]--T<U?$K[TSW> \]7UYFHAXNO/G37NQSWK[8?F_
M/IXNO'G37NQSWUPU+]--T<U?&O\ =3/=X#SU?7F:B'BZ\>=->['/?6_3Q=>/
M.FO=CGOK?J7Z:;HYJ^-?[J9[O >>KZ\S40\77CSIKW8Y[ZWZ>+KQYTU[L<]]
M;]2_33='-7QK_=3/=X#SU?7F:B'BZ\>=->['/?6_3Q=>/.FO=CGOK?J7Z:;H
MYJ^-?[J9[O >>KZ\S40\77CSIKW8Y[ZX:>+KQYTU[L<]]<-2_33='-7Q*^],
M]W@//5]>9J(>+KSYTU[L<]]<-/%UX\Z:]V.>^M^I?IINCFKXU_NIGN\!YZOK
MS-1#Q=>/.FO=CGOK?IXNO'G37NQSWUOU+]--T<U?&O\ =3/=X#SU?7F:B'BZ
M\>=->['/?7#3Q=>/.FO=CGOK?J7Z:;HYJ^)7WIGN\!YZOKS-1#Q=>/.FO=CG
MOKAIXNO'G37NQSWUPU+]--T<U?&O]U,]W@//5]>9J(>+KQYTU[L<]]<-/%UX
M\Z:]V.>^M^I?IINCFKXU_NIGN\!YZOKS-0_Q=>?.JN]C7OKAIXNO/G57>QKW
MJ[8?G_-J8::;HYJ^-?[J9[O ?:HAXNO/G37NQSWUPT\77CSIKW8Y[ZWZE^FF
MZ.:OC7^ZF>[P'GJ^O,U$/%UX\Z:]V.>^M^GBZ\>=->['/?6_4OTTW1S5\:_W
M4SW> \]7UYFHAXNO'G37NQSWUOT\77GSIKW8Y[ZX:E^FFZ.:OC7^ZF>[P'GJ
M^O,U$/%UX\Z:]V.>^N&GBZ\>=->['/?6_4OTTW1S5\:_W4SW> \]7UYFHAXN
MO'G37NQSWUOT\77CSIKW8Y[ZWZDKUZSC6CE_(.F[)BS14<NWCM9-NU;-T2B=
M5=PNJ8B2*29 $QU%#%*4H"(CK\\/,Q5@C&$U!R+*7B)-LF\CI*.<)NV+UJJ'
M%-PV<HF.DLB</H3D,)1X#P'B Z^>^STH8Z5/3ELO!GICTI:2H(4Z&]_?+86I
M*"O=W0I023D@5&>[P'9_'DFO"\77CSIKW8Y[ZX:>+KQYTU[L<]]<->S.3T+6
M8IW.6&5CX2'8$(=[)RCM%BQ:E45(@F*[EP<B28*+*)I$[HP"=10A"@)C  Z6
MNVZ3 6/)1I"VK)4&SDGB*+A)NQ(_G 30<'$B"KI>#9R+=F53@)B^%*I#WL.^
MB )B!AU]QO5DLZ"Y=KO;K8A/1$KN%QCPT@/+4ADE4E]L .K;<2WD^VI#B4Y*
M5 05!/XBD=^!]>[Z\S6T/%UX\Z:]V.>^N&O,EG-B@(]S+3=\I\3%LTQ5=R$C
M6563-LF <1.LX<W--),.CH Q^)AZ"@81 -5;L>;,HYBR1S#VORM:2K-69.%+
M[E2>@E)^LMYAT@92+@X8"/&@OG)2I\556??NZ55%4/X(S5,MX]TVLYIO04R"
MOV=/91H@W.#G;W6I^L1=9[AC$E<K*$KSVOI>%.06.NJR\#D%$!%)5%T#@BS8
M0-R$G;>5,9N"]D=FKMM*F+(7 8NK3]OCV&1-2MII2FI3UQ3.F08K[BFYDNW6
M^6V@L2$MJ<Z)>*EPG.XDJUP#[.[G3K)R0#H2 =01SJ'3?* UYJM*L:Z:8LD@
M5)!.IE+CEW'MKH_=2BL2F2%[]<5G*D>BL4CD7QTB>')=\9L4#2!>\ZB5OS)O
M3PT[9Y$R'#P\S5[E76C*.K<3$)'AJG<)DIEH2"DVJ+]O.-7S=R8K)_(.GCEN
M^,L1BBHJZ1  Z.+XJQTY8TZ-6IT$=CC]]&R5,:@S(1.NO8<IRQJ\>*?<&(9J
M*ASE*H91-14PKK$47_O@3Q5%)<G>UDDU2=T0_<*D*H3NDS <ANY. E[HARE,
M4>'$I@ Q1 P (:E[8O;V[!UV[^D%Z#+BAAVQJV;@_P#'PH\I6\N8;O!?=?-W
M905"+$:>DI1T#8D.(3)<<S7<</XG,8_#N)">1.\#G>QP'9QU)KFU5-G>2;NG
M:[SF#(CVMY6M$RJ\9V.CRLZ=]%5]U&-DN;YTBRD1%(L$%CNFI8?P!XFR;@=-
MM(F[[WP+:XIQ!*8?HT+0ZM9H08Z)(LHL^>4Y<TC+R+Q8SA_+2:J-L236?/%C
MB*ARIE*5,B2) !-(@:WIIKJ]G]A=F]FG42[?"4JYB,_&?N\EYQZXS1+D)ERW
MI;V\E#TF4^VVM^26P^ZEIIM;BD-I2+I0E&J0,X(R0"3DY.2>)SUG70#.E::R
M/C^<OM&M%1LDM S,+-Q#IL\C4JI)MEG(I%!VT!!=O<06273>MVRR!R<1!9,G
MS)@XE&KNQ+$]RI6'3S;CP&K3ESG'T@^9SU1>K39&,6<8J.0='/-Q"R* *(/7
M3=LHUX 5UW\AS=_$==!]-9$O9.W3-J[/M:Z!Z_9K7=+8P.C25+3<7(JD.KD$
M]*/5&VYK;#6J1_R,E:2@E0<%(*DKTRD$#0=>[U]F#XGF<P\8Z\^=-=^_37H]
M';#52<W;*:]EQ)_+-G52K%X?R!9!W:(BHR3%636<.D%)-690);';>0<N6Z1B
MI.56HK)*"(D.0%53#>;369?]F['M/;G;7?K='N4)U*AT<A)4ME:DE'317LAZ
M+(2E1W)$=;;R#JE8J5 *!2H @]1 ^1X@]HU[=359\2;=DL0X[7QM#SL#-P4D
MY?/K -EI9I(U@=R2*#9V>2:C9R,#MSM&K9H1F1J"!6R!"F*H<3J'VW&UNS0S
M!I%0\S48J,CVZ;5A'1U$69,635(.Y2;-&C:V)H-T$R@!2)))D(4.@I0U/=-9
M5NL]LM$6)"ML)F'&@1&X,1MD$%F(W@H82XHEU2-X;Z@M:BMPEQ94XI2B "0
M    !H- ,8'#L^O,U$/%UX\Z:]V.>^N&GBZ\>=->['/?6_4OTUL-T<U?&O\
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M'NZD9Z\'&.&O4./;UT.!C P<:ZYS\S7]::KGEO.$_C++NVC';:@)V"MY]O\
M;<?2UV-:$(M6C2L#BV[Y,AS(5H(F0=68)QO196/<F&0@VL04R3HSI\L=-B?P
MLM9]NF+<V84H@XWC;!CK+$JZK#BT1=HF7N1HR?1@+18G<G%8PBJ1*-).@U)C
M7H\U\MDO=:ZK#EM4.:)AYQ1%PB9D:Z\./OJ,$U9F6_DR0_J+S_95=:ZP4/'"
M6'A\N+,>C_\ ZA#Z_19<E5B,@I%XZ2M8I S<$$K3'U_DEP,JW5*7^"QM9=NA
M* _3% 1%-(O$RABE#CJ&X0ND&AAC$2*A)_NTL7X_3-WNH6U5/NBU&' 1(JE"
M'24(/#B4Z9SD,' 2F, @(UWDY'M)X'K']/;4X.#H>(ZN^M_Z_,5XT.[58%<M
MS/44$G2S0JZ0NDFRYU4T5U&X'%9-%91%8B2IR FH=)0I#&,F<"QGGS >\L/8
MVX_(.N2J6XC&>)>5)S:\R3<0J%=N>W3!E8KRM@93K(KRT&LTD:+B6<:K'B\!
MW(FE5 ;CX&FDJ8Z@]\$>['6ZL]I<O N:8REK>M]L<N*&&6B^Y)Z*7#C*92E!
MW@0F472H)60&]W=]K>3J;I=&[6;>7PA+4ZX-P5O..!IMCI(TI]+JE*&Z<JCI
M;"24@])O;WLX/9G34-6OM<;D647\?H)MRJG746I]O33130*8ZRBJAX(I$TT2
M$.=4YS 1,I3&.(% 1UYL'E:C6:)83U<E7L_!RB .HR9A:Y9I6*D&PG.F#AC(
M,H99H[1$Z9R=\05.3NR')Q[HH@&HXI*QJD%*2K_J%*!*4D\ 5!)*1G) )' U
ML\C>"<C>(*@G/M%((!('$@%203P!4!UBMB::B'/F ]Y8>QEQ#],#ISY@/>6'
ML;<?D'5=]'YD_$/O5L'D?#SS'C4OTU$.?,![RP]C;C\@Z<^8#WEA[&W'Y!TW
MT?F3\0^],'D?/^QXU+]-1#GS >\L/8VX_(.G/F ]Y8?)_B9<?D'\_5IO)_,G
MQ'WI@\CY_P!CQJ7Z:B'/F ]Y8>QMQ^0=.?,![RP]C;C\@Z;Z/S)^(?>F#R/G
M_8\:E^FHASY@/>6'L;<?D'3GS >\L/8VX_(.F^C\R?B'WI@\CY_V/&I?IJ(<
M^8#WEA[&W'Y!TY\P'O+#V-N/R#IOH_,GXA]Z8/(^?]CQJ7Z:B'/F ]Y8>QMQ
M^0=.?,!U]Q8>QEQ_1XAXZ;Z/S)^(?>F#R/G_ &/&I?IJ(<^8#WEA[&W'Y!TY
M\P'O+#V-N/R#IOH_,GXA]Z8/(^?]CQJ7Z:B'/F ]Y8>QEQ^0=.?,![RP]C;C
M\@Z;R?S)\1]^T4P>1\_['C4OTU$.?,![RP]C;C\@Z<^8#WEA[&W'Y!TWT?F3
M\0^],'D?/^QXU+]-1#GS >\L/8RX_(.G/F ]Y8>QMQ^0=-]'YD_$/O3!Y'S_
M +'C4OTU$.?,![RP]C+C\@_^7NZ<^8#WEA[&W'Y!TWT?F3\0^],'D?/^QXU+
M]-1#GS >\L/8VX_(.G/F ]Y8>QMQ^0=-]'YD_$/O3!Y'S_L>-2_340Y\P'O+
M%V,N/R#ISY@/>6'L9<?D'3?1^9/Q#[TP>1\_['C4OTUKV8RG2*]&NYF>DI"%
MB6*1EGDE*UJT1[%JD4.(G7=.H5)%,OD[HX"(]  (]&M1-MY6VQU)'C$LH0_=
M%CRR)'IVDNG'*IB"QE&Z3L\>4HO6Z2(KN&ABD521,100'NA*&KGW^Q6MYB/<
MKS:[>_)($=F;/BQ77B<@=$V\ZA2P2D@%((WANYR0*J2!C) SPR<9[L\:L_IJ
MH33?-MS>HVAPA;I S:K))++.!KDR",L1P[!BV\1&!L(R!G#HZ:2)3E:F.*I!
MX '$0]6 WH;=Y]F]73O"D6^C8]_*2$%-P$_&SK-E'%[MRLO'*1QQ*'>Q*=,@
M+&4.4Y?F2\1X:AG;W8B0MMMG:W9UQ;R''&DIO$'+B&G7&7"C_P!XW]UUEU&$
MY)+3A (02(WT$@!:23J,*&N.6OG!Y&K0.G;5DW6=O'"#1JV3.LX<N5DT&[=(
M@=T=5==4Q$D4RE 1,=0Y2E .(B :K7;MWF#*Q'2KEC<&ESDXN0@8L:]33IS$
MQ(O;$Z,V8MX@G=H,Y)0H)+J.0:NU ;"D""XIN%T$E*GUBHJ[K9^;RAF*QY*;
M8N-8GJ>*<>QM>GV4?)TH'*!_#)IQ!Q#E%XSF"MP:G_A"[U<I5SE?H)D30UL;
M'NV3#]$SA/9.:Q;CFNV:108\IJ=%OCA"LRQ&**$Q+.C2<*[*Y<BZ0,ZAU"*G
M%FL[67*"2Z+4Q./>VH](&T"($K9&Q6FWV*YSC$9O-ZF&1</^-<9E*1M&U:&.
MA99A!3"'(;$B7(DSDR(A5&89?<=CTWG%8*$@))QO*R3C'X@D:8S@C*LJR!@9
M!K5*>Z;<!1[+6,J9C@I&*P79'=[:1<!"U-%I-)@V65:5A.P^,EB/8Y\H*)'C
M8SMRS!RU2>B*2HF0(.QL9[_(^UY';U&]T8,;5V>:N9.N6:>FA:%1C46*[EHX
MF4W[!HW.VEU&BY6<DR7(R((E2#PDI1<FNO)V.F3;!S%S,7)RT8\2.B\CI*A6
MI\R=(G 0.DX:.J\J@NF<!$!*HF8! 1Z.G6N,@TC!F4(=2&N-&4D4O%R,6S?)
MX^M+.8BF37N_ T(B7;5U-_&ILQ.<6J+98B"(F, (B0QB&QSL?Z2+0M+MC](H
MN3+4ABX+M^T4%#YN<LLLLW"$_<@J2_ M;_0%<)B$R%0527""ZMM#RW1NC&ZX
M2!@X4G.]PR"K4@'B, X)Z]*KM$P9]Z]TLL_99HX[><>V64K%1K<"[D(XV0)E
M!DU*]LDS)MG")EXQN#CN6#9(AD5"J=[ P?PHQX5F7:'=:%58-[@*\YDFIR)M
ML:PJ-4/<@2AJ1!3/C!&8=1ADRL3M6Z1E6R;EXNN;O#=59PH4Q@,H2^]8DZ)3
M:_$U>MQDS%0D(Q;Q\<Q;4JWD31;MTRIE$PE@ %593N15<.%.Z6<+G466.=0Y
MC#[W/F ]Y8>QMQ^0=9Z_1?9;M:GSM$X9.U5R2Z[<=IH3SK$]F4^MMQ#5M=6M
M?10+9T3#5KB.H7'9$9J26/6BMPST0(]H'?(U6,@Y.#H>H#3=' :::US%BZ9N
M]S]4ZUBK)M5:UZC5JQ4L+38[NN^;VNR%K+IZZE7!4TES!96,R@LFT4.4J"::
MR#%RB[45%RMJZ^,=J&%<6H61&(JC&8&QR$@X47LS1C,NHV+?HJ-1KT6X<M16
M;1"3555N8G=F<O"'XOG#DZ:1B;BY\U\.I.PA]RF7'_N@=9Y\P'O+%V,N/R#K
M86#T;;/6A]JX7)Z3M5>6&6XL>\[1F+-F1HC"'6VHL4I8:0TRAM]P*REQQ95O
M+<.$!!#03@G*U 8"E:JQI@#30:CAUFO*QCBREX@K1JG1(P\5"GE9*8,W4=+O
M5!>2:_?EQ%PY,=8R212I-VJ1C"5NU120)\R3B.Q-1#GS >\L/8VX_(.G/F ]
MY8>QMQ^0==W#BPK?%8@P&(T.'%:2S&BQD-LL,,H&$-M--A*&T)&@2D #J%?0
M#   P.H 8'N'O'C4OTU$.?,![RP]C;C\@Z<^8#CP[BQ=C+CP]/B'AK)WT?F3
M\0^]3@\CY_V/&I?IJ(<^8#WEA[&W'Y!TY\P'O+#V-N/R#IO)_,GQ'WI@\CY_
MV/&I?IJ(<^8#WEA[&W'Y!TY\P'O+#V-N/R#IOH_,GXA]Z8/(^?\ 8\:E^FHA
MSY@/>6'L;<?D'3GS >\L/8VX_(.F^C\R?B'WI@\CY_V/&I?IJ(<^8#WEA[&W
M'Y!TY\P'O+#V-N/R#IOH_,GXA]Z8/(^?]CQJ7Z:B'/F ]Y8>QMQ^0=.?,![R
MP]C;C\@Z;R?S)\1]Z8/(^?\ 8\:E^FHASY@/>6'L;<?D'3GS >\L/8VX_(.F
M^C\R?B'WI@\CY_V/&I?IJ(<^8#WEA[&W'Y!TY\P'O+#V-N/R#IOH_,GXA]Z8
M/(^?]CQJ7Z:B'/F ]Y8>QEQ^0=.?,![RP]C;C\@Z;R?S)\1]^T>-,'D?/^QX
MU+]-1#GS >\L/8VX_(.G/F ]Y8>QMQ^0=-]'YD_$/O3!Y'S_ +'C4O$.("'E
M#AKG%B[$%DJ&_'*=E>QSU6N3E7G+E$SPLU0C5%;5)0Z)XT'@$\'!^T<DDVYF
MHJ>$F;M@="0$52"-[N?,![RP]C;C\@Z_V;7"$=N$&R))WOSA0J2??JI:FJ/=
MG'@7OKAU#(MD"<?HE5U4TR_YQP#7,[0[,P=HY6S<N2^MIW9J_1[[$+>ZI+SK
M#+[)CN@J #:R\A>^G*TJ:2![*E T4C>W2<C=4%#[=VH^52G333745:FO#6^F
MJ_TA_P"T.O<UX:WTU7^D/_:'2E5MV+\?:>;;./$1]AZE=?7_ "2EU]>K/2S[
MQ9%R,EX&_D?%[!X]\ BFWADF]\$;*N/!(YH!TQ<OG/>^\,V_?$^_N5$DN[)W
M?=!6'8N(CL\VV"/'C[#U*X\0X#_)*7N:L_*%DC1D@6&49(RYF+L(M6117<1Z
M4B+=3P%1\@V6;N5V:;OO)W2*"Z*RJ *$2534,4Y:H_"G^T?059?XU?W*^IKY
M4KABG/F3N4TCLV8?I=VP_.7',F,LF0V7LS; ;S,3%%;N\ UNMRF"[]N(CMU%
M>)&TA5@54LOC-O2T(Z*NKTT;X"^[M207^KE,!!,@&'NC 0H"/#AQ$"AQ'@(F
MX<1XCPXCPZN(\.(_)9MYP-9]N/*2X[J^8<,5US,6/< ]LSW+4'MLY1Y]A"1R
MO;\<OIGQGC;,V8]V%QV^-; 1FU<,XJ5EZ'8'T5)MY2N5\R3MM'$8_6H3Z$O
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M< ]K<?;DI)N2OR<.WG6D@X.#9(\8Y8!)D<F!42F(!60BLHF(=\3*4X&* D,
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MEHK#BFT*6$E*21,----7KX4TTTTI33332E->&M]-5_I#_P!H=>YKPUOIJO\
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MD^Q4G):<?D.N!7FD=6H&!QQ-)6>/@%FY)P&4KD"LM7#QZJ5%%!=J#IS)SU5
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M)$.]D'A2@5RK5RDPS.::52I1D)#UN!/:K*\CX>.K:#=O H,T7\JY[@\2DT;
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M+L:W**!_Q]L02I#$*-N-I:" L+*01QB$;NI)4KK4>/5D#DG3AXYIK @ @("
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M8?-ZAV$']S+A?$14*U +(AB_'X)*GMKQ$ZA.:,/W!S)!4U03,8.DQ 54 H]
M'.' P[OEOY,D/ZB\_P!E5UKO!7U$L/=7U+,>]75_BA#]7Q:C!R/:5P/4G^G^
MFISH=!Q'/M[:DOC&\>:U>[8O?5#3QC>/-:O=L7OJAJ7Z:G=/YU>"/VU'N'S^
M_G)[,1#QC>/-:O=L7OJAK!G]W, E-5:Z)1Z#!SP>&XE'H,'<C4  >("(<./
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M6ZDW=F067C8LD<8'*$<V!,BC=5ZH@D"ISF[,:Y2_V*9L[=9-GG+S*BICETH
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M5'3\S-F]?/E#I23UZLU6.+!%46C1'NK,9TPI";C\>O<7Y=QA6[/3WK^+E#,
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M,P;CYW-=0KUW>2^U[!]3EI:0A"'9064H!K*P2\K"K& 5H64[]'H2)P8.42N
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M;U+5BMS;#(;.)?H-R17AK)T#B34C06*HW;B#- [CP5,#]2HVK::P3YKXE_\
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MM):46"I+VZXI82>B+:PY@^QN*WL;IK=/-:L^;L'^*F/[#0:M6  1YNP?1_\
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M1X+%GM#,A2DJ3)>93-N$DH  4CHDW&,A2#O#.%!9WBE'E'K-<4-W2D##JFX
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M_P C6(<^8#WEA[&W'Y!TY\P'O+#V-N/R#J7Z:85S3\)_=33M\?X[_(UB'/F
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MMP43(NX6,0A8=T_C8MHR>.8F'; #:*C%W""BK"-;@"#!H=%HD )HEU)M2 ,
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M6FT7#P$&S6DI:2D%PMX&2:-&+==9<Y.*@$*/>@%3N '5& SX/S/7I9''^?\
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M[)[XO_S!_P".L\0X@'E\@"(??$.@/BX]?N:@ #AYTQ]!4DDZFLZ:QQ#XP^Z
MA^D _P!^G3B'#CT]/_)-Q^^'#B'W]345'+53:C>8SQ)=:O7;=#>$$=^*;/"Q
ML]&^$I)+HIN!82K9TU%8B+EPB50R(F!%==+CW"RA3?I@JW7ZPW>M*["QD&VD
MIB7L,@A%,F[%)[.3[]:4FY=T1N0A5Y&5D7"[Q^[4 RSEPH910YA'H]O01 .D
M1X!Y1TI337\]V3WQ?_F#_P =.[)[XO\ \P?^.E*_K5?\I[6-OF;+#SLRGBJK
M76RA2;)CE.<F4'2DBVI5N@[;6[% LW"+I$6;>5A+U;(]PNV*F[!*:<F2<)K)
MME4-_P#=!PX@("''AQ#I]/#CP^/CU>[IW10$ $0 1Z@$0 1^X ](Z4K_ !;-
MD6;=!HV3!)NV12;H)@(B":*"94DB )A$P@1,A2@(B(B <1$1XCK_ 'U^"1E8
MR(9JR,M(L(Q@B9$BSZ0>-F3-(SAPDT0*HZ=*I()F6=+H-DBG4 55UDD2 910
MA3?M[HO3\T7YGH-TA\R(=8#T]'#X]*5_6FL<0X<>L!\G$?T<?3H)@ .(B !T
M=?1U]0=/#I^+[VE*JY5]G6"Z=F60S[ P$NVRE+6>T6F4LJ]EF'ZSYS;XEQ#S
M,0HF^<+E0JZB2R3Y.LLQ;0X2T?$2BK59Y#QBC6TFL"8H=8@'N=(@'7U=?W!^
M^ A[@Z_&^DHZ+1*XDG[*/;F<LV95WSI!HB9W(NDF+!J55PHF07#UXNBT:( 8
M57+E5)N@1190A#0 !P\Z8_Q_GC4DD\23IC4YT' :]5?MTTXAU^YY?<U_BLX;
MMD5G+A=%!NW3467765(DBBDB0RBJBJJABIIII)E,=0YS%*0A3&,(% 1":BM;
MYDQF7,..+#CE2ZWK'J-B/" XMF-9XU9ND>VB;#$SKEK#SI$'"D>2;;QBD#*J
MI)"LI#2<B@B=)54BQ(]@;"#' E7FJ?$WK(=YAY&R%L,<KDFSO+=,09EJK5H2
M88LYB0,=ZHTL%C@9K(<F@H<K5&VW>S>)VD7!FC(>/W*S?,I%HU?Q[QJ^9/FS
M=ZR>,W"+IJ[9NTB+-735P@=1%PV<HG(J@NB<Z2R9RJ)G,0P"/Z@$!#B @(>4
M.D-1@<>OGUTIIIK'$/*'I#4TK.M?VK$^+[R]7D[GCJCVN3<5^4J:TG8JK"3$
MD>L3<=-P\Q7_  ]^R7=EAI2)LMBC)".(L1J[CYZ99KIJ-Y1ZFM/^(>4/2&G$
M/+Q]WHZ1] =.HTYCQYX_CQ[:5_"**3=)-!!,B2**9$DDDR@1--),H$33(0H
M4I"$*4I2@  4H  !P#7^FL"8H!Q$0 /*/0'3]WAT_%UAIW10X\3%#@ "/2'0
M ]0CY 'W-32LZ:_#'R<=+-$'\6_923%T0RC9XP=MWK5P0ISI&.@Y;**HK$*H
M0Z8F34, '(8@B!BF /V@8H](" @'6(" \/1I2M&P.VG!%7O[O*5>QC5X;(+^
MTS-VD+9'M56\S(6JP0\A 2\R_<E7$7CAY#RLBQ,FN!FR:;M8Z*!%1*H3>>L=
MT   B/#B/ .Z^9XB/4'3PZ?BU@3% > F* ^01#CT]71Q]W4  < !W=V/H*DD
MGB2>K4YTY5_6FOY[HO3\T7YGZ+I#H^[T]'W]9[HO1T@(B'$  0$1#R@ =8?&
M&IJ*AV0Z) 9/HEPQS:BOU*S>JW,U.P)Q<D[B)!:%GF*T;)HM)-@HB\8K+-'"
MJ17+94BR8'$2& =:^P;MSQ1MSB)2!Q+ +5J'FE8QW)Q_C%V_2>RD8Q-'>/7B
MSPZKI_8))IWA*:G)!=U*2I&,<F[<J)1[1-'>/=EZ?F@#@/ >(@' ?)TZ_K2E
M----*4U5[<#M<AMPTE7'L_E',U-85N(L$<G7,;W^5I=?FW<V1$6\I96\(=H_
MEG,*Z;-'D64LBU!%=HF4%"H*O4G5H=-01G0_;AKU5()!R..OS&#\J\B C%H6
M"A89S*R$ZXB8F-C%YN7.DI*S"S!F@T5E)-1!)% \A('1,[>G1122,Y65,FFF
M00('KZ::GA44TTTTI4'9XRQU'3H6:/HM086+QQ(6$9QE78EI+'GI5DYCI*:5
MD&[5-RM+/6#UZR<R*RBCM5H\=-C*]Z<+%/.---0 !P '=3)/$YIIIIJ:5&+I
M3*OD2I62B7:%:6.H6^%D:[98%^"HL9B$EFRC.2C78(J)*F;/&JJB"P$4(84S
MF #!QU"<48%Q!@U&9;8EH4%0VL^6!++,Z^BNU9.@K$.G 0?\$.NJ@B+"(239
ME,@1,RQ2]\<"JL(GUMW32E----*4UH;.^VS$VY)A3HG+D&_L411[42XP\0A/
MS$/&.I@D:]B!+.LHMVV0GXQ6/D7K5S$2I',>[;N7#5T@LU<N4%M\Z:@@'0ZC
M[:T!(U!P>8J!XRQS6\246N8YIY'Z58JC)2-@FTB_6D5V,:+QR[;1R*Z_ 4X^
M.*Y\ B6*14VL7%-F48R219LVZ1)YIIJ>%./&FO#6^FJ_TA_[0Z]S7AK?35?Z
M0_\ :'2E5MV+B([/-M@B/$1P]2NG_P"$I?$'Z-6NU5#8N)0V=[;.D.'L/4KI
M'H^M*7EU:[B'E#TAJJ"-U.O_ %3]!]QXU9?XU?W*^IK.FL=T7RAZ0TXAY0](
M:G(YCS_L>-5K.FL=T7RAZ0TXAY0](:G(Y^?)'C2LZ:QQ#RAZ0TXAY0](:C(Y
MCS_L>-*SIK'$/*'I#3B'E#TAJ:5G36.Z+Y0](:=T7RAZ0TI6=-8[HOE#TAIQ
M#RAZ0TR.?GR1XTK.FL=T7WP>D-.Z+Y0](:4K.FL<0\H>D-.(>4/2&HR.8\_[
M'C2LZ:QQ#RAZ0T[HOE#TAID<QY_V/&E9TUCNB^4/2&G=%\H>D-3D<Z5HS/>-
M<HY/K$9"8JSQ8, 3#683D)"SURG56Y/I2.3;+)>)CM+611HS0.X43='=-@!P
M842HCQ3,.JE^T_WE?^LRRQ^0O#?[OKI/Q#RAZ0TXAY0](:V\*^SH# CQT6M3
M84I8,JR62>]O*()S(G6^1(4G.-U)=*4C 2 -*U4NRP9SQ??5< X4I21'O%WA
MM83PPQ#G,,)/YE);"E'51)KFQ[3_ 'D]8<ICE?X@'!>&Q#C\?]X 1#CP'AQ\
MH>[T:@SSA'?+9-UN#\RTB-J-II^U9#$==BI&PW5[4KOEYG?Y=DTW<V2!J5<5
M]CI+QU0#03"&C<A*1#B*LU"?A4S^++,=9UV&XAY0](:<2^4/2&OC/NTJY):3
M)3 2&E*4CU.U6JVDE6[D+5;H<53J=$E*7"M*3JD J.?K!M<2W*<5&,Q1="4K
M];N5RGC"22-Q,Z7)2V3D@EL)*@<*)&*^=ZB;7MV] C+4[P!MT>85S4A6]UM+
MR'DVW73';&L;BK!G;-<HCA"]O6=%OEJFK7&8-KMA=9?E;3?(^JW^$@XA7&M)
MB)EY:GD7'^L3D]MQN2:#M_VU9+I>-Z?CS;Y.[H:/5+\T?R6:(6 Q?>\<0),%
MWJE)7:]5/(!LLX^EI:;K%>N%M8O9.K62HMK,>*EH^20D%_H+XE\I?S:<2^4/
M2&M7NIY\NL=6/KIGG[ZV041G0:Y/#K/7[NKJYYKS86--#P\7$GD9"7/&1S&/
M/*RZY7,K)&9-$6II"2<E32*XD'IDA=/5RII@LZ554 A ,!0C>2*[:+;1;16J
M5>GV,[3-12[&$OL;#15A?U9ZJ8G<RK2&FP-%2"Z*8*$(B]#O0"IWSH.0@A-N
M(>4/2&G$/*'I#4J"5I4@DX6DI.ZM2%84,'=6@I6A6#HI"@I)P4D'!J\=Y<9]
MF0T&BY'=;>;#S#,EDK:6EQ >C26W8\AHJ2 XQ(:=9=1EMUM;:E)/,CVFF]+_
M -:!EW\A&&OV6GM--Z7_ *T#+GN?\1&&O<#A_P#POOC\>NF_=%\H>D-.(>4/
M2&M7_P /!_\ YEQ__O-X_P#]_M'C7<__ *E;3?\ ]/L;_P#XV]'/_P#RM<D<
MX[*=R][QKAO'4SN;R%ENSUW=14\OM<R^(J3CBQ8@8T['E\"M3*$/7GL<QNL7
M&9&6J[B5KKP'ZLY$2$G#KLACEG#EO6VET?E0JZTVWKEQ_?,>3RV8\GY SA T
M'(V'[MC99"Z[F['*6N&MZ%NN<%(J5 ^(G)+IBM_5&UCLBZLLPI$] 423B'CU
M;Z .)?*'EZP].L<2^4O1T]8=''W=;!IE#+:&D*<W4)W4EQYUY>"<^TZ^MQQ9
MR?Q+6I0T .,"N/N%QD7.8_.E(B)?DN!UU,*!!MD0*"0@!F!;(\.!&04I&6XT
M9E!45+*2M2E'YV[WASE)\K8SH..;;"9YG*N:YBI+NY^[;<&ENNLO7<YX3MK2
MZ;@:V,S*0-+Q6[Q]#9(+5<985N-WG8VQQL:J\F$&T_'-8'>$5#<IFLYW;>%L
M<RQ-?LERQJZH,4G<<!R=JAJP3<39$LR16U^U2UK5C2/I3;<M!25&E<V0V/XN
M/NSHL(,1&'@5YV2[:<2^4O1U=71I\ST_0]/7U=/'KXZ^F!^8Z]H[.&!W>/;6
M$#CJ![\_>N$^0J#N.W1\G)MO;VVGY(RIDB%W&1]BRE6[#4L#V/(DE0\>Y4RQ
M7@YRT+*,C0L%WF39P3:K)RD:^4)79T4QGX9M*=RS66@E*PARB6,,&4RIQE:R
MQ7BL&E.@';?"-RV_IYN7)3MMM5J&(GEPM&1Y5Q49*M0=^C9)+.42A,S#MI)^
M+HW&9K!B^*(S=_0G\SPX<0$/<XCQ_2(_>_-IQ+Y2]'3UA[GN_>U.!IDZC'7U
MXQ_GAV]NK)QC3P[<\. ^VASI7 "\X7Y2:I63(3NGVK<"4V0LE4^^9#M>+Y+
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M?K_*_']MZ_KGK<OF?GML_P#F?7Z5]WCQ_P!+]W334]2>X?5%!U>[].A;K<N
M?/;9_HA^OTK[T?MO6 NUS^9^>VS]9?K]*^4WVWIIJ!U>[].@ZO=^G6376Y!U
M6VS=0_7Z5\I?MO6>>MRX%^>VS?CZ5]Z/VWIIJ3Q]X^J*#J]WZ=?YC=KGQ_QN
ML_4'U_E?('VWK^ANUSXC\]MGZS_7Z5]P.C_2_<TTU ZO=^G0=7N_3K)KK<N
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%[].O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g550440.jpg
<DESCRIPTION>G550440.JPG
<TEXT>
begin 644 g550440.jpg
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M][CGR6:].K.S7CI^AB%S47VQ9'3:8X.,N\!7002N4L"G<D96T":)KHF?-O\
M@8*9\,&S9O>%9MNW? %NY]9);J![,A7[VD'YUET!=+1A[5'3Y^"AG_1>*K-U
M631A[5'3Y^"AG_1>*K-T I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4
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M_A.WO+:7Z73JP:?PG;WEM+]+H#D=*XYU8-/X3M[RVE^ETZL&G\)V]Y;2_2Z
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MZRZUMK)+=0/9D*_>T@_.LN@+I:,/:HZ?/P4,_P"B\56;JLFC#VJ.GS\%#/\
MHO%5FZ "&WLUGHWMR@W.9J:@G+JF;VD"%TR>7@L.-P.1_8FYDS9E-8>*&L-U
MWGLC=-G3#.+Y':EN!:ZJ;";=+XG"I*.=<5\9M<"Q1MT+I0$2P7!,1::(L:\)
M0.PD&,(H9/3H&FQ6QB,%T%OXW"X59U*^!,+F3!K*6+&U]<5% "UN82Y:XW=@
M*8BY3'@+XI:I2@,5=4VY\ZCGW+VLURPJKZ87,QMT @^/81EG/J5;S\7G;!B:
MR&BXX[SFXK2&PGJ2#)C)4V^Z5!ZE(D<ZS&!!*ERQ2=F9YJA-SFT],X$^-RZU
M+I;7U(Z9H<G".CFE37 T8>:NHYW2Z5>:CJ/9MS1@".-+<UN*.^I\ID8LB.74
M'#<3M*TTHO1496..Y!/.=WW%G^F*!)L$=Y1O !V"%WXK+[@\86B'^^F^M 0#
M;V>7L#R;>QOAV;+=ON!=L$1Y Y: P^?^YGSLMG]0>G!JO6$B.@K5AJ>;FIB5
MRZNFOJW4$R".92CEUS%!,=I2=A&,5QHR^\HN(&"C]<*LBJT<-U^/Q'L93W.8
MVVJ)^X5H; V=G:-PCMY?\ZX;A#X@V[ \%-\&W9[OQ#L]SD$=FP!':&P!':.T
M-@5YH"IFI^,8V.L%9<QR/F.;<AYY138=<!EIH&=;-VF918B48M-*V5/O/F+3
M"9=<G9K<QB\,I"ZXGD"XN(XZEL(&@X=HC#44\HW?]G;/'W1[:-7'=2W\DI_^
MND1?\8&'4\AV/QW?K&@(HXA8.[C44\W3/^IJ<0L'=QJ*>;IG_4U2Q2@(GXA8
M.[C44\W3/^IJ<0L'=QJ*>;IG_4U2Q2@(GXA8.[C44\W3/^IJ<0L'=QJ*>;IG
M_4U2Q2@(GXA8.[C44\W3/^IJ<0L'=QJ*>;IG_4U2Q2@(GXA8.[C44\W3/^IJ
M<0L'=QJ*>;IG_4U2Q2@(GXA8.[C44\W3/^IJ<0L'=QJ*>;IG_4U2Q2@(GXA8
M.[C44\W3/^IJ<0L'=QJ*>;IG_4U2Q2@(GXA8.[C44\W3/^IJ<0L'=QJ*>;IG
M_4U2Q2@(GXA8.[C44\W3/^IJ<0L'=QJ*>;IG_4U2Q2@(GXA8.[C44\W3/^IJ
M<0L'=QJ*>;IG_4U2Q2@(GXA8.[C44\W3/^IJ<0L'=QJ*>;IG_4U2Q2@(F&!X
M-#LPW% ?'';.#]:-7CB(@ON.1/S>,WZFJB^Z72[)T4),/9HV?"\R\JXKO3 K
MY$/*5Q7*.$@F(68GC,B9*&@NM+9#.>_%O L$+LMPW;X-@!DYUXFJ/NZO_P#]
MXE?5%1]OO9$6S8-SU"UJC0Z_.SE.9)/BS$BVG++/2=DI:>AI#68GX$7-D.8:
MQ^VA-]NUVUVS4172GPRV)]Y8HV;2[UI%R6M3Y"JQ:A"@RE3?5TG(:TZH3-.B
MK%24I<S 1(D65>^'M(SUZ&YBN1KMLU.R7Q$07W'(GYO&;]34XB(+[CD3\WC-
M^IJZVG7B:H^[J_\ _P!XE?5%.O$U1]W5_P#_ +Q*^J*Q#\;JR_DS=7@4?>[:
M</KNY]^(?B+\L;'_ -2X/L/A]4T]DOB(@ON.1/S>,WZFIQ$07W'(GYO&;]35
MUM.O$U1]W5__ /O$KZHIUXFJ/NZO_P#]XE?5%/QNK+^3-U>!1][MIP^NZ_$/
MQ%^6-C_ZEP?8?#ZII[)?$1!?<<B?F\9OU-0((@P>0(<B<1[01XSOJ:NMIUXF
MJ/NZO_\ ]XE?5%6.TC:F]0+VU(10U7;+CR<#<65U1+JJ,HF4^\D?P8FRNFL>
M(Q9A3<&2ZRPR7P9[=[EL$,F&P=NS: W.B;*6T:Y6:119>W;E@S%8J<A2X$:.
MVE=!A1JA-092'$B]#J3XG0F/C(Z)M&/=M47:M<J(CK+<FPJOVV;>KUQS=V6=
M,2M HU3K4S EGUQ9B- I<E&GHT* D6CPX2QHD. ]D)(D2'#V[F[=[6YN-O\
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M '8  H!626Z@>S(5^]I!^=9=:VUDENH'LR%?O:0?G670%TM&'M4=/GX*&?\
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MG;]MU 3E2H-Z0:CNZC#_ #+.W[;J=(-1W=1A_F6=OVW4!.5*@WI!J.[J,/\
M,L[?MNIT@U'=U&'^99V_;=0$Y4J#>D&H[NHP_P RSM^VZG2#4=W48?YEG;]M
MU 3E2H-Z0:CNZC#_ #+.W[;J=(-1W=1A_F6=OVW4!.5*@WI!J.[J,/\ ,L[?
MMNIT@U'=U&'^99V_;=0&=.ZX?Z$@K_SQ_P#T.W*Q/K77=/4^2B*-#0O]U,QR
M69%E[@EVM1D+#0O*9+4M $W>>R*CZ>5I_'FQCBLP8\&).N+WV9+\F4T&6VS!
MD57,+9(=>"Y_F*!YOTP[,[$/K!V?]+N?SHJXI2E:,)+BE*4 JUNAWVU\*_UC
M5/[(N.JI59?1UA73&IF(L+:44M)7<B^H@G**VD&EY**Y0;"]=DO.)!)9;YH]
MCO+AFQ68L*TGW69LF/,.<;<5V+)E^'NOUC_6^VO+4D8!BQUK<2?J%>'F_4#M
M06]@/B#]5>:@P$#4=L#_ "HP_P!@/^Q9V_;=7GI!J.[J,/\ ,L[?MNKL"<#B
M<J5!O2#4=W48?YEG;]MU.D&H[NHP_P RSM^VZ@)RI4&](-1W=1A_F6=OVW4Z
M0:CNZC#_ #+.W[;J G*E0;T@U'=U&'^99V_;=3I!J.[J,/\ ,L[?MNH"<J5!
MO2#4=W48?YEG;]MU.D&H[NHP_P RSM^VZ@(?W0CVI$J_^B_[>MJNLU=V1^,?
MUUV$=<:1-)73#)6=W/R-UI LZDN')J!&+B;JJ8WST0+2W!5@]*;C*E.A&[L&
M;-T5&.='P8\A>S@]^6TQCZ]P]D?C']=<\=EIUQ:-]3:?Y:KYU;V"O6HN+]X-
M5\W+4/%*4J+I-44I2@%>XO\ Q^'^FP?/8Z]->XOMZ-AV" #T;#L$0V@ ]%LV
M"( (;0 =@B&T-H;0VAMVAZ9[MO=-Y4/G%_1/[E3N4D_8I?\ H,'S..OZ:@8J
M@:C!+X!LE"( MZ!AV ,+NT1 .@V; $>.X-H]L=@ (\H!: [T/?T@U'=U&'^9
M9V_;=7:QGN&]RWD0_G4=NKPKRDY4J#>D&H[NHP_S+.W[;J=(-1W=1A_F6=OV
MW5Z*$Y4J#>D&H[NHP_S+.W[;JYRS$^1R/3'C =+/<G1>"]*NI1E*[0X'O.C\
M,X?TT>[RZ8='WQ;@W0.EW!NA9NB<*Z/9P<#G-9);J![,A7[VD'YUEUK;626Z
M@>S(5^]I!^=9= 72T8>U1T^?@H9_T7BJS=5DT8>U1T^?@H9_T7BJS= *4I0"
ME*4!Z,I4OGOQ9,V#%EOP7]$P7Y,=E]V')LV=$PW76C=BR;.3?XQMOV<FW9LK
MS>7P7Y,6:_%CNRX0O##DNLM')B#):%N0,5XAOL09+0"W)T,;>B6@%M^^M  K
M*C4?NB;PC+5T;TCQ8V]))UU)<21-(F=3U0:R[],IMTN:9WI*C5:,<1<UT^#I
M@57\O%B<6'%U>R8+TS,2P.%O%"B<H93MM]?(U ;IP\H9<NI!<0--8R+IXT+V
M1W@UKRZ3E;&BN9C*SP:#7DYYDH/C2Z/U;%-.&$HE>C6D>3S#A>\2YKDQ7!!9
MI5R.A.44PN!K<)?!=FM,78<8Y[++L=F8;+1RV8[QM&_'9D$-_9CO&RT;[+1"
MR\0 ;K1$ &O=60DD[J4JL5V2^^$R RSCT5:<=0# TRSSJ4&62J6\4"1'D?8J
M*Y'<PH2ZA%'$_(9AYQR@P4"4'H;DUJN'$8-/!19S*=24QSII3UZM'?!M\(@/
MQVB-H]D Y-H#L'9R]F@(&U+?R2G_ .ND1?\ &!AU/(=C\=WZQJ!=2PAQ2J <
MO(](B]P=G\L##[ [-@_B&IY 0\/9N]P>V/@H#]4KQM#P^(?-3:'A\0^:@/-*
M\;0\/B'S4VAX?$/FH#S2O&T/#XA\U-H>'Q#YJ \TKQM#P^(?-3:'A\0^:@/-
M*\;0\/B'S4VAX?$/FH#S2O&T/#XA\U-H>'Q#YJ \TKQM#P^(?-3:'A\0^:@/
M-*\;0\/B'S4VAX?$/FH#S2O&T/#XA\U-H>'Q#YJ \TKQM#P^(?-3:'A\0^:@
M/-*\;0\/B'S4VAX?$/FH#'C=</\ 0D%?^>/_ .AVY6)];8;K?RHD%=G_ $X_
M_<$/^IVYVZQ/KF%LD.O!<_S% \WZ8=F=B'U@[/\ I=S^<]7%*4K1A)<4I2@%
M6MT.^VOA7^L:I_9%QU5*K6Z'?;7PK_6-5_W-%Q[:R_#[7ZR/K?;7EJ2, Q7Z
MUN)/U"N_S?J!VBK>P'Q!^JO-?FT0V!V>P'N#VOBKSM#P^(?-78$X''FE>-H>
M'Q#YJ;0\/B'S4!YI7C:'A\0^:FT/#XA\U >:5XVAX?$/FIM#P^(?-0'FE>-H
M>'Q#YJ;0\/B'S4!2[="/:D2K_P"B_P"WK:KK-7=D?C']==F7="!VZ2)6[/)U
M%^X/P\;7+V.QX:ZS5W9'XQ_77/'9:=<6C?4VG^6J^=6]@KUJ+B_>#5?-RU#Q
M2E*BZ35%*4H!7N+_ ,?A_IL'SV.O37N+_P ?A_IL'SV.O3/=M[IO*A\XOZ)_
M<J=RDG[%+_T&#YG'7]-?RDQV%2_9_B,'N#_W./P5_3M#P^(?-7:QGN&]RWD0
M_G4=NKPKRGFE>-H>'Q#YJ;0\/B'S5Z*'FE>-H>'Q#YJ\[=O;_& A^N@%9);J
M![,A7[VD'YUEUK;626Z@>S(5^]I!^=9= 72T8>U1T^?@H9_T7BJS=5DT8>U1
MT^?@H9_T7BJS= *4I0"E*4!B+KOTVS-*#JU8,]M[GKIDU%).K#3\A0LTM0*@
MZF(R'BQ,X-UQ-PRGZEC$A8E%YJ3"CYQN#!)$8JNGQ*<SBPWX5%,-,Y)=)%)=
M:G7UYZ%M<<?Q;K7T41\TF_-T;;H:S(I;KBU:.236\VCD-+BII,A_1WJ<=LIQ
MXN#>^'HI+37AS!*<6X8WPN?J@=KQ-M1X&F*31Q=*AV.Q$ #:(@ =L1V!VOUT
M&ZT!"T;K0N'L (@ C\0=D?Q4!UWY%T(:I,K8U::!VE$J KZ7M8NK@A.W719)
M7;2;CB"%7\X(M?D\QPY8J/8LDE.66,"Y'3J;,3G6M8I,Q83)!;Z\['<S##/4
M4I6[#]H; $!Y=HW#^*ZX1 .3M .S\6VO.^M 0M&X-\(;0MVAM$.V =D0KS0%
M--44,1P?9J\]#+?R"YU)XQ78:5L"XY"F>[A<EL1%S7XL118PE2N44VX<&/,4
M+X,V"_>FL&3$;LMSA*/6UQ-<(W"0>@B-UPB(R[,&T1&X1$1_Q\[(^Z/NC34M
M_)*?_KI$7_&!AU/(=C\=WZQH"!NMIB7W@].=V8/7RG6TQ+[P>G.[,'KY4]4H
M"!>MIB7W@].=V8/7RG6TQ+[P>G.[,'KY4]4H#*+4)*^F;3K(%L>.2.IH7U&Y
MOI;B ^@S!(-I#@RJ842^$N(*4HDS/",5R;ENR_P/0M[DQ;R^X=\%L&]>=I'[
MD&H'GB>/VN5#>ZD9\F+4]@MLWNP8M9MP[X!'E%5=@>Y<'N6A_P#.SG)PS/\
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MV2_HMEE@V"&]N&[DKKW\,S_S?Y _MUK5N2&>_-)TOA?O?WK!; AO0V<HN8Z
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M$W805%1%.#9C;"\8LZ J(AU.525X9L..X<I,Z7R76!=BONNPY,F.^JG#,_\
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M+XP*CGNQWET\U<)BW#9?C#%?DR66.Y]6[@XEJG,HY>K;UBH''5*Y] .UW;V
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M4K\[^S[JW\H//3?V?=6_E!YZ _5*_._L^ZM_*#STW]GW5OY0>>@,:MU__P!
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MQC'_ +"E*5E1BPI2E *TYW,)EB]9"E0F#L>K3X&R6Z8X4RE[I ;-]%<9O'T
M[GX(<Z.7Q[WHF+'O+=YDNONVCON3,:M;MR,_E/F'^H+8_M.>K"\1-2Z]]'EO
MZ5"4,SP\UTH/TF8YC-H:U<0E_=GGSG('ZDIQ"7]V>?.<@?J2K 4J(9+TK_Q"
M7]V>?.<@?J2G$)?W9Y\YR!^I*L!2@*_\0E_=GGSG('ZDIQ"7]V>?.<@?J2K
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M')T7%;FQCDMMW]NV@5:.[J599CU/%K<=EEEO%8S/WMEMMH<BJ[0#DM  Y
M^( #L %9Q5,:Q]4;?XM@<BD.+WUMK^79&/\ V%*4K*C%A2E* 5J%N7#\9#"D
M65CKX=[99Y,^QVX6(FG,N)J&7.F<#C-Y<Q<IE4C):PSGQ8LEF7)APW7Y+,5P
M9+K0L_?5E[6M>Y'X\>23IAMR8[,@=0#8#9?;;<&SJH.CLV7 (;-H /Q@ ^X%
M87B)G^!=>R_9Y;O=/RF9F>'FNE!^DS',9O+^IL)UR&GWNW11\OVO]9TZY#3[
MW;HH^7[7^LZF#@1/WH6_,8OV*<")^]"WYC%^Q40R7I#_ %R&GWNW11\OVO\
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MM04B1TGVR+!_>C[NRZ\ Y-G(%]P  !R<@ &P/ &WPT!!&I;^24__ %TB+_C
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M#'DMO$ VG0#:(6CLV^[V:HN(%G9+^7I3<7]29] 5;A_>6:?D&;32GZ\MO?\
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MENH'LR%?O:0?G670%TM&'M4=/GX*&?\ 1>*K-U631A[5'3Y^"AG_ $7BJS=
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M94PE,YHI?89+V9,-UMX@<OI7&";U9ZB365!/=+</$6Z9,DE\Z374HR41#A,
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2;J7:HKK.]DQU]ZNCY]#H#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g26402bgi001.gif
<DESCRIPTION>G26402BGI001.GIF
<TEXT>
begin 644 g26402bgi001.gif
M1TE&.#=A, .!!'<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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M :0H#4_H@PHHZ0TJ]-)^0:1!_1!!!0BQP5)BREZ2 ,#_JR"F#H!76D "3#&
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M.(!@-JI6 ^O$3U@4/,V)>02 CGGE!%*F0^UX!_ 8D!$B/5B'>@]Y .YC)<9
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M*::U^.,&$^"^ _ '#:  SHL)C*L8I*JNBK%]7SD4:X5FP(L5!H"H': !(!#
MFG 0^R! Q*":LV@%DPD"T'8# -  (ONQ . .*AL#BVHEF%!"#9 'RSJ75G*S
M#4 ^>5"8O_8'#P  ^S"+/N"R0:"U],"6 X _V*295N #[I >(1C!*G$!5H)L
M.7#%'L =&& EBAK$R]H3#:BR$\ =;>,#( L90597C)%H@' +OY<3:P5;(9P5
M:'H!>( !?S  #E"Z6O_K W3G =?6M#I0/I.IM$C@'PZ0;2;&O;_('0S@B_Y
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M8L  0FL% UT&!.H.)>3(2) #PP@"&J"GLAQM9*V:"I!A68LCCVE-T=#68PD
M$V"U%? #8VK!69L/>9T.!XX$+_ U?P GYZS<&*X;#'#?=: !=> #R#L0!."^
M2# )3U?$[S6+B%F8(DO/ *  5XS/W6N@10P .*!M=."S5_UK_D"<*29 ;N"S
M&%##*OO:]8Q F&#+=$R,%@T H[W3-0R5$BC$UKO PEW#Y$,/T3"F3IWA7MX;
M!8 %:X !QX8)>FH0%V#6?7<WNSB+=-  K_C*2EV^WPVU5%!"05NU+YS$0?#"
MY/T#^Y #?@?4A6E-8RT0<?\]LODP ?1;=FW]U@# 5U9RQ1('QG=]Y08..2J+
MBRO]Y9Z.&PP0#6Y 8O&+ E^CFN*= Q<PER"0=G$\$ W !:NNFA/ 9W5Y 5S0
M=C!K!>M+YAB0@0SPI!*<8AV 33: IAC OT7JM?\YZP P [@N!G_9 %CP!V..
M P*Q#QT0 ^']LA?@ 2Y+ZQ37 :#B 1.   S@#AAP#Y%KUA3G[)\>[[>1M8:<
M!R7\!P\\ 1APP!V@$=PK@4TL[P(_\ C1 ,X- IB !11X( =\!<C=$/FLJ 0_
M\13_LB=C@3($ E?P!0WPNQBAR67P@14_\O*N*<S[!6)P#W[9$<Z@Q@]/\C ?
M\PO_L0\*< ]W*?,XG_,ZO_,\W_,^__- '_1"/_1$7_1&?_1(G_1*O_1,W_1.
M__10'_52/_5;,0)2$ 4#$P%>'0,#(UD9("<)@Q(B\ (8)Q%!T,=4G_:' 5KW
M^CJ \ <@G#DY3@<RT' GX:NI<$84L05N4/9J__>&X02NT \K:@=I1WLUEPI9
MUPF!  <\XPYP* $.,"W*)P9+^05_0C(A@(D24 $XH !9D@ MH'@&T/F#J+D%
M<@][L ,)T .6'S4,H  DL$D]@(F9\@$*D"T?MP:-L #*DOM?TP(# _C$SQ</
M8 9Q @.P8@=3"L)L@&22FZ^_^09&X". 4 ?1\".J[P-K_P +/_ $:Y '-1"J
M450#Q( &TZ\&B:)S<S)F!7I?G70][B9QYM])D\ )-$ Y=I(ZO&)C?PA! /$&
MSHE <  <1)A0X4*&#1T^A!A1XD2*%2U>Q)A1XT:.'3U^!!E2Y$B2)4V>1)E2
MI401P.Y(464$@!,?(%05.7A&59.#!$0\82+!2[5! M,\,<9AD+DF:&H0>Q)#
MP1 [@(0Y^1/ESQ0)?!8=V6FFAHHSBM0XR1,EE04I@>R]N61'PX4_L-)<4&-*
M43%@3/8!V&*N2! O2H!88@6&P8*5C1T_AAQ9\F3*E2U?QIQ9L^,#;!"IVK.&
MB8$S@,K4P F 34$ #UHX<-,HG?^E/F"+B$!!"8&I-3J>W.*PH8P/)4<X%4F2
M2H<;([/[H.EC0]S808IH;-DC8X\F%&ZBO5%C1U4'YND,=%6% L05QEO6"(/P
MA%(Z4WUH ""P6?]^_OW]_P<P0 $')%"B X[H#8,]:J#!CC7^N.F@$U)A18L,
MYGJB"BV\,"8216Z+@XETBEIF@@ML"&&".-ZP!Q XQG## S>F^,$KL%002X5!
M=HH$$P]<NL>##<P11JX+9NQADPUK<*<#(PJ8:0TX)(A#PSA8<:8"Q@KDLDLO
MOP0S3#'')!.CKJI@;!!/FK"#BC]0.^B 2,IP Q,E;)#BCS\T,,)#&B3(K8 (
M4M&.B1__N/#.DPV0T.0/&8A!PPT(FSBB#RV<*F)"3?90Q8(<]*S!#/#L*,B4
M/_:PSPXZ/1D"RBT0N8.,#,KXPPU8)KRD3%UWY;577W\%-MB$#FB!A(."<( ,
M$<1H88@M 4B@A1S<(0. ('KX8HA]1&AUG2XX..B#',1 8 0&-KA"A:K<N8*$
M A)(\<DT*MCG!WH!B.""(1KX,X0KA)! C 6":( ,"1RX0(AW>YC V3@+(3<!
MAK4=(5EA+\8X8XTWYKCCB0ZXJ(#\>AKY(2CCW.< .Q0!1Z&2&7H9 ) 9&N'D
M@T90Z(!T$,+98Y]_!CIHH8<>^@3VB$8Z::679KIIIY^&.FJI_Z>FNFJKK\8Z
M:ZVW_N\  W[0 @$#-O(Z9H8.>  !C P8>^V(@F" @[8A0OO9B8+0@@,&#'B@
MVH0>B/LOK@<GO'##-1N!#10T@*$)P3$:X0>%(QI$$)L_+J01NR=*P&&'1$"C
MUBG\?FB$# RB:!TTUG!#AR@B8>7D$238H-8H[CL\=]UWY]VC Y) P8@@I(AB
M <#).& $P/=FP :^&6! [1'4_CJ'*?;YFHRQEW<F>@ &82+Z M .''"QS67@
MY'6^:(3MY@V8 4JVS44 2O0+<.(6(5J+7GGO1QC#+6R0A!CPQ'SC>\ /.*"V
M T"/#)'3'O_4)D&$)$ *E- "#MS A?]JG"P!:* $ WX0ATM<KG<G1&$*>W>
M$C !2@D00A"^T($.J.$!&_# "RZ !0P8(0,QF, 5:! !6!1@"R9 @1)4D($.
MY, (!LB #F)P@1S$@"Q]Z, %2)" &>8 %F.HPXEZD -]0>D A;C"#YJ(@65\
M004):$ %0D##YK0@BT.0@B9@(8$<9+$!5=26:F2@ @-T 0%<S&(3@K !%/P!
M#OO8P@4<,(0Q=F ($C#!!;3X@#ENPE@ &$$(=B S8#RA@Q**@1H.D@95JM"5
MKX1EUI)GBE\@I#-*T,(7E,2%*42B!D,H@3$VH 1BF& (;%@$ #I1"@Q,80SZ
M8L,WG&$&8<;_8 @A:,(@+)6#1OS@"T+(@*+Z((0/6+('M[C/"#*7A#K @@V>
M\"($;N".*%1@#-\ @QFFT ,'M&!-D:C"N5 @ POX30*1LN8^G(!+7?X  U%
M YJ., 4I+",'R^@!)2(1A5Q2@H#7%,9!/CC%''@"#:><2114$$N6MM2E3Z//
M+TYV(%@   (F(,8%KG('&CC!&%+XQ0&D< 5D[B,"I< "+&:EIS<T00H[."@(
MHD"&,TCCC+II 192H0A=U#()>SC5>V26 8]6@0PG\$0 $7:$,FP*/)%P0PR,
ML(4J.,,2<" 6,&302OQ(# LP&((9\N"&!1'C!DT0 0PX  PU2&&*_RI0GBE4
M\8<R>.)24O5; C:@"0]@80B16,3).J'2EY;6M*?MF)RJ "4(=. )HSS!"QJ
MA:L8HZ>LP (<UE$"2B"S,[>8P#*B> 4'5( !4C!($$+ !29$(JA?N$(2V)B!
M3.0@J(J[@A@LILY&1, "-#A!)C84@RM(00?:U9+$<A"%$%0!"'$01F=2T8J5
MRBP2(?W@%4RA!#'$\0<Z78<X;G '!$A!"3<HP@%^8 EC** !Q-B'<IDK4O:)
M#0!VB!TJ6\D&%Z+6PQ\&<9BV4(HF/* $59!"%1#0B5MH80)7845/C6$&)CS
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MOHK:P!5<R:A5@VC52Z@<$=B *>'--F"#@'H!DN2!>T16)< )"  &(PB!E9(
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M=WTVVO#JZ&:S"K&WH7/*[!.!(=D=$,LV5K'0Q1F2))2V90=L8<@^"A%P=Y.
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M#$*G2$0A4#$S2:PG,TL*4#@A5HZFL, UG2RE18 GU=&%E*=6C=<(8,I4(9T
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M?X 8;^7A<#10=_F'_FP;QYW)IZ(&%)1&(4+!<*!?QVT;JG*%:'PJQXT&JP)
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MP:^=Y)!XXQ17/&TSC45."#"0G:O\-I5.OABIE3V2E;A27SI%9)I-FA3J<PK
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M58KP2Z[G]-SN<)J056:%,$B+[C#E/>+'VWSCB4;F+#^Q^[:%4TPBB[Z%(@Y
M6=B-*!Y+E^*-6B2*A_:J$!0),B)O%L>%/5 P))QKKSZLVUI0,9WS.:])]!B(
M&!NND'#03)R2!Q.FO#P$D(A ' +QT-C)"!7-W-C$-1R-]YS*?1Z')+OI"H/$
MH\B1T;C0H"ILBXID+Z?$'84& 'Z.)8;*'M\*%OG!+2$L33)L*#@SKW!Q&EU
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M_T\0^OH3K8).#;$/KNYS=::F\JR&07]3-ZZ'()\V<14W0((@ 8 B"$;  "0
M<B4@#2#W<M/  !($<A/D<3$#<BU7;T*# "X7,R87,S C#4;@*A($,TCW=(-
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M 0K_ W)@"&"^UAF  18 T7O@ H0@[UT\"-#@[]>\[SU_G./^"A0_U>6; 38
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M0(*XEO=&(>8@/56F!.LG/01:$T'  !7P-NAB6_XH$+=C#EY(77G&8HLPAV^
MK,0:"3X@#;XC80)A"6]@FN2B!?=Z!#XP!9&0?D#Q $&@!17P:3ZP QK(%H2&
M'VC0FC1:7JK0 )XU+Q50 =$%!^U9#<00L"TP,4U@@WRQIM0 !G$0"$,C+M&C
M0</H.'/@51=!K2J0GHLP$$&"') 1>'3U.E4P+CAXK^<!HD "4VP!$[ P"%3
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M\Q8'[085MN6D2,&DE(8&BO L0>JZ\6L,7RRX0XQD &0B4U$\!C#_ N[3!H/
M:43LQX!,!M1&#$]@#+#YR/#;<+ X;<# ":_L#:HW"'2 RP=19?1@Q@D!GM$C
M#OB1!HCP"Z&%&'C5)*!,+6UL X&7R=?C'??F/PHGIU0 H@C1O_VC+ON#"37
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M$" E *:U936(XIZFOV4C$/]5+KCGB36D92,/5:+H(1 EG#'#',_4;NU+W71
M 9$![C#X597HN868$NBHX8(-QJXL)"E< 03H.!9"X(.F%8":E9Q $N&FVMA8
MHPV*:W@Z%=@,.($X&G:J^YY4C%6AOQ',\$&&"4@>-PW<!1IDC2%9E2 5)#0
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M.Q3DP WLP!.LP-L3O/M30.]#,/";/4!* L!P)@UH$?WK0?)3/*V30;W[08\
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MHH59?&78EC76<17;B%U8C[78?+57H;7:DKW5<?W5@?U:D&56@[76>=56;J@
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M8SFNX2INXCV^XC=FXRC_?N$C[N$>]N,R;N$^AF,>;N0T5F05SF,A)N0XGN1
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MI=[I!F  ;F: '(B!%R"X!JAJJ[YJK,YJK!:#K>[JJ^;JK][J"J"T!A@"LFX
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MQDZT,:(I0 >8F(05!H $?UC!'TC(!Q+BZ$9_#""/=83C'?4(QS>V<8]S1,(
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M!))'N)1MQ!VN(2J%#]4H6BK-IP?I $DQ,0%E C=Y7P0"=1TBR2]^$;B2M,%
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MY:QWNXT0-B"""K!H56"-.Z<;7NJTR&*7"<$B^%XA$'_\>LC9V*6%R>KV!QQ
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MQK=A! /<WZ^-XC49 !NLP0XXG0P(@='1@0^0U@-$0@T,05:(A 1\5JMMP1_
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M $=*:H %$ ,F5N)2S8%>6@ )XP$&ENIG-D$&(*7; <4/[$'_/^R #8S!$\@
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M(QI5&L!.B"-\@,44>I89= HI)IFB]3;"Q0,0"X"K H<G/-.BA2&\!+,F!G)
M(0HT-)FM5CX$4;3='SKLX0DE.,B)#U:8U6"*ZP%]>L(:)MZ9(6-+&]P #I#_
M\.$/$$#0Q/WX08C&C?CAE]_]^^N/GW[\W^^_?^ZCW_W\]S[Y88(S=7H5?B9
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M  -&@!AV/==OG=G1F=B[$TGR=X '=\4E" -Z=T!%Y+4RNW'9Y  BP!ND1DT
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MM:O\;E&Q>_K+.TG+,ZO,D*E ZTT9_PK,>LQF)7^3H808^]SO2I!L?@"%0K2
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MNO)DL_1DU.9A## 1XA1!,',3&* #($"%&" S.\,!(]  #N  \50'=0 "$]
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M:# )Q%6N#  &ED %G+B_/_##,U1%CO<!<4!Y2+ &TQ<) UP&E#?!;. -= ?
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MN3$:" %!1J(!/G F/D '<\>\2AL#/I DF@  !% [H'$@9;L04N&6 R!P#LL
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M#FIL!G2@VPC<>INLG,O@&%24VLGY!AC*V[<YH:9 !WU ?&V-!), "/R+ $G
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MG?@,J'&1FPX2,.&,3&$ "7C@580>J"<M],E0 WB( @"PCS@!H%!WZM4 , &
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M LHITGFJ?+4I:]59:Q7.J=U9^8/$H]723L'4__#+0 Q5/+@L.8FM <@#8L&
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MM3DY"0(%< ,_@2#"M9.!'F@_0>B$5NB%OA,,Z$0?6F(W@ ]6^1R8NU[_&P]
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M%@2((>H$$^1P00?N.%:X#9 U4/CA&(CFFA4^3( "$IAT<('A$\3@ QYU3("
M<KFMAAA6+S%P!3')NOXZL@A@0.7;3*N$ P8^_'&<#6 ]8%V):T(*K'5!.E/\
M0<@?/]"@P =;DA8*H# ;,6J;2"6?/>TU)J$J/RAI@/92ZM%.55)IV(4=PZR5
M@@RJ3-V>3',_]X]S"12I1*@[O/2@/ALVE* ^%+#G$:HL2W.(D ;2I F=;WO
MXEY2<-0GBP20@$2!6%%>@A, <2^!\]K9DI9&(D:1*( 3 4E9<*8AVU%H?3<#
M40&M_Q:W-&$L2RU 11<\DH05R($0B:C1#WCHPZ$@P Z&.!^5/'@O"@IL))2Z
M4[VR1)+Y.:TZ=QEAB1[%)!MDCG1\HT(' / %*GR! *%" CWP0(4_:&%O!C#
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MQ"&&MA>I'I"!JAP@F7IK(AO1EI;G4]A@!^A$!'!1 [52) )\,( !Y,H *!C
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M$>S@@RF@@0HU$((=U@"+FB#3&5!@P!C_SFM1!$# %,JP2 OL0(1S%"2(B<@
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M8$ =7( 13!-1_RA $\Q)321!$T*?)ZB!!(0 )51;C62 !6!;MRG%#WP!"J!
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M6*&K?B"'%F"C3(U  93K3L*;O+Z #8S !.0'")#E;QA 'EQ 7N@$-?W "^@
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M80A&1HP!"%CO!32!D)H"+)!F$\R &2P#,*B".RPE%TBF!0R$92Y#"%A ',C
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M-?-D9.MY*S@ %TS!&,CS-+\B&\RRH[K!MES 3N?S#D@ &G3FZBZ#F^*A#-P
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M2/2DB-S@U@P \,"DC/:LSZ@ M5ISF*Y@46:R.Y'P]JC#DAPM4 8)$S!AZ'[
M/#$A#R[ 4[Y /3'A"BP-!-03!"K-DM03!0#@E."331A@E,SS#SRE >#S"_8!
M +! /3%)3YHH!G3)Y,1#("Y@"#[@'E[@"FP@!"9@0H.@!UY -'( 8=) #-
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ML#MG<E(<KH 8 !.P  4#2P<.-/_QU&@"1@  5D6P%H4!\D"-0,!3?A-4:K
MO 0) @D!4 !4UNA50.5A<0U6J@0+>A/7RN!X'G!"T* *<J #L$ &+@ %!M48
M5O8>,& "GL 'H@ +HB $;B '9" .C.$+@*(J/< =4& (O* &L& 3W"$F4F$'
MD,E80J(,[N +]J CE& #8@!KAN (E"<*A" ]C.%DHF!EP]8.[D *O"<'8H +
M<N,"O( 5B&%[T'1;3*$/L. %U. !2J &T* &[@$%W.$)E*!$L2 0HH +8B F
M8L (K.,(RK8#-D &;@ %8,$,9(!MPY8V[J$4OB=Q+\ ,^B!PQ2 '/.!FE< 4
MC*$%T"#_)"X@)NX6"Q[F E"4NGA1NGP/%040KS93Y\Y']DKSX" 3>,=/R+3/
MR/BK_:KO9&/JX)YK&+7OY+)3.IC/62F0QG@,?4*(0TPD*5/( D5(^G;2_.RQ
M)4ERYUP/>G=,W.BJK""P]<8/A&1S#[T1XPSPMTS.Q_+QNZQ ROK$#0'XM>0U
MC@:X3R[@S]9H^#@09TP27V=24#J$/!#%!_Q13]+AEWC(?'#F0 $ FF;)DSKJ
M.WS$DK L#]P@75DS7>N5AV#DU@B@IU9$)2D+ EOI![P 63H  SQ " :A%4RA
M:KB@#D9B$*3&'6S (3+B"3+7<DVBLX !%GZX!V B4<U@!TI"_PM:X!YN=AG
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MDL=X7KS &+[B"V+ ';R@#"Q@ R[@'CS@'G0@&J+@'@K"&7!T<,VB*%RT:)_
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M"2GI7XZH0;69A(?-=E9IKZ7%9ENIE>059G7"-=-:8)$:5:DVWN225E)&!N-
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MBK_T:K^:F(OY"P!-PP!F_Y"_M>B=O:&+>8 )96#;,H"[6[ 'DLL /X#!;?
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M@ -L L$Y8$:1"@  V&A@Z+ (  )V*!Z(%$A5G0M>,,$Y4D-%@8@1.P5J@_+
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MB<05! $X PD$7W)E(*YR1?%HI)-6>FFFFW9Z:0,4J.#II!'@XL)UT- $$>^
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MCE*<2L@>E""J- UB3;1+DT8NP9E **$!<9B$*N!P@B=P8@@X\$(I21*Q(F7
M3_-ID>, $#ICV'$/?!L.#>U8!B4@( -YD($NAU0PW@ @4ZJ8PD%2 H$GJ.("
M#G@"G [0B5+9+E40\$8;"E8#$L@M>0F(PY "LP91HJ$,_;&#&U1G)>[\:GM]
MO"42?" #%03*"B-!E15\@(D\X($3:AC!$:@PD+>1)E_]R=9>N.4MA!#K%^NH
MCRI04 8\S.8$7O#!&\JPACQ@+@$5U<$>,DHO1" A#P#%0YML0P7_4PJ,(99
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M@1>(@NWNW02N3O.F! W,Q096S\J<3I2D8MDU@"1 A-219FD50=(.QA[  ",
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M!F@!Y<9ZCC0#-^IP:!?4L\]D%55(,P7/*ZA961[#^[5+67I[18$ O\BT+^B
M*R!V!F#K"Q #!Q@""=@$%?#+'L@!#Q!N*=B#/C#U#\""%Q"#MW:&%E  Q5;O
M-WP '-B #KB )I" F2&N+1G$'F@ &P@"'&B K_Z!$-@$X99]Y$> #V@ Z:\
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M)#4TD08*:\#BC"FJ6/"$#$(D,6L3IVH2E45II+*L%(%H4L8D:S"AA1>:P(+
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MI?*8QSTRQ0!VRN.ESN*."D0JD8I<)",!,"D !4IK<T.$$B:@ "RDX@UWT\"
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MQ2/DNE]SD0 ^76QA:^.UC%W:) EN>-H']B Q=D;UL[! ;,;&H($IV( -&:E
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M%.S$22P%&[@!=A6&KD@, H#!'-S:^+%!RAP)\X4@F$2"(D3%$=1 X)%!$&1
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M"$'Y6$##^>E7Q!Q+M886@%L?  $#) 6#%0-D:9 !W.,0[)Y\JO]@"V&"#+S
M?N8(XM 2(,3 ?GZ%%(@;2FA!I1J *6U0*DR!L07!'+ "V!E!V)Q:V6$D"E"I
M180??HS.S_#$?%2!L2EH'X3 8B& 1V8, S9?')R+ :R<,_R( KS63E -M6B:
MMR%)DWD"V'47 R"?V6! #G16<:E/M9J"(BA0F!68?#86\F#.J&!74MA!BR'
M&$C.^ 3H!GA"1=@!TL3,*7D!LL2  7$K2T4 [S7-@))K!2*G!&A:D*)G!WC
M!1##'3U ;N5 OTJJR#GD,J2!-P@"?F36$- '"3 %@#@ %^P!JP!+OR) ^3!!
MS&B #'1 C-D J[; 'K@!J7: ._S(S W_DR4 3I@U ?^]E6SLWA0 4!7%P:8M
M$1'2A](ZU:#8@>$$C:8Y:UPD+-.&G5\H ;3]0B^A05[1@0SXZ018$!ML&I;
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M2< 9T P2M+B92QS2W_*S(NW94?A10KC%,UE$$-@!'53!ZT4!,7B2Q !0%#A
M2"W"+Y_7UR1&'^! *B39;2T#,7B0RGCA'4U6$^3H>-F5DIV$33 1%53!6 S
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MNZ$<W/0O]DZ!("Z+[S;;&Z@!"(84E>*'"UE,XV@'':3>5<\-\;("%88,7F;
MJYD(4CT!'KS,3NB*#UC.<AW4/5433,(=S0B5(JA!4BQBZI5;[;C"'3R'Y%R,
M!9!!CO(,/2C!$/B2/=4.(CBI,Q%P4%2+/;UY_ Q2/()1&6@"**6F=B@ZV+B0
MK,@ BQ36)4N63 [! YA! 'T?;\JG$-+-I&L )0CK3C3\'SB6*FK"D_Y&QU!?
M?,XG"ER/X 6M0IS:+Y?X$GX\_)1,[!1.QJ3%I&/_0JEX$HLL7LD$@OHXJPI
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M4TB-59Q"Q)=U]D=8SFGQ@ZK2;!2EZ]@;2C*XS=*44,D;5 -@0GT@W)<Y6PA
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M40>!'MHZ%:H ;+< !2Y@ SY:"_8 $);AFJN M>DA"L2H#W)@#V0 "_9 %52
M6IF G@DY$M;9"P:[O=_  DP!"?K@'O9@MX/UO,U;"[S H9=<%;Q@$FI@R&O
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M@ IN(1HXP0BN6@D>X06N8 Q2@=4GX0VB8 BD( ;<P1).G0TRU0(\G<SC@!+
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MTYX).+$)X, @.K\ G$AUAXS!+9.D 8B02DFD2:K<_)%1$( =Q<(UP8D4: >
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M:8# [O!!$0CX50R8 H<M($(5.KF#%H!ACBI$PF_!HP,G2/0:&<1! VWPBV[
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M<<@?'G?+V][Z]K? S8RR-)! "^$5%K2:F[R\L1<#*,N;;/S(<_'*-<;@:AW
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M( --\(&6 3@B2(*8,0(<('^5(0)H4 8:D& NEP$R0&:AT0EE (-_$ 5*(0'
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M#U3 "0D$,ZY #UV(&8, "!9 +_I3%C&Y'3SFEMN1$=]6!-7C"OO("E;8@E[
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M>T-S\ 8-(0Q@<5.LVT^+8K]20 ]10"^F" '$@ !A$PD+XS9]P/\!I'A+1?
M<R QR](&#LI13]('%]4/_4 -$W.H7@:G,:&$9!,5V\4X@Y P1P @C$HK0I@*
M6QPJ/@5>,> D_&1-AW<"K7)[:> DSZL"A<<>4&5#F=FXD\(& AR)_M1AP!%]
M$"$-A#$;G' /=/!3]/!B($L"@/,D,F@'3=BPE(L'NS 94[$&.O $%U%92F"7
MG. N-= 3>8L&>& ,:  @4 D&P(!75*4!'@!)O<MG,F!+-> .P* $0]7 &T '
MX,$&.\@44X ;-TL']+!)-$NJMPQ0]& !7M B'&4,CHH77K1)*F('5! %6% *
M%X!F], *0Y=7;$2_GA"0ZU S2  (2M#_!*:+"<UB#JE+!6YF2ZP@7]LA$_J4
M"JIP 8P4JOS\!).BEQ:0 QKHH&Q !5NR 4A$ Q !DD[0(>Y7>*H0F,8Q+K8T
M3(C0![8DJW/C WW0 /C2!X_ !36@%:HP+5&RQGFQ%UDRNM*Z+)J@$S1R6+_,
M"3S /C(@298F&8,@.!76(NXC.'+8$ [P21?04#SU!&] 55^K!:E0!9V@4[E4
M/II05&NP#); 9[MD5#< 23E 9"<(,R#; ;NK"$T0%(#Q%T90NZQ T]% !]DT
M"?PQ&=*\A\P,,+>D"<L@!=OA)L7\!.Q8JTW00,Z$@5'@!3%2&#Q)80CS%5/Q
M)*IP!3IC)7#0_PG?@2]3$ 0Y7$:3L 9T<$&UTLTNR;-(D!_)-8K?E ,G3167
M$#8P)Q_MY:B!@MJ;BE;;=+RSXA?TX $?-0560P^8P 1,7 5405+2U:K7LS )
M "D_  1O4P2R>#EHQE8&L8X6L#O+\)!OH!"%H05@4*DL]P-Q8 YD=@)\8#=K
MS 1Z*0R*TV3>0MY, 0L!HPHWX$TRH,H,HV?#W4#OVAU7$0/1X+8FU, YP,P+
ML"P)E4B/8$B_/!,60L0?]9@ FQ$_E ';-N#AY05TT :=(%(Y "8+X$EL(LHP
M,PFM<)KM(P$!-5#%@@32L!$UT"22@R02<3^7! YA(0A^\8EHX ,[ /^ZRU!B
M>S#68D "(8'+);L RN, %M$&+C%I>H*YU,14D;0X= 4FZR 233 'B@ $7N H
M^&)*=" #%]  9! 2<,HT#(*\$4#AF?@$9=# "L!(CV &"W/? ,K%?% #1-&/
M9;$(I*4 #N 3#4#HOX!J,3 !#6!O&$F5T^:^]N8$7O'1EO 3!M&2SA#?]N #
M%M DPPW72'"9RV  .>0 6Z$"15$,2.%DJK73(0 7:[$G_F$.-X 'HR(IL&#A
M%S#EE-%YXQ(K:Z"W.H(1HHO1L1$]Z[,'B[ /84$-E"8#,DL%RY#HQ)!#G+0%
M%[$;>V ,#9 N90"7&BHX=,!G0P  9T /SF'_/<[P 0W06;\[8DC"OH)]9^TQ
M4IX$'@9@"OW(/F/M#D+03,[A!)/@Z.7A!M' "2)-K7QV'6M0&Z3U@GG07&YR
M,+5,# B- GCP6@"@R)%D5&H .,5[>X!F8+W-%IC30>HC!1JP90F9 %)0!I[
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M;_"DFU")-B.+$'BG#5&!4T*(.'"]"4$F(W "K".T$!3!$92:'Z@ &YBE WB
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MVZ:4Z1"H)K #XZJ<L_&4*/^X!PE1@_^K+?&&\1AG;#,9XE.!#K^K@;F!)"J
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M^:\#&/,+=+1).)4/-)35Z -G4"[M::95F[IT.( QR!(\  2</O:$5_AYCFP
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M5QYV&"-A'5;8X5('3$B;C2<>->)2'3HH& (T1I4.CUT=,(.269F(8X\&1(A
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M#F[X!":T*%#_#]B   EX!QN<;H.KN]47.E. 04C#1"Q,G04GU*$?E( 5-F
M#EX0!=UU,4U!@-P([, *!(R@31YB7 C0D9(3P, (/]A %8B8J.3M@T/N^P .
M8C"$ANF/?0=(1P:8(,4X* Q"W;L2"FV4! N0 8LB ,H04J*\#CFC<<@[D1.4
M((0Q>$(*40C!)IK@A%L0HP1,^ $:9/ YI(#I0JD[010NT 0#.*$&&'C9]!*
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MT-*;>A6L*EC'%3+@T\]BP0U3:$%R.4J,VIKX ".0 GT/0#YG;'2Y!F!I!Z*
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M?!3,Q< &<()N44+O@0#_*RQ #-H#') 8V=V"&?2! G!!%82 $DA6!=S#)OS
M(C)3_0V0;22 %Y@*5!"5&'C+ IS +6A!' S!$V@"")0!+/"@R81>_P! K!Q
M(5!"!@S? 0!#-+1"#JB!")C *6H "/R!)^# !4P+K;3! 7Q!(SQ #WS!$RB"
M%&C"!0C!\+3"&\'!.FP",9B"*MPC[1'0(A1 )"@!%AR4YTP. +1 %K B"K;"
M#\3C 9@!#\C8#WQ!;"PB HA *C0!NZR#)"R#.+1+&J2"#+A#%8##"=S3&-#7
M1#B!&\0 E9FD&6"@ 40"$SS ! Q!)&""#D1#(!3!1*SC JP#,'0 $[Q; PK0
M_["A@ 9H@!+LBT:MF-]P @A$@R(8UBYR0=+90!PL7@9<P1A4P0)L@2=<0+M
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M%@Q\#0!!!B#"G$M!(/S!U&B!MYMG)P0"&R6 &6"4*3S[MHC %8B1).% *OA
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M>YB !RQ92-T60  1$*,\+IQ=5$9P."$$3@6PTUG_?"2 ABJ0X0%U:PUY!'B
M$O2A 6A0 AD:: "TJ:T .E3 &%36GMG1X&R+VP?;QI )ZP2! >DX0 72 8&]
M00 %V7D T)B2.C$XPPQW"%37/&&$2%1!;8G#(5=^T((]MN!T(T@"[<@7@B9
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ML ,1; (-BV URZ.W\0(D(14R@ ,;+*"]4H C#6U6PQ9D  0SL L )X#Y$=H
M #8 I6M1$ (;/%&$"(BT"8.T009*H0-8%( -%Q>!.UK'A2$PX-<[[[EU3K!Y
MQ-_@ LM@DRE^X2>?5^%@!^@!XTQ@!">P8A]1OP$L,O"O=: !#E*\0A*^02BP
MB_T%.6B%SEL>E0/,WH52B$('BB""4A0A@N;>A 6:P'0MX !9L^?]T?Y5*",H
M[P5 W_\"QTTQ:Q-0PBXTV$(@," ,$<2>)0 < @YB9P>Z0J'M4,^"5,?O"U#
M'MP@/5+D $*@#3KA F@@ 8"!.48 !U3@ TI!!2*@%<Q- 3U@"-(@$+A@$2:N
MXBR@ &8O*!*@ C@@ KX!'")NXC[+_13!.D1@ H:@!& !]?H)!92@"08A"C@
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MF& !WL\>BB !+"8R,L N"V IN\85Z($M->$2(& W8> /QDQ'%B2B$M .2O,
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M#V!N800$IM!@LX;2! ZO%4RA'A*B6U1 !#+A*"#@!A#,&(2QZ1K_4A&,0 2
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M"WY! BAS8AB1KC( <>'U"VB@!'Z!(.P@"NHS"VQ@ RA!(F[M#UH5#9I@!-
MJ5B!%+]FHFHI#J0!QLQ  QX!&#1!#:1@!PK4"%:A%<R %BO@'C0F9:Q# B9
MJAS5"6J "Z+Q!89 BC2!$O.7#%,!$WZ61H[MUE+O(C>0"8M!!:KUH-JJ:UI5
M7T[I"19!9(]18T"6?AR@!S1/,T. XWQ5(4J =!OA!S+L!2A!"FZ!39Q $U"M
M$<[' SH <J4"#:)@OE3N"&(  Z) ADD2#63@'DKA]ZK#"73@ F+ YK#_-1/&
M8)%?H FVMP>L%05NP1ER8#INP0P$X=@:($%F"@;N 06JX")C0,M@K"(2P 3*
M+AW\&) )Q0Y4X0;NZ@*$@7P/= K @+!" ,H"@>\ 0 0P8 K8( 8ZX 5(9@LR
M# ,VH9>OX)<MN0,Z  :P%-::.0JDH HV()6GH!-DX 8ZH!%48Q!NX1ZXP+_R
M!8Z1>1.V>"MC+ HVP!.&0&@/H!-NX0>ZRCK\Q%J/:@N>%H#DK_BVB]BB:B#T
M;R*D8 KNP0,&K CL $H-% ,L0 H6N6I?#R2VH Q:] :.ZBJ.0 D:[(\I@:S@
M( ,,.DZ98!^VH!3N(94#200BV*U2N0T0P XX_R&9+P +/( +;F%QE2#?3!D<
MS("Z4"0?;Z$8-CD'E$ B($"/Y_GNZ%D*E* !-OD%.CD^OP =3H":XX#( . '
M,$##Z"L2VN!H-L$#/, +8A G@"$[G* .#O0*<B DQ]J9CX(-8, =!NP>DL:R
MW  6]+$0TIJ3CV)$$8SC[$"DM_86A/>B-P$+E$ E8W1G@6 #>KJM80VJ/>$#
MNR:3-X"OVMI/2/F1%P"E[_A5H+,0TI@+,EL7OJ8#LA1S!D$5&'D">#H'?KIH
M+.NNSLH (!@DG& -A"$ZHL"[ $<#AJ!"J[G:.H +9DN*/*$)+*$/$. E6EGV
M%J$3D/D%)D!C<-2R</_9">Y &(U!C^?+/)P@F G""4  U:(@!!89!HP@9E>!
MV&QJK'. 1XDM"HK!!"[.(!#O$:S8I2^Z$3Z@.K;@HBGA ^XJ!SPA! *IC*E&
M!48@"#@ 6 @+ 1J'#"1"!.0U/+'N%R4X)Q2@ 4AJF+^ !A] !0H >'[@"]PA
ME"7 Q5VO5Q @ 53  -[(&7J !A-'!92I \3 FR3 L,R1.0Z@$ BF0&=<" R@
M%?%J0_BIY9A#>6A0@G7X O9("PHG#;#@"G)<"[#H@0!Z*P%@'=Q%9": E0;B
M W+@"E3@ :)G!H@! 9X,KWZ 7#Y@ L3\!R;00,6R!>(\1!(@!&@0!;5@EM[_
MAP87H,4OXSH? 6]@ISV$8 0HKI,,J@(, 'B.PISXJ0)^0 T*]!=-0@1BAT14
M0(:^@+YJ_,(9P'<?(#_%8 9Z8!HGHFY^&6;#Y O$0&UDO6[,[0+&Y $2Y &Z
MP1D0'6_">W($'0 XB 8YW$ 31 2^P'1:0 400 3,@V-2QP9R8LJ;(@DF8'!R
M7)*"P %LX <VX(8E@#G8:(4NP!VZO5(FX!%>80%J7%+67<8)YBI6L2E^'&\^
MH $0 ,ZOP-!_W(%PJ4,J90CVG0&T@-T'<R]L0'NP!$+NJ!PE@M!+$P+$0 O"
M20W,@@,>8)GF>;?\HL\;P %P -[;Z<C=X7='0 )"_Q[*WR@X,H#81:+&@269
MT@"A&D'DIP>+H%P"W('K.!S):WY>#,?/:>#"#R;-\WTB))-OAN6.B/U[QOE"
M)( 8.HXY /U^1(#D,X &&8 #/.>!KB)Z$N"A1* )^EP!'" JSIP@GH6PR&#8
MAT O7(\&V;SEG<% ^]Y=M,,!L-%^.-WC<]P&[(?QL6D"6IZAFN >HV0$LH0I
M1L CWF+S4\)$,#\E//\J#((C;N( <"!"GN(F1M\S> ,ZR^(M)$#G#L0K#@!.
M6A\Z."(=(., O(( LF0U4J) 1H -?M$C@!]2FB+W"^)>Q& #/&PW(J-98F<D
MO&($9H7Y"0(PML2&3"*B ?^@)B+#\KNS*E;'*N D)C B_(D?4Y@_]*=_./9A
M6@ C)M0_)6Q8#$#V0H1_)+C3;  "@,"!! ^,((AP( &%"0D>%+AP8<(#!0A*
ME @ 8T.$&O=M_ C@@$< $HXP23BBHL"'!0TP? G2H<J"(Q>.C(DSI\Z=/'OZ
M_ FTYP$"&H,2W )G)X0K*HPZ?9HS08\A"Z!N'(%CPQ4212>.N&GUH\B-2,.:
M/8LVK5J=!UI,8+HVKMRY P^DN5*$KMZ]?/OZ/6MP9^"_?%G&-3"3L-"NBAL[
M=GS 8.+'E/U&KHPYL^;-G#M[_@PZM.C1I$N;/HTZM>K5K-,^0 #@M8&1(V#'
M/##_PR5-P;-SUEZ)8'+.( S /AVZT>-OD"-^<&!@^V."!1H9@WQ0/#8#E:^-
M3S2@.^B((,$!')R.TT 0#N'_CH!.T #\D.3;MYY[@#S. _9[NI1 QD8 (C1@
M0R($V- # 29007D(?370" 8X$YU5_R'HVW;O<2!<3R.\AI"""/%GU@@4(M2?
M7P0D@&%,!!C HG<?72B:$[\D((4%%Z@AD!V"X+2."4;,M.%.#]S31(<(;7%+
M55M8T&).(J!10UY6-2>$<"-H84,$3%0X(AMK:.)&#$W(*) 3/T;8X$XCF.%)
M$P<<H8HPD5G2!PTQ/2!%4D;] $P5"S"(@!/2[!E"*FXH_]$471NJ-((47"A!
M0D4XHA %CQ_DH -5]^F5P!=#H#D0!$,$)<(0!@RR9IA^#N3$(ANQVM !D=R8
M@2>C(L0@&0<(M)04EYB5@!C[L+'#3B=\@T G;EQ1E5$)*,!C7;<B)$(C2O[T
M@ /5 CO$MG,ET((*3GR)4P):D'!N.CH5BX =AVIFP P%@ = $!\T@:..U=JQ
MB'[C;5>7OIL(8=X/"$B00QL%-(> 1]A!1]P^Q!F@A:\3%Y#??-CUT"0 :5A
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M 4D\T(A.5$$+'/(AS89(DA>$<8P<>D\"M6>#D6SA>_)S('L:(X$O(" #8C#
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M!$FS+)W@"<^(( _0 CF0"I[@#CN@/);0/K@'$4$@!06(!2IP  &X" 6P!5E
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M3O -#/ %L/ _&] '"] "!;BD^B.\/]D0Z^ %.R !*!!&4X  '?1V'U '5@D
M!O"%PF",@.8)(3!&> ,!6?!W0%-C+Y #W>>5JWD+*G &=ID!6<!02ZP"^78/
MKU*L6A "OR942XP&@C"6 /DZ;* (.?"7M\8QIM &#V &U  &W"00;" #_"L"
M!U.LSM"AU;>[@V"9?.HZ3<!<.&>!5S"R:G &BW KZ_ %+\ H8D<U/K,LK3D2
MJ^ #_[\P)S;'O)V@!+##"LIC"HK  7Q0 S8 N?58S0A](\GI!'?@#$> T>1D
M";\  28PG6R':1['!,?S7C9 @,X 3<N@ O<: L9:6E% !H.@"-&2!HD%H8@,
M!E]P!2U@ 6QJ<]4E5.VK K'+GSAD>QEP"P\ K0^:"2GX ]OWM@S:2+KKI(%@
M#TU@9;0G*]0[;?WTS&/9"#W@ 1:FP&JV<4U03UTF" EP#\O@#HUB!WG@ S)0
M7GM #U,0+5&9!ZK02W'@ ZK0!!\W!"5 !U4IV'!P O8H?P4P!E% 2$X@R_=*
M#$] !665 &9 !QH A%OP!&OP!NS$!AX$*S]27/105LL"!O]SX ,UH 8GL QD
M %V5K0804-CU# YSL ;-G)ELHSP9X 9#$ EH^<@?AP6.?:\+T FIX - 2 #G
M4A$'/ 1F4-D6E@J8H HD($^=@ AK %=Q( - X 7!W000 -0"(0)/X /'5<_<
M1C@2*21BA !C&MP* -3BJ-%HD =KX-BL/ F2K=]!#=XUH"<G^P;)X@348"E4
MD@'@W *4D Z1L > \ LJ 33Q_9"L[ .&N. =S09M  'W38O;^P<RD'G%W8DT
M,'H8$@%ED.,O@(M_=P"FH '&!]4/@ 9E4"<'$ &IH &PX 1Y0 >JL,B$I+ =
M3K"\XP2I  (P< 4?L Q%F7F,.$G_,Y$$,55:>G@)=P@+/? $>>#84 0!LC@%
M8S %F;,)*IX_&6#1+4"?<MD&!M )%SFBE?<'96 X3I.%*O@+Z6 -0^!-(* #
M**"8(_#)&-J[)X4 1]#, E%<-9"4)#!UF"#<P%+FYV( #F $8[D'6KB(SVWJ
M^=,)OS &EY  K^  4O 'FL L/0 MJPF]&< ZQ^H&?O4#C#@UT(4),D )T<*D
M"S (Z^PM-N7D[@T'(U (+C:(%2B+%F ;7V[I5Y $T<#>PI .9C"54^ ,UZUN
M"? (CU#<ZW +8  ,07MZ(& /M[ _=^[D1@!=:Z#8^GW@4JX$0- "LAAD.W
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M!522-J$$=/"!(H8@A: FU@E4B,&?H >1 RBNHQJP !HXNX$8D%0%&SV"*D"
MB6ZZ(0I>$,1HDEL#*;SA BB8DD'XIHH+8* #@7/#!6[T .3FH 8T&(0,L/ "
M8J AN4JP2%\LX$\TL$*@4[T #O2$ABH8  UY^(,&*-&2==BP 5ZH0>9"X(8)
M<&$'/G&"=@N;7AD(P0[:384,"OL(%$2)"3Z!P'__J_"#.'B"/H,XL!-8(87D
MMG5: (#"+7[PA!K@S0ENP (&)A"-&'!!OVSP1(]SH(/M7@*=$PCF,*=;!8U
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M-U$<(0J!*%"#2P$";RN!/X@!,6@ &S"%*G" .*"$,?B.+5@6 + V>:,W>_N
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MYF]^YR>] X@=!&A] (C:ZC^ Z0>)!%#]"VF)!^BS[&\(FAAUF: (":&) B"
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M7V!$D/,%(=I0@!/S<3"0 9898,<B!TAA%P07F*>1>K(!D( 68]SB# <+6(8
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M:"?0C (9%#0(;Z(  _ 4YP*.4(4>N"P$?#O"%,Z9 U6\YP ],.?>LE2!;OX
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M%K!"7.S .FS 'AB#.XB!3@# "0P,W[4"ZXT NJT;_-% !G2,"#C $S!!.HA
M#J!<(:"!(@0%GBF! [P #PS%V-W" F0 &O]\@U<<P(2]H2OT03\Y@#-LP%PD
M0 ^\I"5<P@&TP 0X@$UHQ4V( !: P!2\$>LM4%M!5^_%'0A@0#J* 0*4P"^
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MP!L-V$$UE&,,>$#SA,4"H8$PI)<4$$7 ]0 7-&%,28,:[B.2D1T9F,$4_SQ
M114 ^>D;!=W,+QY!*T2"741 #*@!!+@!%P@"!) 88VF=*F !S$5 %!#,P:79
M4[%!%=J!(N02UGE*2>)/*:K!7SF#(HYB#A@# @1<.S6!$WC*(%3#"$C!UPDK
M4Y3"6?&CC94"&HRK?;T=*R" 7* H'I)!+=[$C06%7TW!#:( $QSE-V0L$W1"
MW P"421 )89/#GC"L.77):0!"EB>,@5< 4# $V"L0AR7!&S 5*E G)&!7,@<
M;&KK(LS-%:")Q.Y$ K0.N];B3D1 !Y" $\SL L9%#" 9!(3%MCJ?T]@JO0)
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M0K0LZFNRP5RB  Q4 3@TVT)1X4ZL@A+,=P<L QNTPNORX$:)P1'(+5%CA'>
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M@6:H@ET@QX,"L$$&M&S"$4 8@WNT, =38(L3-."!'-1! 1T8PA@L@(!!, &
MBLR!!F+P!&,HP%@?C 0$C8,6 +"A67;@Q!G;<((&/O!\.3% "[B  D4T(0)*
M3, $Y)>4$WR#&'/0P!\T802[#.(7(NB ]\J9!S>X(0I2V,-"W?!#5O]T;PL6
M4($(,O$$81S@"[=BWTI9VM*6'D""J8S"&'QW D_<@PD;>H3O[- *5V[ #91@
M0RL6,(A6/  +* "!-0.A!O\X9HWY&0@$1)H 8#A5"5S@HALN((8QO" *6GBC
M&&P@P0F@( 8G&40-4N@)8DP #NO(@@H<Y$HL>.(*;&"%TB2 !7=$8:294 H
M<D3 5NQC8M%0 E!M]IY(P.( 9D $$Q8@@KF>X EWR,\!(B$(QZ3BCEAH*AUE
MH :A#'8$4I#!!6AP &"4CK!?@(,3JH" +8@O@6Y0J6;:<( 0I((57+,$' X
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M( Z'D6" :(KV(5RV(!ZV:7<E AIK(AS#?.^"#955(O)-@1&B*'9X(3HA"AJ
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M>2ZO$<QL 72L X;R!;S'&+SI";\@%?0$ DH!'([ E-F@FW1,!;Y@*-B@Q))
M"#J+NH:@) S@=#S 7##<!B @$%  %G;3+NQ@$6:1P$/"#I3P"'9 -L5@%3[9
M"!Z@$"@! D!H$4SA%V3C LA#!:A/*0;*'M!+Q]1@:;'@$8!K#(R!QE.**8Y
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M#'0,(!8 2( %Q+(%!RP) R ""P8N,M (BO1KW9=&3JIX^04  (0)341D40&
M314)($5RF$.'SIH8+ZZ8: +@0)H<>U3Q8+-H'1]Z+J/L _!@PY,UGBRH$7%+
MA1-64N D^#+$S X $E+)H.F$R8]4JI:%V./#1QXDP@YDV"3PQ"T@"@&TF$ F
M00@NB%AIR:&F8X0J @]\>+''7(,GJBS0&&A" 8HF"@^TN-!#\8E,NCAV[+I
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MS( [,M"*=,QA#650Q6@.X 1IG,<$#:#2$<;W0A6(X F L4,KGJ@!#<0@!W^
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MF U60'*>&%P!#;>00LJXP%U%Z*(XQ^GG/63@CAQ0X@<YL"YO%VH= V3@ CA
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MSWB-YEB0^OB.]9=Q]M@1X7@ !VD]ZM1@WRAS&6!6U5&1YOB.XL@O[PB2^G8
M#_!@0Q $!M<O"6 # R(96" &TY$ \__3 !7@#&8@ R!! $[0!ZFV $'P!1-
M OMP D+P V_$ (=P>'<G<R& >1* <4*P#Q)PB4/@&B+PE%<9E4 T?<<D!(P2
MAD]9>2)PB%U73^EC!WTP 6)P3%JP  20!%A@2D&@!610EPP0AN<U!#, >%=0
M86J#)B0A 1+W 4-@ '(IDQV1 "UP!1O 6S^@ B/0!1Q0$X#'<(M9DQ60#G9Y
M %TP(!ZA N(W AR0&EJY#Q]0 =0W(0\F!I7Y <_"*"'0EH+Q+'7'*TH9D!F
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M?4[X!@PL[+F A@,8R$")+TR@!((HI%AD'4N$\0^85FB@5DY@L1"VMS%TBP^
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MP1/$N, C-E&,M,R!AAJ(PG6RQB?4E=*4I[P+!'07@D L8Q6M*,"KK&4$$;Q
M)J[:A!8NT"1/#$5.9?%(!%0AA5\D[PK@P5DQ$X$"!SE!$4"0@O\%+M"$$\3
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ML  XVD63$\2AD9G PB/O,$< B" 5K/A!*O*P[('*+ .;N,<>WD")?1R T#]
M 9>)K>@0NJ4!7O"!!IQLKS+X0!6N+N81_O &;.Y .1]V@TNI1X<W[/_ 7VPH
M!0:.K08[_+BQ-0E$?)+ /25H; \T=#=W!^T#3SQBER+(0E=&7(8_J(('! '
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MZ"(B;"&#03 &+]@!ZFF$3J@C17B9A+@"&C, WG./U"LZ-,$/#>""'9"1*9B
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M";A##;W,!." [APA+0A1$47*R;L'$5)1(A0!!4C1%R65(0D-4^I0&@45$>B
M"<  E]+1(!72(272(C72(T72(14!&[A..$Q2U F"[WQ2O$@ +>B3*<TL"6@
M#L#2+O72+P73,!73,273_S(UTS-%TS15TS5ETS9UTS>%TSB5TS?= C@P@$Z
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M"] K4CR"0(A9*!*#DMV"&'"'#:B"\8N!R5T S>T=$<B!&(B0W673!%#/(.
M Y  +1""T6BI^0R!A@@"*TU?!)" >S " X  ,:@ C?$P\"6#,;*1 X  !3C%
M\&B%#!B"!5C4^VT.+Q3:$/"$(]JL!=$@$;A9\&V "F  !CZ M7"'.<K85I4
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M>"\< (8H*&S0T8$ZB($2=H8X6 ,-<+L7L"8F,(6LD %Q"P__#9@ %(@!#/
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M  8Z@($+," '8I "UU#@ 0R\P +4.T&*5XP%C&  !5/H1!TZ$ -$&@XLA[T
M%UZ @38DQ68QX((BTJ0=';R :URX  HH@:.RS?@6-%B%!G0 !^QYH,I2$,3Z
MMG6$&$P !9[ @ <(69H,P* !.2BSEEJT0E/T(7#B-,$2/<"%*!A "F4PQAI+
M00,VZ* #,&!H8"! "40Y(0:2B_*N&@$!+G0@&C?]:@@\\36^8D!&/5@Q!K[;
M4+K=H]%!.X 76/&#)]#/ 21PDC\9FX,.=#F= (# 'Z3B!%<K  -12 *<N0 #
M+L1H"K-J414,<F<,4&([2?_IU[\"5A$T5"$#"=S"+<*(D2>OYW\U&/01I%&
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MM( "2($G@ , BH$3VD ZC$ %//^  WP&9*B!)J;##RB  HB!#2RC"2+ QUR
M%QI ^N6B)O[ /5P!,2!%)SJ#_0%("SQ@X## K!#A$&28"!!##YS/SY#B%SR<
M5OS'A#56#%K6]B5 2HT !\Q* E2 ,_1 +*XA!#P@/^)3 U3 !]!B'7*  !K$
MQ22!/7X!QEPD3B#@ 8SAQ_2?$,1A04*B%N:D2Y0@V2FB".R@!.A6^D% 0:J
M!+C&MIS3"!Y #QX -^2D1@[! M1*I6Q+$$SBM7F!,: 6?V0@^C50 RK  Q:
M!QYB4A1@4OQ "(@!&1Q !6S?+@XF89+( >@B@(P B2@FA(#3MC FBD!F8HZ(
M9$HF@"#_9E(X"8N," $@A9-H9HF YHJD0XI8I@BP3V**IHA89HE()FE&9HFD
M)%.2"&9"2(8UYF,>G$4T 5*PYLR(YFT^"1;PYH@<@&J. !MT0$IQ9F%VWP%P
MD!DP@8JH)H"\9F:VYHD$)P!0I#_64TWXYHBPP7I0IXF )VX""'F&56A"B&96
M)K]HR6.Z1 ODP(.TD&CNS@&8)XN4@->Q9XD8)X0\IXBD)XH<)@!TPJ2=YXF
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MQ*JN3NJ*U%*I)B:VAI6AGH@M1>N<<O]8Z<T,5L#0"2Q#LKH0NR6H4JQ'88K
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M7, %V(#PO4 31(#HI,$5+#-$C)\)=$"6W?]-G4SS!1SNUWG %>3 !2P# D!
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M'7B$3FB!L0%B)-S!KS/!&-S"!BR" 9C!%#B *RM%'Q!#"40! V1>$41"'S@
M"L0-"N2 $GRZ2D"S [A\P^LP*VA!JO< TKU\9"7H'V<0M4M!'<!""1A#ME_
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MC!(P<6,/>V7,6>>=8X1(D'4*::23&-P)0;@D<E "39\'<T6391RH0 LOHG#
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M@@&C@  GJ,(><(B !YI D",4,7#_2FA"&DJA C.TX0%E"5 !M"80@I(!I _
M)1:$H)Y(L,(99O"$!^ @@2PT 55!, ,3Y'*&1;#4I8VXFS0DL %82* L3=U
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M<N8!6J!!54K)'$($_R!3(1B@ =$SAPZ@!6PN--=+!MJ-(7I.9QX@!/8P)QG
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M 0>>B!AJ*W&$,@. 9Z0>X1Z\P!C$@#H)0AO3%0!$(-B8Y2H3*02KP!RW30S
MM"%257^\D%,+XEX-@L0B8<+*E86&8!^0=03,\F(1L@!H<SF0-9%6$@"T\F*A
M V-1[ "2H%5V=AN!I+Z <E:#,=B\4%WW<P1Z@)P6( W<T6HEQ94D@&4,9FJ-
MX >$@ &FUAW)[ J$H!H'P1B^X)5$0 C([ (J !S_DV "L,"6&, &/B#2W')L
MQ9:<6D!O.^@K%F $YG8(&* %%$ LP#$(0B#8+(*<KG73*B\)+F (/J5$R0!#
M:2 (,J"V)N!L#Z 'UE:F0, ;FD$*5C%\0N *2,@=OB Z1\!@M^D!<. +Q,(
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M!**#D@?"@?6-CS\G5"ZADUNF0:;8@U5Y0'\1"SK "%;M$5" [>I =W-  ^I
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M#5A/ZG[A!%[@!C @9O=EU+  !CJ V1 \"+ @O_7UV0Y@"Z@X"7#GI*'V/@^
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M5.FH<^5'E V+"D2XU>.))A1UN$@#_P R9!HL'9[<<79#F(@LX"S5(]!C4P$
M3A8YJ;$ Y(,0*&(,B2/L0 8Q.>U($[K)P00:!RQAJ($F!HAE9$(">" %C@@3
M32QI ('B0LYU)NYYTH*FR($25Y+4\*)!!PI80:2@P-!D1(@V,ZWZ_0LXL.#!
MA L;/HPXL> $(6 EL2"%2;I!K0Q\61:I# @=,1IP@=BC"ID('7*X@6%!C1-C
M"]@P"3)!V+HX//8!@/!"Q;H7>[[JB*)E0A,1*%*I GL!QP4U$$B:=/8%SI$_
M&Z/]*4*61\A!@H2^,.&N5)&0(B[D8+)@RS<M<S;6,6([P89?(!-4Z,2*08\7
M321$41'2 ?\?+#!"$EDT<0!W?HF !@I1")%!#IL8P6 =41 S@734]80!'!!X
M(,P6=[3&1%];>*("=Q#DH-810PPBS3I'"'+"<B#=%%4=%H2 GGI@8&'/!30
M8 !W0C5B&TV5994 &G]\U5-5 $1@@0T;]$1""QC,9<<B +!Q2R>I; 2#1R&M
MD\&6<-070@<8>-)54!F4\8<,*.A @I&%O) :2 <<\<L!;&  PQ SC3#&"UP4
M5-$)P#21@SU[V G#>  D,,$0)<!2@ AQ%-&78J*.2FI@!YC1!@,M#/' !F_:
M@$8;03B 1BL(_/G+ SU,8,$]3=A@BC%HT/6%$ 4DV%TA8B1110C__<7QRTQL
M1+& $YX L<$R#=AP1"LS'M"#%*D-H@09'US! !8WB&9D)STUL4X6  (@P; ?
ME-)!$S^8(@A()_P7B61);#)D G%HT 0?-7" 4+S@F,*$JF+\X($4B^QSD18=
M#,' %VA\1*0!QY)+1@:W!#?<)BJ@FL 7E,Q4DQ.LY$1O!0P<(2PL!WQQA6UG
M'!53#Q>H<$(6Q:0BPSU[3(& R/5A<0E935"&0 N-T#Q(&4P\@ 8<+0^QA3%>
M1-R"& P0PX 9BQ@0R2\&.%UJW'+/37?<>K6QQ3(6IU/"(@_< \NT0D@ GA!C
MQ." $L *PL &.JHV,QM5@)'##O$: 1*#_T8H%(TQ0*1QA18()8""%[:>^\-R
M)(_Q#72!*_Z#"1CL(,(F/,QT0,#K?'%!!M&,2-X%'521GB=@O+!#QT+XR08,
M9 A5!1NL'"M%##A$H49(3;:QP#K &%$D?0%"H:^]3[!B0PMJ_!#'%)FRH00)
M/^30 2P?&B'B G:4"))Z*AA5KZB9P ALD,8(-M &"5R@"?Y"6@C*,(5.].@;
M8!#7?TY "1@=H! OZQ\K$+ !.) %!4I0 >AH1B5?,< 456B %C(0!2FP(ATF
MPP$&C/ #CX&,7MLZPO1N4[DME$((,S) "3RA Q[DD Q&"H$)HH Y .3N%Q)H
M 0<B,3-ZQ0$6'_]X 0:,08,3<4 *'O! ?PB6N0L8P0[$@X!XZ@;'./K%"2
M 0R,D($8V !58Z@C#+# ! 30! 4@B,$]>D7(.L!A#-$ 0?Q  JB6-:(3.ZIC
M#+(' !'D  1/J 8#Q(6&.CJ&D#&XPG).L"4W-.(!1\!$,\BP!13(\@(74$D6
M+%4O%"R*"V"1@3 R%X<J).%.*# "[DQ1 P2,[0<(J9T*MK 9&/" .'MHQI1N
MX0PIU+$*1_C("'K0B&.QH2 Z.%DMBP:.6(+ #1V,F2)0B(%UPL%=6)J)402U
M"1 ^A!)@\$(5/H "VJ&17E*X1 ),( 1UUJ$V((E (((R!E(6X01ET('_)G10
MJ#1PP0T@@ /7AM"#(21)CB0MJ4D/DSM/N ,RBTC'$;;V!=JA82-*V, VM8""
M*D3"#9_Q1&ID1B()'"RG@I1B1$&@TGB"H!$_$,Y*'I%(IB['6EQ P4F.< <'
M;!($4> )"#1P.P 08!!O0,$MFG""5+3!*DW:0RMH<(+698"0Y>I+O>KX'B>T
M8B81>,$%4. &'122!BT@)#N'%(E^!:@3?T"!#-1@L"H@P EN>!<:LKK)G(;P
M0TW(GQG6Y"]/@&,0OT"4+*- !J/(2! *C&("_(D#%/# "3VZQ8_TA@$W3"&Q
MZXB)B2#(I"]\0:F42!*50H!7Z=1Q"CT@Y.\0_V 7-W!SAQ"(0QWA,)-<OJFS
MO'3#+;!0QUO0@#OK*,0%,*"$G(R@;1(P#0A@$1\S=*0@&M!$*6 A 2PLPZ;1
MJ$*2FJ2$!N1 EK XJ8%)): &"&$?#Q!D LCP  8X@ 0-QIV$.6" IGU  <9:
M1Q<F3(#ZW,H ,S@ 4S[@@ 6#A  2:$ %#E$ 9R!@5A6XU84-X(SLAC0G$;;!
M/@[08B%D^%8("%40*D ,#D18 1P8:1 P+($4C_3!]+J5,W[,@!]+@,/[8+$6
MJC*"0P!@!"UP  (>,*0#M. *,TG !X9@ P:D(\<'*/(()"R$HB: !B,H,DA&
M$.4F8-D!318QD03Y@/]5"5(""+CS/M:A,C\A8 $'F$%.?B#E &692!^H  D(
M,((G_X##!C@ GA>P%17,8 8';K6K2WJ $6B! 4!H\*7(D(X9&. J(3US"QK0
M: G8P  MJ$"<&5" !Q=@!&3(KP6 ': 6:&$_1I! KRM-:02D(\IYKG.IWQSG
M @1AV$'8<8(Y("4 !$$+#O!Q[3 9DG4#Z,[I4+,#R##2JY29 \LF05\8@( ?
M$$,+6L#P =+@@ 9(*0%%#1#H?/RU8VU8R!$V@+6'<&:F9/D S3:!I:28932/
MN0+WOO55B#Q2"?"9 0O8\YCEW. $N!@!# ? #$9Z9P@/:08($(&+:29%;:?_
M00PJ,$"B,7X "(B! X@NL\X#-"LA +W%!3= IW&P@2@XX]=5"4).2/SD)#5X
M!#ZO<;P5S  &:&%5I<YP A1ME2=;O $B?;7=XQ9B.!X@)'FW2M^M$BK%C" Q
M?_=+X0M3^,.+U2H"(H$<\[YWQ1O&/D ?E>3]%&)!\>7NG._\22\/DL O""%^
MP4H4T% NP@S>+WN/FP3,0#RY@7[QAC], JKG>,%<GK:B)]7L_61Y4[4^,+^G
M_8II[X0[W..&O4=\\#T/_>A+?_K4?[RKU9SNZFM_^W5+@!;F%?<0B"'[=I\5
M&8H/_;<;:U38Y[[[#S"&+QC3_?2OO_WOC__\ZW___]M'/___#X !*( #2( %
M:( 'B( )J( +R( -Z( /"($1*($,F Z[5A_@AQ@'8 !W5GG4=P#EI@ A*%(2
M0'Z 86H.4 $EJ'T::!@::(&'P8$P^ ,V,&SUL3SW]P ^9A4&X'\[*"HL.(%!
M*(1#2(3W=W"&TE#+D&^&(0)7D XAQ'U)YP5EL 9_X#QM0Q@'$ %;4@="4G\)
M,'Z%,0(XL'ZVIP"Y5QCRL0QA" #JT8'<%P&P '1D5H:((0(8IQ@G$$Y%R(=]
MZ(=_.#=&5W#[X'T8=@22I7;J0P /D((?*$AW)FY?%B"#T =C! M:@ "VD6BX
MICUIAV$,P $ZP0#&,@(?(/]D-0-F/U!CV64S32,!%;  A3<"SI !2I!G#Q )
M4_!E!_  @V@5Q(%Q#/ "EV!J6K  ,^")!H")^W!GH+AL#+"*"6 #'_")Q[)I
M4C1NF"@!IV@ JH@ #+!KD"A%$> 3.:B-9J=N+: "[<4$+PADP&9TQM9WWD<&
M:6>,D#@"/)=HQB(!][ ,QKAN/? -0+>/^=:,319A6L",.(!A07 K3S8#SSA2
M$69V"=DT00"*M@%D9B<"0H"1H/@#'= &$0:*!N",=T8,FO@#7S8"-P%O$59H
M;T<&RV:1=M '*@B(.:F3.\F'M^<&Z+(!;K(,<= '#8 &=L($$& "'9 O24 4
M6\#_!#^  AUP ?XF14>@"D. !C6  :@E B_@ 1T015-2!QW (<LA'QB0 [ P
M!F$I!CB0 W^E DF@*%%  EMAEE'@ "_0 5?0< $"E8)D $=0 UP0!140E"^
M72'A!*G'BPR0)J7$!C)@EEZ$6M 4!6MY.(9)!M;B)A=P!2I0'D-R*5)0!QB
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M MH #4 @RW@I:. )0K"QRIP&C^#'ABP$/>"7$)!/ K+(39*E4I3+0Z %95P
M'\ S-)!H\?P\8W:(]T"*$K !A1L2S!S+,E(%'#89)CK."< !$L"I1$$ 02!^
MN/9-$_ "B0L @V ,*#B(">  AMMJK1(4)1 #Q<  #< C"J0:K> %4X #!;<6
M7/!!EJ"++Y;_)'IE $R"4"Q$<(5&$Y+Q4K<[!)'@$V<3<%'1!+KR!$R0QS@
MNLM+ )2E _^XBG_A!+&'%99C JF@! -7 2/5F "2 (3I >!P .+P!-(PF*RU
M0.>[!6/R3Q/B!$?1 K<P!EP  _"6 %@ !UM00GK%-;:ZJ6; !=0 =#5RL(L@
M EYPB34V"#) <KV:N']B#!7PP4G@!17A+Q> !:8:5]+L!3XQF<O2.K/M 5PP
M!?O@AB#1"1B@VRQ*)30@ I!@#X'"!D)B,$8 %W!P ';P APL$EQP!9UP"TS4
M'1D@UVK@/48 %&D[!E2,%%"DQ91A !N@"1[@0C5VO5_0"/D3$E:'_WK^--5
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M)>F[)M !FI'4A4XP5+!$( 4Q+""#PX( #U5Z4Q>F 4 S78T$-I EUCBA- "
M@#OHA%.D)E6IVD+"&E2!)/T(:UDM.4$.8H"!*0 0"BBX !>NA09-P,=$G,
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M 3BP :$/P(UT2, !9&: "OC"C>E)FI!T/@"/?_ %,937"4J I8L8$"!)B\$
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MPR,_3[B'%X"%CZ"13.""&C! Q('."<  .72"/JB !D #"^B!%[B /YS/#=
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MHEF7E0$%R %%::ENA! V2"60.(%2" '#(;\JT*C/H(3S6X-H*(-HL@,9@-E
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M7;Q?"P"K.M"K*-B,MDB'W & ))@ 5:(1L#W: \A0AWJ)<&0%!B#1S?R#.O_
M@&AP S58!RS*+B."T6FY@3A0A'M@@A.X 0PHB-%A%D(^TT[;AQ$8+6=8H!.
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M.'<=D*XY#XQ$D%XG0($Z@ $2.($72/U&& /]("@=:#'KBM&XC%,NT(%N/O:
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MT0  (8<1@DW2SO5XX BL A"RT#B0(="4?0G,[ # Y@*-=5G4;)5\@<0!4[\
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M( I#Z,0W$. S@O:O"::8 @.R\P.Y9N ._V.X S&P< ,+D(&!4JA"#U! B8_
MI@9<H.D7>-") 66@)000010P,SRR;( II<B!,2K@UQL,A1C^F<A%5> ;&VS
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M$(+$54(1!XR %+R750&8**F("+@#I2'&BMC!9U@5H1W>ETE "!#@ 7#  X2
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MI(?_"@1!!F#/H R!XR@ %RA!G 2;$9320D%6L,VF$BR4JX3K^@U,M![.%31
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M -B!!:* B3A!*YB",=P#%]Q"-E? !BB" (L!,62 #N!O(%A.'4: ^6Q!(&!
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M O@'OC=" *5#!C1!)Y#@1FY"\\:'5-[QK.= IWT!9YA"7!^2$4B  >7-P-C
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M"@9,[4A3HU^%RM<*+7C*1C_@0+-V)"4A]N@#9'C #0^$PBEH04()T,*7CE2
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MAQY(_Y?F^U&[7B_P@3H8@0V>6%54V2"#)D0^!\O0PMP]XCJ4N $6V^VYR-$
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M $(@+2P@ ];@#V0 #@2N ]S "+[GN,2@P)[ ^R# "^Z && 0!6!C!/Z."V2
M#"0 &#Q@O2K+=#SP!E#  K"@ U  #H@$#80AHAS@!6+P'D;B"X3 "1)'L-"
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M 0.J( FX8!GN#:1DXF+N3TS2S 12@2#6 1C4H!UU[ \XYW^\0 F&H 1 *P&
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MY=.3&HPHFT F1L L<M0A6%,@8$4@6 $&1\L="'-!8:X#C,:AT@$*1.<$6&L
MJ6H30F /[I<>W*$4'H&!#R#4[A((E,<.[!=_*0+17N N\S(3XS0["_\@ FZA
M!W;W ,P@&E!/"GZ!!=<@!FS ?.^7"I1 46\!I'8P ]!J;(7A -(@!\K ')K
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MJ&BVK(&T *C2=,+$V;X$]^"4Y5IU+UF@!@C\U.D79]"F"7H(B1!#Q=@1?A_
MO1EX<,T'57WN$TQ3LM,9DRW7Y,Q4-  ";RV7[EG9M.O7L&/_? H!39TA/YH@
M2'!E7X07%ZXX&%)4PA$=5VR$2$GF*PXU"72O>[7@P/.O;##$:)*DR9@7[C;1
M$+%!# X527+$$'(@B9H#+4@ 2" %E@0I&,2P/<#"R(,>)#P@'77/2:">$&G
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M.9<IL!)L(V" "C[P!3%H,YW$:($")M"@Q(#, %CY4A(F, %W@.P#&Q@7 20
M+AM$0A4K2D +W'$%%:3##M(X&SW;U(,<B($,$&@G&10X 7=.TP$7^$(3/J"
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M#4S1!V)\OP,Q%$%OTL#&!ARA#T/0'?SW3R%5)S0A >,B IXG!D5A)9XG!.G
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M1G  9A!#!Q 'B,(H52$"<; B*F5RP% $IZ,]-$&*!] )WG +X'  )D ,0 <
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M T6$*/25#B70!UFD'6#9!"7 "E,":1>T!=\ !)%@$A8@G$W@<@X1 B\ EV)
M14513.YV!Q8H+;8I!I'@(<(Y1K*F "7 1X^4 ^4& T PFR3@&W5@ 9;0!^Z
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MGEKPATJ3!*Q@ (.P$.]A!D^P"^WAJ!QB3-I6(Q5A!XV2 &_;HB]@IS$0#9D
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MRS!981IQ $*$B-$P!5+& #F5M5RP#"AID%@@#"*P"<3 E!@P(19QPNM0"?1
M?37"R1$,'Y0 5>#[H5<3?!:0 RCP!VU0%+;M#EL+#EN  G40$1M0!RC04RJ\
MI7%PJ92@>,8=!1^@ =<C 7&@ :95=]+0"6FZ'6Q0!SD0#46;IA:  UQPJ;M=
M1Z<U$H25"#P@P#J0;*B(:Y'PM."JF9JPM&GBU]=,G\)=!PU1!T^@"&G,!$<
M KSU W\P!9,K)^4;$A!U@&A@X/_7 Z+6N E"0&MX2ES_[ 9ND"2Z<*Q\94Y4
M_0AI"I!%$=R%S1W&-,FM=*MMT$<@@ $:T@DG3!-)@ (8H 1H(I2T2J[X 0*
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M$KP)2:"*T8XU!]!C$N  %4 N/687Y?.&:+,/_U$!X_, "S "_PQV%</1% ^
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M;0@;A &H8;TO3"U4ITUE\A$(P$&G+@'I2D'U =^A+@(-K)T!6O""#EPA..:
MA?"^\ (,4&(!$:"J&S8Q 0P\01$+B(0;HI"#%W !%@5@0PQ>< 4M8*$#+]!4
M!(!Q!V)L@*I#"*L%6L"%&*   QW @*8 X*,;O& (1_#$!: % 11T  6-<,87
M,("!J!HD"=&H U-?4-$,#$$")FB"!#9!C"\P8 -#>( 7/*$"-ES !E_8R0$R
ML(P-Z. %57!&"83QT&5D@*E7Z$$,.G !!SS!6?\;>"L<$K !L9(5 SM@['!5
M$ $,Q( +%O "*QR !AE<P 0=Z, EV(C<NR4! X$K&AMV<( >-")!' "M02*
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M,."5G*':(=C$V,60!$]$@A4_N#8".A$%,H@<@U&F61(44 $$V$IK03AC#\3
M$ D0HP=":%T$W( !\6HL$I(& &.+<I("0J !*&F &)S1 HR:I'*JDL#KM:D
M,DA@)YBW?07240(KI_X&RXB<03Z@ !6 Z0 M<(<\GQ4$!T PB)W^#^M#U (%
M; )O2?A"$_8Q-,VK!"/=5QJ -(\ "'C '9L'P/(U5_^]?:RC G-^0 ]"D(6P
MC" 256"?[ L!*!N:3I. >S"" X  +J"$'R ! LB:'WB]"F@!^)L@B "*+W"
M/UM 2MBO+S B4-$\RCO ,F&L*<@  &P 3%H^,D@'$:@ W@.0C="""H26-$"!
M,F@&!W : /D ,2 #@%D_VX._W&,?!I!!"%" TU&= 32 'Z@ DA(GAN@QI8*_
M2#N %GP +>B!VFNIS1NTO%' '%"# R@!6,@T>U&W/5 $<+ $85@'*=@#"UB
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M<,T.*(,2@X4D< ,ER  FJ$-/0(,W^(,\J('L6@ V<(/J;/^"+2B%#DB%&EB
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M8@B$.E"# -& "7"#/Q"&",!+1^W_FP.H$,-8!SL[@#C  &SC C'  6(0HPP
M@67X CA0QO$#AB8PC$ZX !I8AQ8@N!K\(/.D3W=H@RVX !5H)2VH "U0%3N8
M@NWI ;@R0Q?"0G!* @_8@-+PHE>-545!16C+.1KX 30E,3+5&@(@2(,T@'WK
M@3$U5F.9"A(PPS\XR-;X@0L8D16!@DU(UV585X,(.ZODC&_0 B]8I@P8-F/=
MATSJRQ# K3BXA -@ V PA@1:APUH Y5P AF(2V/E #NU0X4%@PEH@FE3 F(
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M]@1GX(.3U@ Z*2$_ [1D/"OL^-\B$($<V .P/I&DZ9/\W /N2.<I8 ,WY0F
MB\:SN)($F( ;J()_!8.O3N>(2CU@T 2GZH$.8,-0V\L.H%K;7(/Y@#:F# P-
M< ,=N(]$:#%@*(8L< !T5F<[:(:;E*W;1 !3+ ;"I@^3C9O0X0(W4*$3L*J&
M"((8PH!;4&LT>&@Q&(-4 ('T&(,$;(&[/"ON=(,I< ;Y6"WAJ1PDC09/:().
MJ"$)<!HP2P*^,PB'7BT'&+.>C.XH0-+(G,=V@0$NB.XQ<P(+,( 28/\,4[H"
M%>B$T B0(8" ^&YI&NB$9?#N=7@%1CF!;IZO&:.,,@CL,3"U#$CO-2U#.XAN
M83#-/V"\_+K':<8 ;"(#QTCI2>W"?7#PU3J!.$CL(-@$$L#'AV[F(0!H\P00
M-AC9#*A-P7*,/Y@A''B"Y$: ,;C+Z-QNLSRK-+B"=/B NS1LAXP#^F #6 B=
M*P"#8NB!9>B$J +R=$@"X^X6VLNO!>"O!?B G*V;W4A )'&#^JB3!^#M%!Z"
MY]&@5/B#RC8##9 !%<B]##>!'T"!*WB$S(4-3Z@@J=Q$Y?);OG$&4]"$BLO2
M'W  ,HB*ELM9,+$#8] "@;N",2@/U&OI*X#_1BU/!<V>:-)H6J3LHR-@!8:(
M"A'H !ZHVB-(CA1T!BVPME:@WO\X 2$C7C6PA%]@@!8 O=!AN,EDVUN-@$S8
M +@-,9"S@0^X@J>]A"\2@G0PA<GP6^6TPU^^A/U5:@BP ;NQ #$CWFA8RD\<
M:A7(.2Q0@AP0ALNM(?]K@XGUQ$?\@2OXCQFFWV,?@B!0W699@-CDX1DF7G!
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M4 21)NGU?2N\D + XG.1O0<4H 2674Y00W T(""/B 3E/WVK$(%2" $=N/\
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M&R9'_CKLL<L^.^V1/W!$% T04X(,[K1)#!9PG!"#"N+ $8D2.:BQ#C%'U*
M&E/5/CWUU5M_/?8B?\ %"LMXX88..ES P01-)&""%%,ACT41!#S@A288U''%
M DUG?S_^^>N___4 JC!8#HQ!AC1<00M8$ 8 [/"'5J0C$E7 PB5>9 96(* %
M]#, VOBGP0VZ9@09>$&1-I, ,[@A&FZHPP5@D<')B$#_"#_X0OT $ %8<.L
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M$\]Y7F80@G!=!)BP1T-JS%]-V,*!+&,':91R8S0B!@(*( +=[8-H-F, @AZ
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M0BL,D($Z<"$&%4I B]AP1B<PQ T=0 $L+E<%'  #)*U+@(%*L Q@J"$#;8#
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M/$#0N/-"7W*N+'1I4&\!KXLIO_$LL\9UP+!F/(V)_S6OOR!EA:2!.\2NS"8
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MO46!&-@[43B!*MB#,+3Q%:Q"70I"69Q%%4 &+Y$],53@4FC!G'']$+#!(AS
M/9)XC=I,NR_I'M3 /7R;+05%3AE@NG8"!8W%!S1 ^J"!-!@ \GB!&9;!'AQ=
M!AQ>G>\,L:#0F^1 !PS!!WP%=T@)CD1X#]SE*W" O:& )4G)Z?< K3(*92!R
M=["!!;S009PT#13"$#C#8TB "?_<P$D?R!9,P0]0I#N0 =DB4&0,-QJT4K\L
MB'#809DS2GX8B+3]80L,01I8  =L@)>^703L=P(70!J8OACLK:]JB!#01P>,
M=1S4 !9\A<>*@ EP 4"4HE0 P($CJO;4P')!18(-'3K @>"E"AD (G) - *
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M-AF2R&X&R!L 06@ !_@V@@4D("8S6/>JQYT.! 2!&#9@P -48X"-E[L $J@
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MEL$45,&?#H#^5$!_-D : " #DB4*[*_\;HY,@N (+*!6RB2)1G %>2O<R.0
MRL0%20,&QT0%99 %<3 '=?"W4(=+#F ,]@ 0I@ "]F -E( &V* ( \D.?J$3
MHLD3FD $4B$/N"0)BG#_"E9!$+IM$PQ@ QK!*B* _;A)#!C ##!!%=1  B)(
MF53C!)Y@#3R!!%QJ(T3@#65@R98A12@+ I9!"\:&VPP"$=X #IQ "]-@$T(@
M%=[@+=:!#]9 %1HA"?KP"'Q  ]:G^:*!#LR!DR#@#4/D93)@O0IA""*A#-:
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M2@,_V0 .\A/G'N (ZL (S/)!)< +Z  3\D 5>FQ"YR8]1:@Y#< )?H$&W<1
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M;@M@+=@7?#4,+8Y@R[0%HC8 )C*U,P\@R(3A@SG !-! ?B*A%:(+0C3  N)
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M.H"K$@_YUH 5"-!<#P(%UB &QL9ET"\&PIH,#B(M(H#$.@6?CV\A,( G*NT
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M*0/VG01XI GBH D.H! NH 6.,#@>8*,O (^  04*QY/ /)"@  5@X"%?;P-
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MM-/' 7#"+318ZYP;,33QPQ<"BI##)0AZP80-&7PCGQN8RU1+B1XL;&>*13!
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MH0J:X]P7)O">:"C"17L-U$TP'5CVE6$*$4Q >B3 !12X851PKKK5[S("!B#
M  Q80 +^(P(:/  !T2:[ 0YA !RDL4(,*/ /&M  LI/& 4)8LP@<4($*X: !
M9$@'R_\4P(%#.&,!!V# /K).A@>HG0,$>"4'R Z $3AC'R+H4 )B69 TV. !
M!D?  QPP!,SOI 5\7T<%AM!V PQ> GA?P @^((;'KT/L/:B $!!0@"!H(84$
M8( "A#!VY3' )#P1 WD24&  !($#0:#!/A(P?,4K@ PW&D0K'$ " U"_(!_X
M?1(\L(P&%/L#C^! Y&E @*QSP ">/Z;G0S,#R!-$ K_?1Q#D[S0M "<(^SC
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MN;O+NW"1 (=Q D:&$\Y@"5.@!2V !C+0@150/>52$:W0&V6  6HPK-UF!DJ
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MXP ?*&,3'I"!"XB!#.O $1'+R$8H"+,@> PF#:I$11+L\@LY\ 0)^@B !.!
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MA$Z($.R#.Q4 /._3,CC 1A30QX?QR8!"OR1X@0V(AF?L)S2X!'A) @NX/D5
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M"4 #QUJAM6N"#T #"U  &X@$Q+,:KVF$## P!<, .,@2IX$<$HT<,EL$ (B
MV%,#-OB#*F@3*+E0)DB')( !Y#K&!;"[+V@$-E ",H" 3>B0 [ #*JT_9S"#
M&\T"&TO22(C'"U #)Z#2#]@$$Q2"_,*"(6 M08  &QTR+V@%!&B!*_B )0M1
M MD!"8@"$H"<.("%1:L^F\R^'&@"""B%0"4(6;2 1["!$F@%96312*@"%S4
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M P;8*"%CX(&4*1HE<"A@4R3"!!0KT'1X-($6D0_4QD0KH;#.DC-/7!@B9!^
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MJ$FXP84;E*3DA"I^[K#.%QA0BX =:^B :0Q1T' ",!Y@8 0$7,B  A,IK76
M$P/79(HJ7$0A11L(L%%'!S'0 $ $?T3!Q2\)=.I!%1EH4(<1&>@0PQ4_O, %
M!K \@(8G7"C1@Z2(2G"#.\O0X 0,$]O *+7D<E%&%0L<D,$:E) [L1H7N_&'
M*A@\$8,.4QT @!VD'GH%P8.HTD%P:/ [A;<U-%'T'TRPL48=?F*@! FA>H#"
M#A)@@0$*0YCQQC(]\.IJJ&O'JH0:H<; !:G_<#P@;AR)OMFX>BW0!  ! $1.
MWGB3TT03955+3KGGYQ5PP'*3(T03Z>450+H!:V7>^7*4I3,YYY2/P#KELZ_^
M.>F5 S!>YJ2GXSGF")T^?.>WETZ[\LFO%7SGJY,^7N>I,U_]Y-)+;_SRNB-?
M^NG4NVZ[ZYQ/'COSP+/^_>GF5R_Z6MI+_SE;HY_?^^R\QY_[6LN1-P+UH0=&
M 15P' $+:$#T1*(-!_A"(SJA!!5LP1- D$(4+D"""'@"' ET%PI<=8)25$P"
M.6A"!-4PB#:DHQ 7&$,4A/ !(42B%3F  P1>8 0VL (!&;C%(\@@@2RHP FL
M ,,&X)  $PQA$$PP_T )AD8 $0QA 4[P1 =@49(-5($&$&B$"(T@ 1-P81'I
M2,,MM) #6&Q!($*DR0D\8(039($+.92 .RX0@R9@D 89:$,2+B $.$:C#0;8
M "6X4@,:=**,&VC"#U5@AVK\  M&$($)C' $0;QE$SV(@1$B6#'R1&!H %C'
M!MH ADUPH14+.$(;9J"%WSP05AR0)"71T <:/, ,._@!#C(PM B4@@,YF(($
M7N .([SE%C^HHP5LH$0$M* '%U"#K9Z R4)4@2815 $K4[B)) C.#JQPQ@:8
M ($+- $A=F@%&N#P@\D@9!"M<(840! %2&5!#79@ AOO*4YG]$ (1[PA*_]H
MP(8RCO #052$#8[0+B2RH0\(&(,0@L# 3AB#!A&X$QPB< $5?+ (!R3@!(@Q
MTI.B-*4J72E+6^K2E\(TI@!P0 -D:M,V': $&_L".B)@@7Q]@YXRF  91/ -
M&D3B%R.0PAY\, DDO$&D2<A!$2C)@3GX  EK4 ('XH ))=!@$,9 0Q'644D[
M2., ;-@$,>*PAV> HRL_X ,2?+"&9;03 "W8RG<ZA0A59(HM);A Z-)A*17D
M= ]B3"0#W-$$$0#1"8N@21JFN0Y@1$,0!1#!#6Y@@2*<X!LZG,(8O%'724Q"
M&(-J1+H68;%;], ;3ET#' ;Q"PC(=A)WM80P /#_ Q/TP (J$ $(RW,PL"35
M72\8VA;VH I84.:X(@"&._: !WKXX _2")T= B&#(1P!%M^)PQ"D( Q*#B$#
M3UC#'7YP RS\] 1[T, R,F!='_@ #W H&E^WZ075]C&X\I)& DIY@A;&4Q!L
M0(0,C!"Y00AB!(4H@P46L(XX"(,-3$#("6(01&GX-@?.-8)D#[!7<JXA!H-3
M!!#X@-TUP *M!$&#<QMQW!- 0A-PR  BZ(&'-ZCAIN29P "%;.0C(SG)2EXR
MD]-C  $V^<@03L 7AM")@6WA&Q.TQT<_2(8I;^ /,1@" UARE1R0X 2WL($E
MF, !+0AA+C^(PR(BH80<_ZCAB$(H<0O<H(-E)$&-K9@S')1B!@4>-"5LX&0G
M,F$/.-AD U-8 !1KJ(9UE" :K-B'$\HX@4NL X@18 4;+0L,%(#X!,S,%P@S
M,(4><,$(/W# $W[Q  ?P5;(%2((FSQB2 4, #; PBC/,\ MC=8 873YJ_$()
M%BG P:QH6 1.&+ K[VAG 1#(0C'B (O3'&&R(_!)))8UA0+ D1CN,*()GF ,
M(8SA%F"XP 4L0(8$6'M;&""S [SP"P"P@58 .$$&+>&=#%R@!T-#:SJ,+0%T
MQE,:#V# $61 @@07C<)D.  PU*#A?JK@#-*0 !JBH 6(+N( @<;)#]# B@CT
M ?\,<5A&:R2;#E,PX;=6'MH)4O%H-G2 S"Q!,I&C;/2C(SWI2F\R39?^4K7*
MX!ZEN$(2XEL*<BYC A?8@"(,*H,0E"(&'N#340DBZ2,\R@DR:( )KC"&#A2*
M"9%@ @4W\"FTJM4-&."3)Y;V*0J&X(Y.4(("N"!P.\2@ 4=0Q3VB< \/?"$&
M8D #)=(1B2C@6@I*>$0<6+',\VZB"%,4*00Z&();2$$0!,'"!98!4M%F0 DX
MZ, %0N )"MX#!84$P,'2$0%ELCX$,% !A-<!^%N 2O(;:,0/A M9HQ",]PA;
MU$-SH,HC.+X#O9WB,HY0A2!0T $PR(%K6W:!+T0A!![_$ ,%R1EM$T2C"CB(
M0WLO %\-;H<+RV"]U#= ^%,AA"?!A0,PD$_1@!T(0H$1TS3%4Q68@04TWB=!
MV*"\@ >XPQ?<P@+LT$"(0'!$@C2( !I<@>V16,JM%0[DP-9-02<HP@)0D +
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M4Q]@6<-"U=W#4#_!'3@#&ES /<3 EW&"&*#@^0V!!/#B5$: ,4G!+=  &M3
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ML=?:3LP &\3\M?(6S =7OJ1U<GT!%I$E!-S >64!.%A"/0!<PGD %XA7I_5
MU'QPL6HQM<1/T23D"%A"$T ;><B8","796_!T5>6&H06 G"]C56!%^S77DEZ
M:('!',@ ZQG!E26+!3PC6X371-Y")X@[[:E $(3 "SB><%U^$I1"V)N5$'3"
M'&, LJ"3*;3X!8C!&,0\9%UE@3GQIZBYU%-]Q?P ;Z4#U6?]%F1"ZKE+(VS!
M';#PNUC0>9R3N>-=!FQ""(" !]#>:PJ9:+()HK+%D6FE!!_/Q(-_TCW9!0__
M:;@]0 E0PAA4@0H<"PV$  J)@RH4 S"H @<(&Q@D0A/$$#1M@A98$'$!1!$
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M5J$1C-!"(WC:"&9 0AO>$(<W/(#0<MA#_CV &RIAGP]E5C:E 2 -!91@$$C
M-0:)8 A.U% :%" $*1*1B._;T!D(000BC.,5YG-0 E!1PPR=(!$S0",6V=A&
M-X(H?_![XQSI6$<[WA&')HQA M(P@C-T8R G6((U]G& -$ A#37D(Q2"P#H)
ML# -D4R# 40026O4< 2'3$,01N"$<70C >UP4AJLD08427*3(U A#/'82E?V
M+!T*:,$K*90 H%3@;/<KFQ)MD@ '?*$)8N002ESX UYF: 05.&*&B$FA-(3@
M"L(K9D8R-,$)"(T,!_@!"8SV@?\OB*%W(CK #*[X(!&HX6KA'($$J)D5(4@
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M<KP@:$$+9Y/ 51'' "W@4FT+Z*WDG+3=XI7MNPA(W =:8((HAHT-,2##C2R
M .AV][NV(T;=KIO=YV;S 2W P#(0$& KJDT+'$A'&AHP7RE,H0&2VZX5RU8!
M#A@X9B(H!0UL9^%T> T 2#/ #W"I$@87\ 0OF,("#&R _B[."7= @ @N$$4,
M]U8+-G!<XQA AK)1%P!!L+!*#*P@&@^! 3\ AAHVH-9 NB&8_Q_(U%XFK)($
M5( 8^]FN#:R,@_TF@ ,X($,!.FB$O:!7F>ML )<)LY#JM8"Z!X@$$[0P9A'
M11H'^  Q7G %#E2M;'MQ@AM@L8_MCKEL+3AF G" RP38H 7E0UK=.'#"G46H
ME@P]1R(!$%#()D($1##$$E;Z"LP:(HT).,,YEM % *R#$!=]!0%$((EV&#("
M*S!$.R+PSRUL(P*&F &MEY &RD+4MFFP RJ6(,KC/AO:*XGET(C[I B.0"\0
M0$$'7J"E..@ !1]!P3(V((,76( ,VNX !F"QIQB@8 K.,(,P$J" (:P$(3GX
MJ;9CP 68L0$%&-# )6Q6*R<G  $2V/]VM]V- AV\&PZ,DH$)+'"NR60 &)J
MU@L\P 4MH<$-;2@0%E @!"_4@ OJV4(IUMUN+KC! A_APB7VLJDB1,(-'C!0
M!J+8K1Y@H -]V0(&;C#8"*! ";/QP("/H(HI\'(G0T! $&:0@!>L.^(@M\#=
MR%R%J+ 5WNKN@)9RT $4B&XEQ?G/.B AC"9#SPY5 %MOE;9R+G1@!^N0P@LP
MT 9MOR *0JA53QN!\Z!S $>-*!D7ZH !:*'@!1=H0IM_<9@A;*"GFFEZT$DR
MA4A(@U >>$(5-A# ;NFM!&N@Q \@WP$U'%T3&J05YC%0A0QH(@8Q, (;Q+"
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M:1;"J99!#! @5FA@SAA@ QJ!#9B KZ1@&2X #IR )DJ -58B5KRB#9S! Y-
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M%]*A$#*Q,_E#,38%!#0H RY@%@4!6)9N&9(@$V@ KSKP"I[%.QY &/=R,U"
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M$E2A#JY O3)C+Q+ @J\ "(X !.+0=J6"&(A!"C#@ C*'#?+8GDX #B( #D8
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M( #=&&0$RD=!OM**2 3,BOJ=I8!7+,0. I4!8)RI(J=;=/Q#V#('T.T *L
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M 9%,$<*A48"CZ' )J.D$:Q'<@@,*,6 !ZB QG%F5!S<$0FA]6*AQ@!:F['#
M!R_T$(4:)Y0"!!J7K+,!!L9NP8HS4L1P01'KF&#$(-*D V<2&*B45)<<=^PQ
M01-L21\4!0[$(S=G&%(("ZB<(Y!^(Y;_X#( _16*RBL_+DC "2T7@LH201P
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MTH;Q P :-\@ !SC ( >YS1:0H  C*-$FFF#3!1= <Z]$\@/2H> #\)3!# 8
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M-NL0#T16$"?P"5$#>37R_W3!5P@'V 4?EW\#02,C4(%XM$8]Z#.$,#,&42&
M%(*']WQD>(9HF(9 IP4-,7R%D 9I<'635R@+PA^YIW3G8 !/5WDY$WJV1Q!_
MMW*20  'L@3Q@  G( EPJ!]!X'$&T2)7HWVHD BS(@(M\P ]\G9"HG=JPP(X
M4Q#E1P##)PEVTR 1@ H7J(8^ER5LJ(JN^(JP.!"+QQ Q$B41$"(P"",G0C/
MQWY=,(=0]XD ,"$CP'8S0(A7!P!#)Q 1( >?T(!J!R17)P(]PG^LIW =@G8%
M9T8K, .\1Q '\'M,$D?B"(K38"#)6"CR9VRQR',YUX[P&(\>^$,,D2$M>#(A
M)_]RAK B2G<*>D!OT7A^J!"-!P!P"2!P\B8@(T CQJ9TVR !W7@WRB "+B!R
M<E C?U%V,#(S!R)RB6 C//*/]/9_IR!RRI &4%>2(D<([5!^L^($^Q@MZE:2
ML2>/X$9X-IF3.BEX7]  E89(E_:3&U%NX%B"0HEI.UEM@).43-F4V18?1.F4
M4IE?.#F55GF5^A4R6+F5 6:&7/F58(E(\<%X85F6CM2!9IF6:GDE/;F6;ME#
M!/".;SF7=*D14.D0&4*0'+($%G*,T,272R C\^$$[>!U@+D$64.85?0S5=<9
M@OE;8%<?8!@DI1@M-DA& E&,?#DD4&<WFLF7A9"9D ?_F(E@ &4#F*]0BAD2
MF)59EXB4#@K0BJXYF[2):H6W$/FF=?R1"' XB2^CB/91=74(AYO91>HG- _"
M1$GG!'(P-PK'<$#" D30#082<=98<1\I(5)3-J'YC;JW!+U)BB8'G'"XD"=Y
M1%?W(T+C-260=[4)E$OYGO))FV/9$&94@4KS?5(4(':H>T@2"^W0&N@W'R,P
M(998"*^$-TX #<H@("=0?UOT,Q ")/LW<1JY!3+"@ TB>M9P@#"7 %:8  A2
MC"5#$'@W:TM2*(0&(UHWGSL4E[?IHC*JEB%SE B1(2UP,[Z6BS3S@N,G@S2H
MH^G6#>RG@T1@>H:P!-VX<,SX_X:[N YRD(2S=XT1\)&QT((UZ)V_A0J]QX!<
MRFK&QV?GQGA*IPR#-*-\XY5HNJ9E69_TP2$K)W9'YX+BMX")\ ![2" YTPY%
MRD83PB%!$)@G$ \%,'SG<" X Z5C.'O0\(]Z< HU,B'@&#5!@( FXS4+N!^H
MX *.J@P16))ZX (=$H;C0 B]QZ8?@Y:HNJI7V98,48P@ B+O-J=[EXL+F36<
MYR"O\'G=  &C]W%'VH,S0'9VP'#4: @:1S0>RB+7*'I!D(Y 8H!$0(6H$W<2
M^0!":J)Y5R&[BA \0JVLVB4'()?A6JY->9<*<0 G("/YH0PTXQ_[N2*X%RU>
MHR"4U_\R=,@-PU=PN:8A!@"G'_()^^ $P)=O[:"H_)=\:1":,.F7HM<%'OIV
MF/I;H%>#3^*I,!*3A1($ B&BIVJN5.)?L@FR)"N/6CDR8'B MR<):-,R+],V
M4#")07-TZ*=W_L%^A1"S0*.,6I=O1_.'^=$T<I"S4) @?T&E,E)Y%.@R/"()
M4%"T@<JR,:LV#B().7L.4! WSJETI-@@ZXDV$5FR5!*7T">V9ON*;IH00C2&
M9A0W "@UMMBR6A0!=@.',7A%(Q*:#4)&/X*A890D7Y2%_P>W)F.T6V1%#4(R
MY] %)/8VJ- R07!'#_)$]0& YR S,\"W Q$$-G@ "8!$8'C_ME*BJJ);NF3H
MJE82E8IDHZ:;2&K:NK"K@>@:N_)9E;1[N\UWLKC[GO&YN[X;>&G[NW0ILL);
MO#V'N@WA:N 8!"/ O#\R C.0 #.P:Z]T(\W;O![B:S\BBME;:\<6:\<V5(B6
M:[/6:LR+:[RV2 EPO95VO1R[:B#F(1Z2$"MJO!%!KO:;OT\I'_8)D:69:[&@
M<1O'=$JG!^SF;FNS( ="!/_8;D%@D-+9;MMX<-$XJ'T%DX"4(K)WM#]2I5H3
M >/ ;KP))-6(.OK&;LHP)"9GP <L(M# ;B]W$";2@OJ[$+9;PS@,:;K+$$ZP
M ACI( P2 4DWK]CXBT$JC!-B<J,J_Z)SXP1ZH'6K)Q!!\'6#Y(A*B+1!\*!=
M &5.( D'.YT?QZ4# 0%T!\0&(3<OPC0\Q1]Z((PYG!!B &!O/,>*%KP)D2%0
M4+' B(?[D(M49Z\V4S(%V0T50GHJ)YUG8P /RAE,5 BA20 (:Z&SAC7/VH*&
MJK)LY#78PS2"RVI., V;C+'JN 1@3,<'P4BFG,KZA;P*D7TS0HI*-WXGRJ-
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M_WMT0-@DE0J 2BV!K8L&7WD %9O TBO";T$MX1,@M5RG1<?L JL%90Y8\:[
M)''0,+1=:NRQR":S&#.?XA.*/U59/6&)TEPX+36J)'Q<2ED%O9(RHZ@%JH1N
M$_FVU0R(0([<L(<GOGCCCT<^^>WBG>$WE28LP3UK_^"S%LMLK1D!ZD)T3L0M
M+0-D2IS6*G2=84M+@")BZI>H>)SDK,E8, 'M>(OHN3PL]A2]3O[+U@A8!@[T
M:I09 \PL/^=H&LZB1I02" I% !"!,M"3I#.T8V$2<E^4(@8AVS"-5%V2VCC,
MD@8HB&@>*UA"%\JE/!:VT(4OA&$,YV22!*#B""MIB8XR)1^W?9 SNVF4-0"P
MEH-)""IVZ,9O6A.[K?QD</Z*T*?0$BH/*:=Q08$9Y#ZQ*LHIXU6VHL^L-I<6
M@4&A@'8('?V<%I]$R.U(@5'&#$1@"!:(HT.)0&)<EKB-:$G""?H2W)5TDJUS
M<,D%NO,6N( GE/?M0X:/A/]D)"4Y24I>I#SG44FMVA.3F<1G4_1IV@-$-"Q&
M%:(+OV$*PY8@*19P(U!R:$Q=&$2E&KJ ?5CR%/PTQB$/G2,-.)-/B3(0GP>F
M81Q'"M82/O"*&+F,1M#PD!E!AZ2=W,PR/T*-D'P602<@B5FH. 31FN28$LC&
M&A+S)--NIKUNG2-,)V!!P P1I156TI[WQ&<^]1DG.RV!# D8Q//  I4&38]M
M%:,?5Q15NK(<18@":HDDH#(TP_$MA7]36G!RDHBJ1&:*@W#!-C*0PKC\D 5@
M,=F*^I<6PFCN2F0D2B&-4IG.-*T 51,8*O"BEU;Y125"<Z7@^ 0;3,TD<8*L
MS\C_-J,[6YEE"U!@SSS>A[5]5M6J5\5J5D>B- ($P8:(P0MC8J.O^+0-E%H"
MV9A04906@&] K4G8DA!T%?1%+'L4DT.%W)>(#&VH0SQQFH]$QC/)G>R-+H)1
M (<2/2( J04CF.9EV&#-+\V#"-FD4(KZ<J0DE0^#-I$=.A>#$S;\:S-C6@&X
MY)G">FK5M:^%;6PA:9) 60DL:<$<H$@WGW]Q:3C0N&Q_4EBW<4!BE9/2XZVB
MM95T *<0.-%)%,%%18]=L72-.EU/^Q<KKM#JME8A"@M&P()=G4)T3QN.P-ZX
M*CFNX"_+FM3KK+*-!34Q0IO2C1->4<BE?"61,X  5/53_Z+ER-; !T9P@KM6
MDAG\1*!$@8DUR,JO3UBO1^DEREIYXU9/Q56<L41%#]3'H0GIM3.ZE-\IMH'&
M=@2JLB7B64I1%A1)1("9 00,C6 &&<GHZ#+V">P"@Z0_GQ6)LZV3*^P(H<%\
MK8\0/=P2.[_TSG"EUQ"22(,C%;QE+G?9RW6B84HVQX(E^'$F*MF>O^QP-7;6
MU*%#9 NT\#:5L:R@)5G9RL2^XJ^Q'&Z*M?%0(=* GU.=-"^:]0NL9N/2M-V*
M@ 8DBZ_6^$.='IH HUD=LZ227(O*)@V)?6)^/]3<0^[N<$^-ZF6%^&56M]K5
MKV[..LB6I_1 3QG1ZN2@<-,#(/]NJ4ND7*LI8S0@XZ)187.%DI2H- (2S\A"
M)X[?QMCB%I\$#$CYDQR16'0O&S=SH .4IJ0\E<!K#A8P*+HTT#I[H'$FNT%D
M;8T<Y'!6GX#PO\:Q<I2T#&M^]]O?7F8PK4]AY]PLX4^!L@ETL_0*9_WP'&]>
MBC),$8_C(E%OG[!;'ULJJ"/@A#(1PMP,MO"*%21NR6]IG'G=B-+)%>F+L4J$
M&%]ZJW-D $?E+0J;T_NE5.6$56D@C:F$)H3DQN[=ZZA-VW1S.T,BDC@ %K#N
M&OEOJE?=ZEHMR3X2$*K&V&JL^T(%;EJ0U-%]"1H99FN V((@J+020DJNKZR
M<R43\S7_V@+RF/VV5Z(W%O.8*5O"LG%\"AU[KL>)H&;35B-DGNTO@NB!K\)
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*A=[HE=Z/" @ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g26402bgi002.gif
<DESCRIPTION>G26402BGI002.GIF
<TEXT>
begin 644 g26402bgi002.gif
M1TE&.#=A, .#!'<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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MD (26+I0.% @G&-& *$$K@HA0&\*&@2!"' !7"1M8FUH!!7$5QH9,&!5#&"
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MK.@TZ3X'ZL^)L"M#&6HD7.$J0@5%,B?OZYI!/ G*@5!BA%2X61BF4$H;YL^
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MI6N8B) /3_>IX/E_^(2^D@EB2IA@;*F9: $>X0$"N ,".RD3VS'  &# +0D
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M!*>>ZKW>!,>PZS70,CIP F+ !9XH" ]P J#P"&=PYFGN*(*@ W10>:YP!7$
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M"!XERO$)CE@! 8^30 3:P QO#B]" .!#[N@0A=YU@ K=L!EI=/#/H]4A' L
M1"#>LAU%Z$ ,2@! 2UKP#O\L@8(%L,7"FC) M&A #X38P3I68+S-K$ "5.D!
M5N3 -@!011@8F"E+].!-!'A!$>60 QYZDK)A9B$E U1 &+1CM0>,Y29*N&<4
MFM YX17  70H3M%6D@7PB64Q=R@#%0(CGT"00*<2Z(E=5F90$7"L ;%$ACKZ
M<Q5*P$$5!0B"&*( !K4VQJ ;$P8/-%"*=]BB#B_M0B)(0(EMR"$)_P[1P@\P
M4(84_C*8C"U%R,*W-!+<00$*X*;-K(/1D1)0 I2X3$_FYP((E. &GS J#)"@
M@2DTI:<[O<#4_B>'!Z2"&3^]"F1_ " $-($$?#"H W"A$2^T5FX,6D(YL,<
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MJ*VC JI0@$]@# 0H)AB *%G+'BU0@+)JC'*(@A-0"A:PG$E(A:O9JE-XA61
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M N5I0]?H@!)(B?:80E"@SV>;J2RH@SC !;5B "W8!COXNH$[!3O@0PY$!F&
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M%&& GA@$DS,1&1!8!KC9$V%7%<E9G!W:?@6!IC41!A@ ^S.18=A8J+W7%2J
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M(20ZUN89_];IJ=Q>$=2R.1.A!/X1QT&P@=7N/N6M!)&.@ :P;6.AA)) 6"1
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M&_2";;!,[2 -_SMXQ2K8'-*P@8FK-!^X_+KT&8[()T(8@C,@A.L@!N7-#A2
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MT?%RJ,,==HD2LK!$!Q@E."[<(@P^<)9&9/"%8I@$ Z<0A@\D< <C8D #Q0-
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M!$P50X'90:T1 IK]P"U*F!)XF!W8P0K4#B2LPRMM51F,%"7 @432P"U>0"H
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M+3[%/<R>GP*J&D5$%0@"%+!!$PP#!<C> L3!(U# %0@"*&2+1#S ,<3 HSI
M"@A"#4C4/<   AS#HR+  2Q!KDJ +\6!,;CA WS!Y;! '!#6%C2!["' $3PJ
MU\@>!6S!['%&*H0&UWS!G\[%I K"%CP %.B$+[D"";! IW+-)&#_7A.PP!;
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MK*+]3"7%><W_2['>H3>13"W+*>"X.A0S5QD0VM>290%HIG&<^P+8.(?1L3)
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M_T0U*5N'2"LT2L]% L!$ +A#ZE@ "B J7)K@DE2G:]G(#3Q@2@' ;&W@;D/
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M$+P9G!5!$7P  Y!A$$C!K-%Z&-P EA7[7&. !_C:K\\3 >[@% ;!I0EZ"D3
M#;"9IC&I!%Z;!#YZ'<89 +*@!XPA$G  /!? K"& "Q[A B[:I"6  N@ $DS
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M!X8=#M2A?5>@& ;!\2&_??/T%L@ "KR@$JI@G,N=S@' FJ< G%U<"NQ]5".
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M1I0#.]0 P!W+%,-%$SPPD40WKQA#1X@C)I&8 .\($<,(. 1!AGX %" #&UV
M)Q<")Z"Q0Q("=),(*88!0 D-&"@F%QLZP+" +N%LQ$ D0R 110L%-!@!'4,<
MX$5* -#U!E$W#G.4 6?H4!((+!RSCCM$Q! %ARXD8@ 2(TC@0!02%" ""QA$
M(<B&'9:RT4J04:*'2AEM%&4XX0FPI@X57CC41A<P\<483KD#7P*NL(%!("R
MV$28R;0W7 17=?A),4H $(0.4P+ AUPF:2&% S= 0L@/Q&Q05 %GZ$+*"#:@
M^<DM@;!QC 6Y_\DFUP(G)%!''$W<D@B&$:Q320TD+$!';A?L@,$K)(B P:P
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M0A6F0"MV.($*,XE"#"20!44D  T6 !P (N"<?'T"%S^P@ 4J<99$%(&(&;!
M'J!P)P$PX I2< %%I%"4F91C#1#X1!: ,0S_'Z%A!26)G9$.<P%)%$,Q0W&
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M@A0$'I "$Q%ODN$#U6,DE;"$4] N]&0!@B (J^& 6C@$ 20=\.1.\Q0!&7
M$R$$GN5 ,7 "^.<:MQ %#T '=7  3C $50 &$5()LH;_?Y[54-<%48[W#H"@
MB3'3,0=@ 3X@!$RX$2A@!YQ8 U@H"'1P4EG !*2  5=U$G6@6>O04@FX@%2
M!"18/59P 7 P% @ C$X@@@N@!2LP"71@-'R@@A (%FA%3T[0 DT% ]7H3FR0
M AS4 (CH&B,B@(WS57H% 2N@$#0D!':QB;G85EXP!",16'!PCWJ3!U^@@ !X
M-'=0!RE !(3C!WG !H#P!B#  R1(!SC1/-)!#!Z8 JGP"44@!#:"!":0 B>P
M#NOP UH(."C@ 8)P CH@"+<X"=;H F]@9%,  @#@5C0P"400$M A-\20?X(
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M!\ A%* &), "1-!;7/<[][ NQR ! \,G0K"?1($ T>(#/'@%*1 '-2 "NED
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MA# (M_+=IP;=Q(+(/1G)DOPN-#!I^5J<(=!R&L',ALO=M4O-APP"PR #/4D
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M,.-L[62+VH$  K<0 'HP W1!!?;G"D2MY]B.XI%L)OS'# R3"E&37?!YR .
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MP />"ISVLOL?CV8Z\/_QS3Z3Y7D&5C\)&  0&L@LF0)@@9 1,4A=L1"C!@
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M 0+HX -0"B +GUA +(S!@P0D@7E6*  6SHFK=8CS#I\@Q1<L((@HE.86I:#
M.T. +AX,H@4RD,!&5B"!;E0J/WE @PU0P(6=7H (;Y@E#3 0"%M:@!A]P $2
MTG4'C*(@3%PPP#NT,+(@' 4 ?*"! *H@"74E])PN6"@*\A".=P24 E!(6:KJ
M8%$O<&$2>3C#F/CP"@,$P0_AH,0*A# (*Y3-5!2A 4NK=H$&%&2FPH-"6G'H
M@'T"X (FL$&&/A'8J\C2!7J0 /\%BNJ%,74#L1C900:F0 KA\>"<"U*#+JC
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M0+ "CT*9GQNIGQ0!%EB=T..G"]B!8[H#J%("I(P%R:"!8<!+O6P!V1* 5$P
M-=@ 9]0ME>06Y7NN8K <GH@%$'"!,<@1YJ*>Y^*!.M"!Z4*"AV" ZY(9/Y@!
M2NFN<EN9"*C$L!$#/W$ .BBWNY"M27B#=_^(2A+HAG2@M(9CKG4BDV+@ D$@
MKBS@@F&X@SK8 5UT %_*R%PH,+++( <8QSM0!A:H39!4KNT\, K[!!*P3#;0
ML!#<J3]Q#A*X@WH "1-S !T4 5P8 SJ@@<T(!+*! X##A4\X@P[ ,5NH@SC
MA<[ -2+2@R%;@6* H46K D+H 6-H @F "?>11 7PAT0SJ_-P!3X0LQB%J+_*
M DRP@5#$@\U!0Q]M@C.B!$;"A5"( B+X,CI3 CY H5MXA3WL "I@@%O0 S41
MED'#"P Y'@(H "V@-0R8/$< 302X SFP $6@/GV\!5D(  50@%"P 3=-CR[H
M@2^HLSL,$0W- DO_H ($P 4/B)<AT)A42Z,6N  X6 84Z  \P$5SZ45,S50
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MC)8;%R"&88@$E7" 'H O.2B!*$@"^A!G'? !0<B*Q):9[/7%D?F(8JX!-]"
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M 7B!1@E/W0A""C0!!FR3%Q01"D#$FIU!.?2 )/V 0_Q "B!7 J29\ B8"]Q
M)<A8%4B0G-%9*0V5%'R!'["% T  #D !\42 !5#!.W3!,NA2D4S5#D!!; &0
M"T2!!) C9FC&'21"EJR##^A B7F&3<G!$!#/+9"+"R2 ($0!B^35";S!&8R
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M2,<CJ)L,."D#/,(PM,N[  "4#H2D0$$(&$,!Q(IU"(#_"!@#V83 C(3 !B
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M+Z^KA5@S"&3!*P#'*!NJJ):R$,\(_Z:R.CN8XPHQS,K IP(;"HQ!U=1(N:!
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MYB#88"405!<T@BN0 A$$/9%^R#JLP:Y!@@_<PBODR(>NPPX<56LX !C U50
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MBQ-<.4/) @HX)HXS=J@AH3LZJ,2).F! 8M(&!!%C"#8(60$#2V^Q0Y$>A@2
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MR 4 !+RP(P8HS ZD""$$(0*28GYXP )0Z%A!$#B0%R7LL;4>""!)XM$#$7I
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MP5Z"4( "^B$#VL:6 !$I@ A",))A1(0!,B!! 1 29!"$(%T%H( $AB$"#/3
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M>9_7$1SA!UK@ F"6"!0AI&QE=+F/>^Z@=(< /0P717J O7# "[2I:%00 3#
M#L#IYSK #GX 7*9)$82D PTW"79B!8JA VX7%+H@%.H "A 8I^8..-B@"S0
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M:.!Y"LI% &6%#OAQL"GAX&1 "Z3 &/;FCP(! USKLO^F!2* #FQ "+23B;)
M&'3 !A:@_$;B?D<C"[YJ$%I@ 9Q XL# !@9F$B.@ 3I[L%% %T1OTOX$#H+5
M(,Y@!2)KL'F@P2+)!8ZX?,X PKASJA.G ;X2!7;+XB0N/ 3[$S9& H)@!T[
M/R@J6.5($::72K:+#4Q@M^% ,S$@ M$@N6^AD&C "BZ;%(SZ'6Y!,U.@NX:;
MN6V#"6H K]^[$LH#!+0@Z8)4 (+[4YT(-3[.!73#C\[  J0(<2X %S1Y",8:
MDY1QK-^;&-Y!$F)!I!O_]0C4QP<DX#8 XU=Q ,RX4PC> ))JH,1#8+LN+T8@
M6PTP8'J% !1 0$=&HY/ U 'B9$XJ"-)R_$HGL(?6X3O.8 2.01".H1;J(0A6
MX 1J/)+$*.D,!5 ,VJ,O ,PE 0-*P<JF@$^!. 02#$D@@ 9(0")%( 5PX QB
M)#T%@ <JH1*H8%>20*1O@1A88 1<(1'#=L?6*_ ZG?!&P!-E%17A3@$T8" E
MNI, H0,488\9]K@@P0<>P'4(O9(^[OO6] L2(,#@6XI'@!B&P1KF5J13]AB<
M8!GXX#0T%YS)!0M:"@4J 0.$8;ELAP+00)AHX $> ##,5Q=^[O46()(0HAMJ
M__>CUYS#.XF=)S"EF4@$V& 2N@#?+J 5FH .*N$!A&"$LT<2V* 2DKN/VD=J
MS_D Y)J)KH 5SJ!$!D8=6'.Z=@ 43H4 +H# )4,/>*!&GEU&*$$/#*"P;D?_
M;(!VY4P&OF 2<.&]WZ#_5H (0ND=>. '*J$O**$.K  +EJ$!7L\%UJ\56@ !
M3N -\#I@<+L8+G!C%,H &* 8IJ /9%<GYO<$/, '4%2*Z6 VYOL5K*";E2 (
M$D 0'F!CELT!1B#F"Z;Y%&*7W\$,>$@0KN+C_NCDWX$1P.6(:P0! (82A$$+
MFB:XPDC*S'P=O@X-CD+C,:"E<&4=6HH 2IP%Y"B[X?\3"?* #0)_@M(+6*M@
M'6)]8P@?=RIAX),@\3V@$J0^O@)! 'J^-:(@!9;@?P3AP5S!@SY!!+3@*) @
M1L0H$!0P#_X#YMA@"8:#"L@:KY=AZ)=@8U*O%UO8'?P$[FO DWX@!MA@NMH9
M[6N!?_\6F2J7P^+@%GC*#J)@2"*@_";(%?J@@-U .:?H*Q'@"^C A23  2QS
M*:6X"\B/%/P$ 9R $([" 4[@ -1'!SP ((H1XZ'N':,: @!T*X5 ")5WDFH
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MP, *2("$2DQB$!*@0#$JD0&1N( &6C,1,0J @F7TCV""0)$6IC S&H!/  X
M114V1)PI] $[K(O,$F)! 2<8!0 (P, ;0(""%7AA0Z%20@3R(!$DY&9CN"D
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M(B0(L 5+  J.EW[Y=RYT5WP1L 4'$$M?<B[_ " #?U)T(E %*0<%UB<#V7<
MI39\NG-L&->"78$V24$ 2B&#2$&#8,$ ##"#25$ # "#,PB#!>"#7U6#$T$
M-NB".:@42;@4!."#21%2"*$4/.B"5%B%6Y$696%6"K -V@*#/I@M1-B%T.2$
M0U)K7$&&6P&&2@@7:@A-;<@M!6"&4]0[3'B$2($ 53 &416&[R JSX0"&X(V
M=FB% ) 09G@6<;@4;RB&7$% 9"@ 3FB#E( H,D@D=:(40%@WPQ 6:+B#A[B#
M_-)Y\P067\@ZRD>(J)B*JKB*GR8"6["'K!B+H&8'3\%Q8-$W:"6+NKB+5K@
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M%("J?T(!@HJ<ILJKVKFF_\3*F$LZ),1U-A_9#:$@'$.B!670 *=@":?0 TM
M"#>@",C0" C"#)7@!,Q0 MO #(*%!'#@"#?PH2@PK3K: 0Z# MO@K O0!7H0
M!R$0 :D 0DA "-O0 3U@ $$@!AJP#3_P'5E0#C=@";*CI:]0!:<@-%A0!CZ@
M!:?@#Z_  Z'0$F= ",AP"GKP?:&@".70 9_ /W!@$C\0A<6ZLBR[BUD0"NH0
M1!U@ :<@!S$ 2S;+ ^6@J%G0 45E"5S  \CP"L. ,:!0#!U@ Y00 #]0"0\
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M:Q4!U<$&N-"PR( 3+G"^Z6L +G #GY ,<%"E ( ]"< ,;U  6F /X2#!Y:
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MH0O@V*:,'N+4B*4,;FKN##IV<"5.2O(@(@8)4 )C!Q@0H@ #,%9X](H>!%C
M4DP!0."80]70 ID5)FW. 2+6V2$)!B(@PH(84 5 A"O ,($80!>XM8%6DKA@
M"!"^8 PT(L!PM/_6*Q+(HPDM3ND!!H8BA2&"OF( -*KJ#(B@ 3!P( &XL7:P
M@:48B$!40!? @*J@""!BX)@F6!#D!#1@0&(O5T"H8HIA&#@#E%W[:"%>@8-U
M89"Q?)"@ %B1;1> "/(X(0\HJJ!CA1I$N .9*%)PQ=:\DG" #B8$9LG;*>)<
M !0)*IID'1PD& 8W),!8AV$0*EW'41$PUM@T0T\.M]X=+G8"C6\W<*"!=?*
M081C!&F B3@$8* *?3> U01L(V*H!J[S>/2!6!;089U3:(@% R8:L,"5B!AP
M  XYB#EC#$'6J612"I:%^J "7-@!@U? /B:Q=9#Y01"/$.#! HO8RSK_XU@V
M>.?62L0V"&"5C7'!C#64V T)-$Z(0J9*+>B;WP0LD+( "H0  VJ6#G5E@P7
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MH,@%".(+LS&(".XQ*4JTPA2+-0 %FA#&,UP-.+GXR *T( 4#. "EE!"%%;Q
M R@$P0,W<8 NU-" -PC@ B\=* 5HRRE )& 0X1B01$3;@RSHH6'KTN80#%#_
MV19X(0HM6( D7 $=%R#C!M?]! G8\PY&#,$!BI@""%9+@G=T)!FZ",<"Z$!*
MW'B3#;C0PSJ)@0(YG*0/0W!!'6 @@#.(@5 S:H4:9JG(/!*#$K-Q@SZ=P)HL
M2+, ;D!#%2!!FR^TZP*FO&L2&+(I^WE$-:SX A.0YX!S\60!*8!"%F)"TCRP
MH9 <HT&X_#"$$#Q )DA@ BF(P,,(M"(<68@Q @BH7P#<K 7]B[$M.J"$*C@*
M)H\-1T&?PE'FD%02+[.#8)'@ 5(T0$H4&*A!(C""7+RC"Z4 %0:LT]<I",08
M1%#N GS@ C(88[$R)D9<K2"" $&GN 9@,2G.P3_[_XU@"N^PQB<*< N>:#:_
M)SD""4XDV#UIP(#O.$8L(L#3",B-(S$8HP#H7 0ZU'8!@%#"3Z0U H^<U=6O
M[LKT E ]D%P/+OU00/<T$@)<<]4J@X$,6;<7 *?"^BIULPY3@@"&)#3'FP5!
M@@6:/:-7R,0!P4Q  I"A!"]DNP&*6 /..N"*U7P! HI( !B000PBU-9^9IAV
M<Q8@JFWH 08NV(8<DH6;+Q"A!&4@M B(0+H%Z&(&E-"#,;S $Q1H !+K6(<=
M?$"'*4#G C[N%FT*8(M3&!<CU%D!!@(1D0@X@1B&YA2"3>P'T *  3>#P7QJ
M1CDW#&'3-5BT'-)M3V/8HO\4$=#%D06'XTDXH0X/T 45BJJ:/'@AN['Q QX,
M0HE!M$ $MI"#"=8!AT\LIPH]*((?_)4%9J1;$75H A&$E[N"$. "S*9ZP]S
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M!P!5F+L"I )5  @""R"E.S#5=HQ3("(# H6DF@J"03" 5CV!AT6!'T@!04@
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M/EUFC/"2#EA :=ZUKVJ3-^EFB4 ?L*;JLC;K5PL5-S[KM6;KMG;KK%Q=ZU$
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MJCUBR=4-&%B %E)!3:C!,0A@)6B>+93""-J='YC6M:#6#L3:!>C"SBV %GB
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M4O$/V, "9>TW5IT=?-%6_WRC"B> !8QL!P)".*" $?\ &+Q!E#( $L0 5<&
MTN'!0S!NU3H* DR$IU&!#I]"&=R30E2!,;V7&)P"05HO(:Q!4CE Q7&3$R #
M,RP;+J@P,5@+"N3Q#=#A'1CL'DE" NDP*V//,-RP!90#%!WR.]Q"!WC O1)"
M%U,!F"Z;)(RA?%Q!#.1!!^;MM6A!.?0P&(3#$G=QK/'!-G3 "IA."C]7,]^I
M&'2 "3"!,89S%!""$J! 2S! ).# J&G *=  741 %]Q &;S!0_ 8%PR#VS%
M-PZ#$8$!@BA-/Q%$%FN !R $ C@!,V,!,MR I"(.19<%&*BDQ2T/%YS!D.WB
M-O\P R/K,@!@03A'9A!Y<$;[J#+C\(1,KZQU@7_*6CGAS@UTP%8@@1'K&%9L
M [!RF%#3P%1X(Q-W0.&& TBS@ =8@4IW@&N818PF7Q6\K@,+TRJM:DJT:EHT
M06<@< %G'ZWV0ZZ&!,2<@BYE-5L/! @,@+5<!*)QQ57)P'\@FK44@ C0]57M
M=5>X=0CT! .0P"GY25Q;!*M!!%P3!$B(P&'[*'/E"ZL5]D PP(+@R3%!! .
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M.EL0#)47\BAO>6%(=94('L"(CO,,CO4ZJ1<H_G[F E#B>XH(05_$HPCE;[J
M%0.@0N 8[Y:ZH <!& C!OEA@2DY  FTJP L<*&2).@2VJ"$ZXHSCJ0 DUGGC
MN )<R"-#G_ZCCX)'YFOLA@#Z42  ?&RL\<8<;<0Q  U2TQ%'(14@4L@3=++
M1R)I[)''  )00#NV+@!$ 07TL(&^EA"H0H=U[$A ARDF&\X-*;9<:0$_PCGJ
M'5ULH*2'%?_K8W,G!K18 3^A1BP#.@ H&:/-EB@9!#\*1KAM)P)0((/.G!9P
M(AP0(E$4IPLD\;"G MP Q3R6$+ABB@@D>30F2E8P-:DWM5Q*3@&0$*2)$5IM
MZ9T^<J%$#U5?NJ -/5IH:<UP#+14)0;.3'.F=[I8(8[C%H"CD4%_DO-3-9V
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M"F=H0/^TEKJPM7 (51###?0 !214\I)&1*(KC!@*2!C*0O K#R440<8?I X
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M(@D.@,"HRB %%A"A96\%6A;XBP0/3$$X"-BL<\9 !4JL-0(-J(0?+GD'&O
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M@@$*P(!<S*R0 *T YJ14(A$'I5"&CQ @P0(:  )< 0,@H3<4P00R( /6@0H
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MB@#_$-IG$7_  BP #D8(AA1A!UPP @#!#DS@[5+%@[J@$CY).!@P DX %ZD
M8M0 L*J@$I0# ;I "20L#8-NW:[$W6JB=^;0)IA' 1[ JOQ! ;(*)[('X&;"
MWZ"$W\[" ;J# @H-!D" =%XB$74FGQ9N1!Y.)2!'HQ)@"$KO&"3@"Q[@ 7@
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M$SKXP,5(K?A(0*V((4F73PN&P &>[Q9XT$(J@4R5$@ET#_N *?H<1S4-*P[
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M W3FN^),"$"A"F* 2+6 [SR($*##!43-0@XL0SI5 (X.)'5MNB2A!39/@;J
M]%#UKJP@"Z)  B+ #]Z@46*5*0$5GK#WL^9+"H8!"<2@ASI4'-' !,II$(J!
MLQ88!U15*1.*!() #*C@#EY! /)GSL:0+6%@Q4;5 ^JH!43@"G#@4Q# %N3
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M;A"BCJ&IAR'_ ^$: E; 3A7:K0 F>+<: =[X*'< 03A%$70@G8,C"!1V';@
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MCR!4  B_%M#$!@11$ L)!?3H8[SAQL)K <8:0) (1QP#"A3N%B0"O@4A$,O
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MG*X*X 8F).X"C!.!%U8 .B;FD 5>@,02 '$*)1#D#*EX!10*D(5!J"$$%,#
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M@S<+P  88B !!FSA'BD01 /_T)"$"'2A T-8V05:48,J[.![,F4<01RP#A^
M@1"!$  #7+ -881C 5UX T\?L%,7D(%UK7C=._I P(5I87X$R:0)T  #%F#
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M R' 8,IHB(, +H#A,CM."+Y]&!)TH -7#/FG28#C<0F#04409)T&875!.J
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M;BMP6N#$&PR !,13 'XP!0YP4@5P!9(0 H#%:(,P"2%65OSWD^^ ED@P""T
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M8 $GL + !0C$_W "(\ $O_-5)>@!,74!;1![$"!#/[H".A #B"-O5& +I>
M?C )Q-@ZC1,!?K .<I"&8-24;;0^L.,!E7 "/L S!D$!/'!@@W "=!9F4H8
M5=  <! &5 !/\Q=,6? )O%%S(;!/"^"9MU *"^,"]/9Q;[4-=C $(@,[ZM!Y
M*V *@+"ECG0\@V %;"D)55 "D& !52I##J"$PX8".T!Y!_D)QF1DT!<\@? .
M0K"B6F!'9W "A% &:. !UA,!NE"$:- $1)"&!S%*?.JGGEH0>G5S ND%)'>1
M"9 ":+ .=5H L)0X=]!63 8&:A!,@I0$%T 'J45(#(  ML ,"9  &O_ !;R1
M1F0@ '"$?$1IG<8 G>\C"G.).@D'K A@#5-P!W(0C8HP<QKGK+I"EK[Z#ET@
M!<8$B9(0!W>0"*NT \@G"I%:?\:@!3?P ZZP 2Y  ]<%.N^PI/':![G@+@A0
M#,3@CSU@E5NZ -900:KC7%B0!SQ@!R;@H=.)<)*0! 2 .VK0!=!X8.K 9'#0
M U9 5]E),&P*!XV0!,#Z#HR DC6(/9) "B.0"Y=&J]9%!*Z:EI!*$$& !HV3
M3+=@KQ;0 5(0!)#*E@TI!HIPJ1W@"E=P3 !  5>0 ,CP;VCH2UB!$PH  6P8
M:R)Q!$=A:QP1 AO5% IP"GU8$((0% % N(C_$3QR@).,ZTL%$ 04&CSU\%JN
M2!!Q6@ 1X%L^$@=0< 5@L *()WC', :FH+8+=PLMFCS8HP/%,*.=,P2GN ,Z
M.@8PX)=+U%=P]+KO8%8&J0M4 )6"( 5?X(JA>3!D-S!(D)@=UXPY$W(7(6T_
M  H\,'D.4 R.((#Y='>54 5C, -,B !N, 18L R\@3M0( 1O\([ZN' N,&ZC
MR301@ %Q]3 %P*>ZD@6[: V2&'+($ZEN@ :3H @^L 5+D 9>I0NYZ@ CD%J@
M$T"EL)D&P'944*H#H*)N=0>? ';EYP<C, 91!),78 $ZP 1;:A#%Z0KLFT:6
MZY3+9 ".= O/&@%0_]8 A%"GF!E+!)'!"^< "4 %P20"^YM)/F !UH:/MT #
M<5# !D.6Q/.<4Q !8AL^6>F:<DF7"V &RG1,[T $,9 %>N *!=PN^@H,1^2^
MY(*QI7#!\E8#=U#&3DF1T2>VE4D"UD4'R/ )RW1=&1- >7Q,STE6>8.H )#!
MU&J0R!NGYKBRD$# #Z!+"/?!%^D!!\!F/H(X:80)42 ![Y#  X, S_AN??4$
M %D ?0 *$:"TX1,"WB-3K0 #GO=N'H!\";1%A,A$:C!82GP,6!A/])<'50 )
M,; %<7 /Z%M9E$ (TLL#G)6^<WL5J>81_1D7 #J'NV:@#'%L&$$ Q684V?_L
M& N0"GP1B,.0N-B3 )0'1C1@!>_@!LUU;?%D7PU0.,&U4RC !!G#!X/@N0#Y
MLZHS:/-X#)#0.&>@@D* HVY'";3J LN+<&85!! @60EG$&S,1)"@3.=LOS\Y
M# S@ )[)*X;(ER"PBC9  #[C2#$E95F@R0" !8,@"!GC=(!) 72@10X@!L"[
M.C+@!$.@O)-FB.CKCH! K]KCA)9)>=7I=O;,QW= /*L5 \9PE2#75>(T?T_X
M!?>LG()P-^]P"R28&4^X!&B0"Z!I!FK@!L<4 :-IO[[7!Z@IU$@,B7Z0 &0P
MLPG= @6  1H E@LCT@8IU/_XPA@ 5;^*2L^) WS_H ?.Y0)@T 1H0 <_B:4Q
MU0UBN]A3Z8Z,TU,/H .2%0&M<(DK<'/NXZ?F=@&>67.4*0GJZ@.,]@K3ATQ9
MK%?EVIHNH ?\P@91MC#=X)', P&Q*E-P0 5G;7Q^, /=<(A7X <YVCHM\,D]
MT 2(0\B)H+8LH&B7=I4N_%=/FS,80#SOH 5#,+('8PVJ6'-5G0=+$ 6@$P&#
M+5.2  6I(PE-P)7&)VD+0 <[8 'JVP6YJKG9B0**0(X"\%=3< 8UB,-!>+)R
M  /Z:%^F;7.%Y9FOU %4@ %<$-H4N+"^3+S6<P&"X+FL8 !.E[(_MT_.;!5U
M>[<=T88_,11]NQ$A$!1,_W&'"Y&X +"'#E'CAL$ ;N \&G *PM $QR"Q'-&I
MZW,!$(!A8("?R,,O@]-M&+ Z'9< )V<+@U #=Q<#&$ #6&B!\/8XY:=)>)H'
ML]O*16AC"R/1!> %H\E$)HP NL!]N)#82+ #4>0$_(:+HL<K*&"O1$7@F, $
M1!4#30!8"G21C%4%3M !D #FX9I/&! %#X !5GH!8A #+LB%1+ "*,>.(X #
MPV -](;D\(;*:'P%3Z?I]:NID>9U04Q-!8 %L0I!IT0*?5!^&)"E:,5W1* (
M4Q!W.Y "@P4%('9IL5JJ(' +7R8$B9D%$2L$$& "HB=3,%D 3Z !V^B\?F4-
M4?^08>Z7J]79W=]- :KW #L=A*"@>B@'S_E$[CL]#$#,J)D4W,!>#-JCJ3&0
M B;02G",Y!A@!U4;J>%C#+=PSZT#8JCS#H!0"2/0W8 U[N/V5#'U\/ '"CD&
M"H,5DU)0KKI@ ^V7[_ W>K!W#*U'"@TP;L95!31@#/]W\770 I%P3 S@!QR[
M10Z5 J*' (PJ95Y@ M&70 SYEF!.BS(U<WJFT&#@ QC@1@MMNTS0!-90PJ(D
M;DM !&7P=43-"#C@   &2U,)A?:PX#0@Z79 #(VF<9^K ^M0!FJ0@#& F+N5
M/&_%"B'@!<".ZYXK!</@ (CN!#\0"WUP:F0!S?RI /[_^1%-8!0NKA$R8,UY
M,13>?!%[N!"0_Q@,< >?,SFTG#(1 -VO10=,4%\(AP-V)@0C:L+5F0!C)013
MZ0$9$#WDJ0.1E6)$D'B3=@_W -WG!6/[M#*G6K\1D (U<*J 21"$YFF@ )&=
M7T;K8 (^L%-,9@'BI51L< (NA0:5,.P)<Q$,9@+EEP('0/N"EB^CU?Q"D 35
M"09&&@N-2 3-CP,@ ([#@ 0C0 6P)?L(@-MEE #BWR^)/E;:!1"18  @6,#!
M"1L4< @H@"2.  I$UN492)"@ XD[:FP ( -#@A4P"K!Y2 '4(P N;(CPXL'"
MCB00,:R+D2(%#I044A@ 0"E!_Q*""_Q0L0@ B8XD2.@P 46BJ(-< AC<BS7,
M00,3."0@> "# M84H'A:=.!GW1 )#:M&:B'BF(0%0L!0!/"NBI,$KIP21'!E
M7:48CR@,8>@@C8&K"7&P<27 8H$G&5)$+1"I!H"R-%L4Q>S$@JL-"V;F:<&
M3:ZZ]R0 ..,$S11C)XV"23"YH42T4 7$!0.3==2I$AP#0% %C(F-E2L":#C"
MQH6%1N-LB'!BXO(%30&8)"'"KT8&56QL?Q#K2X,9!!D@:< DA2 8N@L<B[4
M!XD")@5$()+ 1PP#^#/!!R%F4&BL B)(801!6FFA !=HBPHZYMA(8YB($J"H
M@"-B$?\  1Y,V&&)%*#H<#C.4E1Q119;7/$&!0* P$6+8-2 QA2/B#$%'$/P
M)P!!","Q* L"4  $' 4)P$@DAW3R22A9' F4K8YQ92PH&6BR*"&+ H&C%!D8
MIJ KI"!A.$K(L ($% %@,THX5_RRS3A3?-.B#<#D3$_FON1L2Q6U9-'/%/F$
M\DX[Z01T10:$&(($/0E8M"BW8JBHKW XZ[* 25?DE,X"#+5H&%&[? Q1@D0%
M@ !3ZUQQ SH)(H#//%L4],\V&=BKJ$]Q#!7'5BT:(%859W5RF$Y;--;+%2EX
MH(8"4!AD,P!(=1%5B[!U=5L7-0C 'T6&U$ !1Z)LPDA!>ES_<H0H=5"@GQ!H
M)$ 0!=Z-EUM\\]5WV[ZD0!$%,K#<=V"""S;X8!?[(FQ(!+Q09(KA"FA"580K
MMOABC#.NN&$($H! "8U#5A%&!6;$T<8HM_B11QI]#""&*"VH-UG.E&129)Q%
MEN$1%!& @=B<@Q9Z:!9E6&W( EB(8U>BFW;Z::B=!.&8!Y:.NN)Q%0@7QW'+
MA?)<!5AV,808=8ARA!AE2'))?]2^^FUN@X5[;KKKMOMNO//6VV*23:8192AU
M#&"2'OM1X(28ZV6:14$,#X#FO2.7?'+**[?\<LPSI]%;<,4EUUP%\!&[11G*
M;O?;>Y6EM][4-7?]==ACEWUVVFLG_PA&&8<$_$D=%7B@QQ_3A;+(Q]>^V?9]
MM60@!*"'%(&-&H!F@&<XEZ=8/>J9DV%QY+OW_GOP9\]:@UA8:,+\\YM(_WPH
M8/3ZR2;J;4!]^M%?OXE[8F072G?[V6)]] 6P"2%H0+W@%3Y7%: *, "8P*!4
M@#O8@0Q <\$$X72!$5!!;A8!V%Z$$A4$AE"$(R3AVTBF@!\MR4AL6]*[ZJ6
M&P7N1_7RAP%?:#@4OE !9H,2&HSDPF^I4(B.^R'D:$>  A!D4@S05%  ,04*
M>,A3%-N4-8:0/25R,&"&FE27ND0!26RDB00!F!4((H,^-":+*VI>"=WX1CC&
M<459B]$*:_^XPA_J\'U. EN,_*C#%_YP23Q\4@$!V<(8U3"0+VP=\D:2@DE4
M(@Y?&$$,G(* +Q A!AX:B2;C  (DF*$.#\ !"-CP'N=LH"$GB,$#FK K-F!
MDJ"$ R2(PAP*"&$$Q$")"\8@"!WHQ2 G0$,,)."6%&PR(L'<P 7\4 E6#@23
MK(P% #I8!1V<8 RHJ0XS$7 ,05BJ+PWP@13E>$YTIE.$DQ!$.]WY3GB^\W=0
MDH$[A=#.]\03GDTPES[]"4\F?J\ 69"##NA@!S3H@! @0P(88M" D"S "3H0
MA E<X8):%D--7K"##AK@ 1A<  PZ(((&5G"T"S@A#R>PZ!=J.1[_XEPA 8(
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M3,&#(1A *#.H>$XU %B"4$(,%P?#$-X1YZ 48P5;( (7!(!G/0_!!3^(0Q4
M$858"%H %1_"$H@P!!:$,=UF"(<+/."*EC!P$$L  RB\, @;1  0,?C_@A^D
MD/3+%  +48B#$'8 A2O ].!K9WO;W3ZPD2Q$)P-Q 3$^Y)>'(2E"BD!K0P71
M@V$< 34,2,$C&' >"\P%2TA8!R2,61F@%(0-1%"$;QRPD,K$008.B\)[H'"/
MRW1&$96  0)2,)!WC*#T?MEI,X<P#+]8( ^7.0,81E_ZT_,% XK(RS#<8 ,A
MOUWXPR=^\55$J()HJXF7W\V&<P6H8!5 !&U4?I]<Q !#]>HQW,O6]8S_??"'
M7_PNHD3'+("&R(]?_>MG?_LSAP1!G-[[[J=__>U_?Y$M"__[YW___?]_  Q
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MP-1'"-358%7U(9'H&0EA)8XM6(*E$55!_1!S2P$U8($]78T%X*1>U5%1A5(
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M_"("RO52*QCL[G=Z)-"% UB'&7\/@,! Q@  !%H\Z" R2((+20=&_]2X\TE
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M.@6P 05-41 AS'-G  +)$"!$T$I8D7YT 02$E&+@FFU&$LLM\.V*0S+? 5"
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M)[B +LK'% 2!(B0!^N$-(%3""++$ EP!)B#11T0 J8S3)[$.F;Q#?A1 A0#
M,.;0-N!!U*'B.))C.9KC.0(378%,]BC!'>C! RR!$W !#T01 H0 &ZQ#)2S!
M$IB1&X03)7A D$3'%;Q$ 7A!#+@C*"P!$9C (F%?B'P!$3"!6E" !3PD8S"'
M!]@ ^EFB%G#!!FRC)7H!)(Q ,92!**)C2JKD2K+D2JIB"WC9 IB!*W2?(.C
M"( "#V@+2[!%%,2 #C3 _Z3*>E#_00$D!P^DBE%R@1?H@0Z<@ [@ !OL@ PV
M!AE*8P/0QV.H(01H!/IAXSGTBGOT$ 4<@PZD " 88DNJY5JR95MNWOF,CB*$
MPR=-!QO$0K8\AP.DP!> P108@P@<0RS$22>"@2L892 < T8=) \LQ()L 1N,
MP PPV0(<0U=:@Q)(HT4^XAGT)5,89 ^T%8* )*<@0," 0&)PFUNJYFJR9FM^
M''.XT!$<@QC(A0NLT +X 3&P@!C8@ A@ .H0024\@JT)92=BAU$F F/N47!%
M@!U0@6_F 2G,$F.(0!J10!#8P7&H"7T4P!>8$P70 22 P@%L@00@@0F$!8"$
M#&GB) ED_X$P"( ,'(&RN69]VN=]XN>+H8 PG4(85,)S(, M]-ZD,,<VE $(
M500A])X4#,/)&( #3.5A\D 5=@ 7D,!/A-X@U  %Z!&4)58'L%5F2A0"6,,;
M^(17M=XI,(,-,, M;$-M>>8MR$6"GL)BG8$?I&9^ZNB.\FB/5H8X.H8(:%J(
M0 &3,4 (T"=U#FE!+.EC'"E]N@!F^@20LL0 .%IC%( ] IZ/<FF7>NF7YIN^
M0!"8DFF9FNF9,EP!@"&:LFF;NNF;PFF<RNF<TFF=VNF=XFF>ZNF>\FF?^NF?
M FJ@"NJ@$FJA&NJA(FJB*NJB,FJC.NJC0FJD2NJD4FJE6NJE8O]JIFKJIG)J
MIWKJIX)JJ(KJJ)+JKEF (K!AJJ+JJJIJJ[+JJ[IJK,+JK,IJK=+JK=IJKN+J
MKNIJK_+JK_IJL +KL IKL1+KL1IKLB+KLBIKLS+KLSIKM$+KM$IKM5+KM5IK
MMF+KLBJ"U#!<<+  N(IK!HYKN)+KN9IKNI;KNJ(KNZIKN\+KN\JKN])KO-;K
MO-IKON+KOMYKO^JKO_+KOPILP!(LP!KLP!YLP2+LPBILPR;LPS(LQ#ILQ%+L
MQ%JLQ&)LQ6;LQ6ILQ_(K"UQHJ8KLR))LR9KLR:)LRJKLRK)LR[KLR\)LS,KL
MS-)LS=KLS4YJ 21ID^DLS@:<#EA  @3_[= *;=$2[=#6GF6$@-$R[=$R[1*T
MQ@,X[=0V;0*L:< )'@0, 6Q%A@AH@2(0(MA&8R^M(+M8!@;^H'-0AE.X0I8%
M01ZTWP*, +Z< 1M-1@1PK4^ ;.+M;;49V)9R#07\"= L ",$H="@+6040!"L
M@Q9-!MK*5F7H%R0D0%JB&8H!;B\5P#'$0<&=T@A\UQJR80)09= @259B!@5@
M@-9J%0X,KF, E")P 8!6P3J,U$< )N+MRCKPG6T@@!# 0)9%X,Y:6=_NFV;D
M7&DH;_(RKS]T0,0M;_0R;_0F;65,G?1B;_+VP]7Z6[YHP2DH0!BHEI7YG2#
MX0X(0GB1;9( _UZ^[(MWC"EDI$SO0LHZR620 )0Z3<8"Z$*.JL_A&H@3 #"T
MY4JN92/!$:X ::[-Y*U/: $3Q('*(8 ;I%@!6QD60$(*8(#E4@9-..ZN#1(K
MM%_@]6_(_&$,F&\>=LWO]LJF^8T@=$$/M>@/U "=&<2WQ=)U@H$@T$%2(H$=
M$ -%W$(4I, ZO,$(7P9=1)X#Y$'\BD8$^,$ 8YN,">#]Y5S^44835$T5^Q^/
M/1,79\T69PW<,1PE($,/L $NZ&\',T<"!"&>-4:M3).:QAD=L\0P# !+@ "5
M7H4=3Y87.$?@@,#R^00<ATAU9!GBX%K$H*5OPA1DP-E5 &$A#YJF /^P)1<R
M(8>,(>>9GPV'F@[#)V^8HM'Q55 "Y\2QJFURG$5R(3.9F"W?H.$FBZRR8\!9
MG-4*DZEI!)0P'JGI5:2<3_AQ+1>R"'C!< 7S)9T#FWR$(5/$-$&G?@3&R1'S
M&^% D_0Q)^,Q'E4:<SC?*U?SFU$S)X=,IX59,K^9#%Q!#! $)&+D:?8R]!77
MF[U*!W%R*_O$E<IQ.<_%BC0I/@/ ,,19!$PE> 2&X)7#*T#!8S@ =HP5!*B!
M$,0-F*B!"Y2#'6 F1]"'(J?R*S. )JLI;N:"3]CF=U'SG8$TJY61APSSM:&>
M(BC9+<OT3"<=]*Y&3,_T3#?!TTU- /1#".3_=$YO -4T6\AUPPU\@C&00.8*
MB7'X!!9L@R6,U'"@0!F4@(ELE-Y%B."]J(6Z !S<P \D >.$GX46@#^R01?H
M'9F$3!7 02CTP!F K58/ UMLPXH.1S;RRT?4[R69@0UX05KD&1(0PBF\HS4H
MP(IF]2FL "G8@@+(@2+(!?^J02H$P ]0@7Z!S1L,@PN402T8]DJ "4L3]@V$
M H-Z@1T4-K!00M@HE@U$@"10@82TP@$XP2D<J 34SB)[D ;<P"EP-GCJG6IE
MP8O6 110E-[9  @H3@#9  J$38U&!#*$PAM<@(+N7>X(:%C#-ABL0^]Q=E:7
M@#T8XJYPTQ"X0.C]_\ K%I;>$86>O&A648)5G\(IA$(4T($CG$+UA<P=((,"
M? ((P"!Y[4P)Y*'?M4$H<($#/!(R\%==8W=6GK5E+\-Y)/?C@&1Z=X")E/8I
M!'AS0T<XT82UJ+4<L(G7_K98%[@*A\R%LVAJET HK  )O,/@_5:J$#95!<D9
MJ+4B;%"($$:!4 *:H-&"7BA49Y?@*"AF^R82=D EJ+4>-$$?)&%M"<B J]/.
MP($>&**7_81R., )3(()A(,-DY_.Z$(<*$O(=,'Z@0(=D D". $Q,/<'8ZA6
MP\\Z.$(9*)]P:\ @1$\WIH("'+>+#X?$Z'D9!/=4[1T"##J7ZY=[,_6+$?]-
M )1=9)S=9>08%D)&"$"-MTK=9H@ SAD@R!FE O">+@(N323 <:! *U !&GTD
M7]=6$QA#<)+  ]FF&K !&@B""PDX$[  ]'S0=-P"%UB1><KE*3UP"S@ -!8/
M#82 %CC' QUR[UH.;R=* FQ##P7>DA@S,7S!7Y, #SB' [2"_<RD1 L ;M8
M"@")ZGJ3"QAC%L@!#AR#^B41*WUN'+F Z^2B*PQ)GY1![Q1##Q TNR2&(-B3
MHX!)^UV '[0'%BP$_4"!2'V!'03/"50"W, %"2%E*\VW;J81@VRM$DE %<2
M1Q0 F+0 &O4 !1""X7C!()B"%1V.AC8C$4#>%_#_IF_BC1, B^7  !88RQEP
M)0I4:$0RP21$ 168AT<5 &[Z $,8(QLTP!!$@!APP0CNRDCMYQL4@>JP !'P
MB^4\Q]3[00Q @2TH0588 P_$4_[<>B4D3ZX'4ER@37BT /HANS=I1SB$1WD1
M2P1H0-=W$&Z>?<7_@/V,P:/ .F?V /QP=OM440] P1TL5L@<,]K\B"OPP F=
MP;HT9_#HP!3HEQRV#PL4@P>H@1<D%QO0@104 PT'P1C\CQ@DP=N@/B9PP1%
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M=U@#*)-:#@KJ(!$'5) \5[B?&,C @A& 1SQJP$!BE+0=XWE  BZH1$)BEQ@
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M)@84H<UNU"U4G/$,=\;0!"(H071AZ=0+F:.'5;)!3%?L2Q=D5#LM2 $%IRF
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M 3B@,1@LZ/\"$(7@#(10AP!D$(OP6+-36J"!!-@ A84L0 A3$($+ZD"*I["
M"%(8A@OL8(.TN (#.'8,7)X2XS=1XBU8614"M-"!+2_$ 2:@PCON8 \U^ 8X
M?I@!5M;F!E84P0DX ,$MR@ )E""ASFG+&Q+\58!;#(* </* (,80C@7T@0E"
M,@ *[) $+(P9":T8#FT<EP<1=($J67B3 Q*@H-D(( * Z $+P#"#C^@""AA
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M'=;A0#R# .J+S.@@" ?A=!! !R0G=PCP!Z8 1DI@#30 IRB@"]2O!T;FH5"
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M8*\!VD4'QJ5<E.7UFB4E,](EQ4(EMN 1K"($2*  E(4!0. 0 4 $@*KWK&(
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M#>+@)]?B$*4S*BDS-;!2*X.2->%2,18) 2QB*@E3(7I2-:.S,1]39T*)?!:
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M$RJS"F;L5)U;5@I-K[L*JQ$%)T*:K-D: CK@#3;@'090$<9@?X\Z"A(B KI
MH^T!N=[!/-+8RB0@ N8Z WG2!80:?(Y:_A#@!"Q _72B^>!L#5S:PC%\ RY@
MI>TE6P$ "\H&"4Z@&+@K463 <64[#FJ7N8 % SX8\"S.2?"7H),%!#+3OP;
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M7XY@W9Z[1!I@"(Q!#?-$E([@")J8(C;@(O+@"]ZB+[R@($/@$=+X#NHATG!
M?*HB"#PFY!E\!//@KL.Q2MQ 9":I(Q8 ^B4<3["@(MZ!HXX+( !< .2*B!0#
M* :U0*"%"Q$N A*V>*>E5#(P4XPM@$/%#0T2[_RXRI+(  ,W/0P $&@F' (O
M/4A<T&6#I 01&/)(6$E)CY4"6/(T.6)*1A5)(:[$"'%+BL0%#8@)(&G@#HV;
MUH:<:16N !(FQK3@(+%R@4$!!;1($0$HW$H ")J$ !&D%90K/00L +/$3)((
M#9*\S?)*  .E+"3!N,#5@84X(VKP>?]ET@V3+R9<:81CPP43$@M$4D6 5R6
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M"4#BUDH#I0C_EQ>2?.%!%8/L=$$7/R20@!C$W/))C:$1,T\I'KJ00!P>" ;
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M$';EW'"(\[Y^>$,0QI $K\2 #0W8E0O>LQ($6/\C!E#XWT,ID.*[>O@ST6E
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M@3@,"$!]"5@ (4@!2.B+(7  I$@6!$ !Z/>$FBB"U > L3& ;N1 $7 /VO<
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M6S"KM%JKMEJK32 D('"KO'JK(2 D(="KPDJK'<F5#:6<M<0C"<.>QKE-BLD
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MR21P!\CP TF !#B0:X3 !"5&R<X6@ QPRB90 PQP"Z=0!SSC MM@!\4P"#H
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M&( &#T '87T:EB'IWF(;:N!;M04(SAX57K#_ P\@!-Z"QB^^ \=@:5*S!8
M"3\^"!FP)Q&P ^'F!Z].[OX""#&P!.3>!%V@S%5@!LY.!$@6Z1A  U] 'WX>
M!Q&P#5'PH7CT$-OR$K1.!QQ_X7&#1QX"=AS" L6@X!@0)P[E \=@ EF>PQ,+
M 3Y"Q$+"!A.[J#P2 OY0Q24[L5V,(8( LPK0]$(9X#]PZ=I:QH9"& 8P#&Y
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M#P(0-P6XJBID0_.(@!38"UK[O?,H **(DG@:@1%PA?PQE0:(@6-H@KJJA ;
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MR*2 !^BNV= !5YB,G;R<#6E'&!@&!_##!WC+-XR#!5 1L"0JDQ "-*A+CKF
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M1:B8*1#;!ED)QOP/2ED'18C$A5B *@/03(& ?HL%"EF'-=B!4YK41&A+(H
M2(A$T67>YG7>YV6(:(-<RNW:B)W>5[4=XX'<KK4/RKW>$P >[D7<[>7>Z0V
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M #%#;+RA#F5KBA%D@I0XB9PF!@$@G7#X:08*2]*" 0;P$]<";3.P <<R#5=
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M;BPZ2KLNN^WJ1H"[\<H[+[V&%<  "-[B&U<!(E170+X BN#M, &_!;"W V^
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M 5Q@@G 48![_>LA =H30 #%PP0N#L,)9WH&+4JB)$/K[!!*,!PD5NB("1-
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MFXX0%I>UQE>\Y0W+M<B37_E>>"L :R]>T#N7@#'@$=[=2S\4@(\4KUC%_@A
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M!C1C# A"RS" %>H++5:B%6[C#U( ("C">.C?#W;A& Z15F3@!M:C!TJC)78
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ML[GD5@B"LYGK9!2 +9Q"*.A!#4QE5J" @V8%J4B "'@!Z $ )=S1%>Q,YM@
M'Y39U>4!!:QCI@[3,:1 "L0"ZXR!!&"!H%VC*PP#"HP!32$<%I29"&C!$#@
MLXB &S!<5E  !T8"$TQ*8<;(R+)!GAC J%*!"_R ZDF"*^@6 O3!KI@E%2!!
M"F%9!.@"?1*L$^P9PE*."/1!5T&"HV&!(F2L5CB #5;:%" !S>:K78X #C@=
M(-% _Q$T #$(0*.ITAX*01Z<@1@00PCXK/:@0<9F81)T[!"8K(-$@B20@@6,
MQQ?4P MX;0,,P3!40<MPA=!MS1,,@EOZ 0X$ >(ZS?! IAS8P# LW &<)!3
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M*?3!&690!C0 !"SK&.B.*A&('YU0![A",3S' DA"#<35RO 3-P% 1H_0"F#
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M"V UPGT ,3A D]O:]U('F=VX/:M9RZS"*RQZU\%-,3@"EM'RJ@6!!\0"@9^
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M(Q),T>+YO/BD,T0QC"5@X9DP ($$Y($I&I2@#%(P&P:4[WP8(> Z$#- 161
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M0P:MID$=9A:'FM0<'G6I,5SD([,'J?)1JI/' V4"N4<!5!X/%+R*Y0%I^7D
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M*,%2..H,HJ &^*0&OL '/D@7J" "S( *9*!+UF$*-@ %%*$U/$ -'$ 7&!
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M\C$TSL(5KH"#!/]F!OC"9K'I':Q!'2[ "82"[@!A3QG5)9JQ#EI@^NY!52X
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M6;E#@PT8"W62W'G%@FV"%3P4$0IDC$B/VJ?KV[^//[_^_?S[^_]_TCL87%:
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M;@SX%KJZY;H"+, ,*@IE ]Z0511X /\*2/" #>B8O".82P1:\%%2V?  8HG
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M@V="!LG(3#X8#CGBBV(P2@0@6;3R#H"@!"ZPD&D6 2RX 3R  Y['3,E@!N'
M!X/P''8@;;;P"0*5! ^' T6HB3VPDA=1/$<A!G2A>Q8P!2F1DF1@#+,!$EK
M!:Z# +,Q#$@@:IBPAU#29F_&$AHU9RO4#P&X$B%00R,0$R/ 0B*0@'P3 '[V
M) 5 ";@@![40 $DH*RYP@7-S!W11(!)18^L#  ZP#BL@"(( !\1P?@)  #*
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MI\D#B,8 (9 ,8% )@C )V^ ;8"=S#70'B< #!'(+0[ 0QDH'3+ %8-"6)($
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MM-(E0_ (#O"#7W>JC' APE 5B90Z&-(",C @+  &N1!*@. *2*NANLJZ!F!
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MA'1(WM@"E" *Z?N"7<%,&:'GZE>12?3ER0T&</ *5J#=7"'#9L2*6)Z#-EL
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MV@H/AT8>UT=!#&< !S>P!M'1/R?&",T2]C_PE2/ 993P^#^0 !R(!7F_M$Z
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M@A!Z4$--O(\@%] ]&C"%.S"_-PC #E@!"? O0@")+KB!FX@,,#.  C@Y!_"
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M&7@[,W %&<" 0:@!%QB#&A X*F !/\@O-VR%^.-*./0W"(  ^F0*%&BUI+@
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M P/@$5:( $_=0"8X@ ;X.ND*!]G3XR%(!KZ4C.H0 1Z @$KH@A]H@ 10!!N
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M&\,!$$1&2( !G3TP4! @!";4$,$@<17$6G00*"+5_W/!T7!=@Q>2<HL=5+A
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MJ%R,6$! C)1MJK:9T9O=L!@$CB6MP69;^!- "HGYHP!BFEFP&'EY"1)   J
M<+388]M5  @LQ,4 &RG$LD$!(I"R=8P%A#!?03)\ <HC=A=0 !L/-!'"93)L
M\4 LCPC  -H@( [ V8FS<$P<"<E $-TD4-"$YH$K_L#D<B'  A0@2'";""$0
MH'@*G\<8 AM-L-%V>3+(VW@!,ASS0.-X&P[K$8I^P;8 !.Q=G@.>-QXC!<=L
M0<K_(P4TS@#B?@/>A !OYRZ!V\D+NGP*323$  6>)U0 !?<\4+H(OR/P?.1Q
M$"3"[H_,=7X<4-R&P!&]ZPMC0:J##P ,D('="I(Y$ R ?I<#@ SV5[R+**X*
MH)"=^!+2OB:)H D@J-MJ>'>X_ZU-=B%(B/RN)X,0C" &#ZA!0D"POUBP@ 32
M@]7S.,B %U(N;[*[6PB:!)O1L8!\ ,@<>4('.\TEQ'[D:6#Z8K0V&!2P/'<H
MA>-8T(18R*L UKM=]J)X$01H[G5M*T 0L6C 8S2!?@+\&PQ\2 &YR6!O"/A"
M[Q# !OS]SPO(D@L1 < "]/E/!%^(0RQ"\+Q8""".??M;_P 5MT,R/N !,GQ$
MV+0X# 04#H8D8-QMR#B)-):'#9.( _< ((+<X8\!/03=[Y*U/RB2+99XT<!B
M_#(86@I&,TWXVM7RHI@ C& S.E  /F10@+]T30']N(PLF^E, /BP;'5AP+B.
M*38XC>LNV,S,-H\6S6Z2K0#1?"8TY0+.O/3-,=8TIV/..1=WRF6<SZ3F7.0Y
MET?E0I[V).=FQKG.B[B3$I+PWS/'.4YXV@6>A H47N2)T(N$#2\/_6==]GE-
M?O(S:0I8VF":]C3#/" QAM'!9K(&MLGT8S$1Q2A+6^K2E\(TIC*=*4UIB@ A
M3*NF-;U%T70J2Q=(P:(^'2I1,_^SE[XX!I>;*<QA!B.#D0J3+\R4*&46(YFB
M8C6K6MTJ5[OJU:^V5'I@Q8P(O#C6L](T:0'@Z%\\JIDCI#2D?R%%2GN)&0M\
M;:5XZ5I>T>K7OP(VL((=+&$+:]C#DHV6"K#E7Y2J2\/8]2X#,$PP-3/,94YF
M,9A%+&<[.Q<0"-6SHATM:4MKVIIJE*UY<6MFV+"8J?TE!"DE*=94.IFOG?2T
M+A6!W/@8!R\B@'5FZ2U=>"LV,!)T, @ A0!8@$C'($$0<0CM8$!0UJ$R +1<
M16ZRB%L0 E!@NN.ZKF/"2UW=HC>]I%7L-E(@"/<*XKWQE6]\DY;+S#!U'?"=
M+W_G.TS_!= V,Y )P GZ:^#W0@"W4U6O,Q%P!2O11: ^NP@EQE"6\E1!DG<Y
M"T.-=H'LG%<N J4.#<Z+@"YX()_A=$ ,DAO3 DC0NT.E@"!B(8(^O&9<2.B!
M/QT@"!?7I6!D"#&#BVQDP&I4 5%+J=>8G%+#5,9IFMF"DPWCM2MCV6N+B>Q@
M3(KE?F3YRD_FBUZ/7! 0E'FE:)8+/=^ABREX$4XS%*#=*$$&"3 @?WW(3XR\
MV*T<F]5Q=[G 4+0;(T.?65 "C 4(JF =+Y;97=9J4C<+8-8TQPD,%X[TF?]9
MYCQ+5*\,6%1:YF*VN8 :+Z?^+*OQHDH0<*2GJ%9C>>R&!%TP_Y33Y0D; :IC
M $0[+HIJ7DV@S6SL8[=4L5"N#+.9S9? ++797YLVE'%KY<IF9IC6K@QN^W$*
M:T][P49^FQ<@D( 1N$(K=)@5!8HA!D5,X0Q,*(8=8@"%.VR#*6:Y0HFF$ 'K
M<"H!:(B# \:@@Q(P00U(@$,'^.4%#4 BI^_0 C)^8(/W*,(&?(L $30@H9-)
MP@"L 04%P* J2!"(#7101+H*< 9"U @*0BB1('H  BS\@$C$"%L08#X$,=FB
MXJY@E)L(X  /)&!/QHL.7!!P MEP)0* .$5(.%Z"*%RX !S7 -8=3(A;"8 2
M\[9#'J!0!1\DQ &2L(*R:L85K22@!/_;D,-T"M*O^[28T U*%Q)\0) /6PX)
M3E#$"@B" (Q/(6P.@+F]CY'/!?A! B0Z=QZ:0/$];"590JC!? K@@(NEH '1
M65,73K&")AC( QW&\#KL$"\7#"(#-9) P2!@AW11X.ENZI@B\E-[.PQ!2\@>
M/O&=N;GC-\&*FE-^\C?'@LV  /G*?]WTFZ^YJV8F!&%</O<W][KN(YLU$ "%
M$# A!0?<8 4/@ (6=N:%0?#@%%R8!!@\!(=9F04#/ZA$#1PPB"^(P13P@/DE
M0SG0@,KU "D @@<D 0K\@!JX (M<! J4@11<@1B 0A5X@ W "@^<GA;$BYVM
MQS%( AMT@3#_'  &D($I7$$EL $1< $+ ((4L $8"((3_$ ,3(*D9$$'^  /
M;&":>(@3# '?5($9,(@)Q $0U@ EG$(E@ )Y7  @<('*20$+T$$.6@0#_(8K
M0-[IJ:##:,'I%4,/@ <H'(.;4 (R<$$5U%\5)!P W$$@-!H8N (0P@ */"$1
M@($'U$"3H, 8J %X^-LV<,$2T$$/U"!7' 1HT-@0?($3((N($$,5;$6:Q, 1
M-$ EC$!)+ "N\4$'K( 0,($K( $FQ  =!,(&$)J5"!FE_  H8, @P  6R$$2
MJL'[T<K)-  .?$$7*$$/^D :VL %B($KL($3], "X& ,'  <#.$0_[  &!##
M&8@!A!5?-FKC-G*C<F% 4%V )*Y%H#B2 %R +@C"(+2 @RTC230) A"!I@
M)0Q",01"LOA!#"!'.!2,))""%^0'"NB!!)S-UG2+&F# )R2+%A2A 'E!2!@#
M(M&CR$5"'DQCG5P '+A"0I* Z*B'W]!?\%&"*%@!#]  [3%D%KR" 0R#"^S
MA4VA&C0 LMP),:S%A0$ 'Y"!<I!('#1 0Y;'K;5 $)A H$0 '+R& S#!A%R
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M]!D>* S#^*1 ##P7!0B!#D3A:MR##'U!@;WG J@8'\5T%#) $_@/ TB. 5!
M%<BT_SB83,L+$IQ #/QA<-U&YER/>9G%%Z00%.ET5$O..Z: 3&]!+,C =-W.
M<VFG_U! 5W^T\0C"/,\'3)OT=UIT)&'.>_XT[0FF!/]0 !'DE $QVFT*4$T7
M "K==(O53T_/]?7<$0A\ 1JD -,^ E [B3R[@KSX6 Q,=A^E<V9K]F;?Q61V
MY1E(@BN4$P2-#1)(183L]%T$6C<-PS296IRUVG?E!35%DZX!5+$)RD.AFEU$
M$44-!C7I=GG0TS3=6-0*RJ<-MVS_#VY_EPA400/D&$#]!3Q9FJM9E*C9-F=K
M]W:;L^<1@AVXWJ(>303 G!V(*'=S53+_@$._5,$ 'W.C=WS+]WRSE/@< 47/
M4P,U 7S3]XN)#I&1#6;W]X 3>($;^($C>((K^((S>(,[^(-#>(1+^(13>(5;
M^(5C>(9K^(9S>(=[^(>#>(C_B_B(DWB)F_B)HWB*J_B*LWB+N_B+PWB,R_B,
MTWB-V_B-XWB.Z_B.\SABH1E_]WB0"_F0NU1(OY<9&<T"\,\<+SD"+$$*/ "4
M(_EF(,!65],C=$[I$/F6<[F#M_(I*$ HZ %[:P8**(#T3N"9-TE&$M-BC#F
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M'#2"!/3["BP!(0#<RV. '%!!!%C Q(3")[#!_81Q>IR"]%*"S5O"#80"6S@
M''Q""&0!,Q"#+>B!J^^W'GY"%9?!%#C IKL ,RC!Q-E#T_][A@3<0B,( K+"
M0 2DPDO0@1P$J= +W\X;_N&K%P.8C0G*:164 S"@"9E,0BH(:CE8 A<D3(<Y
MX2<L0+@C0R@H@=JO.2$P@P[  =-G9SE<?"V ?A8@@P(P0[S<01AP11"( 1?(
M>3KP@2.HP\E3P0640\5Z 3,D@"/$2YOJ01/D_;7__80A_O-#OV>E>L;!!AWH
M@>.7:P1(?BW\@ 58@ ZXP@D2R A10@ $ @;<P Z,<$N<0CT@,QRL9!!LPP_
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M^A@P&<! "9QH$$)@!,QH =**J8J "%8 "J)+!.*.+C0PR0B!"AC "RQKWEH
M!>CO#,*D!L7.V(@ QZH@ 5U #%QA!(CAFZ0 !&YAXAJ &$2@"W:J $H*#99
M#-Z@"\D@!(H!QWSG;S 0":)@"<; -+1@*U)I-Y0@"_[L#"" B%#B#GZ@_CQ
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MP(PI3**+! Q\\4 330APGP BL %%1W=\8F6#5;3748 /Q-$DBP^LN0"2380
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MAP(C8"4[YTI7NMIL./+,:SSG&4]\#E*>_SNH0>-)-*/U,[!\K>=P+#G' C@
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MP1A^R ,I[D"&E\8F"V,X0 -LH!1KO.$6;OIX'C!0AR[<H ZOZ<A]J3"JDRP
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M6>"$V[<#0V%HGA53!8$2*)@Z+J!4(_^' 4\VB#*0B43A!\0@8YY87<>P#L1
M)O?0'070>U)@$Z-&B0@ "#:0!=137D.0!;V(!'X0A8"P I#D!%$0#B@0!8TQ
M(U=@73#I)@@@!#Y  <=8#ZG$5"LX8P@0"3'  [UX 5TP!9@E$X9F!\0 =SB@
M@XUA4W% 9 C0!<2@/7"(!@U @7."6>=(/=](?U*H7X4Y!2Y@!S&P!2>0!T7
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MZAV_720Q!I%E<YDVM3)R]"<SM4K_\UHR(V7R&&,  TGK[?:AZ 6G\]]K(2%
MZK[#[ ;_3 L@!#R*)6#B JWP8@S"Z.BN(2P ][ NZPK_933"[/@^$O<1';)T
M D,0+9#_" D"V?H^ZV4A;Z2.[G4(!3)R!%IR]446]="F"XJ&]@[O"MSQ'@P/
M^@8#!==.Z]H>]F51$GTR;[P.+8B+VBNTAS(@!%Z>$_Q!ER)P CBPK26@!_BI
M PVP!HYP WH0"SR@ 91&"K;_$ IZ0 >6@(LKT&/(Z "XT &.< H*T AA60P=
M< -RD ".T 'NH 5/-I.6H022AA5#4 7S/8C%< IZ4$T T2V,G34KV."R-(A4
MEST0#%J8$F2,&BU*"B")(0% !%QR%$4A1:2$AD## %# 4&G=C1O,J$3HHFB;
M,!@H:!3!U4&1%&-:[)30LP1.&2X8% &%$8&0HG(T 6QDJ"C&EW7;;N@)=S%5
MF 1[-#CZT>*"#A].%#GZ)*" BZV5B/RL$ZN8 CTG2CBZFK-.BZ< "C#P0H,$
M@'?6IF2QM*U#CR\K2-'YV8,4AI&"46Q3I,B&   +8I:(,FEK@I&.],! 0DC#
M#RH%_^Z$*H<U2QT8E,:<^"0"@P8--[MT6"-E,  4B;PD[L"%A-*S4;::*'&5
M1SH!$8C8\&*GEL)4959<&?DCR84N=F*'*WQ*3S%FY>P(?V?+(Q>-*$K((:0'
MRBT%/T 9!0H*#*1@P0]7;BFE .N2(.XL]:KZ@2([")%##2(L<B&C FQ1!X @
M1H#"BZ/T(&6K%80HH81!U "  1<T*,$.8C:( #,[-B-.@W)6@\$%U5CS*PA"
M[%!D"A?P"D0 !"CK38)NF'%$@Q5,\0)&/33J3 N9 L&)2"Z,R0XH"1#@@;<H
M8.@L%60&6>>44^RA8J,A%1G"@,MN2!*!*F.T 3$O6:!#IO]/6.ANA6(FE(.*
MV8KIX 8YE.!LR2@2<&0;9FQXB@(ZKHICMQ)H($6(&##X20Y7NH-D!QM$\.G3
M)HJYP=(I.(M@J!4 / T !%Z,\;#V.EBA!1<JD6!#/&2XQ1)%?L TBR0=:$"-
MF+8IZI,+-K74!L\Z^"$&4LPJYY-ALC 3!EIC4J02#,H)@XH+NO-@C:_DP%0I
M.WZ8$8 LH'1D#45NX((4+>0HH0<)W@F3Q*W2;6 -O$Y;ZZAR C&@+XLOQCAC
MC3?FN&.,%S"#"@KZ*+8/'%P(9 %=#M!!D 16O:,4SBZ(00=%6K/&'2*(62 %
M&%2&P0LR6G!@A1I<^X2''H9!0A#_7>+4%8,>2-!B!1*<55H$(:80H8]P[NC!
M@#,R$&0%& JXY1,MIB: .#U:6("(2L!XPX L$B%A 3J(<0$-0H@!P 4:C+D"
MA\%0D,* ".@01 <;+LA#(P2$F)N886+V(FP73 @'A4!XH,$ !P19P@<8XBL%
M"4G8&,$5$.[X)',07#CSJ2QH$, !'73PP(8-WVBQ<"042>*=BBAPN9)8(!^,
M@2N&0.),M%<@8FH4?@CG CB4H,!QSIXJP W!_+*FSU<D.*,!02HYH0X)*"BF
M$AU<H2 CV$6X)XX-"K!I3#J&$ (.@C (]&B!&$2H4Q9Z(( LZ"$.='"%%^B5
MA:1](@(-_Z"?('APO@MNAG^)R,+YSF"!<+A@!1*(0 R.L3HPS AE AB+#]!0
M P#<@@JJ(T4#IG"Y3]PA24@P 8,6T(H6W($,!D "L5!P)>LH 0 .@$"<8%>,
M$P9A!T=+&QOH8 )B46(0)#B#)#1"B2B^ P[$0%XE?!"+8=BB% K4&B@XTXU
MD* *4[DBTG"H0QX2YABN& 86E ,[$" !!YQ! 0'?L3<BO.%R7!@& ](F "3L
M  /B 4%G,(@\"300A>I#@PU>)[,G.@YR/"##)P7!!#6,4C?$D('/GN( 24!!
M5*WS2^8$< 8=U""1X<@D AY@ X1](@N#^*0.*E$#R%%2$J1(0?\L0) V9S4@
M;((<3 %XL((&U EV&XB:P5  B>)I@0OK\X$:$( @%#S3<4&(0@L62;W$8=,O
MJF-#*%V3) 9, I"";& + $4%2DB"F;H84_7LIAQG54<'#:A$4O* @5*PH %2
M$ #L[@;&!BAS>7DP!@;>(()H<F:C%W2%'S!%G&=VDX?#R!P)*HFF;EPI"!ZH
M01!6P(,KP4\)$4"#*Y#63E*T[&8;*D7<IO".M W'8T^%:E2?>@$SA.,,"UR+
M#[2@CKBQ+P4)\,$#Z! V %Q@!#HP&]K>Z($8U& #%R"B%SZQD1V<#7:W@%19
M_0 U!%SH'29C8""^((D#C* &"ZAE13K_,X(,T$">MRC*&[[7C5<H20@[V$%K
M8J8K(;Q!*8/@BP/ $(<3K+0 ;$@!$2!!C&*80):=D9NJ '!7)P9!!YT3!H(
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M0 -!.),%T,EIFRS0H@"Y^;S;49R=N0(T< *,8@ >D(,AR"8?VB4P<(<40"%
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MW+(?2  +6(<A((*)327":+EE&M8(<()U@ ":*(XB<(+O2H$O"%@+Z()/0 )
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MYO9E8"MI%^_NB$;LE#YNJI[H?0L!)3EI&M=N0O-ES-;J$,CNC1AG-F"# \
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M.0"FR._6I6?]WP?^CE^ W+<!GF8#;8[&*1S-!K  OLD#7CV!./S;)*\")DR
M*0"3<@"6)A!1(3*9<<:(8TB (4"^=0BJC Q^D-_[7R..<GB%84B?PRT6+("#
M,(@H$*B"+2*6?$___O?_BP>( N!.R=D!"LH&  M2V0L'P $A.>O6E6L4#@4R
M.Y!PG7IEP $N/>O$A'%U"UFH**Z\('NSX5T;/3 *W"JG05$=.F4@:?AA(R&
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M@!A^HEC76EB]P-4L11]Q6^(^8@.YO>TP) R ]#9WO)JEDQW:-E3"'JL B4H
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MYL!?8FB!F*%))>"B4,"E 8!;"SA .Y:B"!0#,40 $4! '7P!\0F% ^Q W[B
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M(*S  ^@ &A !$R0!!="E +PI!8Q ;R! 'T@"#.RH6JZ ()B #C1 'H1>E.[
M"3 !#(3E C2 #@"LP!*!*[ !&%#!5GS"4)0B=0VF[H&IXBE"#)Q  IR !QP
M(*0* $) LT) #02!Q+Y>3#6I#FQ:G** !@SK IP &IR L.II;/8IX7C T-)
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M9_AN;/L*Q7<)"1* @C$<@^5N$/>TK@C L"M<B@/ P$,U& 6H@?%2_U1GT9<
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M#TBML()5$9 9#D@,"G1 OT?/&:!!.+S#.72@^ G\%&0!S:\#;_PE!)3K#J2
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MBBXJD<B22 *;!CY&3+DPQFZ$C@+X+-4C@<#%+(%(Z!UR!<<%2510D#%%9(H
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M4G4!<&"$4"D9A(=X+RK@#J0B6F$$'"C0)8G@2"DF*HU5U0$,'%A 8]=+=04
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MD&HP!W601!BIU0R)N**$_: DE%S$2J3D^A#@M4P01O[/ZBY'\EHIX%IK ;1
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M]& )6.H+GJ,*&@ 47B((%"%V%@(!A* 2ML /+$U?K@ -'@ "N( -Z$!U5N
M6"I.B*$*P" .&D!E\D TX@4)QA, 5@,B7. @,6 (Q(,'5F )Z( &3!!38F )
M0.HV1( ./& *OD >A\P&X#,.Z& =RB 7AH&;M@ #T$4.8@ @U\6EZK '1$ (
M8@ VB6$VXP #^BL*_USA#&CS&#*@@_)  APB#D3R ?(E#FKL#$:@"48 0O=R
M1CW$#D+ALF@T1VDPZ!"I-E#N^HB)RS13XAC01^S-00#N"_.M2%UNLB*B#FJ
M_H(H'&I$!KQ@!_8%66J"",QHK6[!9R (?0J ,EH@J S@A.9CB8JAFUP!+7HJ
M)PW$VYHO+A- $':B>G#C$8K /C @$'B$!5A $(A!,@1@-:#@"BREAB3 9DBA
M"J* HVA)9BK!!&7(0+P 7F+2C) @"I9H/CH"?%A@:8Q"42)@!P3!"KT$!7X
M%-:$ JXS!.X@$3 @4-X.$HZH)J#@"T[C8WY' HRA)'U@[0IU#& @@8R!$?]P
M@$EU=%DO8I#RDEFA]><8SR^C52]QC0BVH0Z2((B2@,\Z0!'J(#*B8C0$05%
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M%9>RT($8LN$ M?\9Q-&0-HCW^48#4DM@G5Y'KGYT#BUP@1T"*PC'.,KQ9@[
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M'R0DH0!L $4L+GR%%CC@ 1) P1 $< <N'" \+@A'@N*0 NFRX8.+[K:WIUJ
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-OO&/C_SD*S_S 0$ .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
